<SEC-DOCUMENT>0001144204-13-059668.txt : 20131107
<SEC-HEADER>0001144204-13-059668.hdr.sgml : 20131107
<ACCEPTANCE-DATETIME>20131107164347
ACCESSION NUMBER:		0001144204-13-059668
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131107
DATE AS OF CHANGE:		20131107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		131201185

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v359133_10q.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the quarterly period ended September 30, 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings; color: black"><B>&uml;</B></FONT></TD><TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><B><U>Florida</U></B></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;<B>__<U>65-0643773</U>__</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation or organization)</B></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B>&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Snunit Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Science Park</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POB 455</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Carmiel, Israel</U></B></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>20100</U></B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>+972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U></B><BR>
<FONT STYLE="font-size: 10pt"><B>(Former name, former address and former fiscal year, if changed since last report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT>&nbsp; No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &ldquo;large accelerated filer&rdquo;
and &ldquo;accelerated filer&rdquo; in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%; text-indent: 0in">Large accelerated filer</TD>
    <TD STYLE="width: 27%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 1%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 46%; text-indent: 0in">Accelerated filer </TD>
    <TD STYLE="width: 2%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Non-accelerated filer</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings; color: black">&uml; </FONT>(Do not check if a smaller reporting company)</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Smaller reporting company</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">On November 1, 2013, approximately
93,561,765 shares of the Registrant&rsquo;s common stock, $0.001 par value, were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-Q<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 79%">&nbsp;</TD>
    <TD STYLE="width: 12%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Page</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>PART I &ndash; FINANCIAL INFORMATION</B></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><B>Cautionary Statement Regarding Forward-Looking Statements</B></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">ii</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;1.</TD>
    <TD STYLE="vertical-align: bottom">Financial Statements</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Condensed Consolidated Balance Sheets &ndash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">As of September 30, 2013 (Unaudited) and December
        31, 2012</P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">1</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Condensed Consolidated Statements of Operations (Unaudited)
        &ndash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">For the Nine Months and the Three Months Ended September
        30, 2013 and 2012</P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">2</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Condensed Consolidated Statement of Changes in Shareholders&rsquo;
        Equity (Capital</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Deficiency) (Unaudited) &ndash; For the Nine Months
        Ended September 30, 2013 and 2012</P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">3</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Condensed Consolidated Statements of Cash Flows (Unaudited)
        &ndash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">For the Nine Months Ended September 30, 2013 and
        2012</P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">4</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.3in">Notes to Condensed Consolidated Financial Statements</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">6</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;2.</TD>
    <TD STYLE="vertical-align: bottom">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">11</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 3.</TD>
    <TD STYLE="vertical-align: bottom">Quantitative and Qualitative Disclosures About Market Risk</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">17</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;4.</TD>
    <TD STYLE="vertical-align: bottom">Controls and Procedures</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">18</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>PART II &ndash; OTHER INFORMATION</B></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;1.</TD>
    <TD STYLE="vertical-align: bottom">Legal Proceedings</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">20</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;1A.</TD>
    <TD STYLE="vertical-align: bottom">Risk Factors</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">20</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;2.</TD>
    <TD STYLE="vertical-align: bottom">Unregistered Sales of Equity Securities and Use of Proceeds</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">21</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;3.</TD>
    <TD STYLE="vertical-align: bottom">Defaults Upon Senior Securities</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">21</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;4.</TD>
    <TD STYLE="vertical-align: bottom">Mine Safety Disclosures</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">21</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;5.</TD>
    <TD STYLE="vertical-align: bottom">Other Information</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">21</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;6.</TD>
    <TD STYLE="vertical-align: bottom">Exhibits</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">22</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top">Signatures</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">24</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Except where the context otherwise requires, the terms, &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company&rdquo; refer to the business of Protalix BioTherapeutics, Inc. and its
consolidated subsidiaries, and &ldquo;Protalix&rdquo; or &ldquo;Protalix Ltd.&rdquo; refer to the business of Protalix Ltd., our
wholly-owned subsidiary and sole operating unit.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements set forth under the captions &ldquo;Business&rdquo;
and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;, and other statements
included elsewhere in this Quarterly Report on Form 10-Q, which are not historical, constitute &ldquo;forward-looking statements&rdquo;
within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities
Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies
for the future. When used in this report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and words or phrases
of similar import, as they relate to our company or our subsidiaries or our management, are intended to identify forward-looking
statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results
to differ materially from any future results expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to the commercialization efforts for taliglucerase alfa in the United States, Israel, Brazil and other countries;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk of significant delays in the commercial introduction of taliglucerase alfa in other markets as planned;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that we will not be able to develop a successful sales and marketing organization for any of our product candidates
in a timely manner, if at all;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to the acceptance and use of taliglucerase alfa or any of our product candidates, if approved, by physicians,
patients and third-party payors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in the approval or the potential rejection of any application filed with or submitted to the regulatory authorities
reviewing taliglucerase alfa outside of the United States, Israel, Brazil and other countries in which taliglucerase alfa is already
approved;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to establish and maintain strategic license, collaboration and distribution arrangements, and to manage our relationships
with Pfizer Inc., or Pfizer, Funda&ccedil;&atilde;o Oswaldo Cruz or any other collaborator, distributor or partner;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to finance our research programs, the expansion of our manufacturing capabilities and the ongoing
costs in the case of delays in regulatory approvals for taliglucerase alfa outside of the United States, Israel, Brazil and other
countries in which taliglucerase alfa is already approved;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in our preparation and filing of applications for regulatory approval of our other product candidates in the United
States, the European Union and elsewhere;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our expectations with respect to the potential commercial value of our product and product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that products that are competitive to our product candidates may be granted orphan drug status in certain territories
and, therefore, our product candidates may be subject to potential marketing and commercialization restrictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the impact of the development of competing therapies and/or technologies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any lack of progress of our research and development activities and our clinical activities with respect to any product candidate;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inherent risks and uncertainties in developing the types of drug platforms and products we are developing;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">risks relating to our ability to make scheduled payments of the principal
of, to pay interest on or to refinance our 2018 convertible notes, or any other indebtedness;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>potential product liability risks, and risks of securing adequate levels of product liability and clinical trial insurance
coverage;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possibility of infringing a third party&rsquo;s patents or other intellectual property rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the uncertainty of obtaining patents covering our products and processes and in successfully enforcing our intellectual property
rights against third parties;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to biosimilar legislation and/or healthcare reform in the United States, the European Union and elsewhere; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption
of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors,
collaborative partners, licensees and clinical trial sites<FONT STYLE="font-family: Times New Roman, Times, Serif">. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results
or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the U.S. Food and Drug Administration, or the FDA, or foreign regulatory authorities may not accept or approve a marketing application
filed by a pharmaceutical or biotechnology company for the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements reflect our current views with
respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These and other risks and uncertainties are detailed under the heading
<FONT STYLE="text-transform: uppercase">&quot;</FONT>Risk Factors<FONT STYLE="text-transform: uppercase">&quot;</FONT> in this
Form 10-Q<I> </I>and in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2012, and are described from time
to time in the reports we file with the Securities and Exchange Commission, or the Commission.<FONT STYLE="font-family: Times New Roman, Times, Serif">
We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. In addition, any or
all of our forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future
events and financial performance and we undertake no obligation to update or revise, nor do we have a policy of updating or revising,
any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the
occurrence of unanticipated events, except as may be required under applicable law. Thus, you should not assume that our silence
over time means that actual events are bearing out as expressed or implied in such forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I &ndash; FINANCIAL INFORMATION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;1. Financial
Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></FONT><BR>
(U.S. dollars in thousands)<BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,&nbsp;2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-left: 0.25in">Cash and cash equivalents&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">91,397</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">52,035</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts receivable - Trade&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,053</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,410</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Other assets&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,686</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Inventories&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,577</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,039</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Total current assets&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">105,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">61,170</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">FUNDS IN RESPECT OF EMPLOYEE RIGHTS
    UPON RETIREMENT&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,467</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,247</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">PROPERTY AND EQUIPMENT, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,340</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,310</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">DEFERRED CHARGES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">149</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; font-style: normal">&nbsp;&nbsp;&nbsp;&nbsp;Total
    assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">121,156</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,727</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0in">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0in">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Accounts payable and accruals:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.25in; text-align: left">Trade&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,267</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">Other&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,051</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Deferred revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,513</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,437</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Total current liabilities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,226</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,755</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 5.4pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Deferred revenues&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,419</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,888</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Liability in connection with collaboration operation<B> </B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,425</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Liability for employee rights upon retirement<B> </B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,273</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,016</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total long term liabilities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">112,636</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">56,329</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total liabilities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">137,862</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">82,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">COMMITMENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 5.4pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0in">CAPITAL DEFICIENCY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,706</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total liabilities net of capital deficiency&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">121,156</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,727</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT><BR>
<FONT STYLE="font-size: 10pt">(U.S. dollars in thousands, except share data)</FONT><BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-left: 5.4pt; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30, 2013</B></P></TD><TD NOWRAP STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30, 2012</B></P></TD><TD NOWRAP STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30, 2013</B></P></TD><TD NOWRAP STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30, 2012</B></P></TD><TD NOWRAP STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; font-weight: bold; padding-left: 0in">REVENUES&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">8,116</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">33,698</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,284</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,724</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">COMPANY&rsquo;S SHARE IN COLLABORATION AGREEMENT&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">678</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,666</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">COST OF REVENUES (1) &#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,876</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,966</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,587</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,367</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0in">GROSS PROFIT&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,515</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,410</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,772</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,023</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">RESEARCH AND DEVELOPMENT EXPENSES (2)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,467</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,717</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,723</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,326</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Less &ndash; grant s and reimbursements&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,049</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,655</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,086</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,963</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">RESEARCH AND DEVELOPMENT EXPENSES, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(17,418</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(22,062</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,637</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,363</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">GENERAL AND ADMINISTRATIVE EXPENSES (3)&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,065</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,353</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,780</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,220</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">OPERATING LOSS &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,968</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,005</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,645</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,560</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">FINANCIAL INCOME (EXPENSES) &ndash; NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">63</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">264</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(102</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">81</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">NET LOSS FOR THE PERIOD&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(16,905</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,741</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,747</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,479</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">LOSS PER SHARE OF COMMON STOCK:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -0.125in">BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.02</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.06</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.06</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING
    LOSS PER SHARE:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">92,307,170</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">90,491,421</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">92,433,502</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">91,929,445</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 0; padding-left: 0.5in; text-indent: -0.25in">&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">220</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">220</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 0; padding-left: 0.5in; text-indent: -0.25in">&nbsp;&nbsp;&nbsp;&nbsp;(2) Includes share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,198</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,690</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">609</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,247</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 0; padding-left: 0.5in; text-indent: -0.25in">&nbsp;&nbsp;&nbsp;&nbsp;(3) Includes share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,255</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,155</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">345</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">840</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENT OF CHANGES
IN SHAREHOLDER&rsquo;S EQUITY (CAPITAL DEFICIENCY) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands, except share
data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">paid&ndash;in</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock (1)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">capital</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">deficit</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR>
shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 45%; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Balance at December 31, 2011&#9;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">85,630,157</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">86</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">145,814</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(171,977</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(26,077</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Changes during the nine-month period ended September 30, 2012:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0in">Common stock&nbsp;issued for cash (net of issuance costs of $1,780)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,383</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,388</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0in">Share-based compensation related to stock options&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,217</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,217</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0in">Share-based compensation related to restricted stock award</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,847</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,848</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0in">Exercise of options granted to employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,156,184</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,136</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,137</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0in">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,741</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,741</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Balance at September 30, 2012 &#9;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">93,461,341</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">93</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">178,397</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(173,718</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,772</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-left: 0in">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Balance at December 31, 2012&#9;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">93,489,809</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">93</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">180,145</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(183,595</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(3,357</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Changes during the nine-month period ended September 30, 2013:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Share-based compensation related to stock options&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">895</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">895</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Share-based compensation related to restricted stock award, net of forfeitures of 1,667 shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,667</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,558</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Exercise of options granted to employees &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,768</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,905</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,905</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Balance at September 30, 2013 &#9;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">93,552,910</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">94</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">183,700</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(200,500</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(16,706</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><BR>
(1)&#9;Common Stock, $0.001 par value; Authorized &ndash; as of September 30, 2013 and 2012 - 150,000,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>The accompanying notes are an integral part of the condensed
consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-left: 0in; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30, 2013</B></P></TD><TD NOWRAP STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30, 2012</B></P></TD><TD NOWRAP STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right; padding-left: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0in">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 0.125in">Net loss&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(16,905</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(1,741</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Adjustments required to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Share based compensation&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,453</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,065</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Depreciation and write down of fixed assets&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,689</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,772</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Financial expenses (income), net (mainly exchange differences)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(140</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Changes in accrued liability for employee rights upon retirement&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Gain on amounts funded in respect of employee rights upon retirement&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(26</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Amortization of debt issuance costs and debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Decrease in deferred revenues (including non-current &#9;portion)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,393</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,981</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Increase in accounts receivable and other assets&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(798</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,099</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Increase in inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,538</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,779</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in; text-indent: -0.125in">Increase (decrease) in accounts payable and accruals (including long term )&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,413</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">369</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net cash used in operating activities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,911</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,186</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0in">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Purchase of property and equipment&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,668</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,817</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Amounts funded in respect of employee rights upon retirement,
    net&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(121</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(93</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Investment in restricted deposit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(42</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net cash used in investing activities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,831</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,910</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0in">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: 0.25in; padding-left: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Net proceeds from issuance of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">66,930</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&#9;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.125in">Issuance of shares, net of issuance cost&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,328</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.125in">Exercise of options&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,096</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net cash provided by financing activities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">66,960</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,424</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0in"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; padding-left: 0in">EFFECT OF EXCHANGE RATE CHANGES ON CASH&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">144</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(113</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0in"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0in">NET INCREASE IN CASH AND CASH EQUIVALENTS&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,215</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0in"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">BALANCE OF CASH AND CASH <FONT STYLE="font-size: 10pt"><B>EQUIVALENTS<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>AT
    BEGINNING OF PERIOD&#9;</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">52,035</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0in"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD
    &#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">91,397</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,216</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B></B>(Continued) - 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 78%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Purchase of property and equipment&#9;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">187</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">821</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Issuance cost related to convertible note offering not yet paid&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Exercise of options granted to employees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">73</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">72</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>a.</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Protalix BioTherapeutics, Inc. (collectively with its
subsidiaries, the &ldquo;Company&rdquo;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused
on the development and commercialization of recombinant therapeutic proteins based on the Company&rsquo;s proprietary ProCellEx<SUP>&reg;</SUP>
protein expression system (&ldquo;ProCellEx&rdquo;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under
the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&ldquo;EMA&rdquo;) application process
in the European Union. The Company&rsquo;s two subsidiaries are referred to collectively herein as the &ldquo;Subsidiaries.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On May 1, 2012, the U.S. Food and Drug Administration
(&ldquo;FDA&rdquo;) approved taliglucerase alfa for injection, the Company&rsquo;s first approved drug product, as an enzyme replacement
therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase
alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa
was also approved by the Israeli Ministry of Health (the &ldquo;Israeli MOH&rdquo;) in September 2012, by the Brazilian Ministry
of Health (the &ldquo;Brazilian MOH&rdquo;) in March 2013 and by the applicable regulatory authorities of certain other countries.
Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory
authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Taliglucerase alfa is being marketed in the United States
under the brand name ELELYSO&trade; by Pfizer Inc. (<FONT STYLE="text-transform: uppercase">&ldquo;</FONT>Pfizer<FONT STYLE="text-transform: uppercase">&rdquo;</FONT>),
the Company&rsquo;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix
Ltd. and Pfizer (the <FONT STYLE="text-transform: uppercase">&ldquo;</FONT>Pfizer Agreement<FONT STYLE="text-transform: uppercase">&rdquo;</FONT>).
The Company, through Protalix Ltd., markets ELELYSO in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Protalix Ltd. granted Pfizer an exclusive, worldwide
license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel, and, subject
to the effectiveness of the Brazil Agreement (as defined below), in Brazil. The Company has agreed to a specific allocation between
Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date,
the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly
thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0
million milestone payment in connection with the FDA&rsquo;s approval of taliglucerase alfa in the United States, which was considered
to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period
in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related
to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the
profits or losses related to commercialization efforts in Israel, and, subject to the effectiveness of the Brazil Agreement, in
Brazil, where the Company retained or will retain exclusive marketing rights. <FONT STYLE="color: black">In calculating the net
profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales
for certain expenses and costs of goods sold</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On June 18, 2013, Protalix Ltd. entered into a Supply
and Technology Transfer Agreement (the &quot;Brazil Agreement&quot;) with Funda&ccedil;&atilde;o Oswaldo Cruz (&ldquo;Fiocruz&rdquo;),
an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO<SUP>TM</SUP>. The
first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed,
to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer
to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole
expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz
has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement.
In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally,
Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately
$280 million worth of taliglucerase alfa. The Brazil Agreement becomes effective upon its approval by the Brazilian National Institute
of Industrial Property, which is expected to occur very shortly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">To facilitate the arrangement with Fiocruz, Pfizer amended
its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization
and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization
and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as
defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil
on Protalix Ltd.&rsquo;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Protalix Ltd. is required to pay a fee equal to 5% of
the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement
pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to
the Brazil Agreement until the termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to the approvals from the FDA, the Israeli
MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Mexico, Chile and Uruguay. In addition, the Company
is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions.
Currently, marketing authorization applications have been filed in a number of countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Currently, patients are being treated with taliglucerase
alfa on a commercial basis in the United States, Brazil and Israel. In addition, patients are being treated globally through the
Company&rsquo;s clinical trials and related studies, compassionate use programs and other programs. On July 13, 2010, the Company
announced that the French regulatory authority had granted an Autorisation Temporaire d&rsquo;Utilisation (ATU), or Temporary Authorization
for Use, for taliglucerase alfa for the treatment of Gaucher disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">An ATU is the regulatory mechanism used by the French
Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need
exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization
for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations
to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or
named patient provisions in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to taliglucerase alfa, the Company is working
on the development of certain other products using ProCellEx.<BR CLEAR="ALL" STYLE="page-break-before: always">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to the approval of taliglucerase alfa for
marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&rsquo;s development
programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell
its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to
support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory
approval process for each of its product candidates during their respective developmental periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Obtaining marketing approval with respect to any product
candidate in any country is directly dependent on the Company&rsquo;s ability to implement the necessary regulatory steps required
to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD><B>Basis of Presentation</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States (&ldquo;GAAP&rdquo;) for interim financial information. Accordingly, they do not include all of the information and notes
required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature)
considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results
for the interim period are not necessarily indicative of the results that may be expected for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">These unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for
the year ended December 31, 2012, filed by the Company with the Commission. The comparative balance sheet at December 31, 2012
has been derived from the audited financial statements at that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 17.85pt"><B>c.</B></TD><TD><B>Net loss per share</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Basic and diluted loss per share are calculated by
dividing the net loss by the weighted average number of shares of the Company's common stock, par value $0.001 (the &quot;Common
Stock&quot;), outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Diluted loss per share does not include options,
restricted shares and shares issuable upon conversion of the convertible notes issued in September 2013 (see Note 3) in the amount
of <FONT STYLE="color: black">7,169,035</FONT> and 7,879,601 shares of Common Stock for the nine months ended September 30, 2012
and 2013, respectively, and <FONT STYLE="color: black">7,508,240</FONT> and 8,817,090 shares of Common Stock for the three months
ended September 30, 2012 and 2013, respectively, because the effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 17.85pt"><B>d.</B></TD><TD><B>Convertible notes </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="color: black">The convertible notes
are accounted for using the guidance provided set forth in </FONT>FASB Accounting Standards Codification <FONT STYLE="color: black">(ASC)
815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately.
The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Inventory at September 30, 2013 and December&nbsp;31,
2012 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">September 30,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">December 31,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">(U.S. dollars in thousands)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 78%; text-align: left">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">2,574</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">2,118</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,863</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,729</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total inventory</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,577</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,039</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"><FONT STYLE="color: black">Prior to the FDA's approval
of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed
as research and development expenses</FONT>. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company
capitalizes all manufacturing costs associated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &ndash; CONVERTIBLE NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"><FONT STYLE="color: black">On September 18, 2013,
the Company completed a private placement of $69.0 million in aggregate principal amount of 4.50% convertible notes due 2018</FONT>
(the &quot;Notes&quot;)<FONT STYLE="color: black">, </FONT>including $9.0 million aggregate principal amount of Notes related to
the initial purchaser's over-allotment option, which was exercised in full<FONT STYLE="color: black">. In connection with the completion
of the offering, the Company entered into an indenture (the &quot;Indenture&quot;) with The Bank of New York Mellon Trust Company,
N.A., as trustee, governing the Notes. The Notes accrue interest at a rate of 4.50% per year, payable semiannually in arrears on
March 15 and September 15 of each year, beginning on March 15, 2014. The Notes mature on September 15, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">The net proceeds from the offering, including net
proceeds from the exercise in full by the initial purchaser of its option to purchase an additional $9.0 million in aggregate principal
amount of the Notes, were $66.8 million, after deducting the initial purchaser's discount and commission and the estimated offering
expenses payable by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">Holders may convert their Notes at any time prior
to the close of business on the business day immediately preceding September 15, 2018. The initial conversion rate for the Notes
is 173.6593 shares of the Common Stock for each $1,000 principal amount of Notes (equivalent to an initial conversion price of
approximately $5.76 per share of the Common Stock. Upon conversion, the Company will deliver a number of shares of Common Stock,
per $1,000 principal amount of Notes, equal to the conversion rate. The conversion rate is subject to adjustment in some events
but will not be adjusted for any accrued and unpaid interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">Prior to September 19, 2016, the Company may not
redeem the Notes, and no sinking fund is provided for the Notes. On or after September 19, 2016, the Company may redeem for cash
all or part of the Notes (except for the notes that the Company is then required to repurchase in connection with a fundamental
change, as defined below) if the last reported sale price of the Common Stock has been at least 130% of the conversion price then
in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on the
trading day immediately preceding the date on which the Company provides the notice of redemption. The redemption price will equal
the sum of (i)&nbsp;100% of the principal amount of the Notes being redeemed, plus (ii)&nbsp;accrued and unpaid interest, including
additional interest, if any, to, but excluding, the redemption date, plus (iii) the sum of the present values of each of the remaining
scheduled payments of interest that would have been made on the Notes being redeemed had such Notes remained outstanding from the
redemption date to the maturity date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &ndash; CONVERTIBLE NOTE </B>(continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">The following table sets forth total interest expense
recognized related to the Notes (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR>
2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">September&nbsp;30,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">2012</P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR>
2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR>
2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 56%; text-align: left; text-indent: -10pt; padding-left: 10pt">Contractual interest expense</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">104</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">104</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Amortization of debt issuance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">119</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">119</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 - STOCK TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"><FONT STYLE="color: black">During the nine months
ended September 30, 2013, the Company issued a total of approximately </FONT><FONT STYLE="font-size: 10pt">64,768</FONT><FONT STYLE="color: black">
shares of Common Stock in connection with the exercise of a total of approximately </FONT><FONT STYLE="font-size: 10pt">64,768</FONT><FONT STYLE="color: black">
options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $103,000.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 5 &ndash; FAIR VALUE MEASUREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">The Company measures fair value and discloses fair
value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale
of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">The accounting standard establishes a fair value
hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">Level 1: Quoted prices (unadjusted) in active markets
that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level
1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">Level 2: Observable prices that are based on inputs
not quoted on active markets, but corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">Level 3: Unobservable inputs are used when little
or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">In determining fair value, the Company utilizes valuation
techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers
counterparty credit risk in its assessment of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">The fair value of the financial instruments included
in the working capital of the Company is usually identical or close to their carrying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">The fair value of the convertible notes as of September
30, 2013 is $71,760,000. The fair value was estimated based on quoted market prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;2. Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with the consolidated financial statements and the related
notes included elsewhere in this Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2012. Some of
the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business
and related financing, includes forward-looking statements that involve risks and uncertainties. You should read &ldquo;Risk Factors&rdquo;
in this Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2012 for a discussion of important factors
that could cause actual results to differ materially from the results described in or implied by the forward-looking statements
contained in the following discussion and analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary, biobetter or biosimilar versions
of recombinant therapeutic proteins, based on our plant cell-based expression technology, that primarily target large, established
pharmaceutical markets and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex
therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We
believe ProCellEx will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to
existing recombinant proteins currently marketed for the same indications. Because we are primarily targeting biologically equivalent
versions of highly active, well-tolerated and commercially successful therapeutic proteins, we believe our development process
is associated with relatively less risk compared to other biopharmaceutical development processes for completely novel therapeutic
proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">On
May 1, 2012, the U.S. Food and Drug Administration, or the FDA, approved for sale our first commercial product, taliglucerase alfa
for injection, which is being marketed in the United States and Israel under the brand name ELELYSO<FONT STYLE="font-size: 10pt"><SUP>TM</SUP></FONT>,
as an enzyme replacement therapy, or ERT, for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher
disease. Subsequently, taliglucerase alfa was approved by the Brazilian National Health Surveillance Agency (Agencia Nacional de
Vigilancia Sanitaria, or ANVISA) in March 2013, by the Israeli Ministry of Health, or the Israeli MOH, in September 2012, and by
the applicable regulatory authorities in Uruguay, Mexico and Chile. Taliglucerase alfa will be marketed under the name UPLYSO<FONT STYLE="font-size: 10pt"><SUP>TM</SUP>
</FONT>in Brazil and certain other countries. Taliglucerase alfa is our proprietary, recombinant form of glucocerebrosidase, or
GCD, that is produced or expressed through ProCellEx. Taliglucerase alfa is the first plant cell-based recombinant therapeutic
protein to be approved by the FDA or by the regulatory authorities with jurisdiction over any substantial market. Gaucher disease
is a rare and serious lysosomal</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">storage disorder with severe and
debilitating symptoms. Gaucher patients suffer from mutations in or deficiencies of GCD, an enzyme that is naturally found in human
cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since May 2012, taliglucerase alfa has been marketed in the
United States by Pfizer Inc., or Pfizer, our commercialization partner, as provided in the exclusive license and supply agreement
by and between Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement. We granted Pfizer
an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but we retained those
rights in Israel and, subject to the effectiveness of the Brazil Agreement, as described below, in Brazil. We have agreed to a
specific allocation between Protalix Ltd. and Pfizer of the responsibilities for the continued development efforts for taliglucerase
alfa outside of Israel. Since 2013, taliglucerase alfa has been marketed in Israel by Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 18, 2013, we entered into a Supply and Technology Transfer
Agreement, or the Brazil Agreement, with Funda&ccedil;&atilde;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian MOH, for taliglucerase
alfa. The technology transfer is designed to be completed in four stages and is intended to transfer to Fiocruz the capacity and
skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a
sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The initial term of the technology transfer is seven
years. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during
the first two years of the term. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth
of taliglucerase alfa per year. Additionally, we are not required to complete the final stage of the technology transfer until
Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement becomes effective upon
its approval by the Brazilian National Institute of Industrial Property, which is expected to occur very shortly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Brazil Agreement may be extended for an additional five-year
term, as needed, to complete the technology transfer. All of the terms of the arrangement, including the minimum annual purchases,
will apply during the additional term. Upon completion of the technology transfer, and subject to Fiocruz receiving approval from
ANVISA to manufacture taliglucerase alfa in its facility in Brazil, the agreement will enter into the final term and will remain
in effect until our last patent in Brazil expires. During such period, Fiocruz will be the sole provider of this important treatment
option for Gaucher patients in Brazil and shall pay us a single-digit royalty on net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To facilitate the arrangement with Fiocruz, we and Pfizer agreed
to an amendment of our exclusive license and supply agreement, which amendment provides for the transfer of the commercialization
and other rights to taliglucerase alfa in Brazil back to us. As consideration for the transfer of the commercialization and supply
rights, we agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license
and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on our behalf in connection
with the supply of taliglucerase alfa to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay a fee equal to 5% of the net proceeds generated
in Brazil to our agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between
us and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are cooperating with Pfizer to obtain marketing approval
for taliglucerase alfa in additional countries and jurisdictions. In addition to those countries in which taliglucerase alfa has
been approved, marketing authorization applications have been filed in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2012, we entered into a Clinical Development Agreement
with Pfizer under which we will continue to manage, administer and sponsor current, ongoing clinical trials relating to ELELYSO.
We are currently sponsoring extension studies of ELELYSO in adult and pediatric patients. New clinical trials for ELELYSO will
be conducted and sponsored by Pfizer. Under the terms of the agreement, we were eligible to receive a payment of $8.3 million upon
the achievement of certain near-term clinical development goals. The goals were achieved prior to the end of fiscal year 2012 and
the $8.3 million payment has been paid in full. This agreement helps to maintain the continuity of the ongoing clinical trials
for Gaucher patients and physicians and reinforces the companies&rsquo; mutual commitment to the Gaucher community.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
performed a number of studies on taliglucerase alfa to supplement the pivotal phase III clinical trial, which we completed in September
2009. We initiated a double-blind, follow-on extension study in 2008 which consisted of eligible patients who had completed nine
months of treatment in the pivotal phase III clinical trial. The patients were offered the opportunity to continue to receive taliglucerase
alfa at the same dose they received in the pivotal trial for an additional 15 months in a blinded manner. We also conducted a nine-month,
worldwide, multi-center, open-label, switch-over clinical study evaluating the safety and efficacy of switching Gaucher patients
currently treated with Cerezyme<FONT STYLE="color: black"><SUP>&reg;</SUP></FONT>, which is produced by Genzyme Corporation (a
Sanofi company), with taliglucerase alfa, which was successfully completed in 2011. We also conducted a 12-month clinical trial
of na&iuml;ve and switchover pediatric patients, which was successfully completed in 2012. Based on the data from this study, </FONT>an
application for a supplement to the NDA for Elelyso, allowing a pediatric use indication to be added to the product label, has
recently been submitted by Pfizer to the FDA.<FONT STYLE="font-family: Times New Roman, Times, Serif">Patients in the extension
trials are still being treated with taliglucerase alfa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, patients are being treated with taliglucerase alfa
on a commercial basis in the United States, Brazil and Israel. Globally, patients are being treated through our extension trials
and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed
to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. In France, Gaucher
patients are being treated with taliglucerase alfa through an Autorisation Temporaire d&rsquo;Utilisation (ATU), or Temporary Authorization
for Use, a regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients
in France when a genuine public health need exists. In addition to the United States and France, taliglucerase alfa is currently
being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.
Hundreds of patients, in the aggregate, have been treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) PRX-102, a therapeutic protein candidate for the treatment
of Fabry disease, a rare, genetic lysosomal disorder in humans, currently in a phase I/II clinical trial for which the first patient
was treated in December 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) PRX-112, an orally administered glucocerebrosidase enzyme
for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot
cells, the subject of a phase I clinical study. We recently announced initial positive results from the trial. We also announced
that since some of the patients participating in the trial who suffer from thrombocytopenia and had low platelet counts demonstrated
a meaningful improvement in platelet count, the trial has been extended to enroll and evaluate additional patients with low platelet
counts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) PRX-106, an antiTNF, a plant cell expressed recombinant
fusion protein combined of the soluble form of the human TNF receptor (TNFR) and an antibody portion, which is being developed
for the treatment of certain immune and inflammatory diseases, such as rheumatoid arthritis, Chrohn&rsquo;s disease, colitis, psoriasis
and other autoimmune and inflammatory disorders, for which we have performed several animal studies. We are now conducting additional
preclinical studies focused on our proprietary orally administered delivery treatment with the PRX-106 protein using plant cells,
for several attractive indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) PRX-107, a proprietary plant cell recombinant human Alpha1-antitrypsin,
or AAT, under development for the treatment of emphysema due to hereditary AAT deficiency, to be administered by inhalation. We
believe this will be the first recombinant form of the AAT protein drug. We plan to hold a pre-Investigational New Drug, or IND,
meeting with the FDA during the first half of 2014 to discuss next steps for this compound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(5) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease
1 under development for the treatment of cystic fibrosis, to be administered by inhalation. We held a pre-IND meeting with the
FDA in 2012, and plan to file an IND with the FDA following the completion of toxicology studies, which is expected to occur in
early 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
for the rights to commercialize taliglucerase alfa worldwide (other than Brazil and Israel), which we licensed to Pfizer, we hold
the worldwide commercialization rights to our proprietary development</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">candidates.
We have built an internal marketing team designed to serve the Israeli market for taliglucerase alfa and we intend to establish
internal commercialization and marketing teams for our other product candidates in North America, the European Union and in other
significant markets, including Israel, subject to required marketing approvals, as the need arises. In addition, we continuously
evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies
and academic research institutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing in this Quarterly Report. There have not been any changes to
our significant accounting policies since the Annual Report on Form 10-K for the year ended December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and results
of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles.
The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments.
We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily
apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Three months ended September 30, 2013 compared to the
three months ended September 30, 2012</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $2.3&nbsp;million during the three months
ended September 30, 2013, compared to revenues of $3.7&nbsp;million for the three months ended September 30, 2012. The revenues
represent a pro rata amortization equal to $1.1 million resulting from the $65.0&nbsp;million upfront and milestone payments we
received from Pfizer in 2009, revenues generated from our sales of taliglucerase alfa in Israel and the cost of products we delivered
to Pfizer under the Pfizer Agreement. We recorded revenues of $1.4 million for the three months ended September 30, 2013 from products
we sold in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $1.1 million as our share of net income
from the collaboration under the Pfizer Agreement during the three months ended September 30, 2013, compared to revenue of $1.7
million for the three months ended September 30, 2012. Our share in the collaboration agreement recorded during the three months
ended September 30, 2013 represents our 40% share of the net income generated during the period, which was primarily the result
of revenues generated by Pfizer in the United States which exceeded the expenses during such period. During the three months ended
September 30, 2012, the majority of the revenues generated by Pfizer were from sales in Brazil. Under the terms and conditions
of the Pfizer Agreement, financial information of Pfizer&rsquo;s subsidiaries that operate outside the United States is included
based on the fiscal year ending November&nbsp;30, while financial information for the U.S. entity is included based on the fiscal
year ending December&nbsp;31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $1.6 million and $2.4 million for the three
months ended September 30, 2013 and 2012, respectively. Cost of revenues for the three months ended September 30, 2013 consists
primarily of certain fixed costs relating to our manufacturing facility, including rent, depreciation, salary and maintenance expenses,
and to a much lesser extent, the direct cost of products we sold in Israel. Prior to the FDA's approval of taliglucerase alfa,
manufacturing costs related to taliglucerase alfa were classified as research and development expenses. Effective as of the FDA
approval of taliglucerase alfa, we capitalize all manufacturing costs associated with taliglucerase alfa and expense such costs
as cost of revenues, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $5.6&nbsp;million for
the three months ended September 30, 2013, a decrease of $726,000, or 11%, from $6.4&nbsp;million for the three months ended September
30, 2012. The decrease resulted primarily from a decrease of $1.1 million in certain clinical trials expenses resulting from the
winding down of certain clinical trials for taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
for our various development programs to continue to be our primary expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">General and administrative expenses were $1.8&nbsp;million
for the three months ended September 30, 2013, a decrease of $440,000, or 20%, from $2.2&nbsp;million for the three months ended
September 30, 2012. The decrease resulted primarily from a decrease of $506,000 in salaries expenses primarily due to share-based
compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial<FONT STYLE="font-size: 10pt"> </FONT>expense
was $102,000 for the three months ended September 30, 2013 mainly due to the interest expense accrued in connection with the convertible
note and the devaluation of the US dollar against the NIS during the period, compared to financial income of $81,000 for the three
months ended September 30, 2012, mainly due to interest earned on short term deposits during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Nine months ended September 30, 2013 compared to the nine
months ended September 30, 2012</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $8.1&nbsp;million during the nine months
ended September 30, 2013, compared to revenues of $33.7&nbsp;million for the nine months ended September 30, 2012. The revenues
represent primarily a pro rata amortization equal to $1.1 million in each quarterly period resulting from the $65.0&nbsp;million
upfront and milestone payments we received from Pfizer in 2009, revenues generated from our sales of taliglucerase alfa in Israel
and the cost of products we deliver to Pfizer under the Pfizer Agreement. The revenues for the nine months ended September 30,
2012 included a $25.0 million payment we received from Pfizer under the Pfizer Agreement in connection with the FDA's approval
of taliglucerase alfa on May 1, 2012. The revenues for the nine months ended September 30, 2013 include $3.6 million from products
we sold in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $2.3 million as our share of net income
from the collaboration under the Pfizer Agreement during the nine months ended September 30, 2013, compared to revenue of $678,000
for the nine months ended September 30, 2012. Our share in the collaboration agreement recorded during the nine months ended September
30, 2013 represents our 40% share of the net income generated during the period, which was primarily the result of revenues generated
by Pfizer in the United States which exceeded the expenses during such period. Under the terms and conditions of the Pfizer Agreement,
financial information of Pfizer&rsquo;s subsidiaries that operate outside the United States is included based on the fiscal year
ending November&nbsp;30, while financial information for the U.S. entity is included based on the fiscal year ending December&nbsp;31.<I>
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $3.9 million for the nine months ended
September 30, 2013, a decrease of $3.1 million, or 44%, compared to $7.0 million for the nine months ended September 30, 2012.
Cost of revenues for the nine months ended September 30, 2013 consists primarily of certain fixed costs relating to our manufacturing
facility, including rent, depreciation, salary and maintenance expenses, and to a much lesser extent, the direct cost of products
we sold in Israel and products we delivered to Pfizer for which revenues were recognized during the period. Cost of revenues for
the nine months ended September 30, 2012 included an aggregate of $2.1 million in royalties to the OCS and to a certain academic
institution in connection with gross sales of taliglucerase alfa during the period. Prior to the FDA's approval of taliglucerase
alfa, manufacturing costs related to taliglucerase alfa were classified as research and development expenses. Effective as of the
FDA approval of taliglucerase alfa, we capitalize all manufacturing costs associated with taliglucerase alfa and expense such costs
as cost of revenues, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $17.4&nbsp;million for
the nine months ended September 30, 2013, a decrease of $4.6&nbsp;million, or 21%, from $22.1&nbsp;million for the nine months
ended September 30, 2012. The decrease resulted primarily from a decrease of approximately $2.2 million in certain clinical trials
expenses resulting from the winding down of certain clinical trials for taliglucerase alfa, a decrease of $1.0 million in salaries
expenses primarily due to share-based compensation and a decrease of $725,000 in materials which we have been classified as cost
of revenues or capitalized as inventory after FDA&rsquo;s approval of taliglucerase alfa in May 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
for our various development programs to continue to be our primary expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">General and administrative expenses were $6.1&nbsp;million
for the nine months ended September 30, 2013, a decrease of $1.3 million, or 18%, from $7.4&nbsp;million for the nine months ended
September 30, 2012. The decrease resulted primarily from a decrease of $1.3 million in salaries expenses primarily due to share-based
compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial income was $63,000 for the nine
months ended September 30, 2013, compared to financial income of $264,000 for the nine months ended September 30, 2012. Financial
income resulted primarily from interest earned on short term deposits, net of interest expense on the convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant research and
development expenditures we have not been profitable and have generated operating losses since our inception with the exception
of the quarter ended June 30, 2012 due to the $25.0 million milestone payment we received from Pfizer in connection with FDA approval
of taliglucerase alfa in that period. To date, we have funded our operations primarily with proceeds equal to $31.3&nbsp;million
from the sale of shares of convertible preferred and ordinary shares of Protalix Ltd., and an additional $14.1&nbsp;million in
connection with the exercise of warrants issued in connection with the sale of such shares, through December 31, 2008. In addition,
on October 25, 2007, we generated gross proceeds of $50&nbsp;million in connection with an underwritten public offering of our
common stock and on each of March 23, 2011 and February 22, 2012, we generated gross proceeds of $22.0 million and $27.2 million,
respectively, in connection with underwritten public offerings of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">On September 18, 2013, we completed a private
placement of $69.0 million in aggregate principal amount of 4.50% convertible notes due 2018, or the Notes, including $9.0 million
aggregate principal amount of Notes related to the offering's initial purchaser's over-allotment option, which was exercised in
full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In 2013, the OCS awarded us a grant of up
to approximately $3.6 million for the calendar year 2013. The award was granted to promote the advancement of our drug development
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In addition to the foregoing, <FONT STYLE="font-family: Times New Roman, Times, Serif">Pfizer
paid Protalix Ltd. $60.0 million as an upfront payment in connection with the execution of the Pfizer Agreement and subsequently
paid to Protalix Ltd. an additional $5.0 million upon Protalix Ltd.'s meeting a certain milestone. Protalix Ltd. also received
a milestone payment of $25.0 in connection with the FDA's approval of taliglucerase alfa in May 2012. Protalix Ltd. is also entitled
to payments equal to 40% of the net profits earned by Pfizer on its global sales of taliglucerase alfa (except in Israel and, subject
to the effectiveness of the Brazil Agreement, Brazil). In calculat</FONT>ing net profits there are certain agreed upon limits on
the amounts that may be deducted from gross sales for certain expenses and costs of goods sold. Pfizer has also paid Protalix Ltd.
$8.3 million in connection with the successful achievement of certain goals under the Clinical Development Agreement between Pfizer
and Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that the funds currently available
to us as are sufficient to satisfy our capital needs for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $25.9&nbsp;million
for the nine months ended September 30, 2013. The net loss for the nine months ended September 30, 2013 of $16.9 million was further
increased by a decrease of $5.4 million in deferred revenues, a decrease of $5.4 million in accounts payable and an increase of
$3.5 million in inventories, but was partially offset by share based compensation of $3.5 million and $2.7 million in depreciation.
Net cash used in investing activities for the nine months ended September 30, 2013 was $1.8 million and consisted primarily of
purchases of property and equipment. Net cash provided by financing activities was $67.0 million, consisting primarily of net proceeds
from our offering of 2018 4.5% convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $1.2 million
for the nine months ended September 30, 2012. The net loss for the nine months ended September 30, 2012 of $1.7 million decreased
primarily due to $6.1 million in share-based compensation and $2.8 million in depreciation, which was partially offset by a decrease
of $5.0 million in deferred revenues and increase of $2.1 million in accounts receivable and increase of $1.8 million in inventory.
Net cash used in investing activities for the nine months ended September 30, 2012 was $1.9 million and consisted primarily of
purchases of property and equipment. Net cash provided by financing activities was $26.4 million, consisting primarily of net proceeds
from our February 2012 underwritten public offering of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We <FONT STYLE="color: black">expect to continue to incur significant
expenditures in the near future. However, we anticipate that we will generate revenues to offset such losses as Pfizer's commercialization
efforts for taliglucerase alfa in the United States and as our commercialization efforts for taliglucerase alfa in Brazil and Israel
progress, and as taliglucerase alfa is launched by Pfizer in other countries in which taliglucerase alfa was recently approved.
We also anticipate that we will generate additional revenues after additional anticipated marketing approvals of taliglucerase
alfa are granted in new countries. We expect to continue to incur significant research and development expenses, including expenses
related primarily to the clinical trials of PRX-102 and oral glucocerebrosidase and the advancement of our other product candidates
into clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that our existing cash and cash
equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for the foreseeable
future. We have based this estimate on assumptions that are subject to change and may prove to be wrong, and we may be required
to use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated
with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital
outlays and operating expenditures associated with our current and anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our future capital requirements will depend
on many factors, including the progress of Pfizer's commercialization efforts for taliglucerase alfa in the United States and other
countries, the progress of our commercialization efforts for taliglucerase alfa in Brazil and Israel<FONT STYLE="color: black">
and, if anticipated marketing approvals of taliglucerase alfa</FONT> are granted in other jurisdictions, the progress of Pfizer's
global commercialization efforts for taliglucerase alfa, the progress and results of our clinical trials, the duration and cost
of discovery and preclinical development and laboratory testing and clinical trials for our product candidates, the timing and
outcome of regulatory review of our product candidates, the costs involved in preparing, filing, prosecuting, maintaining, defending
and enforcing patent claims and other intellectual property rights, the number and development requirements of other product candidates
that we pursue and the costs of commercialization activities, including product marketing, sales and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Inflation and Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the nine months ended September 30, 2013 or the nine months ended September 30, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us through
increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material
effect on our results of operations during the nine months ended September 30, 2013 or the nine months ended September 30, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of each of September 30, 2013 and September 30, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the dollar. We currently have no significant source of revenues; therefore we consider
the currency of the primary economic environment to be the currency in which we expend cash. Approximately 50% of our expenses
and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars.
Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using
the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue
and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency
translation gains or losses are recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approximately 35% of our costs, including salaries, expenses
and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations
in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A revaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended <BR>September 30,</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended <BR>December 31,</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%">Average rate for period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.639</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.861</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.856</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.537</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.912</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.733</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due
to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while
maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily
in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest
rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in
the future as a result of changes in the financial markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Item&nbsp;4. Controls and Procedures</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We conducted an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report
on Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of management, including our
Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to
reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly
Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s
rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated
and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow
timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Based on the controls evaluation, our
Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly
Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required
to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by
the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management,
including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are
being prepared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their
costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company
have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns
can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion
of two or more people or by management override of the controls. The design of any system of controls is based in part on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are
subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of
compliance with policies or procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in internal controls</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes to our internal controls over financial
reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended September 30,
2013 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B>PART II &ndash;
OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;1. Legal Proceedings</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;1A. Risk Factors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We describe certain risk factors below. In
addition to the risks, uncertainties and other factors set forth below and elsewhere in this Quarterly Report on Form 10-Q, see,
the &ldquo;Risk Factors&rdquo; section contained in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended
December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Servicing our debt requires a significant amount of cash,
and we may not have sufficient cash flow from our business to pay our debt. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ability to pay interest on, or to make any scheduled payment
of the principal of, the Notes, depends on our future performance, which is subject to economic, financial, competitive and other
factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt
and make necessary expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives,
such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive.
Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. If we raise
additional debt, it would increase our interest expense, leverage and operating and financial costs. In addition, the terms of
the indenture governing the Notes and the agreements governing future indebtedness may restrict us from adopting any of these alternatives.
We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in
a default on our debt obligations. The failure to generate sufficient cash flow or to effect any of these alternatives could significantly
adversely affect the value of the Notes and our ability to pay amounts due under the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our significant level of indebtedness could adversely affect
our business, financial condition and results of operations and prevent us from fulfilling our obligations under the Notes and
our other indebtedness.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The outstanding Notes represent a significant amount of indebtedness
and substantial debt service requirements. We may also incur additional indebtedness to meet future financing needs. Our substantial
indebtedness could have material adverse effects on our business, financial condition and results of operations. For example, it
could:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;make
it more difficult for us to satisfy our financial obligations, including with respect to the Notes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;result
in an event of default if we fail to comply with the financial and other restrictive covenants contained in agreements governing
any future indebtedness, which event of default could result in all of our debt becoming immediately due and payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;increase
our vulnerability to general adverse economic, industry and competitive conditions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reduce
the availability of our cash flow to fund working capital, capital expenditures, acquisitions and other general corporate purposes
because we will be required to dedicate a substantial portion of our cash flow from operations to the payment of principal and
interest on our indebtedness;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;limit
our flexibility in planning for, or reacting to, and increasing our vulnerability to changes in our business, the industry in which
we operate and the general economy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prevent
us from raising funds necessary to purchase Notes surrendered to us by holders upon a fundamental change (as described in the indenture
governing the Notes), which failure would result in an event of default with respect to the Notes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;place
us at a competitive disadvantage compared to our competitors that have less indebtedness or are less highly leveraged and that,
therefore, may be able to take advantage of opportunities that our debt levels or leverage prevent us from exploiting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;limit
our ability to obtain additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each of these factors may have a material and adverse effect
on our business, financial condition and results of operations and our ability to meet our payment obligations under the Notes
and our other indebtedness. Our ability to make payments with respect to the Notes and to satisfy any other debt obligations will
depend on our future operating performance and our ability to generate significant cash flow in the future, which will be affected
by prevailing economic conditions and financial, business, competitive, legislative and regulatory factors as well as other factors
affecting our company and industry, many of which are beyond our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Any conversion of the Notes will dilute the ownership interest
of our existing stockholders, including holders who had previously converted their notes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The conversion of some or all of the Notes will dilute the ownership
interests of our existing stockholders. Any sales in the public market of our common stock issuable upon such conversion could
adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling
by market participants because the conversion of the Notes could depress the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;2. Unregistered
Sales of Equity Securities and Use of Proceeds</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><B>Unregistered Sales of Equity
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">There were
no unregistered sales of equity securities during the three months ended September 30, 2013. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;3. Defaults
Upon Senior Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;4. Mine Safety
Disclosure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">Not applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;5. Other Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">Not applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;6. Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: windowtext 1pt solid; text-align: center"><B>Incorporated by Reference</B></TD>
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 9%; border-bottom: windowtext 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 31%; border-bottom: windowtext 1pt solid; text-align: center"><B>Exhibit Description</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 13%; border-bottom: windowtext 1pt solid; text-align: center"><B>Form</B></TD>
    <TD STYLE="width: 2%; border-top: windowtext 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 9%; border-top: windowtext 1pt solid; border-bottom: windowtext 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>File</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="width: 2%; border-top: windowtext 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; border-top: windowtext 1pt solid; border-bottom: windowtext 1pt solid; text-align: center"><B>Exhibit</B></TD>
    <TD STYLE="width: 2%; border-top: windowtext 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; border-top: windowtext 1pt solid; border-bottom: windowtext 1pt solid; text-align: center"><B>Date</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 9%; border-bottom: windowtext 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Filed</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Herewith</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amended and Restated Articles of Incorporation of the Company</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>S-4</TD>
    <TD>&nbsp;</TD>
    <TD>333-48677</TD>
    <TD>&nbsp;</TD>
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD>March 26, 1998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated June
        9, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>001-33357</TD>
    <TD>&nbsp;</TD>
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD>March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated December
        13, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>001-33357</TD>
    <TD>&nbsp;</TD>
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD>March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated December
        26, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>001-33357</TD>
    <TD>&nbsp;</TD>
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD>March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.5</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated February
        26, 2007</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>001-33357</TD>
    <TD>&nbsp;</TD>
    <TD>3.5</TD>
    <TD>&nbsp;</TD>
    <TD>March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.6</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Bylaws of the Company</TD>
    <TD>&nbsp;</TD>
    <TD>10-K</TD>
    <TD>&nbsp;</TD>
    <TD>001-33357</TD>
    <TD>&nbsp;</TD>
    <TD>3.6</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">February 28, 2013</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.1</TD>
    <TD>&nbsp;</TD>
    <TD>Indenture, dated as of September 18, 2013, between Protalix BioTherapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee.</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8-K</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>4.1</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 18, 2013</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.2</TD>
    <TD>&nbsp;</TD>
    <TD>Form of 4.50% Convertible Note due 2018</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8-K</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>001-33357</TD>
    <TD>&nbsp;</TD>
    <TD>4.2</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 18, 2013</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.1</TD>
    <TD>&nbsp;</TD>
    <TD>Purchase Agreement, dated September 12, 2013 between Protalix BioTherapeutics, Inc. and Citigroup Capital Markets Inc.</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8-K</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>001-33357</TD>
    <TD>&nbsp;</TD>
    <TD>10.1</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 18, 2013</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.1</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.2</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.1</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.2</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.INS</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL INSTANCE FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.SCH</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL SHEMA FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.CAL</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL CALCULATION FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.DEF</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL DEFINITION FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.LAB</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL LABEL FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.PRE</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL PRESENTATION FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 54%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 41%; padding-right: 5.4pt; padding-left: 5.4pt">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Date: November 7, 2013</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">By:</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ David Aviezer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Aviezer, Ph.D.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Date: November 7, 2013</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">By:</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer, Treasurer and Secretary</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial and Accounting Officer)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v359133_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, David Aviezer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt">Date: November 7, 2013</TD></TR>
<TR>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ David Aviezer</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">David Aviezer, Ph.D.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">President and Chief Executive
Officer&nbsp;</P></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>v359133_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt">Date: November 7, 2013</TD></TR>
<TR>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Yossi Maimon</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Chief Financial Officer,
Treasurer&nbsp;</P></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>v359133_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2013 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, David Aviezer, President and Chief Executive Officer of the Company, hereby certify as
of the date hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best
of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt">Date: November 7, 2013</TD></TR>
<TR>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ David Aviezer</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">David Aviezer, Ph.D.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">President and Chief Executive
Officer&nbsp;</P></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>v359133_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2013 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify
as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the
best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt">Date: November 7, 2013</TD></TR>
<TR>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Yossi Maimon</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Vice President and Chief
Financial Officer&nbsp;</P></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>plx-20130930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-07 @ 1:47 PM-->
<xbrl xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:plx="http://www.protalix.com/20130930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20130930.xsd" />
  <dei:AmendmentFlag id="AmendmentFlag.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="CurrentFiscalYearEndDate.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="DocumentFiscalPeriodFocus.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="DocumentFiscalYearFocus.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate id="DocumentPeriodEndDate.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">2013-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType id="DocumentType.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey id="EntityCentralIndexKey.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">0001006281</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="EntityCommonStockSharesOutstanding.3894.0.0.0.0.0.0" contextRef="as-of-2013-11-01.3894.0.0.0.0.0.0.0" unitRef="shares" decimals="0">93561765</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory id="EntityFilerCategory.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="EntityRegistrantName.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">PROTALIX BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:TradingSymbol id="TradingSymbol.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">PLX</dei:TradingSymbol>
  <plx:AmortizationOfDebtIssuanceCosts id="AmortizationOfDebtIssuanceCosts.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">15000</plx:AmortizationOfDebtIssuanceCosts>
  <plx:AmortizationOfDebtIssuanceCosts id="AmortizationOfDebtIssuanceCosts.2551.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:AmortizationOfDebtIssuanceCosts id="AmortizationOfDebtIssuanceCosts.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">15000</plx:AmortizationOfDebtIssuanceCosts>
  <plx:AmortizationOfDebtIssuanceCosts id="AmortizationOfDebtIssuanceCosts.2553.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">73000</plx:CashlessExerciseOfStockOptions>
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">72000</plx:CashlessExerciseOfStockOptions>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.2549.23598.5386.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.23598.5386.0.0.0.0" unitRef="pure" decimals="1">0.4</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.2549.23596.5386.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.23596.5386.0.0.0.0" unitRef="pure" decimals="1">0.6</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:DebtInstrumentConvertibleBaseValueForConversionRate id="DebtInstrumentConvertibleBaseValueForConversionRate.3833.0.0.0.0.0.0" contextRef="from-2013-09-01-to-2013-09-18.3833.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>
  <plx:DebtInstrumentConvertibleConversionShareNumber id="DebtInstrumentConvertibleConversionShareNumber.3834.0.0.0.0.0.0" contextRef="as-of-2013-09-18.3834.0.0.0.0.0.0.0" unitRef="shares" decimals="4">173.6593</plx:DebtInstrumentConvertibleConversionShareNumber>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2689000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2772000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6049000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5655000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2086000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1963000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">187000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">821000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits id="LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.2618.27186.5386.0.0.0.0" contextRef="from-2013-06-16-to-2013-06-18.2618.0.27186.5386.0.0.0.0" unitRef="USD" decimals="-3">12500000</plx:LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits>
  <plx:MilestonePayment id="MilestonePayment.3896.23602.5162.0.0.0.0" contextRef="from-2012-01-01-to-2012-06-30.3896.0.23602.5162.0.0.0.0" unitRef="USD" decimals="-3">25000000</plx:MilestonePayment>
  <plx:NatureOfOperationsPolicyTextBlock id="NatureOfOperationsPolicyTextBlock.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;General&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#39;s proprietary ProCellEx&lt;sup&gt;&amp;reg;&lt;/sup&gt; protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&amp;#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&amp;#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health (the "Brazilian MOH") in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;trade; by Pfizer Inc. (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;), the Company&amp;#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer Agreement&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;). The Company, through Protalix Ltd., markets ELELYSO in Israel.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel, and, subject to the effectiveness of the Brazil Agreement (as defined below), in Brazil. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, and, subject to the effectiveness of the Brazil Agreement, in Brazil, where the Company retained or will retain exclusive marketing rights. &lt;font style="COLOR: black"&gt;In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold&lt;/font&gt;.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the "Brazil Agreement") with Funda&amp;ccedil;&amp;atilde;o Oswaldo Cruz ("Fiocruz"), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO&lt;sup&gt;TM&lt;/sup&gt;. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement becomes effective upon its approval by the Brazilian National Institute of Industrial Property, which is expected to occur very shortly.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.&amp;#39;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Mexico, Chile and Uruguay. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil and Israel. In addition, patients are being treated globally through the Company&amp;#39;s clinical trials and related studies, compassionate use programs and other programs. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&amp;#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;br style="PAGE-BREAK-BEFORE: always" clear="all" /&gt; &lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&amp;#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&amp;#39;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</plx:NatureOfOperationsPolicyTextBlock>
  <plx:NumberOfSubsidiaries id="NumberOfSubsidiaries.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="pure" decimals="0">2</plx:NumberOfSubsidiaries>
  <plx:OtherGainsLosses id="OtherGainsLosses.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2275000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">678000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1075000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1666000</plx:OtherGainsLosses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="ProceedsFromIssuanceOfCommonStockNetOfExpenses.2548.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="ProceedsFromIssuanceOfCommonStockNetOfExpenses.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25328000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <plx:PurchaseAmountToBeSatisfiedToReceiveEntitledRights id="PurchaseAmountToBeSatisfiedToReceiveEntitledRights.2617.27186.5386.0.0.0.0" contextRef="as-of-2013-06-18.2617.0.27186.5386.0.0.0.0" unitRef="USD" decimals="-3">280000000</plx:PurchaseAmountToBeSatisfiedToReceiveEntitledRights>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">17418000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">22062000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5637000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6363000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:SupplementalOfferingAndStockIssuanceCosts id="SupplementalOfferingAndStockIssuanceCosts.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">150000</plx:SupplementalOfferingAndStockIssuanceCosts>
  <plx:SupplementalOfferingAndStockIssuanceCosts id="SupplementalOfferingAndStockIssuanceCosts.2551.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:SupplyCommitmentPerYear id="SupplyCommitmentPerYear.2617.27186.5386.0.0.0.0" contextRef="as-of-2013-06-18.2617.0.27186.5386.0.0.0.0" unitRef="USD" decimals="-3">40000000</plx:SupplyCommitmentPerYear>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12400000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">11051000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3313000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5267000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2053000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1410000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.2548.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2548.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.2551.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.2548.485.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">895000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.2551.485.5169.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">4217000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.2548.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2548.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.2551.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">895000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4217000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1780000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2548.4573.2652.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.4573.2652.0.0.0.0" unitRef="USD" decimals="-3">2198000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2551.4573.2652.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.4573.2652.0.0.0.0" unitRef="USD" decimals="-3">3690000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2552.4573.2652.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.4573.2652.0.0.0.0" unitRef="USD" decimals="-3">609000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2553.4573.2652.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.4573.2652.0.0.0.0" unitRef="USD" decimals="-3">1247000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2548.2476.2652.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.2476.2652.0.0.0.0" unitRef="USD" decimals="-3">1255000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2551.2476.2652.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.2476.2652.0.0.0.0" unitRef="USD" decimals="-3">2155000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2552.2476.2652.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.2476.2652.0.0.0.0" unitRef="USD" decimals="-3">345000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2553.2476.2652.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.2476.2652.0.0.0.0" unitRef="USD" decimals="-3">840000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2548.1254.2652.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2548.0.1254.2652.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2551.1254.2652.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.1254.2652.0.0.0.0" unitRef="USD" decimals="-3">220000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2552.1254.2652.0.0.0.0" xsi:nil="true" contextRef="from-2013-07-01-to-2013-09-30.2552.0.1254.2652.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2553.1254.2652.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.1254.2652.0.0.0.0" unitRef="USD" decimals="-3">220000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCosts id="AmortizationOfFinancingCosts.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">15000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts id="AmortizationOfFinancingCosts.2551.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="shares" decimals="0">7879601</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="shares" decimals="0">7169035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="shares" decimals="0">8817090</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="shares" decimals="0">7508240</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets id="Assets.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">121156000</us-gaap:Assets>
  <us-gaap:Assets id="Assets.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">78727000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="AssetsCurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">105200000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="AssetsCurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">61170000</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="BasisOfAccountingPolicyPolicyTextBlock.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2012, filed by the Company with the Commission. The comparative balance sheet at December 31, 2012 has been derived from the audited financial statements at that date.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;General&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#39;s proprietary ProCellEx&lt;sup&gt;&amp;reg;&lt;/sup&gt; protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&amp;#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&amp;#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health (the "Brazilian MOH") in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;trade; by Pfizer Inc. (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;), the Company&amp;#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer Agreement&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;). The Company, through Protalix Ltd., markets ELELYSO in Israel.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel, and, subject to the effectiveness of the Brazil Agreement (as defined below), in Brazil. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, and, subject to the effectiveness of the Brazil Agreement, in Brazil, where the Company retained or will retain exclusive marketing rights. &lt;font style="COLOR: black"&gt;In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold&lt;/font&gt;.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the "Brazil Agreement") with Funda&amp;ccedil;&amp;atilde;o Oswaldo Cruz ("Fiocruz"), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO&lt;sup&gt;TM&lt;/sup&gt;. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement becomes effective upon its approval by the Brazilian National Institute of Industrial Property, which is expected to occur very shortly.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.&amp;#39;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Mexico, Chile and Uruguay. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil and Israel. In addition, patients are being treated globally through the Company&amp;#39;s clinical trials and related studies, compassionate use programs and other programs. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&amp;#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;br style="PAGE-BREAK-BEFORE: always" clear="all" /&gt; &lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&amp;#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&amp;#39;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2012, filed by the Company with the Commission. The comparative balance sheet at December 31, 2012 has been derived from the audited financial statements at that date.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 36pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 17.85pt"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Net loss per share&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; Basic and diluted loss per share are calculated by dividing the net loss by the weighted average number of shares of the Company&amp;#39;s common stock, par value $0.001 (the "Common Stock"), outstanding for each period.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; Diluted loss per share does not include options, restricted shares and shares issuable upon conversion of the convertible notes issued in September 2013 (see Note 3) in the amount of &lt;font style="COLOR: black"&gt;7,169,035&lt;/font&gt; and 7,879,601 shares of Common Stock for the nine months ended September 30, 2012 and 2013, respectively, and &lt;font style="COLOR: black"&gt;7,508,240&lt;/font&gt; and 8,817,090 shares of Common Stock for the three months ended September 30, 2012 and 2013, respectively, because the effect would be anti-dilutive.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 36pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 17.85pt"&gt;&lt;strong&gt;d.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Convertible notes&lt;/strong&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; &lt;font style="COLOR: black"&gt;The convertible notes are accounted for using the guidance provided set forth in&lt;/font&gt; FASB Accounting Standards Codification &lt;font style="COLOR: black"&gt;(ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely.&lt;/font&gt;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">91397000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">52035000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.2554.0.0.0.0.0.0" contextRef="as-of-2011-12-31.2554.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">27001000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.2555.0.0.0.0.0.0" contextRef="as-of-2012-09-30.2555.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">50216000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">39362000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">23215000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.2549.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.2550.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.2555.0.0.0.0.0.0" contextRef="as-of-2012-09-30.2555.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="shares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.2555.0.0.0.0.0.0" contextRef="as-of-2012-09-30.2555.0.0.0.0.0.0.0" unitRef="shares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:ConvertibleDebtFairValueDisclosures id="ConvertibleDebtFairValueDisclosures.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">71760000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtNoncurrent id="ConvertibleDebtNoncurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">66944000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent id="ConvertibleDebtNoncurrent.2550.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CostOfRevenue id="CostOfRevenue.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3876000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6966000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1587000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2367000</us-gaap:CostOfRevenue>
  <us-gaap:DebtDisclosureTextBlock id="DebtDisclosureTextBlock.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;NOTE 3 - CONVERTIBLE NOTE&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &lt;font style="COLOR: black"&gt;On September 18, 2013, the Company completed a private placement of $69.0 million in aggregate principal amount of 4.50% convertible notes due 2018&lt;/font&gt; (the "Notes")&lt;font style="COLOR: black"&gt;,&lt;/font&gt; including $9.0 million aggregate principal amount of Notes related to the initial purchaser&amp;#39;s over-allotment option, which was exercised in full&lt;font style="COLOR: black"&gt;. In connection with the completion of the offering, the Company entered into an indenture (the "Indenture") with The Bank of New York Mellon Trust Company, N.A., as trustee, governing the Notes. The Notes accrue interest at a rate of 4.50% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2014. The Notes mature on September 15, 2018.&lt;/font&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; The net proceeds from the offering, including net proceeds from the exercise in full by the initial purchaser of its option to purchase an additional $9.0 million in aggregate principal amount of the Notes, were $66.8 million, after deducting the initial purchaser&amp;#39;s discount and commission and the estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; Holders may convert their Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018. The initial conversion rate for the Notes is 173.6593 shares of the Common Stock for each $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.76 per share of the Common Stock. Upon conversion, the Company will deliver a number of shares of Common Stock, per $1,000 principal amount of Notes, equal to the conversion rate. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; Prior to September 19, 2016, the Company may not redeem the Notes, and no sinking fund is provided for the Notes. On or after September 19, 2016, the Company may redeem for cash all or part of the Notes (except for the notes that the Company is then required to repurchase in connection with a fundamental change, as defined below) if the last reported sale price of the Common Stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on the trading day immediately preceding the date on which the Company provides the notice of redemption. The redemption price will equal the sum of (i)&amp;nbsp;100% of the principal amount of the Notes being redeemed, plus (ii)&amp;nbsp;accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date, plus (iii) the sum of the present values of each of the remaining scheduled payments of interest that would have been made on the Notes being redeemed had such Notes remained outstanding from the redemption date to the maturity date.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; The following table sets forth total interest expense recognized related to the Notes (in thousands):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6"&gt;Nine Months Ended&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6"&gt;Three Months Ended&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;September&amp;nbsp;30,&lt;br /&gt; 2013&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt; &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt; September&amp;nbsp;30,&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;2012&lt;/p&gt; &lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;September&amp;nbsp;30,&lt;br /&gt; 2013&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;September&amp;nbsp;30,&lt;br /&gt; 2012&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 10pt; WIDTH: 56%; TEXT-INDENT: -10pt"&gt; Contractual interest expense&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;104&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;104&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 10pt; TEXT-INDENT: -10pt"&gt; Amortization of debt issuance costs&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 15&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 15&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 10pt; TEXT-INDENT: -10pt"&gt; Total&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 119&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 119&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="DebtInstrumentConvertibleConversionPrice1.3834.0.0.0.0.0.0" contextRef="as-of-2013-09-18.3834.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">5.76</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentFaceAmount id="DebtInstrumentFaceAmount.3834.0.0.0.0.0.0" contextRef="as-of-2013-09-18.3834.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">69000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="DebtInstrumentInterestRateStatedPercentage.3834.0.0.0.0.0.0" contextRef="as-of-2013-09-18.3834.0.0.0.0.0.0.0" unitRef="pure" decimals="3">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentMaturityDate id="DebtInstrumentMaturityDate.3833.0.0.0.0.0.0" contextRef="from-2013-09-01-to-2013-09-18.3833.0.0.0.0.0.0.0">2018-09-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtPolicyTextBlock id="DebtPolicyTextBlock.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt;&lt;strong&gt;Convertible notes&lt;/strong&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; &lt;font style="COLOR: black"&gt;The convertible notes are accounted for using the guidance provided set forth in&lt;/font&gt; FASB Accounting Standards Codification &lt;font style="COLOR: black"&gt;(ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely.&lt;/font&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; &amp;nbsp;&amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:DeferredCosts id="DeferredCosts.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">149000</us-gaap:DeferredCosts>
  <us-gaap:DeferredCosts id="DeferredCosts.2550.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">9513000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">9437000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">43419000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">48888000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1467000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1247000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.18</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock id="EarningsPerSharePolicyTextBlock.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt;&lt;strong&gt;Net loss per share&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; Basic and diluted loss per share are calculated by dividing the net loss by the weighted average number of shares of the Company&amp;#39;s common stock, par value $0.001 (the "Common Stock"), outstanding for each period.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; Diluted loss per share does not include options, restricted shares and shares issuable upon conversion of the convertible notes issued in September 2013 (see Note 3) in the amount of &lt;font style="COLOR: black"&gt;7,169,035&lt;/font&gt; and 7,879,601 shares of Common Stock for the nine months ended September 30, 2012 and 2013, respectively, and &lt;font style="COLOR: black"&gt;7,508,240&lt;/font&gt; and 8,817,090 shares of Common Stock for the three months ended September 30, 2012 and 2013, respectively, because the effect would be anti-dilutive.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">144000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-113000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:FairValueDisclosuresTextBlock id="FairValueDisclosuresTextBlock.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;NOTE 5 - FAIR VALUE MEASUREMENT&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; The fair value of the convertible notes as of September 30, 2013 is $71,760,000. The fair value was estimated based on quoted market prices.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">140000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-14000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6065000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7353000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1780000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2220000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GrossProfit id="GrossProfit.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6515000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">27410000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1772000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3023000</us-gaap:GrossProfit>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5413000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">369000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">798000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2099000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5393000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-4981000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3538000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1779000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:InterestExpense id="InterestExpense.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">119000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="InterestExpense.2551.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InterestExpense id="InterestExpense.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">119000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="InterestExpense.2553.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InterestExpenseDebtExcludingAmortization id="InterestExpenseDebtExcludingAmortization.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">104000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="InterestExpenseDebtExcludingAmortization.2551.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InterestExpenseDebtExcludingAmortization id="InterestExpenseDebtExcludingAmortization.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">104000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="InterestExpenseDebtExcludingAmortization.2553.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock id="InterestIncomeAndInterestExpenseDisclosureTableTextBlock.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; The following table sets forth total interest expense recognized related to the Notes (in thousands):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6"&gt;Nine Months Ended&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6"&gt;Three Months Ended&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;September&amp;nbsp;30,&lt;br /&gt; 2013&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt; &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt; September&amp;nbsp;30,&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;2012&lt;/p&gt; &lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;September&amp;nbsp;30,&lt;br /&gt; 2013&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;September&amp;nbsp;30,&lt;br /&gt; 2012&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 10pt; WIDTH: 56%; TEXT-INDENT: -10pt"&gt; Contractual interest expense&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;104&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;104&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 10pt; TEXT-INDENT: -10pt"&gt; Amortization of debt issuance costs&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 15&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 15&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 10pt; TEXT-INDENT: -10pt"&gt; Total&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 119&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 119&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
  <us-gaap:InventoryDisclosureTextBlock id="InventoryDisclosureTextBlock.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;NOTE 2 - INVENTORIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; Inventory at September 30, 2013 and December&amp;nbsp;31, 2012 consisted of the following:&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; WIDTH: 80%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;September 30,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 78%"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;2,574&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;2,118&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;140&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;192&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 4,863&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,729&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7,577&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,039&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &lt;font style="COLOR: black"&gt;Prior to the FDA&amp;#39;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses&lt;/font&gt;. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes all manufacturing costs associated with taliglucerase alfa.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoods id="InventoryFinishedGoods.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4863000</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryFinishedGoods id="InventoryFinishedGoods.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1729000</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryNet id="InventoryNet.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7577000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="InventoryNet.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4039000</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterials id="InventoryRawMaterials.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2574000</us-gaap:InventoryRawMaterials>
  <us-gaap:InventoryRawMaterials id="InventoryRawMaterials.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2118000</us-gaap:InventoryRawMaterials>
  <us-gaap:InventoryWorkInProcess id="InventoryWorkInProcess.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">140000</us-gaap:InventoryWorkInProcess>
  <us-gaap:InventoryWorkInProcess id="InventoryWorkInProcess.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">192000</us-gaap:InventoryWorkInProcess>
  <us-gaap:Liabilities id="Liabilities.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">137862000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Liabilities.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">82084000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">121156000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">78727000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25226000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25755000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">112636000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">56329000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.2549.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5425000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">66960000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26424000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1831000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1910000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-25911000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1186000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-16905000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1741000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5747000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5479000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2548.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2548.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2551.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2548.485.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2548.0.485.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2551.485.5169.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.485.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2548.4652.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-16905000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2551.4652.5169.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-1741000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense id="NonoperatingIncomeExpense.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">63000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="NonoperatingIncomeExpense.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">264000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="NonoperatingIncomeExpense.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-102000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="NonoperatingIncomeExpense.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">81000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-16968000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2005000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5645000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5560000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4173000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3686000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">121000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">93000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1668000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1817000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit id="PaymentsToAcquireRestrictedCertificatesOfDeposit.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">42000</us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit>
  <us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit id="PaymentsToAcquireRestrictedCertificatesOfDeposit.2551.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2273000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2016000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions id="PensionAndOtherPostretirementBenefitContributions.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions id="PensionAndOtherPostretirementBenefitContributions.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">24000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">145000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">218000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.3895.0.0.0.0.0.0" contextRef="from-2009-09-01-to-2009-09-30.3895.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">60000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.3897.23603.5162.0.0.0.0" contextRef="from-2009-09-01-to-2009-09-30.3897.0.23603.5162.0.0.0.0" unitRef="USD" decimals="-3">5000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromConvertibleDebt id="ProceedsFromConvertibleDebt.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">66930000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt id="ProceedsFromConvertibleDebt.2551.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromConvertibleDebt id="ProceedsFromConvertibleDebt.3833.0.0.0.0.0.0" contextRef="from-2013-09-01-to-2013-09-18.3833.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">66800000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOfDebt id="ProceedsFromIssuanceOfDebt.3833.0.0.0.0.0.0" contextRef="from-2013-09-01-to-2013-09-18.3833.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">9000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">30000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1096000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.2548.23589.3709.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.23589.3709.0.0.0.0" unitRef="USD" decimals="-3">103000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">14340000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">16310000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">23467000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">27717000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7723000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">8326000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:Revenues id="Revenues.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">8116000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">33698000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2284000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3724000</us-gaap:Revenues>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="ScheduleOfInventoryCurrentTableTextBlock.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; Inventory at September 30, 2013 and December&amp;nbsp;31, 2012 consisted of the following:&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; WIDTH: 80%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;September 30,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 78%"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;2,574&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 8%"&gt;2,118&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;140&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;192&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 4,863&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,729&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7,577&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,039&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3453000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6065000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharesOutstanding id="SharesOutstanding.2549.1087.5169.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">93552910</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.2550.1087.5169.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">93489809</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.2554.1087.5169.0.0.0.0" contextRef="as-of-2011-12-31.2554.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">85630157</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.2555.1087.5169.0.0.0.0" contextRef="as-of-2012-09-30.2555.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">93461341</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2549.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-16706000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2550.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-3357000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2554.0.0.0.0.0.0" contextRef="as-of-2011-12-31.2554.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-26077000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2555.0.0.0.0.0.0" contextRef="as-of-2012-09-30.2555.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4772000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2549.1087.5169.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2550.1087.5169.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">93000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2554.1087.5169.0.0.0.0" contextRef="as-of-2011-12-31.2554.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">86000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2555.1087.5169.0.0.0.0" contextRef="as-of-2012-09-30.2555.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">93000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2549.485.5169.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">183700000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2550.485.5169.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">180145000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2554.485.5169.0.0.0.0" contextRef="as-of-2011-12-31.2554.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">145814000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2555.485.5169.0.0.0.0" contextRef="as-of-2012-09-30.2555.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">178397000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2549.4652.5169.0.0.0.0" contextRef="as-of-2013-09-30.2549.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-200500000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2550.4652.5169.0.0.0.0" contextRef="as-of-2012-12-31.2550.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-183595000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2554.4652.5169.0.0.0.0" contextRef="as-of-2011-12-31.2554.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-171977000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2555.4652.5169.0.0.0.0" contextRef="as-of-2012-09-30.2555.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-173718000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="StockholdersEquityNoteDisclosureTextBlock.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;NOTE 4 - STOCK TRANSACTIONS&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"&gt; &lt;font style="COLOR: black"&gt;During the nine months ended September 30, 2013, the Company issued a total of approximately&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt"&gt;64,768&lt;/font&gt; &lt;font style="COLOR: black"&gt;shares of Common Stock in connection with the exercise of a total of approximately&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt"&gt;64,768&lt;/font&gt; &lt;font style="COLOR: black"&gt;options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $103,000.&lt;/font&gt;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="StockIssuedDuringPeriodSharesIssuedForServices.2548.1087.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">-1667</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="StockIssuedDuringPeriodSharesIssuedForServices.2551.1087.5169.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">1500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.2551.1087.5169.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="StockIssuedDuringPeriodSharesShareBasedCompensation.2548.23589.3709.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.23589.3709.0.0.0.0" unitRef="shares" decimals="0">64768</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.2548.23589.3709.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.23589.3709.0.0.0.0" unitRef="shares" decimals="0">64768</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.2548.1087.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">64768</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.2551.1087.5169.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">1156184</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.2548.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2548.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.2551.1087.5169.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.2548.485.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">2558000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.2551.485.5169.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">1847000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.2548.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2548.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.2551.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2558000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1848000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.2551.1087.5169.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.2551.485.5169.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">25383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.2551.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25388000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.2548.1087.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.2551.1087.5169.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.2548.485.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">102000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.2551.485.5169.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">1136000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.2548.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2548.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.2551.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2551.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">103000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1137000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.2548.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0" unitRef="shares" decimals="0">92307170</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.2551.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0" unitRef="shares" decimals="0">90491421</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.2552.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0" unitRef="shares" decimals="0">92433502</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.2553.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0" unitRef="shares" decimals="0">91929445</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD_per_share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="from-2013-09-01-to-2013-09-18.3833.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2013-09-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-07-01-to-2013-09-30.2552.0.4573.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-07-01-to-2013-09-30.2552.0.2476.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-07-01-to-2013-09-30.2552.0.1254.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-07-01-to-2013-09-30.2552.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-06-16-to-2013-06-18.2618.0.27186.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProtalixLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-06-16</xbrli:startDate>
      <xbrli:endDate>2013-06-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2548.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2548.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2548.0.4573.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2548.0.2476.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2548.0.23589.3709.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2548.0.1254.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2548.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2548.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.2553.0.4573.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.2553.0.2476.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.2553.0.1254.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.2553.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2551.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2551.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2551.0.4573.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2551.0.2476.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2551.0.1254.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2551.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2551.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-06-30.3896.0.23602.5162.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2009-09-01-to-2009-09-30.3897.0.23603.5162.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-09-01</xbrli:startDate>
      <xbrli:endDate>2009-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2009-09-01-to-2009-09-30.3895.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-09-01</xbrli:startDate>
      <xbrli:endDate>2009-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-11-01.3894.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-11-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2549.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2549.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2549.0.23598.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2549.0.23596.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:PfizerIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2549.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2549.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-18.3834.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-06-18.2617.0.27186.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProtalixLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2550.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2550.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2550.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2550.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.2555.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.2555.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.2555.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.2555.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.2554.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.2554.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.2554.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.2554.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>plx-20130930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-07 @ 1:47 PM-->
<xsd:schema targetNamespace="http://www.protalix.com/20130930" elementFormDefault="qualified" xmlns:plx="http://www.protalix.com/20130930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="plx-20130930_cal.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="plx-20130930_def.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="plx-20130930_lab.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="plx-20130930_pre.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" id="plx-ccbs" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" id="plx-ccsocf" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" id="plx-ccsocisecd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" id="plx-ccsocisecdp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY)  (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" id="plx-ccsoo" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" id="plx-ccsoop" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ConvertibleNote" id="plx-cn" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>103 - Disclosure - CONVERTIBLE NOTE</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ConvertibleNoteNarrativeDetails" id="plx-cnnd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40301 - Disclosure - CONVERTIBLE NOTE (Narrative) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ConvertibleNoteScheduleOfInterestExpenseRecognizedDetails" id="plx-cnsoierd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40302 - Disclosure - CONVERTIBLE NOTE (Schedule of Interest Expense Recognized) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ConvertibleNoteTables" id="plx-cnt" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>303 - Disclosure - CONVERTIBLE NOTE (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" id="plx-daei" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurement" id="plx-fvm" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>105 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurementDetails" id="plx-fvmd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40501 - Disclosure - FAIR VALUE MEASUREMENT (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/Inventories" id="plx-i" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>102 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" id="plx-isoicd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/InventoriesTables" id="plx-it" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>302 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" id="plx-sap" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" id="plx-sapd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" id="plx-sapp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StockTransactions" id="plx-st" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>104 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StockTransactionsDetails" id="plx-std" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40401 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:element name="AmortizationOfDebtIssuanceCosts" id="plx_AmortizationOfDebtIssuanceCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="CashlessExerciseOfStockOptions" id="plx_CashlessExerciseOfStockOptions" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="CollaborativeArrangementProfitSharePercentage" id="plx_CollaborativeArrangementProfitSharePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="DebtInstrumentConvertibleBaseValueForConversionRate" id="plx_DebtInstrumentConvertibleBaseValueForConversionRate" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="DebtInstrumentConvertibleConversionShareNumber" id="plx_DebtInstrumentConvertibleConversionShareNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element name="DepreciationAmortizationAndAssetImpairment" id="plx_DepreciationAmortizationAndAssetImpairment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="EmployeeAndNonemployeeMember" id="plx_EmployeeAndNonemployeeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="EmployeeMember" id="plx_EmployeeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="GrantsAndReimbursementsReceivedOrReceivable" id="plx_GrantsAndReimbursementsReceivedOrReceivable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" id="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="MilestonePayment" id="plx_MilestonePayment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" id="plx_NatureOfOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="NumberOfSubsidiaries" id="plx_NumberOfSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element name="OtherGainsLosses" id="plx_OtherGainsLosses" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="PfizerIncorporationMember" id="plx_PfizerIncorporationMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockNetOfExpenses" id="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" id="plx_ProtalixBioTherapeuticsIncorporationMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ProtalixLtdMember" id="plx_ProtalixLtdMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="PurchaseAmountToBeSatisfiedToReceiveEntitledRights" id="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ResearchDevelopmentAndEngineeringExpenseNet" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ScenarioFourMember" id="plx_ScenarioFourMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScenarioOneMember" id="plx_ScenarioOneMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScenarioThreeMember" id="plx_ScenarioThreeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScenarioTwoMember" id="plx_ScenarioTwoMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" id="plx_SignificantAccountingPoliciesLineItems" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="SignificantAccountingPoliciesTable" id="plx_SignificantAccountingPoliciesTable" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element name="StockOptionsAndRestrictedSharesMember" id="plx_StockOptionsAndRestrictedSharesMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="SupplementalOfferingAndStockIssuanceCosts" id="plx_SupplementalOfferingAndStockIssuanceCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="SupplyCommitmentPerYear" id="plx_SupplyCommitmentPerYear" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>plx-20130930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-07 @ 1:47 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20130930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20130930.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20130930.xsd#plx-ccsocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:href="plx-20130930.xsd#plx-ccsocisecd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:href="plx-20130930.xsd#plx-ccsocisecdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20130930.xsd#plx-ccsoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20130930.xsd#plx-ccsoop" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20130930.xsd#plx-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20130930.xsd#plx-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:href="plx-20130930.xsd#plx-isoicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20130930.xsd#plx-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20130930.xsd#plx-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20130930.xsd#plx-sapd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20130930.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20130930.xsd#plx-st" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20130930.xsd#plx-std" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNote" xlink:href="plx-20130930.xsd#plx-cn" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/FairValueMeasurement" xlink:href="plx-20130930.xsd#plx-fvm" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/FairValueMeasurementDetails" xlink:href="plx-20130930.xsd#plx-fvmd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNoteTables" xlink:href="plx-20130930.xsd#plx-cnt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNoteNarrativeDetails" xlink:href="plx-20130930.xsd#plx-cnnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNoteScheduleOfInterestExpenseRecognizedDetails" xlink:href="plx-20130930.xsd#plx-cnsoierd" xlink:type="simple" />
  <link:calculationLink xlink:title="002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_Assets.6057.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:loc xlink:label="loc_AssetsCurrent.6084.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_AssetsCurrent.6084.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_PropertyPlantAndEquipmentNet.15211.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCosts.7792.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCosts" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_DeferredCosts.7792.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_AccountsReceivableNetCurrent.5665.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13867.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_OtherReceivablesNetCurrent.13867.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryNet.11816.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_InventoryNet.11816.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5660.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_AccountsPayableTradeCurrent.5660.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5690.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_AccountsPayableOtherCurrent.5690.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_DeferredRevenueCurrent.7937.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:to="loc_StockholdersEquity.17302.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Liabilities.12166.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:to="loc_Liabilities.12166.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:to="loc_CommitmentsAndContingencies.7121.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.12165.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.12165.14.6" xlink:to="loc_DeferredRevenueNoncurrent.7950.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12757.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.12165.14.6" xlink:to="loc_LongTermDebtNoncurrent.12757.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.12165.14.6" xlink:to="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ConvertibleDebtNoncurrent.7358.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.12165.14.6" xlink:to="loc_ConvertibleDebtNoncurrent.7358.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_Liabilities.12166.14.6" xlink:to="loc_LiabilitiesNoncurrent.12165.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_Liabilities.12166.14.6" xlink:to="loc_LiabilitiesCurrent.12126.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.14.6" order="1.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsToAcquireRestrictedCertificatesOfDeposit.14394.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" xlink:to="loc_PaymentsToAcquireRestrictedCertificatesOfDeposit.14394.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.23597.14.6" xlink:href="plx-20130930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" xlink:to="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.23597.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" xlink:to="loc_ProceedsFromStockOptionsExercised.15050.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromConvertibleDebt.14924.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" xlink:to="loc_ProceedsFromConvertibleDebt.14924.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_ShareBasedCompensation.16900.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.23586.14.6" xlink:href="plx-20130930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.23586.14.6" order="7.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.14426.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_PensionAndOtherPostretirementBenefitExpense.14426.14.6" order="8.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.11237.14.6" order="9.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.11367.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_IncreaseDecreaseInInventories.11367.14.6" order="10.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.14.6" order="11.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.14421.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_PensionAndOtherPostretirementBenefitContributions.14421.14.6" order="4.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.11341.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_NetIncomeLoss.13265.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AmortizationOfFinancingCosts.5974.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_AmortizationOfFinancingCosts.5974.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_GrossProfit.10776.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:loc xlink:label="loc_Revenues.16160.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10776.14.6" xlink:to="loc_Revenues.16160.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherGainsLosses.23595.14.6" xlink:href="plx-20130930.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10776.14.6" xlink:to="loc_OtherGainsLosses.23595.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CostOfRevenue.7431.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10776.14.6" xlink:to="loc_CostOfRevenue.7431.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.13265.14.6" xlink:to="loc_OperatingIncomeLoss.13592.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NonoperatingIncomeExpense.13395.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.13265.14.6" xlink:to="loc_NonoperatingIncomeExpense.13395.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13592.14.6" xlink:to="loc_GrossProfit.10776.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.14.6" xlink:href="plx-20130930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13592.14.6" xlink:to="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10699.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13592.14.6" xlink:to="loc_GeneralAndAdministrativeExpense.10699.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.14.6" xlink:to="loc_ResearchAndDevelopmentExpense.15880.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.14.6" xlink:href="plx-20130930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.14.6" xlink:to="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)" xlink:role="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryNet.11816.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryRawMaterials.11886.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11816.14.6" xlink:to="loc_InventoryRawMaterials.11886.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryWorkInProcess.11878.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11816.14.6" xlink:to="loc_InventoryWorkInProcess.11878.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryFinishedGoods.11817.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11816.14.6" xlink:to="loc_InventoryFinishedGoods.11817.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="40302 - Disclosure - CONVERTIBLE NOTE (Schedule of Interest Expense Recognized) (Details)" xlink:role="http://www.protalix.com/role/ConvertibleNoteScheduleOfInterestExpenseRecognizedDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InterestExpense.11654.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" />
    <link:loc xlink:label="loc_AmortizationOfDebtIssuanceCosts.32159.14.6" xlink:href="plx-20130930.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InterestExpense.11654.14.6" xlink:to="loc_AmortizationOfDebtIssuanceCosts.32159.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InterestExpenseDebtExcludingAmortization.11648.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InterestExpense.11654.14.6" xlink:to="loc_InterestExpenseDebtExcludingAmortization.11648.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>plx-20130930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-07 @ 1:47 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20130930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20130930.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20130930.xsd#plx-ccsocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:href="plx-20130930.xsd#plx-ccsocisecd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:href="plx-20130930.xsd#plx-ccsocisecdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20130930.xsd#plx-ccsoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20130930.xsd#plx-ccsoop" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20130930.xsd#plx-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20130930.xsd#plx-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:href="plx-20130930.xsd#plx-isoicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20130930.xsd#plx-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20130930.xsd#plx-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20130930.xsd#plx-sapd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20130930.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20130930.xsd#plx-st" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20130930.xsd#plx-std" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNote" xlink:href="plx-20130930.xsd#plx-cn" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/FairValueMeasurement" xlink:href="plx-20130930.xsd#plx-fvm" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/FairValueMeasurementDetails" xlink:href="plx-20130930.xsd#plx-fvmd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNoteTables" xlink:href="plx-20130930.xsd#plx-cnt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNoteNarrativeDetails" xlink:href="plx-20130930.xsd#plx-cnnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNoteScheduleOfInterestExpenseRecognizedDetails" xlink:href="plx-20130930.xsd#plx-cnsoierd" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:definitionLink xlink:title="005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:type="extended">
    <link:loc xlink:label="loc_EquityComponentDomain.1873.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockMember.1087.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1873.7.6" xlink:to="loc_CommonStockMember.1087.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.485.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1873.7.6" xlink:to="loc_AdditionalPaidInCapitalMember.485.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RetainedEarningsMember.4652.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1873.7.6" xlink:to="loc_RetainedEarningsMember.4652.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementTable.5163.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.5169.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementTable.5163.5.6" xlink:to="loc_StatementEquityComponentsAxis.5169.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.5164.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementTable.5163.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.9.6" xlink:to="loc_StatementTable.5163.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.5164.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockholdersEquity.17302.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharesOutstanding.17056.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_SharesOutstanding.17056.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.17285.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.17271.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5854.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5854.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_NetIncomeLoss.13265.7.6" order="13.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.17243.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockIssuedDuringPeriodValueIssuedForServices.17243.7.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.17220.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesIssuedForServices.17220.7.6" order="12.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.5169.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.1873.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.5169.6.6" xlink:to="loc_EquityComponentDomain.1873.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.5169.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.1873.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.5169.8.6" xlink:to="loc_EquityComponentDomain.1873.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.9.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.7.6" xlink:to="loc_AllocatedShareBasedCompensationExpense.5919.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationAxis.2652.8.6" xlink:to="loc_IncomeStatementLocationDomain.2671.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationAxis.2652.6.6" xlink:to="loc_IncomeStatementLocationDomain.2671.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4573.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationDomain.2671.7.6" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4573.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2476.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationDomain.2671.7.6" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2476.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CostOfSalesMember.1254.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationDomain.2671.7.6" xlink:to="loc_CostOfSalesMember.1254.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.5.6" xlink:to="loc_IncomeStatementLocationAxis.2652.5.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.23598.7.6" xlink:href="plx-20130930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.23598.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.23596.7.6" xlink:href="plx-20130930.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:to="loc_PfizerIncorporationMember.23596.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProtalixLtdMember.27186.7.6" xlink:href="plx-20130930.xsd#plx_ProtalixLtdMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:to="loc_ProtalixLtdMember.27186.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.6.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.582.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.8.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.582.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.23606.7.6" xlink:href="plx-20130930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.582.7.6" xlink:to="loc_StockOptionsAndRestrictedSharesMember.23606.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.23603.7.6" xlink:href="plx-20130930.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:to="loc_ScenarioTwoMember.23603.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioOneMember.23601.7.6" xlink:href="plx-20130930.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:to="loc_ScenarioOneMember.23601.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioThreeMember.23602.7.6" xlink:href="plx-20130930.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:to="loc_ScenarioThreeMember.23602.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioFourMember.23600.7.6" xlink:href="plx-20130930.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:to="loc_ScenarioFourMember.23600.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.5162.6.6" xlink:to="loc_ScenarioUnspecifiedDomain.4760.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.5162.8.6" xlink:to="loc_ScenarioUnspecifiedDomain.4760.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TypeOfArrangementAxis.5386.8.6" xlink:to="loc_ArrangementsAndNonarrangementTransactionsMember.373.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TypeOfArrangementAxis.5386.6.6" xlink:to="loc_ArrangementsAndNonarrangementTransactionsMember.373.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.23604.9.6" xlink:href="plx-20130930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.23605.9.6" xlink:href="plx-20130930.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.9.6" xlink:to="loc_SignificantAccountingPoliciesTable.23605.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:href="plx-20130930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NumberOfSubsidiaries.23594.7.6" xlink:href="plx-20130930.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_NumberOfSubsidiaries.23594.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14867.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_ProceedsFromCollaborators.14867.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MilestonePayment.23592.7.6" xlink:href="plx-20130930.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_MilestonePayment.23592.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.23585.7.6" xlink:href="plx-20130930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.23585.7.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_CommonStockParOrStatedValuePerShare.7131.7.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.7.6" order="12.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplyCommitmentPerYear.27185.7.6" xlink:href="plx-20130930.xsd#plx_SupplyCommitmentPerYear" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_SupplyCommitmentPerYear.27185.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionAmountsOfTransaction.15770.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_RelatedPartyTransactionAmountsOfTransaction.15770.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.7.6" xlink:href="plx-20130930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.7.6" xlink:href="plx-20130930.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.23605.5.6" xlink:href="plx-20130930.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.5.6" xlink:to="loc_StatementScenarioAxis.5162.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.5.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.5.6" xlink:to="loc_TypeOfArrangementAxis.5386.5.6" order="3.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40401 - Disclosure - STOCK TRANSACTIONS (Details)" xlink:role="http://www.protalix.com/role/StockTransactionsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ClassOfStockLineItems.1018.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4895.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.1018.9.6" xlink:to="loc_ScheduleOfStockByClassTable.4895.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ClassOfStockLineItems.1018.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.1018.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.1018.7.6" xlink:to="loc_ProceedsFromStockOptionsExercised.15050.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.1018.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.7.6" order="7.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3709.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3709.6.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3712.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3709.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3709.8.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3712.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.23588.7.6" xlink:href="plx-20130930.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3712.7.6" xlink:to="loc_EmployeeAndNonemployeeMember.23588.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeMember.23589.7.6" xlink:href="plx-20130930.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3712.7.6" xlink:to="loc_EmployeeMember.23589.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4895.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3709.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfStockByClassTable.4895.5.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3709.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>plx-20130930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-07 @ 1:47 PM-->
<link:linkbase xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/changeLabel2012" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#changeLabel2012" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentDocumentation" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#fragmentDocumentation" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentLabel" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#fragmentLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/changeLabel2013" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#changeLabel2013" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedDateLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedDateLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.11.7" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145.205573" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145.205573" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145.205573">Accounts payable and accruals:</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.11.6" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364.205572" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364.205572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364.205572">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5690.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.5690.11.7" xlink:to="lab_AccountsPayableOtherCurrent.138148.205575" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.138148.205575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.138148.205575">Other</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5690.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.5690.11.6" xlink:to="lab_AccountsPayableOtherCurrent.376.205574" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.376.205574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.376.205574">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5660.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableTradeCurrent.5660.11.7" xlink:to="lab_AccountsPayableTradeCurrent.138147.205577" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableTradeCurrent.138147.205577" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableTradeCurrent.138147.205577">Trade</link:label>
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5660.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableTradeCurrent.5660.11.6" xlink:to="lab_AccountsPayableTradeCurrent.402.205576" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableTradeCurrent.402.205576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableTradeCurrent.402.205576">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5665.11.7" xlink:to="lab_AccountsReceivableNetCurrent.138137.205579" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.138137.205579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.138137.205579">Accounts receivable- Trade</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5665.11.6" xlink:to="lab_AccountsReceivableNetCurrent.390.205578" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.390.205578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.390.205578">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:label="loc_Assets.6057.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.6057.11.6" xlink:to="lab_Assets.1134.205580" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.1134.205580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Assets.1134.205580">Assets</link:label>
    <link:loc xlink:label="loc_Assets.6057.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.6057.11.9" xlink:to="lab_Assets.138141.205581" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.138141.205581" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Assets.138141.205581">Total assets</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.620.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.620.11.6" xlink:to="lab_AssetsAbstract.1105.205582" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.1105.205582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.1105.205582">Assets [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.620.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.620.11.7" xlink:to="lab_AssetsAbstract.138133.205583" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.138133.205583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.138133.205583">ASSETS</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.6084.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.6084.11.6" xlink:to="lab_AssetsCurrent.1123.205584" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.1123.205584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.1123.205584">Assets, Current</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.6084.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.6084.11.9" xlink:to="lab_AssetsCurrent.138142.205585" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.138142.205585" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.138142.205585">Total current assets</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.616.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.616.11.6" xlink:to="lab_AssetsCurrentAbstract.1099.205586" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.1099.205586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.1099.205586">Assets, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.616.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.616.11.7" xlink:to="lab_AssetsCurrentAbstract.138132.205587" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.138132.205587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.138132.205587">CURRENT ASSETS:</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.7" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.138135.205589" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.138135.205589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.138135.205589">Cash and cash equivalents</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.6" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.2187.205588" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.2187.205588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.2187.205588">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.7121.11.7" xlink:to="lab_CommitmentsAndContingencies.138162.205591" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.138162.205591" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.138162.205591">COMMITMENTS</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.7121.11.6" xlink:to="lab_CommitmentsAndContingencies.2677.205590" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.2677.205590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.2677.205590">Commitments and Contingencies</link:label>
    <link:loc xlink:label="loc_ConvertibleDebtNoncurrent.7358.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConvertibleDebtNoncurrent.7358.11.6" xlink:to="lab_ConvertibleDebtNoncurrent.3221" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConvertibleDebtNoncurrent.3221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ConvertibleDebtNoncurrent.3221">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:label="loc_ConvertibleDebtNoncurrent.7358.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConvertibleDebtNoncurrent.7358.11.7" xlink:to="lab_ConvertibleDebtNoncurrent.150607.275819" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConvertibleDebtNoncurrent.150607.275819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ConvertibleDebtNoncurrent.150607.275819">Convertible notes</link:label>
    <link:loc xlink:label="loc_DeferredCosts.7792.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCosts.7792.11.6" xlink:to="lab_DeferredCosts.3861" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCosts.3861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCosts.3861">Deferred Costs, Noncurrent</link:label>
    <link:loc xlink:label="loc_DeferredCosts.7792.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCosts.7792.11.7" xlink:to="lab_DeferredCosts.141685.275818" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCosts.141685.275818" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCosts.141685.275818">DEFERRED CHARGES</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7937.11.7" xlink:to="lab_DeferredRevenueCurrent.138149.205593" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.138149.205593" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.138149.205593">Deferred revenues</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7937.11.6" xlink:to="lab_DeferredRevenueCurrent.3980.205592" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.3980.205592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.3980.205592">Deferred Revenue, Current</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7950.11.7" xlink:to="lab_DeferredRevenueNoncurrent.138153.205595" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.138153.205595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.138153.205595">Deferred revenues</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7950.11.6" xlink:to="lab_DeferredRevenueNoncurrent.3963.205594" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.3963.205594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.3963.205594">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.11.7" xlink:to="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140.205597" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140.205597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140.205597">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.11.6" xlink:to="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362.205596" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362.205596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362.205596">Defined Benefit Plan, Assets for Plan Benefits, Noncurrent</link:label>
    <link:loc xlink:label="loc_InventoryNet.11816.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11816.11.7" xlink:to="lab_InventoryNet.138139.205599" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.138139.205599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.138139.205599">Inventories</link:label>
    <link:loc xlink:label="loc_InventoryNet.11816.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11816.11.6" xlink:to="lab_InventoryNet.9655.205598" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.9655.205598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.9655.205598">Inventory, Net</link:label>
    <link:loc xlink:label="loc_Liabilities.12166.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.12166.11.6" xlink:to="lab_Liabilities.10148.205600" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.10148.205600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.10148.205600">Liabilities</link:label>
    <link:loc xlink:label="loc_Liabilities.12166.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.12166.11.9" xlink:to="lab_Liabilities.138159.205601" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.138159.205601" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.138159.205601">Total liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquity.10196.205602" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.10196.205602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.10196.205602">Liabilities and Equity</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.11.9" xlink:to="lab_LiabilitiesAndStockholdersEquity.138166.205603" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.138166.205603" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.138166.205603">Total liabilities net of capital deficiency</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.10173.205604" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.10173.205604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.10173.205604">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.7" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.138143.205605" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.138143.205605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.138143.205605">LIABILITIES NET OF CAPITAL DEFICIENCY</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.12126.11.6" xlink:to="lab_LiabilitiesCurrent.10094.205606" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.10094.205606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.10094.205606">Liabilities, Current</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.12126.11.9" xlink:to="lab_LiabilitiesCurrent.138151.205607" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.138151.205607" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.138151.205607">Total current liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.11.6" xlink:to="lab_LiabilitiesCurrentAbstract.10147.205608" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.10147.205608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.10147.205608">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.11.7" xlink:to="lab_LiabilitiesCurrentAbstract.138144.205609" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.138144.205609" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.138144.205609">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.12165.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.12165.11.6" xlink:to="lab_LiabilitiesNoncurrent.10143.205610" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.10143.205610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.10143.205610">Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.12165.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.12165.11.9" xlink:to="lab_LiabilitiesNoncurrent.138158.205611" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.138158.205611" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.138158.205611">Total long term liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.3062.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.11.6" xlink:to="lab_LiabilitiesNoncurrentAbstract.10151.205612" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.10151.205612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.10151.205612">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.3062.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.11.7" xlink:to="lab_LiabilitiesNoncurrentAbstract.138152.205613" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.138152.205613" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.138152.205613">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12757.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermDebtNoncurrent.12757.11.6" xlink:to="lab_LongTermDebtNoncurrent.11025.205614" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermDebtNoncurrent.11025.205614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LongTermDebtNoncurrent.11025.205614">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12757.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermDebtNoncurrent.12757.11.7" xlink:to="lab_LongTermDebtNoncurrent.138155.205615" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermDebtNoncurrent.138155.205615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LongTermDebtNoncurrent.138155.205615">Liability in connection with collaboration operation</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13867.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.13867.11.6" xlink:to="lab_OtherReceivablesNetCurrent.12515.205616" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.12515.205616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.12515.205616">Other Receivables, Net, Current</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13867.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.13867.11.7" xlink:to="lab_OtherReceivablesNetCurrent.138138.205617" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.138138.205617" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.138138.205617">Other assets</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.11.6" xlink:to="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684.205618" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684.205618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684.205618">Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.11.7" xlink:to="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157.205619" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157.205619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157.205619">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.15211.11.7" xlink:to="lab_PropertyPlantAndEquipmentNet.134116.205621" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.134116.205621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.134116.205621">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.15211.11.6" xlink:to="lab_PropertyPlantAndEquipmentNet.14913.205620" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.14913.205620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.14913.205620">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.5171.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.11.6" xlink:to="lab_StatementOfFinancialPositionAbstract.138129.205622" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfFinancialPositionAbstract.138129.205622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfFinancialPositionAbstract.138129.205622">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.17302.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.17302.11.7" xlink:to="lab_StockholdersEquity.138164.205624" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138164.205624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138164.205624">CAPITAL DEFICIENCY</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.17302.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.17302.11.6" xlink:to="lab_StockholdersEquity.18029.205623" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.18029.205623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.18029.205623">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.7" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020.205690" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020.205690" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020.205690">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.6" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.205689" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.205689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.205689">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_AmortizationOfFinancingCosts.5974.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmortizationOfFinancingCosts.5974.11.6" xlink:to="lab_AmortizationOfFinancingCosts.943" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmortizationOfFinancingCosts.943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmortizationOfFinancingCosts.943">Amortization of Financing Costs</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.10" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.139058.205691" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.139058.205691" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.139058.205691">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.11" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.139059.205692" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.139059.205692" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.139059.205692">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.9" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056.205694" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056.205694" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056.205694">NET INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.6" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.205693" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.205693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.205693">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.23584.11.6" xlink:href="plx-20130930.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.23584.11.6" xlink:to="lab_CashlessExerciseOfStockOptions.145608.205695" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145608.205695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145608.205695">Cashless Exercise Of Stock Options</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.23584.11.12" xlink:href="plx-20130930.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.23584.11.12" xlink:to="lab_CashlessExerciseOfStockOptions.145610.205697" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145610.205697" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145610.205697">Cash due from broker assisted exercises of employee stock options.</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.23584.11.7" xlink:href="plx-20130930.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.23584.11.7" xlink:to="lab_CashlessExerciseOfStockOptions.145611.205696" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145611.205696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145611.205696">Exercise of options granted to employees</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.23586.11.6" xlink:href="plx-20130930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.23586.11.6" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139023.205698" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139023.205698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139023.205698">Depreciation Amortization And Asset Impairment</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.23586.11.12" xlink:href="plx-20130930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.23586.11.12" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139026.205700" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139026.205700" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139026.205700">The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.23586.11.7" xlink:href="plx-20130930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.23586.11.7" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139027.205699" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139027.205699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139027.205699">Depreciation and write down of fixed assets</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.7" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055.205702" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055.205702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055.205702">EFFECT OF EXCHANGE RATE CHANGES ON CASH</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.6" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445.205701" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445.205701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445.205701">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.11.52" xlink:to="lab_ForeignCurrencyTransactionGainLossUnrealized.139028.205704" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossUnrealized.139028.205704" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossUnrealized.139028.205704">Financial expenses (income), net (mainly exchange differences)</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.11.6" xlink:to="lab_ForeignCurrencyTransactionGainLossUnrealized.7370.205703" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossUnrealized.7370.205703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossUnrealized.7370.205703">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.7" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038.205708" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038.205708" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038.205708">Increase (decrease) in accounts payable and accruals (including long term )</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.6" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.205707" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.205707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.205707">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.11237.11.6" xlink:to="lab_IncreaseDecreaseInAccountsReceivable.8785.205709" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable.8785.205709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable.8785.205709">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.11237.11.52" xlink:to="lab_IncreaseDecreaseInAccountsReceivable42.139035.205710" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable42.139035.205710" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable42.139035.205710">Increase in accounts receivable and other assets</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.11341.11.7" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.139034.205712" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.139034.205712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.139034.205712">Decrease in deferred revenues (including non-current portion)</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.11341.11.6" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.8782.205711" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.8782.205711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.8782.205711">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.11367.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInInventories.11367.11.6" xlink:to="lab_IncreaseDecreaseInInventories.8903.205713" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInInventories.8903.205713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInInventories.8903.205713">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.11367.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInInventories.11367.11.52" xlink:to="lab_IncreaseDecreaseInInventories42.139036.205714" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInInventories42.139036.205714" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInInventories42.139036.205714">Increase in inventories</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.7" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033.205716" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033.205716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033.205716">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.6" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.205715" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.205715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.205715">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.6" xlink:href="plx-20130930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.6" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065.205717" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065.205717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065.205717">Increase In Liabilities For Property Plant And Equipment</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.12" xlink:href="plx-20130930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.12" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067.205719" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067.205719" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067.205719">Increase in liabilities for property, plant and equipment.</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.7" xlink:href="plx-20130930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.7" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070.205718" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070.205718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070.205718">Purchase of property and equipment</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.13253.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.11796.205720" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.11796.205720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.11796.205720">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.13253.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.11.9" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.139054.205721" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.139054.205721" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.139054.205721">Net cash provided by financing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.205722" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.205722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.205722">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.7" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046.205723" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046.205723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046.205723">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.13246.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.11776.205724" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.11776.205724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.11776.205724">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.13246.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.11.9" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.139044.205725" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.139044.205725" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.139044.205725">Net cash used in investing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.205726" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.205726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.205726">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.7" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040.205727" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040.205727" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040.205727">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.13262.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.11871.205728" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.11871.205728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.11871.205728">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.13262.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.11.9" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.139039.205729" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.139039.205729" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.139039.205729">Net cash used in operating activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.205730" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.205730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.205730">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.7" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996.205731" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996.205731" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996.205731">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.13265.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.13265.11.6" xlink:to="lab_NetIncomeLoss.11860.205732" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.11860.205732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.11860.205732">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.13265.11.20" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.13265.11.20" xlink:to="lab_NetIncomeLoss.537619.237449" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.537619.237449" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.537619.237449">Net loss</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.11.6" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities.13356.205734" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities.13356.205734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities.13356.205734">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.11.52" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities.139042.205735" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities.139042.205735" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities.139042.205735">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.11.6" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519.205736" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519.205736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519.205736">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.11.52" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041.205737" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041.205737" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041.205737">Purchase of property and equipment</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquireRestrictedCertificatesOfDeposit.14394.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquireRestrictedCertificatesOfDeposit.14394.11.6" xlink:to="lab_PaymentsToAcquireRestrictedCertificatesOfDeposit.14175" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquireRestrictedCertificatesOfDeposit.14175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquireRestrictedCertificatesOfDeposit.14175">Payments to Acquire Restricted Certificates of Deposit</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquireRestrictedCertificatesOfDeposit.14394.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquireRestrictedCertificatesOfDeposit.14394.11.52" xlink:to="lab_PaymentsToAcquireRestrictedCertificatesOfDeposit.275822" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquireRestrictedCertificatesOfDeposit.275822" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquireRestrictedCertificatesOfDeposit.275822">Investment in restricted deposit</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.14421.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitContributions.14421.11.6" xlink:to="lab_PensionAndOtherPostretirementBenefitContributions.13663.205738" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitContributions.13663.205738" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitContributions.13663.205738">Pension and Other Postretirement Benefit Contributions</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.14421.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitContributions.14421.11.52" xlink:to="lab_PensionAndOtherPostretirementBenefitContributions.139032.205739" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitContributions.139032.205739" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitContributions.139032.205739">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.14426.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitExpense.14426.11.6" xlink:to="lab_PensionAndOtherPostretirementBenefitExpense.13676.205740" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitExpense.13676.205740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitExpense.13676.205740">Pension and Other Postretirement Benefit Expense</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.14426.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitExpense.14426.11.7" xlink:to="lab_PensionAndOtherPostretirementBenefitExpense.139030.205741" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitExpense.139030.205741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitExpense.139030.205741">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_ProceedsFromConvertibleDebt.14924.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromConvertibleDebt.14924.11.6" xlink:to="lab_ProceedsFromConvertibleDebt.14992" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromConvertibleDebt.14992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromConvertibleDebt.14992">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:label="loc_ProceedsFromConvertibleDebt.14924.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromConvertibleDebt.14924.11.7" xlink:to="lab_ProceedsFromConvertibleDebt.150540.278978" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromConvertibleDebt.150540.278978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromConvertibleDebt.150540.278978">Net proceeds from issuance of convertible notes</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.23597.11.6" xlink:href="plx-20130930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.23597.11.6" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047.205742" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047.205742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047.205742">Proceeds From Issuance Of Common Stock Net Of Expenses</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.23597.11.12" xlink:href="plx-20130930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.23597.11.12" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048.205744" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048.205744" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048.205744">Proceeds from issuance of common stock net of expenses.</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.23597.11.7" xlink:href="plx-20130930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.23597.11.7" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050.205743" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050.205743" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050.205743">Issuance of shares, net of issuance cost</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.15050.11.8" xlink:to="lab_ProceedsFromStockOptionsExercised.139052.205748" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.139052.205748" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.139052.205748">Exercise of options</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.15050.11.6" xlink:to="lab_ProceedsFromStockOptionsExercised.14691.205747" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.14691.205747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.14691.205747">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16900.11.6" xlink:to="lab_ShareBasedCompensation.17402.205749" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation.17402.205749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation.17402.205749">Share-based Compensation</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16900.11.7" xlink:to="lab_ShareBasedCompensation7.138110.205750" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation7.138110.205750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation7.138110.205750">Share based compensation</link:label>
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.11.6" xlink:to="lab_StatementOfCashFlowsAbstract.138995.205751" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfCashFlowsAbstract.138995.205751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfCashFlowsAbstract.138995.205751">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5255.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.11.6" xlink:to="lab_SupplementalCashFlowInformationAbstract.519401.205752" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalCashFlowInformationAbstract.519401.205752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalCashFlowInformationAbstract.519401.205752">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: [Abstract]</link:label>
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5255.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.11.7" xlink:to="lab_SupplementalCashFlowInformationAbstract.522041.205753" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalCashFlowInformationAbstract.522041.205753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalCashFlowInformationAbstract.522041.205753">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.23607.11.6" xlink:href="plx-20130930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.23607.11.6" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139071.205754" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139071.205754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139071.205754">Supplemental Offering And Stock Issuance Costs</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.23607.11.12" xlink:href="plx-20130930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.23607.11.12" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139073.205756" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139073.205756" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139073.205756">Supplemental offering and stock issuance costs.</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.23607.11.7" xlink:href="plx-20130930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.23607.11.7" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139074.205755" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139074.205755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139074.205755">Issuance cost related to convertible note offering not yet paid</link:label>
    <link:loc xlink:label="loc_AmortizationOfFinancingCosts.5974.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmortizationOfFinancingCosts.5974.11.7" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl.279050" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl.279050" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCosts_lbl.279050">Amortization of debt issuance costs and debt discount</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.485.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalMember.485.11.7" xlink:to="lab_AdditionalPaidInCapitalMember.133985.275821" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapitalMember.133985.275821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapitalMember.133985.275821">Additional paid-in Capital [Member]</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.485.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalMember.485.11.6" xlink:to="lab_AdditionalPaidInCapitalMember.681.205654" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapitalMember.681.205654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapitalMember.681.205654">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5854.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5854.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.138695.205656" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.138695.205656" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.138695.205656">Share-based compensation related to stock options</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5854.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5854.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.747.205655" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.747.205655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.747.205655">Adjustments to Additional Paid in Capital, Share-based Compensation, Employee Stock Purchase Program, Requisite Service Period Recognition</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.719" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.719">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.11.8" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue8.207165" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue8.207165" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue8.207165">Share-based compensation</link:label>
    <link:loc xlink:label="loc_CommonStockMember.1087.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockMember.1087.11.6" xlink:to="lab_CommonStockMember.2694.205657" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockMember.2694.205657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockMember.2694.205657">Common Stock [Member]</link:label>
    <link:loc xlink:label="loc_EquityComponentDomain.1873.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityComponentDomain.1873.11.6" xlink:to="lab_EquityComponentDomain.5824.205658" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityComponentDomain.5824.205658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityComponentDomain.5824.205658">Equity Component [Domain]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.13265.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.13265.11.8" xlink:to="lab_NetIncomeLoss.138697.205659" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138697.205659" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138697.205659">Net loss for the period</link:label>
    <link:loc xlink:label="loc_RetainedEarningsMember.4652.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsMember.4652.11.7" xlink:to="lab_RetainedEarningsMember.138685.205661" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsMember.138685.205661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsMember.138685.205661">Accumulated Deficit [Member]</link:label>
    <link:loc xlink:label="loc_RetainedEarningsMember.4652.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsMember.4652.11.6" xlink:to="lab_RetainedEarningsMember.16154.205660" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsMember.16154.205660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsMember.16154.205660">Retained Earnings [Member]</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.17056.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.17056.11.10" xlink:to="lab_SharesOutstanding.138690.205663" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.138690.205663" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.138690.205663">Beginning Balance (in shares)</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.17056.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.17056.11.11" xlink:to="lab_SharesOutstanding.138702.205664" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.138702.205664" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.138702.205664">Ending Balance (in shares)</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.17056.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.17056.11.6" xlink:to="lab_SharesOutstanding.17653.205662" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.17653.205662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.17653.205662">Shares, Outstanding</link:label>
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.5169.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementEquityComponentsAxis.5169.11.6" xlink:to="lab_StatementEquityComponentsAxis.17875.205665" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementEquityComponentsAxis.17875.205665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementEquityComponentsAxis.17875.205665">Equity Components [Axis]</link:label>
    <link:loc xlink:label="loc_StatementLineItems.5164.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementLineItems.5164.11.6" xlink:to="lab_StatementLineItems.17869.205666" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementLineItems.17869.205666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementLineItems.17869.205666">Statement [Line Items]</link:label>
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.5166.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfStockholdersEquityAbstract.5166.11.6" xlink:to="lab_StatementOfStockholdersEquityAbstract.138674.205667" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfStockholdersEquityAbstract.138674.205667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfStockholdersEquityAbstract.138674.205667">CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY [Abstract]</link:label>
    <link:loc xlink:label="loc_StatementTable.5163.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementTable.5163.11.6" xlink:to="lab_StatementTable.17867.205668" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementTable.17867.205668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementTable.17867.205668">Statement [Table]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.17302.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.17302.11.10" xlink:to="lab_StockholdersEquity.138688.205669" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138688.205669" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138688.205669">Beginning Balance</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.17302.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.17302.11.11" xlink:to="lab_StockholdersEquity.138700.205670" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138700.205670" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138700.205670">Ending Balance</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.17220.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesIssuedForServices.17220.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesIssuedForServices.145599.205672" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesIssuedForServices.145599.205672" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesIssuedForServices.145599.205672">Share-based compensation related to restricted stock award, net of forfeitures (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.17220.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesIssuedForServices.17220.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesIssuedForServices.17920.205671" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesIssuedForServices.17920.205671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesIssuedForServices.17920.205671">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.138692.205674" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.138692.205674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.138692.205674">Common stock issued for cash (net of issuance costs) (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.17977.205673" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.17977.205673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.17977.205673">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106.205676" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106.205676" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106.205676">Exercise of options granted to employees (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.205675" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.205675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.205675">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.17243.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueIssuedForServices.17243.11.7" xlink:to="lab_StockIssuedDuringPeriodValueIssuedForServices.145592.205678" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueIssuedForServices.145592.205678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueIssuedForServices.145592.205678">Share-based compensation related to restricted stock award, net of forfeitures</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.17243.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueIssuedForServices.17243.11.6" xlink:to="lab_StockIssuedDuringPeriodValueIssuedForServices.17948.205677" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueIssuedForServices.17948.205677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueIssuedForServices.17948.205677">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.7" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.138694.205680" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.138694.205680" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.138694.205680">Common stock issued for cash (net of issuance costs)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.6" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.17939.205679" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.17939.205679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.17939.205679">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.11.7" xlink:to="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696.205682" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696.205682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696.205682">Exercise of options granted to employees</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.11.6" xlink:to="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935.205681" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935.205681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935.205681">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735.205683" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735.205683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735.205683">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770.205684" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770.205684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770.205684">Common stock issued for cash, issuance costs</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.7131.11.8" xlink:to="lab_CommonStockParOrStatedValuePerShare.138774.205686" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.138774.205686" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.138774.205686">Common Stock, par value</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.7131.11.6" xlink:to="lab_CommonStockParOrStatedValuePerShare.2741.205685" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.2741.205685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.2741.205685">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.7144.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.7144.11.8" xlink:to="lab_CommonStockSharesAuthorized.138777.205688" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.138777.205688" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.138777.205688">Common Stock, Authorized</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.7144.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.7144.11.6" xlink:to="lab_CommonStockSharesAuthorized.2742.205687" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.2742.205687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.2742.205687">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:label="loc_CostOfRevenue.7431.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenue.7431.11.52" xlink:to="lab_CostOfRevenue.138492.205626" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenue.138492.205626" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenue.138492.205626">COST OF REVENUES</link:label>
    <link:loc xlink:label="loc_CostOfRevenue.7431.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenue.7431.11.6" xlink:to="lab_CostOfRevenue.3224.205625" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenue.3224.205625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenue.3224.205625">Cost of Revenue</link:label>
    <link:loc xlink:label="loc_EarningsPerShareAbstract.1761.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareAbstract.1761.11.6" xlink:to="lab_EarningsPerShareAbstract.5712" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareAbstract.5712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareAbstract.5712">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.9078.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.9078.11.6" xlink:to="lab_EarningsPerShareBasicAndDiluted.5415.205627" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDiluted.5415.205627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDiluted.5415.205627">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.11.6" xlink:to="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.5692" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.5692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.5692">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.11.7" xlink:to="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.370331.488042.237445" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.370331.488042.237445" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.370331.488042.237445">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE:</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10699.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.10699.11.6" xlink:to="lab_GeneralAndAdministrativeExpense.7870.205630" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense.7870.205630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense.7870.205630">General and Administrative Expense</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10699.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.10699.11.52" xlink:to="lab_GeneralAndAdministrativeExpense42.138509.205631" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense42.138509.205631" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense42.138509.205631">GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.6" xlink:href="plx-20130930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.6" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138496.205632" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138496.205632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138496.205632">Grants And Reimbursements Received Or Receivable</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.12" xlink:href="plx-20130930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.12" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138498.205634" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138498.205634" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138498.205634">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.7" xlink:href="plx-20130930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.7" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138500.205633" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138500.205633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138500.205633">Less - grants and reimbursements</link:label>
    <link:loc xlink:label="loc_GrossProfit.10776.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrossProfit.10776.11.9" xlink:to="lab_GrossProfit.138487.205636" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrossProfit.138487.205636" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrossProfit.138487.205636">GROSS PROFIT</link:label>
    <link:loc xlink:label="loc_GrossProfit.10776.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrossProfit.10776.11.6" xlink:to="lab_GrossProfit.7981.205635" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrossProfit.7981.205635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrossProfit.7981.205635">Gross Profit</link:label>
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementAbstract.2649.11.6" xlink:to="lab_IncomeStatementAbstract.138470.205637" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementAbstract.138470.205637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementAbstract.138470.205637">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.13265.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.13265.11.9" xlink:to="lab_NetIncomeLoss.138521.205638" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138521.205638" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138521.205638">NET LOSS FOR THE PERIOD</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.9078.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.9078.11.7" xlink:to="lab_Netlosspershareofcommonstock-basicanddiluted.167675.205639" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Netlosspershareofcommonstock-basicanddiluted.167675.205639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Netlosspershareofcommonstock-basicanddiluted.167675.205639">BASIC AND DILUTED</link:label>
    <link:loc xlink:label="loc_NonoperatingIncomeExpense.13395.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NonoperatingIncomeExpense.13395.11.6" xlink:to="lab_NonoperatingIncomeExpense.12540" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NonoperatingIncomeExpense.12540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NonoperatingIncomeExpense.12540">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:label="loc_NonoperatingIncomeExpense.13395.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NonoperatingIncomeExpense.13395.11.7" xlink:to="lab_NonoperatingIncomeExpense.546799.238879" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NonoperatingIncomeExpense.546799.238879" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NonoperatingIncomeExpense.546799.238879">FINANCIAL INCOME (EXPENSES) - NET</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13592.11.6" xlink:to="lab_OperatingIncomeLoss.12364.205640" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.12364.205640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.12364.205640">Operating Income (Loss)</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13592.11.9" xlink:to="lab_OperatingIncomeLoss.138511.205641" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.138511.205641" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.138511.205641">OPERATING LOSS</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.23595.11.6" xlink:href="plx-20130930.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.23595.11.6" xlink:to="lab_OtherGainsLosses.138475.205642" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138475.205642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138475.205642">Other Gains Losses</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.23595.11.12" xlink:href="plx-20130930.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.23595.11.12" xlink:to="lab_OtherGainsLosses.138482.205644" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138482.205644" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138482.205644">The Company's share in collaboration agreement.</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.23595.11.7" xlink:href="plx-20130930.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.23595.11.7" xlink:to="lab_OtherGainsLosses.138484.205643" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138484.205643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138484.205643">COMPANY'S SHARE IN COLLABORATION AGREEMENT</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15880.11.6" xlink:to="lab_ResearchAndDevelopmentExpense.15873.205645" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense.15873.205645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense.15873.205645">Research and Development Expense</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15880.11.52" xlink:to="lab_ResearchAndDevelopmentExpense42.140375.205646" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense42.140375.205646" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense42.140375.205646">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.6" xlink:href="plx-20130930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.6" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504.205647" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504.205647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504.205647">Research Development And Engineering Expense Net</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.12" xlink:href="plx-20130930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.12" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505.205649" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505.205649" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505.205649">Research and development expenses, net.</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.55" xlink:href="plx-20130930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.55" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370.205648" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370.205648" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370.205648">RESEARCH AND DEVELOPMENT EXPENSES, NET</link:label>
    <link:loc xlink:label="loc_Revenues.16160.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.16160.11.7" xlink:to="lab_Revenues.134146.205651" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.134146.205651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.134146.205651">REVENUES</link:label>
    <link:loc xlink:label="loc_Revenues.16160.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.16160.11.6" xlink:to="lab_Revenues.16307.205650" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.16307.205650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.16307.205650">Revenues</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.7" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681.205653" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681.205653" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681.205653">BASIC AND DILUTED</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.6" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.205652" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.205652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.205652">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_EarningsPerShareAbstract.1761.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareAbstract.1761.11.7" xlink:to="us-gaap_EarningsPerShareAbstract_lbl.237442" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract_lbl.237442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl.237442">LOSS PER SHARE OF COMMON STOCK:</link:label>
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AllocatedShareBasedCompensationExpense.5919.11.6" xlink:to="lab_AllocatedShareBasedCompensationExpense.852.205769" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AllocatedShareBasedCompensationExpense.852.205769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AllocatedShareBasedCompensationExpense.852.205769">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AllocatedShareBasedCompensationExpense.5919.11.7" xlink:to="lab_AllocatedShareBasedCompensationExpense7.138668.205770" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AllocatedShareBasedCompensationExpense7.138668.205770" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AllocatedShareBasedCompensationExpense7.138668.205770">Share-based compensation</link:label>
    <link:loc xlink:label="loc_CostOfSalesMember.1254.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfSalesMember.1254.11.6" xlink:to="lab_CostOfSalesMember.3372" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfSalesMember.3372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CostOfSalesMember.3372">Cost of Sales [Member]</link:label>
    <link:loc xlink:label="loc_CostOfSalesMember.1254.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfSalesMember.1254.11.7" xlink:to="lab_CostOfSalesMember7.155717.275820" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfSalesMember7.155717.275820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CostOfSalesMember7.155717.275820">Cost of Revenue [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.11.6" xlink:to="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595.205771" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595.205771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595.205771">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2476.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpenseMember.2476.11.6" xlink:to="lab_GeneralAndAdministrativeExpenseMember.7876.205773" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpenseMember.7876.205773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpenseMember.7876.205773">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementLocationAxis.2652.11.6" xlink:to="lab_IncomeStatementLocationAxis.8839" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementLocationAxis.8839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementLocationAxis.8839">Income Statement Location [Axis]</link:label>
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementLocationDomain.2671.11.6" xlink:to="lab_IncomeStatementLocationDomain.8906" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementLocationDomain.8906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementLocationDomain.8906">Income Statement Location [Domain]</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4573.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpenseMember.4573.11.6" xlink:to="lab_ResearchAndDevelopmentExpenseMember.15885.205774" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpenseMember.15885.205774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpenseMember.15885.205774">Research and Development Expense [Member]</link:label>
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.11.6" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738.205776" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738.205776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738.205776">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:label="loc_AmendmentFlag.144.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmendmentFlag.144.11.6" xlink:to="lab_AmendmentFlag.8.205757" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmendmentFlag.8.205757" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmendmentFlag.8.205757">Amendment Flag</link:label>
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CurrentFiscalYearEndDate.155.11.6" xlink:to="lab_CurrentFiscalYearEndDate.20.205758" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CurrentFiscalYearEndDate.20.205758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CurrentFiscalYearEndDate.20.205758">Current Fiscal Year End Date</link:label>
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.23587.11.6" xlink:href="plx-20130930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.11.6" xlink:to="lab_DocumentAndEntityInformationAbstract.138116.205759" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentAndEntityInformationAbstract.138116.205759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentAndEntityInformationAbstract.138116.205759">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.206.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalPeriodFocus.206.11.6" xlink:to="lab_DocumentFiscalPeriodFocus.123.205760" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalPeriodFocus.123.205760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalPeriodFocus.123.205760">Document Fiscal Period Focus</link:label>
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.205.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalYearFocus.205.11.6" xlink:to="lab_DocumentFiscalYearFocus.122.205761" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalYearFocus.122.205761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalYearFocus.122.205761">Document Fiscal Year Focus</link:label>
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentPeriodEndDate.161.11.6" xlink:to="lab_DocumentPeriodEndDate.30.205762" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentPeriodEndDate.30.205762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentPeriodEndDate.30.205762">Document Period End Date</link:label>
    <link:loc xlink:label="loc_DocumentType.210.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentType.210.11.6" xlink:to="lab_DocumentType.32.205763" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentType.32.205763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentType.32.205763">Document Type</link:label>
    <link:loc xlink:label="loc_EntityCentralIndexKey.186.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCentralIndexKey.186.11.6" xlink:to="lab_EntityCentralIndexKey.101.205764" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCentralIndexKey.101.205764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCentralIndexKey.101.205764">Entity Central Index Key</link:label>
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.190.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCommonStockSharesOutstanding.190.11.6" xlink:to="lab_EntityCommonStockSharesOutstanding.105.205765" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCommonStockSharesOutstanding.105.205765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCommonStockSharesOutstanding.105.205765">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:label="loc_EntityFilerCategory.183.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityFilerCategory.183.11.6" xlink:to="lab_EntityFilerCategory.98.205766" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityFilerCategory.98.205766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityFilerCategory.98.205766">Entity Filer Category</link:label>
    <link:loc xlink:label="loc_EntityRegistrantName.185.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityRegistrantName.185.11.6" xlink:to="lab_EntityRegistrantName.100.205767" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityRegistrantName.100.205767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityRegistrantName.100.205767">Entity Registrant Name</link:label>
    <link:loc xlink:label="loc_TradingSymbol.176.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TradingSymbol.176.11.6" xlink:to="lab_TradingSymbol.60.205768" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TradingSymbol.60.205768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TradingSymbol.60.205768">Trading Symbol</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2913.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureAbstract.2913.11.6" xlink:to="lab_InventoryDisclosureAbstract.138059.205557" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureAbstract.138059.205557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureAbstract.138059.205557">INVENTORIES [Abstract]</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11845.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureTextBlock.11845.11.6" xlink:to="lab_InventoryDisclosureTextBlock.9626.205558" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureTextBlock.9626.205558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureTextBlock.9626.205558">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11845.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureTextBlock.11845.11.7" xlink:to="lab_InventoryDisclosureTextBlock7.138804.205559" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureTextBlock7.138804.205559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureTextBlock7.138804.205559">INVENTORIES</link:label>
    <link:loc xlink:label="loc_InventoryFinishedGoods.11817.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryFinishedGoods.11817.11.7" xlink:to="lab_InventoryFinishedGoods.135792.205778" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryFinishedGoods.135792.205778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryFinishedGoods.135792.205778">Finished goods</link:label>
    <link:loc xlink:label="loc_InventoryFinishedGoods.11817.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryFinishedGoods.11817.11.6" xlink:to="lab_InventoryFinishedGoods.9634.205777" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryFinishedGoods.9634.205777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryFinishedGoods.9634.205777">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:label="loc_InventoryNet.11816.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11816.11.9" xlink:to="lab_InventoryNet.138062.205779" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.138062.205779" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.138062.205779">Total inventory</link:label>
    <link:loc xlink:label="loc_InventoryRawMaterials.11886.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryRawMaterials.11886.11.7" xlink:to="lab_InventoryRawMaterials.135790.205781" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryRawMaterials.135790.205781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryRawMaterials.135790.205781">Raw materials</link:label>
    <link:loc xlink:label="loc_InventoryRawMaterials.11886.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryRawMaterials.11886.11.6" xlink:to="lab_InventoryRawMaterials.9669.205780" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryRawMaterials.9669.205780" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryRawMaterials.9669.205780">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:label="loc_InventoryWorkInProcess.11878.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWorkInProcess.11878.11.7" xlink:to="lab_InventoryWorkInProcess.135791.205783" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWorkInProcess.135791.205783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWorkInProcess.135791.205783">Work in process</link:label>
    <link:loc xlink:label="loc_InventoryWorkInProcess.11878.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWorkInProcess.11878.11.6" xlink:to="lab_InventoryWorkInProcess.9671.205782" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWorkInProcess.9671.205782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWorkInProcess.9671.205782">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.11.6" xlink:to="lab_ScheduleOfInventoryCurrentTableTextBlock.16610.205570" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock.16610.205570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfInventoryCurrentTableTextBlock.16610.205570">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.11.7" xlink:to="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817.205571" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817.205571" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817.205571">Inventory</link:label>
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountingPoliciesAbstract.414.11.6" xlink:to="lab_AccountingPoliciesAbstract.137967.205554" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountingPoliciesAbstract.137967.205554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountingPoliciesAbstract.137967.205554">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.7" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803.205556" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803.205556" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803.205556">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.6" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.205555" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.205555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.205555">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.6" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.205497" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.205497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.205497">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.7" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029.205498" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029.205498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029.205498">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.11.6" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010.205499" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010.205499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010.205499">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.582.11.6" xlink:to="lab_AntidilutiveSecuritiesNameDomain.1007.205500" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesNameDomain.1007.205500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesNameDomain.1007.205500">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.11.6" xlink:to="lab_ArrangementsAndNonarrangementTransactionsMember.288" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ArrangementsAndNonarrangementTransactionsMember.288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ArrangementsAndNonarrangementTransactionsMember.288">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.23585.11.6" xlink:href="plx-20130930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.23585.11.6" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138005.205501" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138005.205501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138005.205501">Collaborative Arrangement Profit Share Percentage</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.23585.11.12" xlink:href="plx-20130930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.23585.11.12" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138007.205503" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138007.205503" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138007.205503">Collaborative arrangement profit sharing percentage.</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.23585.11.7" xlink:href="plx-20130930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.23585.11.7" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138010.205502" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138010.205502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138010.205502">Pfizer Agreement, future revenues and expense sharing percentage</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.7131.11.7" xlink:to="lab_CommonStockParOrStatedValuePerShare7.134365.205506" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare7.134365.205506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare7.134365.205506">Common stock, par value per share</link:label>
    <link:loc xlink:label="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.6" xlink:href="plx-20130930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.6" xlink:to="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.239032" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.239032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.239032">License And Supply Agreement Potential Future Payment Based On Net Profits</link:label>
    <link:loc xlink:label="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.12" xlink:href="plx-20130930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.12" xlink:to="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits12.239033" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits12.239033" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits12.239033">License And Supply Agreement Potential Future Payment Based On Net Profits</link:label>
    <link:loc xlink:label="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.7" xlink:href="plx-20130930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.7" xlink:to="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits7.239034" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits7.239034" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits7.239034">License and supply agreement potential future payment</link:label>
    <link:loc xlink:label="loc_MilestonePayment.23592.11.6" xlink:href="plx-20130930.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.23592.11.6" xlink:to="lab_MilestonePayment.138000.205507" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138000.205507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138000.205507">Milestone Payment</link:label>
    <link:loc xlink:label="loc_MilestonePayment.23592.11.12" xlink:href="plx-20130930.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.23592.11.12" xlink:to="lab_MilestonePayment.138001.205509" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138001.205509" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138001.205509">Milestone payment.</link:label>
    <link:loc xlink:label="loc_MilestonePayment.23592.11.7" xlink:href="plx-20130930.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.23592.11.7" xlink:to="lab_MilestonePayment.138002.205508" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138002.205508" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138002.205508">Milestone payment triggered</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.23594.11.6" xlink:href="plx-20130930.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.23594.11.6" xlink:to="lab_NumberOfSubsidiaries.137996.205510" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137996.205510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137996.205510">Number Of Subsidiaries</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.23594.11.12" xlink:href="plx-20130930.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.23594.11.12" xlink:to="lab_NumberOfSubsidiaries.137997.205512" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137997.205512" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137997.205512">Number of subsidiaries.</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.23594.11.7" xlink:href="plx-20130930.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.23594.11.7" xlink:to="lab_NumberOfSubsidiaries.137998.205511" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137998.205511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137998.205511">Number of Subsidiaries</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.23596.11.6" xlink:href="plx-20130930.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.23596.11.6" xlink:to="lab_PfizerIncorporationMember.137992.205513" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137992.205513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137992.205513">Pfizer Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.23596.11.12" xlink:href="plx-20130930.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.23596.11.12" xlink:to="lab_PfizerIncorporationMember.137993.205515" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137993.205515" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137993.205515">Pfizer Incorporation [Member].</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.23596.11.7" xlink:href="plx-20130930.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.23596.11.7" xlink:to="lab_PfizerIncorporationMember.137994.205514" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137994.205514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137994.205514">Pfizer Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14867.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromCollaborators.14867.11.7" xlink:to="lab_ProceedsFromCollaborators.137999.205517" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromCollaborators.137999.205517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromCollaborators.137999.205517">Pfizer Agreement, upfront payment received</link:label>
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14867.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromCollaborators.14867.11.6" xlink:to="lab_ProceedsFromCollaborators.14422.205516" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromCollaborators.14422.205516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromCollaborators.14422.205516">Proceeds from Collaborators</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.6" xlink:href="plx-20130930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.6" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137989.205518" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137989.205518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137989.205518">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.12" xlink:href="plx-20130930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.12" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137990.205520" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137990.205520" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137990.205520">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.7" xlink:href="plx-20130930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.7" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137991.205519" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137991.205519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137991.205519">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixLtdMember.27186.11.6" xlink:href="plx-20130930.xsd#plx_ProtalixLtdMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixLtdMember.27186.11.6" xlink:to="lab_ProtalixLtdMember.237459" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixLtdMember.237459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixLtdMember.237459">Protalix Ltd [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixLtdMember.27186.11.12" xlink:href="plx-20130930.xsd#plx_ProtalixLtdMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixLtdMember.27186.11.12" xlink:to="lab_ProtalixLtdMember12.237460" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixLtdMember12.237460" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixLtdMember12.237460">Protalix Ltd [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixLtdMember.27186.11.8" xlink:href="plx-20130930.xsd#plx_ProtalixLtdMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixLtdMember.27186.11.8" xlink:to="lab_ProtalixLtdMember8.237462" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixLtdMember8.237462" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixLtdMember8.237462">Protalix Ltd. [Member]</link:label>
    <link:loc xlink:label="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.6" xlink:href="plx-20130930.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.6" xlink:to="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.242903" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.242903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.242903">Purchase Amount To Be Satisfied To Receive Entitled Rights</link:label>
    <link:loc xlink:label="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.12" xlink:href="plx-20130930.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.12" xlink:to="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights12.242904" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights12.242904" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights12.242904">The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.</link:label>
    <link:loc xlink:label="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.7" xlink:href="plx-20130930.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.7" xlink:to="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights7.242905" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights7.242905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights7.242905">Supply commitment for entitled rights to be received</link:label>
    <link:loc xlink:label="loc_RelatedPartyTransactionAmountsOfTransaction.15770.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyTransactionAmountsOfTransaction.15770.11.6" xlink:to="lab_RelatedPartyTransactionAmountsOfTransaction.16351" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RelatedPartyTransactionAmountsOfTransaction.16351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RelatedPartyTransactionAmountsOfTransaction.16351">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:label="loc_RelatedPartyTransactionAmountsOfTransaction.15770.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyTransactionAmountsOfTransaction.15770.11.7" xlink:to="lab_RelatedPartyTransactionAmountsOfTransaction7.546876.237463" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RelatedPartyTransactionAmountsOfTransaction7.546876.237463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RelatedPartyTransactionAmountsOfTransaction7.546876.237463">Supply agreement maximum consideration payment</link:label>
    <link:loc xlink:label="loc_ScenarioFourMember.23600.11.6" xlink:href="plx-20130930.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioFourMember.23600.11.6" xlink:to="lab_ScenarioFourMember.501181.205521" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioFourMember.501181.205521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioFourMember.501181.205521">Scenario Four [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioFourMember.23600.11.12" xlink:href="plx-20130930.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioFourMember.23600.11.12" xlink:to="lab_ScenarioFourMember.501182.205523" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioFourMember.501182.205523" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioFourMember.501182.205523">Scenario Four [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioFourMember.23600.11.7" xlink:href="plx-20130930.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioFourMember.23600.11.7" xlink:to="lab_ScenarioFourMember.501183.205522" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioFourMember.501183.205522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioFourMember.501183.205522">Upon Near Term Clinical Development Milestones [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.23601.11.6" xlink:href="plx-20130930.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.23601.11.6" xlink:to="lab_ScenarioOneMember.137972.205524" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137972.205524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137972.205524">Scenario One [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.23601.11.12" xlink:href="plx-20130930.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.23601.11.12" xlink:to="lab_ScenarioOneMember.137973.205526" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137973.205526" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137973.205526">Scenario One [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.23601.11.7" xlink:href="plx-20130930.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.23601.11.7" xlink:to="lab_ScenarioOneMember.137974.205525" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137974.205525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137974.205525">Upon each FDA and European Medicine Agency approval [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioThreeMember.23602.11.6" xlink:href="plx-20130930.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioThreeMember.23602.11.6" xlink:to="lab_ScenarioThreeMember.501178.205527" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioThreeMember.501178.205527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioThreeMember.501178.205527">Scenario Three [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioThreeMember.23602.11.12" xlink:href="plx-20130930.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioThreeMember.23602.11.12" xlink:to="lab_ScenarioThreeMember.501179.205528" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioThreeMember.501179.205528" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioThreeMember.501179.205528">Scenario Three [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioThreeMember.23602.11.7" xlink:href="plx-20130930.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioThreeMember.23602.11.7" xlink:to="lab_ScenarioThreeMemberlab_ScenarioThreeMember.501180.205529" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioThreeMemberlab_ScenarioThreeMember.501180.205529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioThreeMemberlab_ScenarioThreeMember.501180.205529">Upon FDA Approval [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.23603.11.6" xlink:href="plx-20130930.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.23603.11.6" xlink:to="lab_ScenarioTwoMember.137969.205530" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137969.205530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137969.205530">Scenario Two [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.23603.11.12" xlink:href="plx-20130930.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.23603.11.12" xlink:to="lab_ScenarioTwoMember.137970.205532" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137970.205532" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137970.205532">Scenario Two [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.23603.11.7" xlink:href="plx-20130930.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.23603.11.7" xlink:to="lab_ScenarioTwoMember.137971.205531" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137971.205531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137971.205531">Upon Filing of Pediatric Investigation Plan to EMA [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.11.6" xlink:to="lab_ScenarioUnspecifiedDomain.16504.205533" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioUnspecifiedDomain.16504.205533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioUnspecifiedDomain.16504.205533">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.23604.11.6" xlink:href="plx-20130930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.11.6" xlink:to="lab_SignificantAccountingPoliciesLineItems.137995.205534" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesLineItems.137995.205534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesLineItems.137995.205534">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.23605.11.6" xlink:href="plx-20130930.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.11.6" xlink:to="lab_SignificantAccountingPoliciesTable.137976.205535" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTable.137976.205535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTable.137976.205535">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.23605.11.12" xlink:href="plx-20130930.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.11.12" xlink:to="lab_SignificantAccountingPoliciesTable.137977.205536" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTable.137977.205536" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTable.137977.205536">Significant Accounting Policies [Table].</link:label>
    <link:loc xlink:label="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.11.6" xlink:to="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.18430" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.18430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.18430">Supply Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:label="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.11.7" xlink:to="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted7.237458" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted7.237458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted7.237458">Total supply commitment</link:label>
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementScenarioAxis.5162.11.6" xlink:to="lab_StatementScenarioAxis.17868.205537" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementScenarioAxis.17868.205537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementScenarioAxis.17868.205537">Scenario [Axis]</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.23606.11.6" xlink:href="plx-20130930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.23606.11.6" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168199.205538" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168199.205538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168199.205538">Stock Options And Restricted Shares [Member]</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.23606.11.12" xlink:href="plx-20130930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.23606.11.12" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168200.205540" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168200.205540" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168200.205540">Stock Options And Restricted Shares [Member].</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.23606.11.7" xlink:href="plx-20130930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.23606.11.7" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168201.205539" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168201.205539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168201.205539">Options and Restricted Shares [Member]</link:label>
    <link:loc xlink:label="loc_SupplyCommitmentPerYear.27185.11.6" xlink:href="plx-20130930.xsd#plx_SupplyCommitmentPerYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplyCommitmentPerYear.27185.11.6" xlink:to="lab_SupplyCommitmentPerYear.237455" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplyCommitmentPerYear.237455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplyCommitmentPerYear.237455">Supply Commitment Per Year</link:label>
    <link:loc xlink:label="loc_SupplyCommitmentPerYear.27185.11.12" xlink:href="plx-20130930.xsd#plx_SupplyCommitmentPerYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplyCommitmentPerYear.27185.11.12" xlink:to="lab_SupplyCommitmentPerYear12.237456" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplyCommitmentPerYear12.237456" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SupplyCommitmentPerYear12.237456">The floor purchase amount that one or more customers of the entity must satisfy per calendar year to comply with the terms of disclosed arrangements.</link:label>
    <link:loc xlink:label="loc_SupplyCommitmentPerYear.27185.11.7" xlink:href="plx-20130930.xsd#plx_SupplyCommitmentPerYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplyCommitmentPerYear.27185.11.7" xlink:to="lab_SupplyCommitmentPerYear7.237457" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplyCommitmentPerYear7.237457" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplyCommitmentPerYear7.237457">Supply commitment per year</link:label>
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TypeOfArrangementAxis.5386.11.6" xlink:to="lab_TypeOfArrangementAxis.19407" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TypeOfArrangementAxis.19407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TypeOfArrangementAxis.19407">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.6" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.205563" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.205563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.205563">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.7" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441.205564" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441.205564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441.205564">Basis of Presentation</link:label>
    <link:loc xlink:label="loc_DebtPolicyTextBlock.7719.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtPolicyTextBlock.7719.11.6" xlink:to="lab_DebtPolicyTextBlock.3768" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtPolicyTextBlock.3768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtPolicyTextBlock.3768">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.9080.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.9080.11.7" xlink:to="lab_EarningsPerSharePolicyTextBlock.138811.205566" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.138811.205566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.138811.205566">Net loss per share</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.9080.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.9080.11.6" xlink:to="lab_EarningsPerSharePolicyTextBlock.5427.205565" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.5427.205565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.5427.205565">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.23593.11.6" xlink:href="plx-20130930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.23593.11.6" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138808.205567" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138808.205567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138808.205567">Nature Of Operations [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.23593.11.12" xlink:href="plx-20130930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.23593.11.12" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138809.205569" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138809.205569" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138809.205569">The accounting policy related to the nature of operations of the entity.</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.23593.11.7" xlink:href="plx-20130930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.23593.11.7" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138810.205568" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138810.205568" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138810.205568">General</link:label>
    <link:loc xlink:label="loc_DebtPolicyTextBlock.7719.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtPolicyTextBlock.7719.11.7" xlink:to="us-gaap_DebtPolicyTextBlock_lbl.267627.275829" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_DebtPolicyTextBlock_lbl.267627.275829" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_DebtPolicyTextBlock_lbl.267627.275829">Convertible notes</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.5200.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteAbstract.5200.11.6" xlink:to="lab_StockholdersEquityNoteAbstract.138077.205560" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteAbstract.138077.205560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteAbstract.138077.205560">STOCK TRANSACTIONS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.7" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.138805.205562" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.138805.205562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.138805.205562">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.6" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.18039.205561" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.18039.205561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.18039.205561">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_ClassOfStockLineItems.1018.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClassOfStockLineItems.1018.11.6" xlink:to="lab_ClassOfStockLineItems.2526.205541" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClassOfStockLineItems.2526.205541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ClassOfStockLineItems.2526.205541">Class of Stock [Line Items]</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.23588.11.6" xlink:href="plx-20130930.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.23588.11.6" xlink:to="lab_EmployeeAndNonemployeeMember.138111.205542" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138111.205542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138111.205542">Employee And Nonemployee [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.23588.11.12" xlink:href="plx-20130930.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.23588.11.12" xlink:to="lab_EmployeeAndNonemployeeMember.138112.205544" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138112.205544" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138112.205544">Employee And Nonemployee [Member].</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.23588.11.7" xlink:href="plx-20130930.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.23588.11.7" xlink:to="lab_EmployeeAndNonemployeeMember.138113.205543" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138113.205543" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138113.205543">Certain Employees and Non-employees [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeMember.23589.11.6" xlink:href="plx-20130930.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.23589.11.6" xlink:to="lab_EmployeeMember.140096.205545" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140096.205545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140096.205545">Employee [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeMember.23589.11.12" xlink:href="plx-20130930.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.23589.11.12" xlink:to="lab_EmployeeMember.140097.205547" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140097.205547" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140097.205547">Employee [Member].</link:label>
    <link:loc xlink:label="loc_EmployeeMember.23589.11.7" xlink:href="plx-20130930.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.23589.11.7" xlink:to="lab_EmployeeMember.140327.205546" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140327.205546" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140327.205546">Certain Employee [Member]</link:label>
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3709.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3709.11.6" xlink:to="lab_OptionIndexedToIssuersEquityEquityAxis.12418.205548" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionIndexedToIssuersEquityEquityAxis.12418.205548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionIndexedToIssuersEquityEquityAxis.12418.205548">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3712.11.6" xlink:to="lab_OptionIndexedToIssuersEquityTypeDomain.12421.205549" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionIndexedToIssuersEquityTypeDomain.12421.205549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionIndexedToIssuersEquityTypeDomain.12421.205549">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.15050.11.7" xlink:to="lab_ProceedsFromStockOptionsExercised.138107.205550" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.138107.205550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.138107.205550">Cash proceeds from exercise of options</link:label>
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4895.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfStockByClassTable.4895.11.6" xlink:to="lab_ScheduleOfStockByClassTable.16952.205551" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfStockByClassTable.16952.205551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfStockByClassTable.16952.205551">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511.205553" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511.205553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511.205553">Common stock issued in connection with exercise of options</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957.205552" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957.205552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957.205552">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtDisclosureAbstract.1355.11.6" xlink:to="lab_DebtDisclosureAbstract.275824" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtDisclosureAbstract.275824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtDisclosureAbstract.275824">CONVERTIBLE NOTE [Abstract]</link:label>
    <link:loc xlink:label="loc_DebtDisclosureTextBlock.7682.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtDisclosureTextBlock.7682.11.6" xlink:to="lab_DebtDisclosureTextBlock.3725" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtDisclosureTextBlock.3725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtDisclosureTextBlock.3725">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_DebtDisclosureTextBlock.7682.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtDisclosureTextBlock.7682.11.7" xlink:to="lab_DebtDisclosureTextBlock7.134426.275825" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtDisclosureTextBlock7.134426.275825" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtDisclosureTextBlock7.134426.275825">CONVERTIBLE NOTE</link:label>
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.2053.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresAbstract.2053.11.6" xlink:to="lab_FairValueDisclosuresAbstract.275826" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresAbstract.275826" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresAbstract.275826">FAIR VALUE MEASUREMENT [Abstract]</link:label>
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.9740.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresTextBlock.9740.11.6" xlink:to="lab_FairValueDisclosuresTextBlock.6756" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresTextBlock.6756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresTextBlock.6756">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.9740.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresTextBlock.9740.11.7" xlink:to="lab_FairValueDisclosuresTextBlock7.134437.275827" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresTextBlock7.134437.275827" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresTextBlock7.134437.275827">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:label="loc_ConvertibleDebtFairValueDisclosures.7348.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConvertibleDebtFairValueDisclosures.7348.11.6" xlink:to="lab_ConvertibleDebtFairValueDisclosures.3204" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConvertibleDebtFairValueDisclosures.3204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ConvertibleDebtFairValueDisclosures.3204">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:label="loc_ConvertibleDebtFairValueDisclosures.7348.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConvertibleDebtFairValueDisclosures.7348.11.7" xlink:to="lab_ConvertibleDebtFairValueDisclosures.1889832.277318" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConvertibleDebtFairValueDisclosures.1889832.277318" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ConvertibleDebtFairValueDisclosures.1889832.277318">Fair value convertible notes</link:label>
    <link:loc xlink:label="loc_InterestIncomeAndInterestExpenseDisclosureTableTextBlock.11620.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InterestIncomeAndInterestExpenseDisclosureTableTextBlock.11620.11.6" xlink:to="lab_InterestIncomeAndInterestExpenseDisclosureTableTextBlock.9658" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InterestIncomeAndInterestExpenseDisclosureTableTextBlock.9658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InterestIncomeAndInterestExpenseDisclosureTableTextBlock.9658">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:label="loc_InterestIncomeAndInterestExpenseDisclosureTableTextBlock.11620.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InterestIncomeAndInterestExpenseDisclosureTableTextBlock.11620.11.7" xlink:to="lab_InterestIncomeAndInterestExpenseDisclosureTableTextBlock7.275830" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InterestIncomeAndInterestExpenseDisclosureTableTextBlock7.275830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InterestIncomeAndInterestExpenseDisclosureTableTextBlock7.275830">Schedule of Interest Expense Recognized</link:label>
    <link:loc xlink:label="loc_DebtInstrumentConvertibleBaseValueForConversionRate.32279.11.6" xlink:href="plx-20130930.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentConvertibleBaseValueForConversionRate.32279.11.6" xlink:to="lab_DebtInstrumentConvertibleBaseValueForConversionRate.277761" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentConvertibleBaseValueForConversionRate.277761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentConvertibleBaseValueForConversionRate.277761">Debt Instrument Convertible Base Value For Conversion Rate</link:label>
    <link:loc xlink:label="loc_DebtInstrumentConvertibleBaseValueForConversionRate.32279.11.12" xlink:href="plx-20130930.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentConvertibleBaseValueForConversionRate.32279.11.12" xlink:to="lab_DebtInstrumentConvertibleBaseValueForConversionRate12.277762" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentConvertibleBaseValueForConversionRate12.277762" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentConvertibleBaseValueForConversionRate12.277762">Debt Instrument Convertible Base Value For Conversion Rate</link:label>
    <link:loc xlink:label="loc_DebtInstrumentConvertibleBaseValueForConversionRate.32279.11.7" xlink:href="plx-20130930.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentConvertibleBaseValueForConversionRate.32279.11.7" xlink:to="lab_DebtInstrumentConvertibleBaseValueForConversionRate7.277763" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentConvertibleBaseValueForConversionRate7.277763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentConvertibleBaseValueForConversionRate7.277763">Base value for conversion rate</link:label>
    <link:loc xlink:label="loc_DebtInstrumentConvertibleConversionPrice1.7700.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentConvertibleConversionPrice1.7700.11.6" xlink:to="lab_DebtInstrumentConvertibleConversionPrice1.3746" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentConvertibleConversionPrice1.3746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentConvertibleConversionPrice1.3746">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:label="loc_DebtInstrumentConvertibleConversionPrice1.7700.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentConvertibleConversionPrice1.7700.11.7" xlink:to="lab_DebtInstrumentConvertibleConversionPrice1.182646.277343" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentConvertibleConversionPrice1.182646.277343" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentConvertibleConversionPrice1.182646.277343">Conversion price per share</link:label>
    <link:loc xlink:label="loc_DebtInstrumentConvertibleConversionShareNumber.32278.11.6" xlink:href="plx-20130930.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentConvertibleConversionShareNumber.32278.11.6" xlink:to="lab_DebtInstrumentConvertibleConversionShareNumber.277758" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentConvertibleConversionShareNumber.277758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentConvertibleConversionShareNumber.277758">Debt Instrument Convertible Conversion Share Number</link:label>
    <link:loc xlink:label="loc_DebtInstrumentConvertibleConversionShareNumber.32278.11.12" xlink:href="plx-20130930.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentConvertibleConversionShareNumber.32278.11.12" xlink:to="lab_DebtInstrumentConvertibleConversionShareNumber12.277759" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentConvertibleConversionShareNumber12.277759" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentConvertibleConversionShareNumber12.277759">Debt Instrument Convertible Conversion Share Number</link:label>
    <link:loc xlink:label="loc_DebtInstrumentConvertibleConversionShareNumber.32278.11.7" xlink:href="plx-20130930.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentConvertibleConversionShareNumber.32278.11.7" xlink:to="lab_DebtInstrumentConvertibleConversionShareNumber7.277760" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentConvertibleConversionShareNumber7.277760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentConvertibleConversionShareNumber7.277760">Number of shares for basis conversion</link:label>
    <link:loc xlink:label="loc_DebtInstrumentFaceAmount.7642.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentFaceAmount.7642.11.6" xlink:to="lab_DebtInstrumentFaceAmount.3669" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentFaceAmount.3669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentFaceAmount.3669">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:label="loc_DebtInstrumentFaceAmount.7642.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentFaceAmount.7642.11.7" xlink:to="lab_DebtInstrumentFaceAmount.172853.277337" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentFaceAmount.172853.277337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentFaceAmount.172853.277337">Principal amount</link:label>
    <link:loc xlink:label="loc_DebtInstrumentInterestRateStatedPercentage.7726.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentInterestRateStatedPercentage.7726.11.6" xlink:to="lab_DebtInstrumentInterestRateStatedPercentage.3777" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentInterestRateStatedPercentage.3777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentInterestRateStatedPercentage.3777">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:label="loc_DebtInstrumentInterestRateStatedPercentage.7726.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentInterestRateStatedPercentage.7726.11.7" xlink:to="lab_DebtInstrumentInterestRateStatedPercentage.152933.192657" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentInterestRateStatedPercentage.152933.192657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentInterestRateStatedPercentage.152933.192657">Interest rate</link:label>
    <link:loc xlink:label="loc_DebtInstrumentMaturityDate.7758.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentMaturityDate.7758.11.6" xlink:to="lab_DebtInstrumentMaturityDate.3816" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentMaturityDate.3816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentMaturityDate.3816">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:label="loc_DebtInstrumentMaturityDate.7758.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentMaturityDate.7758.11.7" xlink:to="lab_DebtInstrumentMaturityDate.160594.184419" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentMaturityDate.160594.184419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentMaturityDate.160594.184419">Maturity</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfDebt.14860.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfDebt.14860.11.6" xlink:to="lab_ProceedsFromIssuanceOfDebt.14891" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfDebt.14891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfDebt.14891">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfDebt.14860.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfDebt.14860.11.7" xlink:to="lab_ProceedsFromIssuanceOfDebt.182593.277653" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfDebt.182593.277653" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfDebt.182593.277653">Debt additional principal amount</link:label>
    <link:loc xlink:label="loc_AmortizationOfDebtIssuanceCosts.32159.11.6" xlink:href="plx-20130930.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmortizationOfDebtIssuanceCosts.32159.11.6" xlink:to="lab_AmortizationOfDebtIssuanceCosts.277327" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmortizationOfDebtIssuanceCosts.277327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmortizationOfDebtIssuanceCosts.277327">Amortization Of Debt Issuance Costs</link:label>
    <link:loc xlink:label="loc_AmortizationOfDebtIssuanceCosts.32159.11.12" xlink:href="plx-20130930.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmortizationOfDebtIssuanceCosts.32159.11.12" xlink:to="lab_AmortizationOfDebtIssuanceCosts12.277328" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmortizationOfDebtIssuanceCosts12.277328" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AmortizationOfDebtIssuanceCosts12.277328">Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</link:label>
    <link:loc xlink:label="loc_AmortizationOfDebtIssuanceCosts.32159.11.7" xlink:href="plx-20130930.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmortizationOfDebtIssuanceCosts.32159.11.7" xlink:to="lab_AmortizationOfDebtIssuanceCosts7.277329" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmortizationOfDebtIssuanceCosts7.277329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AmortizationOfDebtIssuanceCosts7.277329">Amortization of debt issuance costs</link:label>
    <link:loc xlink:label="loc_InterestExpense.11654.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InterestExpense.11654.11.6" xlink:to="lab_InterestExpense.9711" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InterestExpense.9711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InterestExpense.9711">Interest Expense</link:label>
    <link:loc xlink:label="loc_InterestExpense.11654.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InterestExpense.11654.11.9" xlink:to="lab_InterestExpense.277323" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InterestExpense.277323" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_InterestExpense.277323">Total</link:label>
    <link:loc xlink:label="loc_InterestExpenseDebtExcludingAmortization.11648.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InterestExpenseDebtExcludingAmortization.11648.11.6" xlink:to="lab_InterestExpenseDebtExcludingAmortization.9700" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InterestExpenseDebtExcludingAmortization.9700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InterestExpenseDebtExcludingAmortization.9700">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:label="loc_InterestExpenseDebtExcludingAmortization.11648.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InterestExpenseDebtExcludingAmortization.11648.11.7" xlink:to="lab_InterestExpenseDebtExcludingAmortization.205808.278984" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InterestExpenseDebtExcludingAmortization.205808.278984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InterestExpenseDebtExcludingAmortization.205808.278984">Contractual interest expense</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>plx-20130930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-07 @ 1:47 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20130930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20130930.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20130930.xsd#plx-ccsocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:href="plx-20130930.xsd#plx-ccsocisecd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:href="plx-20130930.xsd#plx-ccsocisecdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20130930.xsd#plx-ccsoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20130930.xsd#plx-ccsoop" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20130930.xsd#plx-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20130930.xsd#plx-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:href="plx-20130930.xsd#plx-isoicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20130930.xsd#plx-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20130930.xsd#plx-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20130930.xsd#plx-sapd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20130930.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20130930.xsd#plx-st" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20130930.xsd#plx-std" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNote" xlink:href="plx-20130930.xsd#plx-cn" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/FairValueMeasurement" xlink:href="plx-20130930.xsd#plx-fvm" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/FairValueMeasurementDetails" xlink:href="plx-20130930.xsd#plx-fvmd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNoteTables" xlink:href="plx-20130930.xsd#plx-cnt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNoteNarrativeDetails" xlink:href="plx-20130930.xsd#plx-cnnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConvertibleNoteScheduleOfInterestExpenseRecognizedDetails" xlink:href="plx-20130930.xsd#plx-cnsoierd" xlink:type="simple" />
  <link:presentationLink xlink:title="002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5660.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.12.7" xlink:to="loc_AccountsPayableTradeCurrent.5660.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5690.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.12.7" xlink:to="loc_AccountsPayableOtherCurrent.5690.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsCurrentAbstract.616.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_AccountsReceivableNetCurrent.5665.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13867.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_OtherReceivablesNetCurrent.13867.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryNet.11816.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_InventoryNet.11816.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.620.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_AssetsCurrentAbstract.616.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_PropertyPlantAndEquipmentNet.15211.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.620.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Assets.6057.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.9" xlink:to="loc_Assets.6057.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_AssetsCurrent.6084.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.9" xlink:to="loc_AssetsCurrent.6084.12.9" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_DeferredCosts.7792.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_DeferredCosts.7792.12.7" order="3.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:to="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:to="loc_DeferredRevenueCurrent.7937.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.9" xlink:to="loc_LiabilitiesCurrent.12126.12.9" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.3062.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.12.7" xlink:to="loc_DeferredRevenueNoncurrent.7950.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12757.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.12.7" xlink:to="loc_LongTermDebtNoncurrent.12757.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.12.7" xlink:to="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ConvertibleDebtNoncurrent.7358.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.12.7" xlink:to="loc_ConvertibleDebtNoncurrent.7358.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_LiabilitiesCurrentAbstract.3060.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_LiabilitiesNoncurrentAbstract.3062.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.12165.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.9" xlink:to="loc_LiabilitiesNoncurrent.12165.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_Liabilities.12166.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.9" xlink:to="loc_Liabilities.12166.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_CommitmentsAndContingencies.7121.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_StockholdersEquity.17302.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.9" xlink:to="loc_LiabilitiesAndStockholdersEquity.12135.12.9" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_AssetsAbstract.620.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:to="loc_ShareBasedCompensation.16900.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.23586.12.7" xlink:href="plx-20130930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.23586.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.52" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.12.52" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.14426.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:to="loc_PensionAndOtherPostretirementBenefitExpense.14426.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.14421.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.52" xlink:to="loc_PensionAndOtherPostretirementBenefitContributions.14421.12.52" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_AmortizationOfFinancingCosts.5974.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:to="loc_AmortizationOfFinancingCosts.5974.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.11341.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.52" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.11237.12.52" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.11367.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.52" xlink:to="loc_IncreaseDecreaseInInventories.11367.12.52" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.23597.12.7" xlink:href="plx-20130930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" xlink:to="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.23597.12.7" order="1.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.8" xlink:to="loc_ProceedsFromStockOptionsExercised.15050.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_ProceedsFromConvertibleDebt.14924.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" xlink:to="loc_ProceedsFromConvertibleDebt.14924.12.7" order="1.62500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.52" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.12.52" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.52" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.12.52" order="1.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PaymentsToAcquireRestrictedCertificatesOfDeposit.14394.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.52" xlink:to="loc_PaymentsToAcquireRestrictedCertificatesOfDeposit.14394.12.52" order="1.37500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.20" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.12.20" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.20" xlink:to="loc_NetIncomeLoss.13265.12.20" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.13262.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.13262.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.13246.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.13246.12.9" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.13253.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.13253.12.9" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.12.9" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.10" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.10" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.11" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.11" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5255.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_SupplementalCashFlowInformationAbstract.5255.12.7" order="13.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.12.7" xlink:href="plx-20130930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.12.7" xlink:to="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.23607.12.7" xlink:href="plx-20130930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.12.7" xlink:to="loc_SupplementalOfferingAndStockIssuanceCosts.23607.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.23584.12.7" xlink:href="plx-20130930.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.12.7" xlink:to="loc_CashlessExerciseOfStockOptions.23584.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:type="extended">
    <link:loc xlink:label="loc_EquityComponentDomain.1873.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockMember.1087.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1873.12.6" xlink:to="loc_CommonStockMember.1087.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EquityComponentDomain.1873.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.485.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1873.12.7" xlink:to="loc_AdditionalPaidInCapitalMember.485.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RetainedEarningsMember.4652.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1873.12.7" xlink:to="loc_RetainedEarningsMember.4652.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementTable.5163.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.5169.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.5163.12.6" xlink:to="loc_StatementEquityComponentsAxis.5169.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.5164.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.5163.12.6" xlink:to="loc_StatementLineItems.5164.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.5164.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.10" xlink:to="loc_StockholdersEquity.17302.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_SharesOutstanding.17056.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.10" xlink:to="loc_SharesOutstanding.17056.12.10" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementLineItems.5164.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.17271.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.17285.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5854.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5854.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementLineItems.5164.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.8" xlink:to="loc_NetIncomeLoss.13265.12.8" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_StatementLineItems.5164.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.11" xlink:to="loc_StockholdersEquity.17302.12.11" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_SharesOutstanding.17056.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.11" xlink:to="loc_SharesOutstanding.17056.12.11" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.17243.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_StockIssuedDuringPeriodValueIssuedForServices.17243.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.17220.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesIssuedForServices.17220.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.8" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.12.8" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.5166.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.5166.12.6" xlink:to="loc_StatementTable.5163.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_StatementEquityComponentsAxis.5169.12.6" xlink:to="loc_EquityComponentDomain.1873.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY)  (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.5166.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.5166.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.5166.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.5166.12.8" xlink:to="loc_CommonStockParOrStatedValuePerShare.7131.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.7144.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.5166.12.8" xlink:to="loc_CommonStockSharesAuthorized.7144.12.8" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.12.7" xlink:to="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EarningsPerShareAbstract.1761.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.9078.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EarningsPerShareAbstract.1761.12.7" xlink:to="loc_EarningsPerShareBasicAndDiluted.9078.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Revenues.16160.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_Revenues.16160.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherGainsLosses.23595.12.7" xlink:href="plx-20130930.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_OtherGainsLosses.23595.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CostOfRevenue.7431.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.52" xlink:to="loc_CostOfRevenue.7431.12.52" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_GrossProfit.10776.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.9" xlink:to="loc_GrossProfit.10776.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.52" xlink:to="loc_ResearchAndDevelopmentExpense.15880.12.52" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.12.7" xlink:href="plx-20130930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.55" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.12.55" xlink:href="plx-20130930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.55" xlink:to="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.12.55" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10699.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.52" xlink:to="loc_GeneralAndAdministrativeExpense.10699.12.52" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.9" xlink:to="loc_OperatingIncomeLoss.13592.12.9" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.9" xlink:to="loc_NetIncomeLoss.13265.12.9" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_EarningsPerShareAbstract.1761.12.7" order="14.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.12.7" order="15.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NonoperatingIncomeExpense.13395.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_NonoperatingIncomeExpense.13395.12.7" order="10.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.7" xlink:to="loc_AllocatedShareBasedCompensationExpense.5919.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementLocationAxis.2652.12.6" xlink:to="loc_IncomeStatementLocationDomain.2671.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4573.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementLocationDomain.2671.12.6" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4573.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2476.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementLocationDomain.2671.12.6" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2476.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CostOfSalesMember.1254.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementLocationDomain.2671.12.7" xlink:to="loc_CostOfSalesMember.1254.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" xlink:to="loc_IncomeStatementLocationAxis.2652.12.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="001 - Document - Document and Entity Information" xlink:role="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:href="plx-20130930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DocumentType.210.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_DocumentType.210.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AmendmentFlag.144.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_AmendmentFlag.144.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_DocumentPeriodEndDate.161.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.205.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_DocumentFiscalYearFocus.205.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.206.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_DocumentFiscalPeriodFocus.206.12.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_TradingSymbol.176.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_TradingSymbol.176.12.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityRegistrantName.185.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_EntityRegistrantName.185.12.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCentralIndexKey.186.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_EntityCentralIndexKey.186.12.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_CurrentFiscalYearEndDate.155.12.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityFilerCategory.183.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_EntityFilerCategory.183.12.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.190.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_EntityCommonStockSharesOutstanding.190.12.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="102 - Disclosure - INVENTORIES" xlink:role="http://www.protalix.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2913.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11845.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.7" xlink:to="loc_InventoryDisclosureTextBlock.11845.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)" xlink:role="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2913.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryRawMaterials.11886.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.7" xlink:to="loc_InventoryRawMaterials.11886.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryWorkInProcess.11878.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.7" xlink:to="loc_InventoryWorkInProcess.11878.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryFinishedGoods.11817.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.7" xlink:to="loc_InventoryFinishedGoods.11817.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2913.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryNet.11816.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.9" xlink:to="loc_InventoryNet.11816.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="302 - Disclosure - INVENTORIES (Tables)" xlink:role="http://www.protalix.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2913.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.7" xlink:to="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xlink:role="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.23598.12.7" xlink:href="plx-20130930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.7" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.23598.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.23596.12.7" xlink:href="plx-20130930.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.7" xlink:to="loc_PfizerIncorporationMember.23596.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixLtdMember.27186.12.8" xlink:href="plx-20130930.xsd#plx_ProtalixLtdMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.8" xlink:to="loc_ProtalixLtdMember.27186.12.8" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.23605.12.6" xlink:href="plx-20130930.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.6" xlink:to="loc_SignificantAccountingPoliciesTable.23605.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.12.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.582.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.23606.12.7" xlink:href="plx-20130930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.582.12.7" xlink:to="loc_StockOptionsAndRestrictedSharesMember.23606.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.23603.12.7" xlink:href="plx-20130930.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.12.7" xlink:to="loc_ScenarioTwoMember.23603.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioOneMember.23601.12.7" xlink:href="plx-20130930.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.12.7" xlink:to="loc_ScenarioOneMember.23601.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioThreeMember.23602.12.7" xlink:href="plx-20130930.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.12.7" xlink:to="loc_ScenarioThreeMember.23602.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioFourMember.23600.12.7" xlink:href="plx-20130930.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.12.7" xlink:to="loc_ScenarioFourMember.23600.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementScenarioAxis.5162.12.6" xlink:to="loc_ScenarioUnspecifiedDomain.4760.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TypeOfArrangementAxis.5386.12.6" xlink:to="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:href="plx-20130930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NumberOfSubsidiaries.23594.12.7" xlink:href="plx-20130930.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_NumberOfSubsidiaries.23594.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14867.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_ProceedsFromCollaborators.14867.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MilestonePayment.23592.12.7" xlink:href="plx-20130930.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_MilestonePayment.23592.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.23585.12.7" xlink:href="plx-20130930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.23585.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_CommonStockParOrStatedValuePerShare.7131.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SupplyCommitmentPerYear.27185.12.7" xlink:href="plx-20130930.xsd#plx_SupplyCommitmentPerYear" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_SupplyCommitmentPerYear.27185.12.7" order="4.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.12.7" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RelatedPartyTransactionAmountsOfTransaction.15770.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_RelatedPartyTransactionAmountsOfTransaction.15770.12.7" order="4.62500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.12.7" xlink:href="plx-20130930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.12.7" order="4.56250" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.12.7" xlink:href="plx-20130930.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.12.7" order="4.53125" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.12.6" xlink:to="loc_StatementScenarioAxis.5162.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.12.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.23604.12.6" xlink:href="plx-20130930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.12.6" xlink:to="loc_SignificantAccountingPoliciesLineItems.23604.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.12.6" xlink:to="loc_TypeOfArrangementAxis.5386.12.6" order="3.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.23593.12.7" xlink:href="plx-20130930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_NatureOfOperationsPolicyTextBlock.23593.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.9080.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_EarningsPerSharePolicyTextBlock.9080.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtPolicyTextBlock.7719.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_DebtPolicyTextBlock.7719.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="104 - Disclosure - STOCK TRANSACTIONS" xlink:role="http://www.protalix.com/role/StockTransactions" xlink:type="extended">
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.5200.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.17310.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityNoteAbstract.5200.12.7" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock.17310.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40401 - Disclosure - STOCK TRANSACTIONS (Details)" xlink:role="http://www.protalix.com/role/StockTransactionsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ClassOfStockLineItems.1018.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.1018.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.1018.12.7" xlink:to="loc_ProceedsFromStockOptionsExercised.15050.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.1018.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.12.7" order="7.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3709.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3709.12.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3712.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.23588.12.7" xlink:href="plx-20130930.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3712.12.7" xlink:to="loc_EmployeeAndNonemployeeMember.23588.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EmployeeMember.23589.12.7" xlink:href="plx-20130930.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3712.12.7" xlink:to="loc_EmployeeMember.23589.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4895.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfStockByClassTable.4895.12.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3709.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ClassOfStockLineItems.1018.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfStockByClassTable.4895.12.6" xlink:to="loc_ClassOfStockLineItems.1018.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.5200.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityNoteAbstract.5200.12.6" xlink:to="loc_ScheduleOfStockByClassTable.4895.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="103 - Disclosure - CONVERTIBLE NOTE" xlink:role="http://www.protalix.com/role/ConvertibleNote" xlink:type="extended">
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DebtDisclosureTextBlock.7682.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtDisclosureTextBlock.7682.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="105 - Disclosure - FAIR VALUE MEASUREMENT" xlink:role="http://www.protalix.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.2053.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.9740.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueDisclosuresAbstract.2053.12.7" xlink:to="loc_FairValueDisclosuresTextBlock.9740.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40501 - Disclosure - FAIR VALUE MEASUREMENT (Details)" xlink:role="http://www.protalix.com/role/FairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.2053.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ConvertibleDebtFairValueDisclosures.7348.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueDisclosuresAbstract.2053.12.7" xlink:to="loc_ConvertibleDebtFairValueDisclosures.7348.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="303 - Disclosure - CONVERTIBLE NOTE (Tables)" xlink:role="http://www.protalix.com/role/ConvertibleNoteTables" xlink:type="extended">
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InterestIncomeAndInterestExpenseDisclosureTableTextBlock.11620.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_InterestIncomeAndInterestExpenseDisclosureTableTextBlock.11620.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40301 - Disclosure - CONVERTIBLE NOTE (Narrative) (Details)" xlink:role="http://www.protalix.com/role/ConvertibleNoteNarrativeDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DebtInstrumentFaceAmount.7642.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentFaceAmount.7642.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtInstrumentConvertibleConversionPrice1.7700.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentConvertibleConversionPrice1.7700.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfDebt.14860.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_ProceedsFromIssuanceOfDebt.14860.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtInstrumentMaturityDate.7758.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentMaturityDate.7758.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtInstrumentConvertibleConversionShareNumber.32278.12.7" xlink:href="plx-20130930.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentConvertibleConversionShareNumber.32278.12.7" order="2.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtInstrumentConvertibleBaseValueForConversionRate.32279.12.7" xlink:href="plx-20130930.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentConvertibleBaseValueForConversionRate.32279.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtInstrumentInterestRateStatedPercentage.7726.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentInterestRateStatedPercentage.7726.12.7" order="2.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromConvertibleDebt.14924.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_ProceedsFromConvertibleDebt.14924.12.7" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40302 - Disclosure - CONVERTIBLE NOTE (Schedule of Interest Expense Recognized) (Details)" xlink:role="http://www.protalix.com/role/ConvertibleNoteScheduleOfInterestExpenseRecognizedDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InterestExpense.11654.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.9" xlink:to="loc_InterestExpense.11654.12.9" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AmortizationOfDebtIssuanceCosts.32159.12.7" xlink:href="plx-20130930.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_AmortizationOfDebtIssuanceCosts.32159.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InterestExpenseDebtExcludingAmortization.11648.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_InterestExpenseDebtExcludingAmortization.11648.12.7" order="1.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory Components) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
        <td class="nump">$ 2,574<span></span></td>
        <td class="nump">$ 2,118<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
        <td class="nump">140<span></span></td>
        <td class="nump">192<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
        <td class="nump">4,863<span></span></td>
        <td class="nump">1,729<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
        <td class="nump">$ 7,577<span></span></td>
        <td class="nump">$ 4,039<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoods</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryRawMaterials</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWorkInProcess</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0"GC=:&K@$``#P/```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,EUU/@S`4AN]-_`^DMP9*
M4><T8[OPXU*7.']`I8=!!FW3=G/[]Q;V$;/@EL4EGAL::,]Y'\[%"^]@M*RK
M8`'&EDJFA$4Q"4!F2I1RFI*/R4O8)X%U7`I>*0DI68$EH^'EQ6"RTF`#7RUM
M2@KG]`.E-BN@YC92&J3?R96IN?.W9DHUSV9\"C2)XQ[-E'0@7>B:'F0X>(*<
MSRL7/"_]XS6)@<J2X'%]L-%*"=>Z*C/N/"E=2+&G$FX4(E_9GK%%J>V5QR"T
M4Z'9^5U@4_?F1V-*`<&8&_?*:X]!EQ7]4F;VJ=0L.MRD@U+E>9F!4-F\]A.(
MK#;`A2T`7%U%[1K5O)1;[@/Z[6%+VX6=&:1YO[;QB1P)$HYK)!PW2#AND7#T
MD'#<(>'H(^&X1\+!8BP@6!R58;%4AL53&19395A<E6&Q58;%5QD68V58G#7!
MXJS)?SFK\]D$:'O].T+;YLC/L76K"NR9/VCKIL>4"VY`O#OC4]S9`7[V/L3A
M,\[8*&U]VC-P^A2V<:ZI#K5O!,:5L`MT7<%HI^B3XNF">\D,FBPJ0'1HTS;[
M#K\!``#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P"```+``@"7W)E;',O
M+G)E;',@H@0"**```@``````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````C)+/3L,P#,;O2+Q#Y/OJ
M;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].
MP[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4
M_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7<E.4]AK\>4"T\U<%J"`=[!ZH^^CSY
MLK<T36]X+^9]8I=.C$">$SO+=N5#9@NIS]NHFD++28,5\YS3$<G[(F,#GB;:
M7$_T_[8X<2)+B=!(X/,\WXIS0.OK@2Z?:*GXO<X\XJ>$X4UD^&'!Q0]47P``
M`/__`P!02P,$%``&``@````A`#B30&6&`0``V0T``!H`"`%X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<R"B!`$HH``!````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````+R7RVK#,!!%]X7^@]&^D4=YESC9E$*V;?H!PI[8)K9D)/61
MOZ\PP6D@3#=F-@9)>'0Y=S0:;78_;9-\H?.U-9F`22H2-+DM:E-FXN/P^K02
MB0_:%+JQ!C-Q1B]VV\>'S1LV.L2??%5W/HE1C,]$%4+W+*7/*VRUG]@.35PY
M6M?J$(>NE)W.3[I$J=)T(=W?&&)[$S/9%YEP^R+N?SAW<>?_8]OCL<[QQ>:?
M+9IP9POY;=W)5X@A!M6NQ)")8<K+?F4UB8J%O"\&ILQJ8$K*X88#)!UN."0;
M!<Q6*:"L6C*K65)B0#&K`47*X88#)!UN.#2;!;=5"\HJ%>\'UG*L4DH.]QDG
MCSBW4Z11P(Z&9*-F8^:-K[3#XCVXV*7X&/ARE=],4VDS'U/,T$!<A0Q3EYYB
M3HD!;C5`RE&CWN(^G)O8,5XMZL<D#NX*`W2%63/G"JPI.J,>HR%-K_X,4Y?,
MG5%BN-&09(`;#9!LU*A=1(CO*;RZU`]E_QVJKKQYD&U_`0``__\#`%!+`P04
M``8`"````"$`XK-5&:\"``!W!P``#P```'AL+W=O<FMB;V]K+GAM;)15VVZC
M,!1\7VG_`?&^Y=:[FE24T*[5U*F"DSY:+CC%*N`(G*;]^SV0#3$AJM(GL(W'
M,W/&AYO;SSPS/GA9"5D,3.?$-@U>Q#(1Q=O`G)'[/Y>F42E6)"R3!1^87[PR
M;X>_?]VL9?G^*N6[`0!%-3!3I9;7EE7%*<]9=2*7O("5A2QSIF!8OEG5LN0L
MJ5+.59Y9KFV?6SD3A;E!N"Z/P9"+A8CY2,:KG!=J`U+RC"F@7Z5B69G#FX7(
M^'RCR&#+)68Y\/[,3"-CE0H3H7@R,,]@*->\,U&NEG<KD<'JE6=[IC5L13Z7
M1L(7;)4I`O*VZ."7>^JZY_67M15SP=?5;E,]-#Y?1)'(=?TI6/O5CCP@L&Z6
M7D2B4EBW;;N=^\O%6ZJVDP!O:?B-@W!.\S2*1M[6$0J5HF&AA/JBJ-BX+R24
ML'8=@3+'-,IK`2\E2IR:N(X23/`HQ%$XHO`63<9HY!,8W/EC'P>AAN*Z&HQ[
M)$Q$`.U)A_$TE,;O(\C\1P$=K:93#>;T9V1`1POCZG3.?H8#6UN<<XU.DXWC
M58&2%N9"@[G89Q.A!XSN4>!C0OT@F,PP0?B!/D/-`J1;[.KF7.[#(#P/,9E,
M41AI)[N0PS8D5_M[(!KS<$K0W3BD>$(ZA^G2'7M_9T0FP2,E4Q]'?D`01$P_
M5-?K]*)Y[Z,IG?OC64B?0C^:32%)F.C[H5&UI)U>)K\W3$^3>Z4#]6*I648)
M>\V@'^YJYL$=WY$XE,6.=0<`.O>S%\+O5>AA]O0;ZO1BJ*N(XI0GJXQ3N8">
M\0%]55<$R=XIZN5P/PP4L[*$;OS!Z8CK.$ZG/+T@]G`ZI#0^3J<ZO7#V(U;S
M8"+3JU1WXE83#/:ZX.&H'<#Q]+OE-I&UFNL+S3EF60Q_C?I1M]WF$&O[SQS^
M`P``__\#`%!+`P04``8`"````"$`D^H?'HX#```F#0``&````'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;)R776^;,!2&[R?M/R#N&P+D6TFJ)M!MTB9-TSZN
M'3#!*F!D.TW[[W>,`\/.BK/=M('SG#=^?8[A9'W_4A;.,V:<T&KC^J.QZ^`J
MH2FICAOWQ_?'NX7K<(&J%!6TPAOW%7/W?OO^W?I,V1//,18.*%1\X^9"U"O/
MXTF.2\1'M,851#+*2B3@DAT]7C.,TB:I++Q@/)YY)2*5JQ16[!8-FF4DP1%-
M3B6NA!)AN$`"UL]S4O-6K4QND2L1>SK5=PDM:Y`XD(*(UT;4=<ID]>E8488.
M!?A^\2<H:;6;BROYDB2,<IJ)$<AY:J'7GI?>T@.E[3HEX$!NN\-PMG$?_%7L
M^ZZW73<;])/@,^]]=GA.SQ\823^3"L-N0YUD!0Z4/DGT4RIO0;)WE?W85.`K
M<U*<H5,AOM'S1TR.N8!R3\&1-+9*7R/,$]A1D!D%4ZF4T`(6`'^=DLC6@!U!
M+\W_,TE%OG'#V6@Z'X<^X,X!<_%(I*3K)"<N:/E+08VC3B2XB$#&1<0/1L%B
MZD]G=A5/K:@Q&"&!MFM&SPYT#7PGKY'L07\%RJTSM8[.ZUM6P:,4>9`JC1:X
MX%"?Y^T\7'O/L*7)!=DI9.XZ'3*=Z<B^1>0&2MFHO?$GQ]=3XI:0U0-'G2W8
M+--6"&7_>\%:%S))=Q',]>_;_071B?TU,35$HFLDT$7B:Z(GHAD-_\>H3-JX
M\"5=+>83?04[A4QZR%0G]E8BLA+Q$*'9A(68]9R\>0#;>LHD.&H]#W/#Q$XA
M0S:M1&0EXB%"LPF6^C:'VU7"1A6-$[53R*(YD;/QTJA@/^H'$[--^^'`7R[T
M[+@?#F?+<1?6',UT1_+Y8C^(,LEP9BQNIY"APEF)R$K$0X1F$YYK_<))F_;^
ME$F6_E3(D$TK$5F)>(C0;,J!IO>V&.Y/"1M5-/M3(9.F/\.)<3CW_>AB\J?!
MU,M!16=-+KQ'C>2X'P[\7E@SM/P70Q(V#!F'8J>0H7I9B<A*Q$.$9L^'=UZ_
M8+?U99-E:<P+,^34CD1V)!Y$=+-R&+BY.V%>O*JFV9X7IF\R-"J^OS#J&1L$
M9I?>("%'5[F4:PEE3XVE:FHK,3OB/2X*[B3T)$?.``Y`=U>-PSM_!;,4C$3&
M_4B.R<V@VP5@2JW1$7]![$@J[A0X`\GQ:`X/=Z;F7'4A:-U,1@<J8#YM/N;P
M>P3#E#8>`9Q1*MH+.8MUOW"VOP$``/__`P!02P,$%``&``@````A`+F&J+OX
M`@``[@@``!D```!X;"]W;W)K<VAE971S+W-H965T,C`N>&ULE)9=;YLP%(;O
M)^T_6+XO7PDD1"%50]6MTB9-TSZN'3#!*F!D.TW[[W=L)PA(2[.;-L2O7Y[S
M89^L;U_J"CU3(1EO$NP['D:TR7C.FGV"?_]ZN%EB)!5I<E+QAB;XE4I\N_G\
M:7WDXDF6E"H$#HU,<*E4NW)=F96T)M+A+6U@I>"B)@H>Q=Z5K:`D-YOJR@T\
M+W)KPAIL'5;B&@]>%"RC]SP[U+11UD30BBC@ER5KY=FMSJZQJXEX.K0W&:];
ML-BQBJE78XI1G:T>]PT79%=!W"_^G&1G;_-P85^S3'#)"^6`G6M!+V..W=@%
MI\TZ9Q"!3CL2M$CPG;]*8^QNUB8_?Q@]RMYG)$M^_")8_HTU%)(-9=(%V''^
MI*6/N?X*-KL7NQ],`7X(E-."'"KUDQ^_4K8O%50[A(!T7*O\]9[*#!(*-DX0
M:J>,5P``?U'-=&=`0LB+^7]DN2H3/(N<<.'-?)"C'97J@6E+C+*#5+S^:T7^
MR<J:!">3&="?U@,G6(9^&'WLXEHB$^`]462S%OR(H&G@G;(EN@7]%3B?([,<
M7:SOA0HQ:I,[[6*\(`H)Y7G>!//EVGV&G&8GS=9J%AAU&G^H2,\*70K`ZQ@A
M\C'C#&KX=O;/2'K3$"D,A^_;7DJ"H2*]5(2+3C)@A-SU&:?9M!AZH)>*8!YW
MOB:E6ZN9]S0C_'1*,6`#D^O9M#C!$'A7IB#T1FQ6LS2%GHT6T_ZB[\51MW?`
M!'U_/9,6CYE&S;.U&GAYQSW.UY1BP!;]#YL6?U1+JYEBFU(,V.#\]/.FS^O'
M9T%O&N8OGG5EL>UF)9$I:31?1*/3F]KUMT,8`.J1U[M0I@^"%@_!+IO-:FRS
M^=Z(.[6K5W#%0Z[K$J<WC?E&=\36:M[/G%V?(K1SQU[+-15[FM*JDBCC!SU3
M?*A)]ZT==UL8=V8XN-T"C)N6[.EW(O:LD:BB!6SUG`4TO;`#RSXHWII;<<<5
M#!KSL83?%11N<<\!<<&Y.C_H>[C[I;+Y!P``__\#`%!+`P04``8`"````"$`
MOCC(4>X"``"G"```&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R4EEUO
MFS`4AN\G[3]8OB_$).0#):F:D&Z3-FF:]G'M@`&K@)'M-.V_WS$.+$!+NQL"
M]GN>G/<<8[.^?2IR],BDXJ+<8.),,&)E)&)>IAO\Z^?]S1(CI6D9TUR4;(.?
MF<*WVX\?UF<A'U3&F$9`*-4&9UI7@>NJ*&,%58ZH6`DSB9`%U?`H4U=5DM&X
M#BIRUYM,YFY!>8DM(9#O88@DX1$+170J6*DM1+*<:LA?9;Q2#:V(WH,KJ'PX
M53>1*"I`''G.]7,-Q:B(@B]I*20]YN#[B<QHU+#KAP&^X)$42B3:`9QK$QUZ
M7KDK%TC;=<S!@2D[DBS9X#L2'.;8W:[K^OSF[*RN[I'*Q/F3Y/%77C(H-K3)
M-.`HQ(.1?HG-$`2[@^C[N@'?)8I90D^Y_B'.GQE/,PW=]L&0\17$SR%3$104
M,([G&U(D<D@`KJC@9F5`0>A3_7OFL<XV>#IW_,5D2D".CDSI>VZ0&$4GI47Q
MQXK(!64AW@4"$1<(\1QOZ1-__C;%M1G5!D.JZ78MQ1G!HH'_5!4U2Y`$0&Z<
MV3Q:KZ]9!8\&<F<H-0M<*&C/X]:;+=;N(]0TNFAV5K/`J-7X\ZYDWTA,!0TW
M;`;^Q9!NR*%1F/:!I=875*OO:PI]?[ECC0T3U+/1=_&"I)O1?JCP>Y!P*/&Z
MD,-0<07I&)UVC8X;-&)8?%<](,M>17=6,[O2^-WD]F\JPC<5AS%%QQ\D<MW(
M<7]&O,%0O':-D57?G]4LZU5*)K.>-SL+UY8P778EX2C@,`KH.(/7[?W.C+CO
M;-I-;&<U,^NLW[1F<L18(S'O+^G%'YK)%^,[ON;_X\N(N[X&"])*+@TCJZ[I
MO9T=;=@H`,X-D\$K`&O,'@QVWRR83-F>Y;E"D3B93=^#@K>C]CS:D0`V,]B3
M>N,AG%/UN-M.P#E1T91]HS+EI4(Y2P`Y<190;VE/&ON@155O34>AX82H;S/X
M(&"P34X<$"="Z.;!;(;M)\;V+P```/__`P!02P,$%``&``@````A`/]7G]:,
M`P``]PL``!D```!X;"]W;W)K<VAE971S+W-H965T,3@N>&ULE%9=CYLX%'VO
MM/\!\3Y\!A*B)%4#.VVEKK1:M;O/#CB)-8"1[4QF_GVO;6!C)\-D\I!`?'PX
MYUS;W-7GEZ9VGC'CA+9K-_0"U\%M22O2'M;NKY^/#PO7X0*U%:IIB]?N*^;N
MY\T?GU9GRI[X$6/A`$/+U^Y1B&[I^[P\X@9QCW:XA9$]90T2<,L./N\81I6:
MU-1^%`2IWR#2NIIAR>[AH/L]*7%!RU.#6Z%)&*Z1`/W\2#H^L#7E/70-8D^G
M[J&D30<4.U(3\:I(7:<IE]\/+65H5X/OEW"&RH%;W5S1-Z1DE-.]\(#.UT*O
M/6=^Y@/39E41<"!C=QC>K]TOX;((0]??K%1`_Q)\YA?7#C_2\U=&JA^DQ9`V
MU$E68$?IDX1^K^1?,-F_FOVH*O`W<RJ\1Z=:_$//WS`Y'`64.P%'TMBR>BTP
M+R%1H/&B1#*5M`8!\.TT1"X-2`2]J-\SJ<1Q[<:IE\R#.`2XL\-</!))Z3KE
MB0O:_*=!RM%($O4D\-N3A(DWBY+YXB,L<<\R^Y\E\J)%$B;I^UI\[4O%5""!
M-BM&SPZL/5#..R17<K@$YB$?[69,[*W`("E)\D6R*"[(@D.5GS=1O%CYSU"9
MLL=L;V#"Q,3D&C-WG9$G-!'%@)!%!PNC#\C6]A'#:KE=YT&VG&3*3BQ%VVM(
M%&>FIOP&QD04UXAD/D(,'U#E2Q_3^B485N1E7`LKL*W&0&G'2"V+^;N(8@IA
MJ(?'W*]>@M<N1#,JBV;!F(I:6%N-6:@EE69!8(WG>AR^1P[+73&%,+3#?KY?
MNP3;VNWD-295VF](U\-3TJ<0AO3T(](EV)8>6;%K3!(I[3-OEAF?Q9\/UH1<
M3Y@R,X4PS,#NO[\.$FR;B2TS&C-37JP:Y</8V^MG"F'HEBW#Q4DZO7,EV-8]
MLW1K3*]['GMIDEG6\@'RMOPIA"$_^XA\";;E6QMOJS&9BCWQYJGI+M?#4RMF
M"F%(#^&@OXQ>OL3>/_S5+--$&%V]M"3UVNT/H'1Q=0#U+`,@BZT3JN@!ET8O
M7HVF#_ERNWL)0=MT700KY6T/2O1&CN/$,ICW@$MY5B%E?R8?=!NB#>C^2S<6
M#68'G..ZYDY)3[*W"N'IX[^Z[\MEWZ<ZMW$`VJX.'?!?B!U(RYT:[V%JX,WA
M%&2Z<=,W@G;JG;VC`AHN=7F$!AM#'Q)X`-Y3*H8;V26,+?OF-P```/__`P!0
M2P,$%``&``@````A`.]:'@_4`@``DP<``!D```!X;"]W;W)K<VAE971S+W-H
M965T,3<N>&ULE%5=;YLP%'V?M/]@^;V`(4""DE0-5;=*FS1-^WAVP`2K@)'M
M-.V_W[6=DD"K+GU)L.^YQ^?<:R[+ZZ>V08],*BZZ%29>@!'K"E'R;K?"OW_=
M7<TQ4IIV)6U$QU;XF2E\O?[\:7D0\D'5C&D$#)U:X5KK/O-]5=2LI<H3/>L@
M4@G94@U+N?-5+QDM;5+;^&$0)'Y+>8<=0R8OX1!5Q0MV*XI]RSKM2"1KJ`;]
MJN:]>F%KBTOH6BH?]OU5(=H>*+:\X?K9DF+4%MG]KA.2;AOP_41FM'CAMHM7
M]"TOI%"BTA[0^4[H:\\+?^$#TWI9<G!@RHXDJU;XAF1YBOWUTM;G#V<'=?:,
M5"T.7R0OO_&.0;&A3:8!6R$>#/2^-%N0[+_*OK,-^"%1R2JZ;_1/<?C*^*[6
MT.T8#!E?6?E\RU0!!04:+XP-4R$:$`"_J.7F9D!!Z)/]/_!2URL<)5Z<!A$!
M.-HRI>^XH<2HV"LMVK\.1(Y4CB0\DD2@_A@/O7`>DSCY/XOO%%F#MU33]5**
M`X)+`V>JGIHK2#)@-LXBJ,_;SL"2R;DQ2385T`JZ\;@.HV3I/T()BR-FXS`I
M1B?,&)&_@9@/$!_T#2+!^L=%FJ2)R'2@MSXV#F(OCMW(SS9&`J`RYP+>KXX!
M0Q7/G)/D9,R=[#"S,TP\UI:_AQAI`Y++M1GP"H/-H2LDG8U/WCC,W/4UGH;S
M49B0D[.1*KC7EZLRX+&J,)KVRF%F5A69!6/-^2BZ"(?H2%/R$4T&/-9$TJDF
MATFLIMD\B89CW6TZ#Y,T7`SAD2IX12ZOE`%/59TZX.Z6P[C^I?%4-,Q)0^'"
MLR":JG)#T,V(ELD=RUG3*%2(O1EP(7@==MWLW9`,7B08>I/]'&:RW?>'`,S$
MGN[8=RIWO%.H8150!EX*W9-NJKJ%%KU]<[="PS2TCS5\_!C,GL`#<"6$?EF8
MN3U\3M?_````__\#`%!+`P04``8`"````"$`D5];>U\"``!'!0``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R,2YX;6R4E&]OFS`0QM]/VG>P_+X82`A-%%(U
MJ[I-VJ1IVI_7CCG`*L;(=IKVV^]LIS1MIZY[$V)X[G?WW!VL+^Y43V[!6*F'
MBF9)2@D,0M=R:"OZ\\?UV3DEUO&AYKT>H*+W8.G%YOV[]4&;&]L!.(*$P5:T
M<VY<,69%!XK;1(\PX)-&&\4='DW+[&B`UR%(]2Q/TP537`XT$E;F+0S=-%+`
ME19[!8.+$`,]=UB_[>1H'VA*O`6GN+G9CV="JQ$1.]E+=Q^@E"BQ^MP.VO!=
MC[[OLCD7#^QP>(%74AAM=>,2Q+%8Z$O/2[9D2-JL:XD.?-N)@::BE]EJ.Z=L
MLP[]^27A8$_^$]OIPT<CZR]R`&PVCLD/8*?UC9=^KOTM#&8OHJ_#`+X94D/#
M][W[K@^?0+:=PVD7:,C[6M7W5V`%-A0Q25YXDM`]%H"_1$F_&=@0?A>N!UF[
MKJ*S15*4Z2Q#.=F!==?2(RD1>^NT^AU%V1$5(?D1@M<C),N3_+S(BL6_*2Q6
M%`Q><<<W:Z,/!)<&<]J1^Q7,5DCVSF;8G[\[0TL^YM('A5!46YS&[28O9FMV
MBRT41\TV:DI*'C63@F'RJ0+,^O\5^*!G%903/A2YC9(R#/8TW^QIOM>=>C%V
MY,1%MEP^2Q0U\Q--,2F>.$7)J=/7,WMQ1='$8_^*^<2-%J/F/$R@S,I%.CV/
M>>-"QWDK,"U\@+ZW1.B]7]8,XZ:[\3W:XGN4AXY-#W"/1]["5VY:.5C20X.A
M:5+BXIKX)L2#TV,8R$X[W.#PM\,/%N"^I`F*&ZW=P\&_:],G</,'``#__P,`
M4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q
M+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]
M&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_
MW^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$CO
MVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=
MB%76JM5F)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T
M0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I
M@O%TS?`4P2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L
M@.SC,NUNM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#U
MSG:WVW3P!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<H
MB(8\NC2+"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<
M&M*\D/0%353;^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$N
MCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+
MKS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*
M'>"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX
M.(N#<N9B5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2
M[>Y1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-Z
MAQRZ2$@(S$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQ
MD;)LS6T!^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^0
M4PA1C/:Y*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!
MG$TP,54&2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)
M9,7R%O6N0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]
MMX0-:-R'0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#
MB1(NX;QHADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@
MK,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)
MQW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*
MU0K<6IKL&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)Q
MTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2
M(=4.EJ$-#3.5A@"+-2<K_UH#S'I1"I14H[-)L;X!P?"O20%V=%U+)A/BJZ*S
M"R/:=O8U+:5\IH@8A.,C-&(S<8#!_3I409\QE7#C82J"?H'K.6UM,^46YS3I
MBI=B!F?',4M"G)9;G:)9)ENX*4BY#.:M(![H5BJ[4>[\JIB4OR!5BF'\/U-%
M[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@
MA_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/
MR"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR
M@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NM
MK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1
M?<DV'D@72#LX@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQE
MY^3B11H[M;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!
MIRJ!H8<>F#R`Y+<<S=*MOP```/__`P!02P,$%``&``@````A`-9Q%>A/"P``
M>F$```T```!X;"]S='EL97,N>&ULW%U[;^/&$?^_0+X#P6N+!(@MB:(LR;$<
MG&2S.>#J!#D'+=`4!451-FL^5)*ZLU/TNW=F^9J51')I4EJW,7*6*.W,;]ZS
M#])7WS][KO+9#B,G\&?JX+RO*K9O!2O'?YBIO]P;9Q-5B6+37YENX-LS]<6.
MU.^OO_K=512_N/:G1]N.%2#A1S/U,8XWE[U>9#W:GAF=!QO;AT_60>B9,;P-
M'WK1)K3-582#/+>G]?L7/<]T?#6A<.E9(D0\,WS:;LZLP-N8L;-T7"=^8;14
MQ;,N/SSX06@N78#Z/-!-*Z/-WNR1]QPK#*)@'9\#N5ZP7CN6O8]RVIOV@-+U
ME;_U#"^.%"O8^O%,U?)+2O+)A]5,O5"51.1%L`(0?_S7-HB_^WWRZ]VW[][U
M__'-=W_[V5[]_=>O]S_[]1NUE[$A-,$&U33/^Y5DX>.$<B^5X/IJ'?A$$`W4
MA-JZ?/*#+[Z!GX$S@'CXM>NKZ#?EL^G"E0'"LP(W")48K`SRL2N^Z=G)-Q:F
MZRQ#![^V-CW'?4DN:WB!.4;Z/<\!,^'%7L+AM'R6B":3:8(P.)F&>(7*Y(%(
M)EZLELG\YP&9.%ZC>EYM],?Q8E)4R]49KWV_V--A&UZYK0B?\&$Y4PT#<LB@
MWT>U4H,=B=ETT0=^)V-V,3J99$-C:(P[E8SSQ7V[(<.AT:4J:Q@:[\<W)U-G
M]\S*I$O3\*DB``.N6RTZ$+H5\3TV\.<4?G+B@G8<BS&J7-)GH5?DQGO'LR/E
MSOZB_!QXIH^*I46-?9NKR9SC=4\>6L_XO>L\^$FC$&TWT(M:H;.)$5KN&-TS
M/D0ZKRG[3MY`;TQ]$>C5<=V\5QR.L)N"*]=7T+;&=N@;\$9)7]^_;*"7\J'#
M1JE[R?=JOOT0FB\#C7448@.BP'56B.)AP3JX5-K%Q:VQN&5\"3)1%"5$#6,Q
M/@+1V_ETT3W2Q73:-5'-@)^.B;X?X4_'1`WX;]&93M,<JG<%,J>GQ`[.N/KG
MX^ET.AE<3":3J3X<Z#I3\C+U:,=?V<\V3L(Z4],^@A$@F`XGTPL-@/3U"6-U
M4@1#`#`>C2:CP533X7^6M(^/H&N=CE395B4()%F5()!D5=;T]SK(_&FDP/J'
MY%@E""19E2"09-5QQQEX+-VJ!($DJQ($DJS*EJHZC%585Y0<JP2!)*L2!)*L
MVEGSF6;@J72K$@22K$H0G-JJV;1JD376^YU99_UQR@N;>(,MDC3AQ6:-,$]=
M!N$*)MW9KL9@"'/$Y-KUE6NO8YB1AL[#(_Z.@PW\NPSB&+9+KJ]6COD0^*8+
M+WO9B.QWQ4C84(*]HYD:/SK6$S#CUBL2W20LCL4ASWHZSB;TL=X?ZR/M(IFP
M=<3:LU?.UMN7+N=]T"]!C:C;>L&)#OV<2>H.Q9I9#ZV0FD]P!#,UL[3@`/")
MS"4$1W0A8[%^+"HC&2$F(QD@*",9(2HCA,ZAX,HTN0JVL)>Y:V##F/3[R5*=
M*)]J@@3X`8\Y#(*,V==G[9`#&JT=TU16R"][L3'7\(=UQP<DK1FQ+V?-@`-2
MUHP0E9'WF\RZ'/%\Z0+3\P$D._KFOOXZ&,`H&9CAV4F":7["U=5D$T$XW?'B
M[O'9$:4K/L)B$.T"MD-E,:V/4&XMVW4_80'\ZSJON;",=7WUO"9;_G`.`_?$
M\40!OH2UXO1E4E^3-\"K;!#LZ)<,4LS-QGVYVWI+.S38X0S&@ETU@$_Q;LX:
M@^(]6Z?W;+80IR9D?@J#V+9B=GB$K=&7X1F6X!FDA$3PM.&OE_`'/0GKHPU_
M6.@Y:`_0BU3^X%S"_+OT!SPFDSHUF(`Z=16>+A'`=#Y#`$:0@0"/]:0Z`/>4
M@0"F21D"<-`"`<"I\(HV<3`@V0Q\H&`)_(_%$G),)B7'\HA2EJ5?X%\AI<&E
MWU9J)OD6'+U0,[RI`-"*95F*E95BB-DAT@H5P)L*%1A0=;LI>8.RG"]-(23I
M`H9"(Y`&JC32G5>2G`L\"P#5&IEWV(<0I\!4)!L"P)$"@1AB(*G^#B@&2168
M>H.D$DPA<#7XA#%!+<%52$D8`(^4J"CZA`%7,4ZH!@)!5H8DWJ#)2I$4@ZP<
M69A"DY4B"019&9):0E:*I!ADY4AB"EDIDD``C4C)D-02LE(DQ2`K1Q:F&,I*
MD02"K`Q)+#$\<HKLT6739!&5K)^.<,^R;.D1#)1-_W=M];RN74@=E$V:@%8V
M/)D])3-'L`6;2Y&I--Y(9>(99UP[51Z#T/D-)IEX0Y4%%^Q0Q1OP8L>B5[Z$
MYN;>?H:I:++/\[QN)6`-IH(_K&2K2A/FG>NG!18!2]<HHE9R-JFO79C?\0Q^
M<;O60VI!X.*.;`RHZQ1#YR[048A@Y,I6$Q1)Z1BHJ:!@UB7#1MFLUE<I<U1&
MNN`-E[D&YG`JK=C@PAE:,V)M0[^5)#7,6R2]0=<F;8.E:Z/03(#[]7QM4O#`
M/R[7)@<CJVHD')+OUETZ0X9N)104I1U%DQALSZV->W3MJDTD__]*&(+N!VO<
MD$-[59'1N5X$H?TOQ^Q1=99."FKMUCB83EE-J1-DLYS71NMP=^WK<+.0]BUL
MMZJVQZ;X]@M+K>Y)G3L&NEI-D1D`]<4:+(?G(0;TR#C-?+7^V+$XOC(W4N#N
MLN+;,N\1T-6:MZ35'!X!"PV$MH;DXA2W5\4M.4_W>#,W+&UV*%[!P!4*EGVX
MS:/E54*T53KG$_"$GC>N]!JX;UCIC>MMS9R/>G+;FK_OO7Q6?Y5GMJW;D`"*
M.?XQ$3:J-ER2:I2C7IF3\EEJ_4IN@UK.V]=HWO5TFG?>LA[YC-,(Z:O"1K`J
M`9!L99`S^ZGAMO4#+I[>3OTI4^^IX;94+XA1Y-!2WZV:V34N6Z\AAH?(JIJ]
M5P726RZ*M26G3.WBFMJU`U;0+&/@2Z%%P\/]5&DE.S0S85NOL-E*;EWA;US)
MMV85?,X4/!>S_P?E3'EOH?WR?A27J9=;QX4;SG'/%;?-K6T$]SK.DXOI1F<5
MK=S'-`QB0@M29E-:0"'Q5PV/4A!:,+-O2@O8)[2&("VA!7?U-*8%QUM26GC0
MI<"EPV964UPP)*7%ZWXDJ'O]D!W9D;`"%XHL@HO2*NR(M8[0`I&;TBKL"(:C
MM$#DIK0*.P)"0DL')DUI%78$*U!:X&Y-:>5VU,%PA-9(4/<7!^W(^RJ>WQ#!
M16D5=N1]=2CHJY1684?>5U'DIK@*.P)5HB\=/FA*J[`CGR=TP3Q!92SLR.M^
M)*C[W8S*>[PFZ/$)E<)V\(KH"%<017244"FLQGOY4-#+$RJ%O7C_U@7].Z%2
M6`KH$8ET^$!<HMQ&0UZ[NJ!VY^8JR[J\PV"=$8$!3U"VMBX\V3K`YV*S\TG8
M5!.!\#2J$*5'VWI2%G"[:4Z(CP<LHR*$;I\WKNF;<1"^*'@F*2?'&QT.80F1
M^U,0Y#KB*6CP5@30#_`4<7A`N0)Z233$^S">1VE")H\%7CUX@T(3,C`Z0</[
M'T[NFI"!T0D9/JEB_R1"YH._V>86XG,IEFX1$A\=_\E>\9[#:U@#D"*4[NQM
M')JY__$AI0DJY@YO4LYI\"DB>2YH=D=UVG_>P3W)F1+QO!:)'>RA18#_N(V)
M&G$4(8)G"42(W#LQ/+LA"V*.!,(2(A'`.<&<Q$Y&$:3Q%S/T,5JXT-WQT1*)
MBE.7T/VOGHL;UIG>8WS./KN5/9\/@*)6]MK<NO%]_N%,+5[_F3T5!9PI_=9/
MSN<@9B1F:O'Z(SYN!J(89D"0;CY&\`@3^*UL0V>F_OMV/I[>W!K:V:0_GYSI
M0WMT-AW-;\Y&^F)^<V-,^UI_\1]0&?Y1@DMXJGV+A_ZS/TX`YRX'^F7DPI\&
M"%-A4_"?BFLSE;Q)X+.-=X`-V^^9$+TH_Z,)U_\%``#__P,`4$L#!!0`!@`(
M````(0`0%6:*(R8``/UR```4````>&PO<VAA<F5D4W1R:6YG<RYX;6SLG<MR
MXT:ZY_<3,>^`4%1'J2(DE53ENGGL.L&BJ"I.2Z):I-SMZ)@%1$(2;!)D`V2I
MY/4\2,<YB]G-0_B\R3S)_/Y?)BX$0$F^36_&X;`E()'YY7>_9>J;?_LRFP:?
MHS2+Y\FW6P=[^UM!E(SGDSBY_G;K8G2T^W8KR)9A,@FG\R3Z=NLNRK;^[?U_
M_2_?9-DRX-LD^W;K9KE<?/W\>3:^B69AMC=?1`EOKN;I+%SR:WK]/%ND43C)
M;J)H.9L^?[&___KY+(R3K6`\7R7+;[?>[+_<"E9)_(]5U'5/7KQZM?7^FRQ^
M_\WR_>%\O)I%R3(`C*"7+./E7=!/W/R`_<WSY?MOGFNH&_XN.)DGRYN,H9-H
M4G\[C!9[P<O]G>#%_L'+^LO3^>>]8/^@_64!1J<5C.#OG<MLF8;CY?^H3_NT
M_J"8:G2WB.HOGQ[L[_ZE_K`#`B:&A*-I>%U_^_0JG&:-B8I5SJ(TG@MUD^`P
M7&X>=Q1GXW`:?!^%:7`$TK/&.FU(*Y;QG_O5VB?X2P/GHS04MP7#N]GE?-I8
M\>SX;_5GG@7.H^M8"(<Q3L-98U=/S\X'H\YQ_V_!A_Y@]*EWWCGK78SZW>%.
MT#_M[FV8M`N?I>"@#^]\"?X<W=7'/=W?WS^`@5^\/:B_ZJ[25&Q:1>,FG#_=
MW3UXL?NR,8??VU$\C=*@"[&NYVD3ALYX'#&`UQ-6XZ<Z*'Z:[GPVFR?!<#D?
M_[@3#&_"-,J"P6II$@W2ZY]U!Z>'O=-A[S#@I^'@N'_8&?'+A\YQY[3;"X:?
M>KW1,-B^&!X&3Y[5/^XGP>AFOLJ0TFP':9Y&61;,ES=1>AMG49`MHG%\%3<E
M\C`:(Y%.Z%[4)^U>G)_W3D=!9SADZ:\;K\/LQM3"6#]$_UC%G\,I-&AP+AB3
M8LF"-!I'#+J<1KN!6*_!-P-!'(19%C5GZ2>?F7R>QE%C@=%\"=N,/0NT?WYT
M<7HXA/N"\][PK-<=!8.CH'=R=CSXOM<+SOL?/X'<B[.!WH_ZY[T3-E[?,$Q]
MUCL??1]T3@^#WE\N^F<:M1.<]AI##WM'/9`'+3]USC_VAO6IGO[\SY__67_H
MMM$.?H'#17@G!!KBP_$X7:%]&J39C-SZFH?1583D3*`-Z%T]A-MI'%[&TWC9
M0H3CP>G'8-0[/PF.^YT/_>/^J-]K89HY9$R7L;:0S)?-]8[]"G=!G&"BDB0:
M+S$TP6V\O.'WZ32\G"-\>H2Q<S_5-U7.@:$*HMEB.K^+HB"-KV_@PM6";]-H
M&:>1E'K]8T<%+.YUL(S267#/EOW0S3CI#DY.^B-Q28,#NIVS/BHR@%/ZW7[O
MM/O]!D#*V8,D6@;SJV`<+F(Q_"2ZBL<Q+D-#26W0)<,1*L6@$?>+F3NC/LKF
M<5HE^C*.%DNGR8))N`Q_B:)Y^6C'H*F&VA7CQLUL]@7.>]_U3B^:T@B9SCJG
MWS\=HF4[YSUIB>[@^+CS8>`0%'0^GO=:54)W,#1-LFGFC^>#X3!`<1SU&SH"
M1=3KG'<_F3HY!+3C@2F4H/>W,QF"!LL<2ZGO!M<RNYDI@#2*9Y>K-#-&;JC%
M!Q=H55T?>Z?PQ;%!U3D\Z9_VAR.AX;O>1L`\)R'_QVRWSL='_5,L6)\IL?V#
MDUZPG6_P&;MI49X\LHF"H\%Y@/<0P*C]P6%]7JVE5YYH<+3$#0T^'`VZ?V[H
MQ`^=8;_K<-T_OL"TUN?[:T]6`)W=^0X$?.P%IQ<G'YB>B8TMAOJIND1P(6MM
MS')RAGOC]U_"U(#A%\OE&5X#_C3*"N?PV28Y/8\RW,:QL\:'*/+I?&'^:N\+
M\0#V_^\GT>PR2AO.<2]7C<,H_1R/(R?<NY=AAD7`@='7IFMW@LYT.A][O7L5
MG$?C^742_\0P[W)VYQE,^??C.(F"_C*:98W%S`7R<X\K<]?I\#%*T.M38_#.
M9!8GYFDNX\]1\-!^!(0TY+DS9AOW_1`=C-*?.J=8;M'7R/]I<'S8.T='R/+C
M!&PW-?A&`JV[9PU%6L>`V97ZPZH_N7%CG<D$XSQ/0-\BC">[V-"NMQ:;>`#/
M8C5;3<V?Q1O`HBPW3O\!MS])%#%\"*=A`L.$RZ#J0S9\ZN87V\"4F3?\[,&O
M_9XS^=!!G&4K^$TFW3S.;6\.]=Q@&8L%&Z[QKYDCJ`!9I\,F-L:E<$A<SHG:
M!?!\(5(TU/)C)B!66*;Q6#&&FRN\#=/)3NX!@(.K*%ZN&/9KP'O\[/<AHO<E
M2L>*+A`XOU5GFP`:'.1N5P/"QWYWW]JG>$+3.>90W(!^#'`%";/KR"`"K#%K
M-071\#1JPRM,($Z]]],FG]<DH[%8\XO:>E6Y:GQ=`[4&WLL'$%%;J;JSQJ=_
MG*Y\G''[A>LWM?(]R:'[=,..*9Q2L=116M7'.VC;-"#\735"VO5AG=7RAA`6
MN]F8[C%>;K<S_!0<'0_^NM%EKXPX.A^<Y$X^KDFGBP_7'I3ETE2'J3/Y894M
MY4DH=B?`5Z"(:!/'SY,QN0_31R:'/)4Z-L6\DO>`EO?Q&=:"Q%S\V:+&ADMD
MVC!P'L?X'J_@,%JP;.P\$"4C;]-X&063^2T+7057\1<6;8^=C^($,L;8Q,CY
M0YE4"XM%SYQ&W59"='K'Z_%-F%PS:WQ%6$QD%;78$QN2:8,6?[-L'B+>F3K*
M%=\CX\V/K!T0D88SER2Y6BEUJNE1T^1MS*'YA7-V9G-B[)\*=VT272YK[&SN
ME3V?D'G4TG7J=\N-5BAIN1G[.-\UN8`&5=%=9)VQ#6R#,'4]Q6#8GZY,-2?S
M9#=/W"P$]#QI6/!^4DX&RNNY)`/&<ET;Z%_]/MZ<12J&;4\\],\\D=V*;9F7
MZE;*E$%C!Q*P!T6C@?]2V$V4^Z??]8869=PCRF<KX@`A'IE8I*(;"7N)B\37
M@H+Z,O`*Q,>2_@J^,_&I3ZA$G=,:GHES3V82+>99W."S!G)$HVPIPUWJC?HB
M=3WG@\R']1Q(&4?1A/VF\UDI$Z`+G79_:JJ?.YH,SLR#+1RR-1^T#FN+PU,?
M4N``\#['DO]+E(G36_?BH7=TE"<S_T:ND8@E(%CO*>]HT0OAL%#56(\0FVC\
MO-<9NG2'>$UI3<.K(ISO.L=M::L\':U0>-,W06<4?.A][)^>*B1F9'O\_MBI
M>H"U<9+AQ=G9L:5F.N??LR52!B>6U`K8>45BF*.-18+3@1#QW>#X.\%:<E5#
MHQ7$5Y2!:BY\_3K;('GH.W%O,E\&=TB^(K$Z`8;]CZ=],G\=Y=>[W<'%J4GV
M&7E_LH'#7SC\'A>'#?:"`Q(MOW#%L%&E\7'Y.FBIBH1GJ1+P\9?@0SP?D<$/
M%]&*C$5&M2>AOK"MM*W2N"0F[EPB-T;A9*O++)[$H3+Z.^;$;^$L+<+D;@N[
M+)VE4;<W?'RWBYE'*(I/[G:"8M'CY62/\6D47,;S!7(Y"\>V/@9?'D68L`"6
MF9H:4V!I%2],*ED2+<7`F<(9ME&:3?DYLTM)X5(?Y?N28EU&<9)YM\5/Z8%_
MFIGB95?+,+T3F-UH.NU]<7@#7_KWC/](V72F\74BQ_';K6R%LL[&:;Q8;CVG
MGOJ3>WRPK]_`H`MT9M2!#_0D/:+0ZH:,XAD;/(UN@_/Y+$ST]BJ<Q>#:)K;A
MSVW)Y?N?_W<#CC]F)16HO\X6D.+;+3RWC`13M/4^1YT\,1ZJ\AUD=QGYHF![
MJT#5UK,].$<!%R_(6U$OWG]7H[A<K1GT#!-G^C?P";6P"1.(Y-/PEIK8E?V,
MOH6>I#!4+BLXZ</>=W`2+DN][J#/>RN9TS`)3J()29($E'>NE7P'\MY)9XML
MQF(Q)4]GM0E8!.?1O,2UCR\2MKQ'L2ZR_!K,#K\L;TD95*3!F#G-W29<ZS4!
M`G"8#U_'=K(UK'RXMU50MU*4'P!S>!?X*I\3M8N]X1YUYKD02&4Z75T'U5P;
M9-G>.CKTN\(F@6F)^/5T-48.\"_"Z55H[FZ<_.!*-&[B4@JNXA1-"5+<YQ.M
MP<^3U7B)N"J!3;O#3W<S"C/18@JC6,I2=`D7()5*VS-;0/B3;[5KY9@E?J6%
M)")E.%E-I5^I1\F%L1I1*.JQMI@#[7*=X',XNE/O1Q-^#%<T2Z2\(VF:1="B
MN2\^"*M2O`.(I2H0YVEU(0,JI]%ERAH3867[8_?P&70A'A?8'AFYM@&B52;+
M`,<YI="Z^JV0,\WF)>YP!C1=/TO#:!H')RXG>B<@/D7AE,K8MMYO%0,&G^!'
MF*0J0@<O=N15:."'-/R),IZ8>=-4E2'Y9">68U8;@C&-G\MSO0IZ:72M1")5
M\R!T@:X*A8(2+"TMSF%UTG?R.*7V6[</\@6C8Q\8`S5'Q7WJ,\=50F@R;VL*
MQ5+PFP</)@Y0G0B:JX<'L_`'?F\!]:YA\=HYXQ+INV::],=(^3FP+'`1;/TV
M7))(I<98:)U+JC63(*%)(N@=]XZ_'P[^S__\=]'A[(HT0.HMY);[389/DY5"
M!-?5[!*9AB4)<A,AB99YBQX(`M@I'$:F'$5DF7\MCF598`S"ZS1R,L;J>GX9
M+6^C*"GUGRRIO?&P.:;ROW3RSZ6=1R60@CB=KZYOUN?9\1BB%<AM6XAR_%G#
MLUR(=FN!F#B_P@"SNA<H]O!(?>3;W0ENY^ET<@LNBIVC-KV1MRU5$1FUZ;*2
M9/4-(S8KN7SB8-8G@X.D^V)RL2GS6':DQJ4.E241(2-\07-\,!>%\7&BA?7(
MZ;&-P*N8J]DO*=[<P@9,[,:M(3L@MG.$!`X41-[9,49A%/69!^D*\Y--%A<+
M1J492%/'>6&_4+KH4:(PY=RKWA);(D[WF=>&Z@1:\(X,K#&R@8WDTOW!;%!N
MM2#\0K")J4WKHR*>O-[?VP]P6Z9R"MA^FQ&.OD1C7$L&\(6`K]/*:)V18UO"
M\0S`6EQA-[1F6-9&GKRJ+#6>H@/5>U79Y6[NX`,/L2CM=SFHZ^2H[JDZ_XOJ
M`HTY-NT.784WX#08\&B+#03K6VU\3=_`_S<Q]3]9#M"&,6+CQB&76&KS+>@C
MM!):"8Q2YXM52DSN=+3O`($?K+8G+'NF5M+%^&6*WZTU-"15E&H_6^-(,%E9
MT"/87#)>D#JP]*Q<U\S;^";&`T?=C'A7:B:OT&0!:B;4`FYGX3W--6NB\"J=
M7RE28#N6BLQ)YT6P0M6&(B@29"UXAL?"X*O]/]E'K_D_.<H8;]%GY2R8V9$*
M4E.$>1[^32[[-;A`<@6RJCIR4.1R!=:<FOP-&J6B/L0:,(/QC#<KP.%5&2B[
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MY6!B$GU91E:J$-K7[>L5VG%7GUL+G;FJ"4G7B`HVC(7N6TSQG6W:%@@<75M>
MD*Y%.#-2)H5Q<PX6OT+DJ_DJ5</\-9(JJ!D-(SL890SR#?*S9SR#@':ZD*8'
MYQ-G/Z(/*]4N8ZDUAKPF&$X3%ZMJ+PF5>M2%):M4C"(#L[HB<>W,(3^I7Q*[
MB3VSK-><0,GK#M/PP@BF`I4#CC'5;(",$^'43G!#PV+P#SH\W01>SY1.9>[9
MMSH*>[@(N`'KM-LI=BY'4D8H7DK3"8:\<@"@4R)C'[I_B3E)H+S=DZ]*[PQO
MFYBS==FJ'^#YC>R&8R7/=`4G699'B0^*$Z@>-ZH$$?I5JXZ_%X!X)[;2'AF/
MO%M&CLW96K3!X@GYVRH`:WRKY/S4<5ONB[9Q+(%N/"V0GF\!_MR`Y!=O'X5E
M)R)UA8OQ`D:XOP@[G,D3WQ5>I8^+2PU[:OX'F^G#RC25()@0BB9\6#%5U13$
M6!TI]S)!C1C83"2,,Z>!B.)WE-Y1%3''N]4DC>:!%P;XR7%EBD1>NY#4&0IG
M#B"%BXT)FDW!"/XBUBL"/(EX([2U>=8I.9+RTDPFLXB:0F8?O_"J4`N>.R44
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MLR!K4Z;'679`<AJE\:4/#]0@H;TXQ=(:[C2`<JI/"\CC0%U:W,[O:32_:F"^
M7P;HVH7!M1!FR(0Z1UR/B)!=8J&2Z2P\%`=!X32Z#)U06>@^L>*E4EYY+HF5
MG$.HS9U$7^+Q?"?HWJBU15)_0<YZ%=Z9G<K#>[=^UU6JY&.,YV5[A%,_3GL)
M8U)</E_"4O-+V?9*<%4`9JJ@R:D,SI>%WXJTJ<'V`PY&1B5"6,WV`G\`2H:L
MLG'?;N10SVIY?2(C(T.6T'!QQ6X=[P7)RLHMB$VQ5H-0E86*Q+L5WRPM:NEY
MIC-$M,B>1=6EBG5!M9`OZM9R&IZC1`B?.,0J%0A1SY7/^S>7OY[.+\F(*07D
M<I.:WM,,Y5&D?,S`.6\Q#\ZS)9TIJD@"Y4+B2#<M!HOBH=PT&&?FQCN+D#_:
M"RRV8L6#EQ9;<<JQLB842TAZCZ7^\LS&D1J,;O`P&DGS.Z@S*7@4@:9MC*XQ
MUXH=C&@&X@@,S5C!Y.D%[D7^8KLSNGBVHSR('X)%SAO.2HMSD>%9;N"WTB)5
MBBSU@HF+6<HSGQW@&UU($K3ARG9F!!<47[.9D&<=#1K@M^WK%F@Y!=L.I</P
M*L(/]V4U!&86_JAC0LFN$Q0F416)P9_#F(-`2"F#"C:`BX[P*/"C27G`*`%J
M<*5^],7J$L8/;ERI1)$([@1J%K$9W0"WP%?^]#8KJD,MD[(4>2^E,/$9<OQL
MXO/+"%R2];(J@>F@-5',$0W[:/M"7JZ2O"P4Y49?,3SSF=(-E"LT6T:"U')_
MGO$KX4J9(H94\X`T]D+GB,#"FEBU2*VTG#M=!X.[^@>0N](#,^4<4B!M99&'
MG3I$;Y$^5/:[,$>6JE-%9)+33I+U.9:HF=5WHK59!57`-5O14)SKL@?T!"P_
MB@JH'_%@-2<H9;=6G?(TH8A3J]75&;\.!A,7"KW=\Q#Q2I;PE*YIO3SYY[3?
MCK=*IO)K>%&UP5![M7*=#@35H##W2$IU5]TNNRMUF.Q3Z7L)EXE.CI-ZQHLS
ME0$]%'-S$&0BO\4R:,Z,"9W"I?A<30P5P<^QL!Z_913QS"(6"%9TGCJ_0,J:
M@(P=<9!;J6KQC76FV7;H<`!Q=_`+C.1E2XO[/<)BED^&R8A=:3/11_F)1BR&
M_#4%'2JS+U">"!P[+S=)OA37F(AW.O4Q>65N%^N8R,0)8K`&HT7R1)'(G+%N
MFS/:@ADQO`F%."(">@$LF#QN2'_2NJXZ"M@O$NNQZI;6$RHE5*$JR()@-,!G
M#7,],)]#Q"H9+Z=/PX]3E;0!@:RS7CAYY%PF(&%\QJJPE)SA):MD.G=0%`N,
MWZM\C\N8@%=.=*(.U!M300PM((MU=O'.$BS.N:8%4,D3=%YJ3G60Y&+T,,-(
M7P+/`M6'2V2,.5\MQT3#7APPWV4W80-+EXTG'Y3MU[=GH!S6-VFH:X`1VU%Q
MQ+J6A.-5$N(]R/&'$9`8V3U^(A]LQ"2EK&XBZT6&S>EN869;I<K,I6O&=BCW
M,H=(8$489]YT%E:_R\5FU065EW$,CK$B[O`4J)#6I7_&OM7L:VJ&W.O'3N>,
M#*T8T.0PGE6`B\LK'I#*:OF'J2"[%`5"E%!NGH`"!%L*CU4J'YK*8AA0%5D4
MD@]:UU:%>(JBVC!B%DG3S1?4YIQ*(Z]&="*$(:(L&%::T[=9/<QU%ZR)K1)>
M4"W(Y3.C@"^)E<RGC1/-X4<IB^-(D>\"DM-84N8(<@1Y(1.;B2=`;DDKCPQ*
M6@.G/`'@_GFL1"$\YD"I92M&[M5#A(![E.:35$L41?Y%NQ"B,`%3%W:W\"B\
M_^L8DWS.:JJ:-#O!(X4+8>8?\&/-SCC?A\4K//\`IWN3UW&D/Z<A&%T,?8^4
M#>#NC3\[SY0Y+7OLTC^'*`R+2_*+"O!?+6:!F[3W7!T4\/!@1D<NC./TA0FH
M[)E"'G]PS2Y$D<YOS&[%:HN,2)_RB:\#::5\HVT\J[F,1-+:#74R;CPYI71I
M]4JXQ;43URDG%30V*9K$4])R'#10*:H8[TI<OD[&6]`QX9C%1*PO:)62L"\\
MGFZQTS>:AM`O198JX9YK9\XYSB-4@1*8A#QV!JURR"5X0JU^_\!W'0G=#!KJ
MT)M*.2A>V7"#0_QI]LV)3@T+*DJUMWX<MN]X,D>;2&1RU>,/GEE9-N\S]YM1
MW.A_M/9LA0OFO\##(,!Z#[V(N2>56PDP<G;8$'Y=:Z%Z&6QGY'].T6K!2^NP
M,K8H'!5'0E7\[BGZ_5Y5TC<[!Z_?[>R_?/6H50'T-Y8:VREE#/IFY^V;=SNO
M88F2DZIL48@UAT?QY&C]X(X@)]TE?OW-0"]L1K69U8OMHNBC]OK[8?C5_MN=
M%U_M/VK5/Q3#;W?>'KS9V7^W_Q"&R7C`H;\6Q5000J)UTQ]YLB^W`7++=TT5
MH16]),/GE;+SI$6^WX]014T!4\[&NS#2L*@)%VY)GJY7>$N*X^7U8;B18U09
M8W![XN1?2XNCSO"#>43>]QI*T]%-E6&&.#:6]_\^"LC?BTVW.\/NL^#MP2OO
M:#D#8/:HM(X3*JY*PUIV!"P[OT&&=2(,5Y6BG5L.9M1_9/HS^:#8-.P&\K=.
ML_R=@C?1V5N.?%3I0;4P@`5K^6TO6`U%&20)*!)<VVJ^W\:Y#'AI.%R$':Q4
MX+;">3KJ<3H:G+><G:B\>NB<Q(M@UPZ-;)H)NZ$KB'"N[3@P3J.ZT_,;S0P_
MN3OQ\S]S;T6H55(?!'IS<\61AODM5&J<,EE3AFZ?9:(MGUH7-M7?;5M#]X2)
M5;,WG/GKH!J'T<[#6V)!F($8NW$X^TE]XK^2.=%\B"*4R1H?'*F!^(:]6>=+
M_6N[R8#//=[67\OZ<W8DE@OK,OZ/:8!3?KM:87>M-WGV5A,UTD'!+34'<QO\
MU3DZ@/O?`I@:,;`LBJX6TOT5-M!B>D5NUMU6N5JC$G'G)7R/CP<L/NO\1MO[
M?B_HY;VD@LMSDKJ;\^#8GC7WCEPUNO]S,2W1@3`20+1AEHS+7.=NP<>&9&>K
M0')LFVM41OT/QURDPAFD==(OW]??/R2:+Q'-^C?K<QH[#:H.6]GF!`$*W33V
M[2?05Y'S9[86E.</0.R3U^\J[:'P?J&4-%Z1]EIRZJN]5_M_:K%PDU6DBP[?
M.BC_<`[9X)VY'NY3A>%;7A4\`,KO996\CGI@M=\N&ALV[B($F<(G57+>3TO#
M$U9T:OSNM1(:SO*1>?=&2F"D)J!=1&;NSZ*8R<P;)-3A2J>RW8YA4;.B\T>Q
MP>^%>TN@8'?6;D^3$'CFKZ2)\^.*ZSES93=<X@DD8)=)2_"(;$I^TB3_/6_R
M&S'YAS#AUI,K.XKVO>S&"2E?],\HE2OAE<Y.<+K7V2.'H]0SSR/*4:Y(D<>M
M1@3G3SAZX'.D")-E82)FPOJ&TMZ6(G'BIZ!8*0,%J7=6&>)2+$K!2C%95H5@
MF1P&MM'TH2Y+PEV20U.:7!X`O$6K;JK+XKJ;RD=6W?NJ"A[&5(AA3'4N&_>V
M53<*5VO]`M9Y(?*4Q"C9MWUDSE^RS9;\\4%^@UFU)Y?M=O7W:J<7JJUH@5H7
MDP>UGJ`UZL#TLJY/7K_>>YNWDD!=Z[K'L:2ZE=.U`1IRE%\^8*2`.7W>QG[5
M$I#;&M#D.UWALB#.WCR3"/&4]COW_.4Q7KI-GVC&)=S'N"F';6>\%=[@47KN
M@IM(;[..`HZ*-S(F>6(L=JG0Q`YPN/)1\?N$*6/:A3AG9CUR"Q4(+>_1P@GF
M(.<X<(!8#L(860%0@5*EV`_>O-Q[_>K=RTJXI_=LLLBU6-1D[/KD8(>&ZU;K
MY/:XK>/_)-"18?E:)M!.J54`8?/$7+"+>11ED]"KO3>O*UDG!M0AH==P`?N7
M<ZTK$VLBF7!R#:6I/&W19=">+$"&&??0GNB]S[MP!$ZYMFD&)Y^UA\)KY8!.
MF4&6$&6J%:CO%3=0YWT,Z(14TR6!JN6:\8!$)C&+TTAX$"B05:(#WH5V:O#?
M6<Y3%9YX9]KA]3J:Q*!:$+W+0:V2'9`FEDDH7L6)53%U58/V4H3':]QCK0B"
MTT3P,8OZ!36+W5(A5Y"?"?M(SCIJYVSDCCODZP$M^;BBH\%+H$"#)"H)5N^,
MR<VGD`UAUDP3B7CV1$F80@NU3+MYQ$S$^K$HE>E$[*G:4ZF-D!&`*.K-%^\[
MYJWS9IG.Q6RXQM:#E_M_RC=681$WA4$.B#[[813//WRQKW*I"3BBSS4R-!HP
M/A6V1#DF4_U=B>9G>=U.[/)RO_HJGV-7ZL/E194+DVY#B`1_99$-^D6CE&C6
M%^4AFYP`GC&,#`+,HT9TGIFGXL2C_-VCSWC>BQ4+9+0.0O_M^-G/_^3>Y0)G
M(*KA!0L@QR2N/\#QE#J^%QQ)9`Y-<H_8Z,B*JDG"0L4HY3;?56@3NIN6=&A)
M/JTA5,.=$%7V(KR4R\;/#*5^+P(3+:WJC4['<^&M=IA78/666V%ITA(8NE2=
M`\9P&):FJ-3E$#$K#'5KR;&R"C2CV)Q3L0T=UMEC-4WWUJW&$FM)<UU-XF#)
M">:([1U2<SC4L=Y::ABQB2+#0#2LO+<N5/8)M*5=EESLPEM3MEW<Z%AS?QV@
MNC*,DX_NBNEGC<3%J1)+)RZOV\,W;%QX,;*TY'TC"DU%ZF2_D>#H,K<N>%?)
ML`[\-[5;Z'?K#[CCYJ'[D.J?V"6B`3>?G@YUW0ZWY#X\XJ$8]BMBV(?FM2CV
M<&6>CEC@$0ES\N0:F0N_+UV$2(J4*>R]9L_=-OY54=GKKW;>O'[[_S:+W^YE
MM)DAH;%PK(6X_X]#?V](?L$COG;>+97?258DHSP#.MM2C;/]C4LM=M\T88YQ
MS)4X%F6XQK!X@OLOY=^VQE)'G?YY\%WG^*(7G'";T47[U>WMHQZ2UU?(:_N7
M=5T@G9O+WXS#,\2#Z%OU%IB1,0=.H8XBBK47?K"S+O(URM(RB3=I;?E^E:O6
MN+6CG!9'BRRYK(?S&W(/IC!,^*X*2=:KV.8OB;L)_[0&N7<Y>_BPLB_Y*2DZ
MJ<KD/*1CM,[\ID33-D;=-"R;MY:[[B+S&;D=94&M"-!=(TYECYLMEJ\KF-WU
M)14%?U@OI9=5*ZB@DV:O5)=1J/[/(FR;]E@NO),UYS11:G]CP#"W2BH/XF1!
M:=IUH[)5#U=U8BR+,M&JH'&I!RT/UDV6Y8D=%:TFD2[IN03IESJJW["$Q]9_
M=O!U\)<5WC&^@QQ3'"`Z,'P4875C:T;*&T2]#^UK8D2:=C_^!O2Y(,0Q!X3+
MJ>2NTX`/6_%T#0LX=U"'RI1$\4@#A?/`PXQ*%((:$8Q[_>+K8%`BUV_+\"^X
M"S[T2$YPA__A,`"7K._6.7`<(4_G=IF_<'E'?*X;-<0AS;NG'`0OOZ:+J4E/
M+4_-DORT@@X.RRWQ>,PCK\ZIJ*3H&W8ZZ@%,0=UV1+W<A*B^;CLD<4:938Q<
MSK]NH0D0N&8*>D@Y6&,91R0X7ZN_P>-9P4[N,,8LNPJRR&O+SM$-6FM6&]G&
M]<;8,F^<B(3Z=)(X)F,*A2WJCU*_QTJ)/T5^*'I\:BZ#IO'<*D!*(DE?9)FT
ME0`J]]=@&2G$\K4&R[:6RHW;L\C^.;7G''_H9RXF]4G?K.NK$_G'N7Z%CBM.
MNUA:3TE)N[L!<KMTC=LFBG=,PN].5#`-_$@`7318;01QM9;"-RV+?8#QY,T!
MWLR^V2;+[E1V;#G@(GE52(<7B5Q;FFYHP/;`56W!]AG]A..[1F6O6NG<'LGQ
M;UY?JML9K899-V'UXDJP:8:A#XM$E[ZEB=$F/7_3_'D11M3G?W!3A[J58)IM
MO$3]X-[X8O_>MZ_O?0MU\[]+M?^N#O=9?BST0SP7D?,;AS(VCPI;Y'^-9-/]
MZF?%/3^/&,SI_+WB=/Y&2.QPVJ;U+!/''R82ZT.A,TM.PF>`:]=J4ER7W3[C
M8B6I?JXNVWC=NT&3=^74H7'K4'_L+)1N(-+8!-&0]G#KC$!K=,JN56-BW0]U
MWQ\-."URA</*/6=U6#R..SI@*)W"7R:I73"3>T'U+T_J][O@W,37UV2T&Q%L
M<Y&KE27^RT9S=&D>3ROH$`G([W`3DPZEUY<>NML5QDIZNRJ2_#\I-.S7!+5K
M?ZT&$E6<N/H<Q_@6^@,/<A+]F<?BF`4Z7JI>G?0>4)_&J$_2!"2OIM1'HH*5
M?6ZT`VJ\15GU#P:6;9)C7YXOUX;S22QK5M7_>:?C\=F0?3^R%ZF^ZIH>7%=7
M>0.'C`FW^N"EHF\>TCR5'@BUKM>7:VK.4VR/M9L^8G)3/GFENC[U62W35G]_
MJ(N=*^DRO+*US%Q]?*&O572HO_Q`*.'C%7&BLX5%B:(^NI1,'U_K&^P<=K'\
MLOY1MVR]!%02MALYYT1%-7)<C1EJ?07!]CJ!\5[DM#7MT6-(,>(/QZSE?![F
MC2ZY:(N`K?WU7EW6U=])0U=6[A_.0U]I:A]B-S;L#R?U\K_5LDG-5H439S?O
M7X48:ZGV1RS9'O,^C(NC,C)U+%!QI,IM/>?/5[[_OP(```#__P,`4$L#!!0`
M!@`(````(0`91$7P)`4``"`3```8````>&PO=V]R:W-H965T<R]S:&5E=#,N
M>&ULE%C;;N,V$'TOT'\0]!Y+I.Z&[<7JDG:!%BB*7IX5F;:%6)(A*7'V[SL4
M98LS:FSO2V)[#@]Y>(;DD*LO']71>!=M5S;UVF0+VS1$733;LMZOS;__>GX*
M3:/K\WJ;'YM:K,WOHC._;'[^:75NVM?N($1O`$/=K<U#WY^6EM45!U'EW:(Y
MB1HBNZ:M\AZ^MGNK.[4BWPZ-JJ/%;=NWJKRL3<6P;!_A:':[LA!I4[Q5HNX5
M22N.>0_C[P[EJ;NP5<4C=%7>OKZ=GHJF.@'%2WDL^^\#J6E4Q?+;OF[:_.4(
MNC^8FQ<7[N'+C+XJB[;IFEV_`#I+#72N.;(B"Y@VJVT)"N2T&ZW8K<VO;)FQ
MT+0VJV&"_BG%N=,^&]VA.?_2EMO?REK`;(-/TH&7IGF5T&];^1,TMF:MGP<'
M_FB-K=CE;\?^S^;\JRCWAQ[L]D"1%+;<?D]%5\",`LV">Y*I:(XP`/AK5*5,
M#9B1_&/X?RZW_6%M.O[""VR'`=QX$5W_7$I*TRC>NKZI_E4@-E(I$CZ20(N1
MA/$%#SWF^?=9+#6B06":]_EFU39G`[(&^NQ.N<Q!M@3FBS(UCJO6SZ2"1DGR
M5;(,7*"B`W_>-YZ[LMYA2HL1$BM(8!H3Q,>0Y`*1$RAIT\L/4QN&FV07A'0/
M%%UEP61160[8_O^&753(1D2%A_N+YQ".$<D<X048DLXAA"2;(S02)-29"W4_
MS<R+4-D(<E#W(L1CC!7$U2$8D=Q%I'<1V2T$D@D#T?V\[:,$KTV8PRG5(CSX
M6$'"(54Y#TFR)GK8"3@)IWHX9(SD<::''<>/IKE%FL`F79-<>O=S5#;"VGR;
M:%,0?]#&[("D<(+"OD\&G^IASFGK3(7=@=P//E'F8V6WW9)@HHBL\EA!E*(G
MYH5D024HSAV?Q%,4=\*`:,Y0W(^T.4&&P>:E&W9;E@036625QPHR&A4$))SH
M8<?F#K8YU<,^G`(XG.EA'KALRA*D298H9/^_GX2R$=%&1A<KR&@9:"/Q!,5#
MAQ-+4A3GCDL]S3`@"-AD.A(888&W39-@(HRL_5A!E#!NAV3<B1YFD4]DIWK8
MMUVR+65ZV/.]R5,DB<%)]N.F#:V(N*F#X<"-1\QHF^<[TZ0.@`0#?&<F$`,8
M)-ZT1PP4&49P;OM3XF.9\G#_X=QDJB30=W]M/8\R%6:4R8)P6ARC3`3@,$B\
MNM*QEY'!MWTRDQD&!(XW90(6*8]Z3>3M_&2J,$#BB$7QB+EZZ)*A)03@T0,D
MQ0`&&^+,0S6.L0^XC4Q]8'7R@']<G2H'D#K2<\PN)8,L,I^8/>7.Z)P>#\E!
MDJ+6-'<S%.7^M/*Q)GF\/ZY)%0-($UGU,=,+AB<O<(FE"0&X`6%(,0`<TPP9
M5QWJ0Z[+:T9C=?*`?UR=*@=@SJ^E5D"62BPO2K"I0O]7S)0MHVEW(>E]ENPF
M!(N4!_[C(E5YH%L83+,W*(B9PD1#760O;'HLW(FG)#[?-`G_E/98F#SU-6&R
MIKQ_'6"J5D`N3AV,`A7FIHMW(>G8TPV6["8$BY4E@";VSM:I"H;;+NI%1<1=
MQ_'F&PS"L(A'+MUA4WB+D"FOML>(.S94)V19R/<*#0.E`'/YE%5*J'J04/?U
M2K1[D8CCL3.*YDT^-G!(MNNOZB$D9DNX1<-EF/R>R@>2X8GC&H#WB5.^%[_G
M[;ZL.^,H=D!I+P)8BJUZX5!?^N8TW(E?FAY>)H:/!WB)$G`_MQ<`WC5-?_DB
M;^'7MZW-?P```/__`P!02P,$%``&``@````A`.5(K'H(!0``T!,``!@```!X
M;"]W;W)K<VAE971S+W-H965T,BYX;6R46%UOHS@4?5]I_P/BO0&;KR1*,AJH
MNCO2CK1:[<X\4^(DJ(`CH$W[[_>:ZV!LF@ST(4WP\?6Y'S[7>//EO2RL-U8W
M.:^V-EFXML6JC._SZKBU__OWZ6%I6TV;5ONTX!7;VA^LL;_L?O]M<^'U2W-B
MK+7`0M5L[5/;GM>.TV0G5J;-@I]9!2,'7I=I"S_KH].<:Y;NNTEEX5#7#9TR
MS2L;+:SK*3;XX9!G[)%GKR6K6C12LR)M@7]SRL_-U5J933%7IO7+Z_DAX^49
M3#SG1=Y^=$9MJ\S6WXX5K]/G`OQ^)WZ:76UW/T;FRSRK><,/[0+,.4AT[//*
M63E@:;?9Y^"!"+M5L\/6_DK6"8UL9[?I`O0C9Y=F\-UJ3OSR1YWO_\HK!M&&
M/(D,/'/^(J#?]N(13'9&LY^Z#/Q=6WMV2%^+]A]^^9/EQU,+Z0[`(^'8>O_Q
MR)H,(@IF%C00EC)>``'XM,I<E`9$)'WO_E_R?7O:VEZX""+7(P"WGEG3/N7"
MI&UEKTW+RY\((M(4&J'2B`?LY3A=T&5`@O#75AQDU#GXF+;I;E/SBP55`VLV
MYU34(%F#9>&9!_'YW#-P2<SY*B9U4P'=0#K>=C3<.&\0P4Q"8H1$MJ4@.B+Y
M!+'L(0[0ZSF"Y_,YBDD&QZ@WW[D1(Z2KF^Y!,GB@$8#`#`G<#XX`0Q"'GJ^,
MA1'B#R"!CDCN(31J8&0Z-0'>VN!EGQ3/U1>.$;+LDKHBWLJ(63(<#ZCK*>(:
M+2CKZ;0$V*!%#%H(";'6W,#3AY/A,/&)<DHC%<XA)<`&*:JO&B,$2?DD,DD-
MA[UPJ7:(1@JVR/1(";!!RE@U1@B2BH+(S-]PV'<]59D:*=&X!JIPO^`%V"#E
M&Y%"")(B+M2-RA#NO"$@)"12XQJOE<YKFEJ)208_5;6H!`B1_/S0#)HV3'TU
MK)$CH)O3H]:A#5JJ1)"6Q%QY>;X*"X9-!X3>K<HGALS?3VB'-J@IGR4UE&^_
MVY'$5W4DB5V'!U)S0]V)4-W)Q=:A#6[&XK'$R+!1`AU2K\=$0T3+B"KW])0*
M'9[.#54;/GM]-3,6DWO*+F-W#Z+3FZ7^9"S_OJFS$H.A\SQBJ$NBC0=TL%-T
M8K/T7QREC!WJFUHK,=><^B,%T0$@,LHUG=JL+D#&;<`W8A)+#%);!>.8#1O!
MRO=NU=JL3D#&K<`W55=BD!@-J'E(2PQ`%"A=U&,VJQ\0%'-M&RC#4CX0`Q79
M;Q4#DD@SGT-T>D9;^(6ZC?O!.*5#Q?<]GQ@2DQ`-L(2_7F$T:G163^C0NKCY
MAG3%$H-)#<.5F?5$`H9Q\VZQ,]K"M'Y*4=N'Q\A!2\3\2LP-$JAS$H.>!#Y5
M!:"'T.@/$TF*648H510D2<3(_4%'!SBJC;M$I4(G*/1Z<I.@J.Y@NJ]\LWO&
M$H/$"*&AIY:6L4,K,G:A1U6!ZMP@`S.X";0>M,`X<L04,9*;%RU#0ZH3#;&D
M[E+IDLYM5I,0[[@F-R7Q,J&(N5]U=S$ZP5FM@HY;16"$)I88#-X#"2-WE-AA
MLWCPO.!&MX#KCCF)'7<+\QTJ[BQN;7SU(Y^=FC3$9Z<FO$#!^X62U4>6L*)H
MK(R_BLL1"F?%_BE>W,1D#6_A<&%B/$_$A4YW)=,/P'W*.3VR[VE]S*O&*M@!
M3+J+"-)9XXT,_FCYN7OM?^8MW*1T7T]P<\;@WL)=`/C`>7O](>Y\^KNXW?\`
M``#__P,`4$L#!!0`!@`(````(0"R24T)D@,``%L,```8````>&PO=V]R:W-H
M965T<R]S:&5E=#$N>&ULE)=;C]H\$(;O*_4_1+DOP8'`@@C5DM6VE5JI:K_#
MM4D,6)O$J6V6W7_?F3B$V(%5]@9R>/W.X[''#*O/+T7N/3.IN"ACGXS&OL?*
M5&2\W,?^O_\\?KKS/:5IF=%<E"SV7YGR/Z\_?EB=A'Q2!\:T!PZEBOV#UM4R
M"%1Z8`55(U&Q$M[LA"RHAENY#U0E&<WJ044>A./Q+"@H+WWCL)1#/,1NQU/V
M(-)CP4IM3"3+J09^=>"5.KL5Z1"[@LJG8_4I%44%%EN><_U:F_I>D2Z_[4LA
MZ3:'>;^0*4W/WO5-S[[@J11*[/0([`(#VI_S(E@$X+1>91QF@&GW)-O%_CU9
M)F3J!^M5G:#_.#NISK6G#N+T1?+L.R\99!O62=/M;Y:S5+,,5L[W<$6V0CSA
MT&_P:`Q!5"W`(.K/.<Q]B%&"-DSW^ASRL5ZVG]++V(X><_U+G+XROC]HB!1!
M&C`;R^SU@:D4E@%BC<((75.1@P5\>@7'_01II"^&CF?Z$/N3V2B:CR<$Y-Z6
M*?W(T=+WTJ/2HOC?B$AC94S"Q@2^3XT)&=U%T71V-Q_N,FE<X+MQ(>%0E,!,
MJ\[8`]5TO9+BY,%^!7!54=S]9`G&U],"^4#M/8IC?PX+%_L*UN9Y/5X%SY#]
MM%%LC`(^6P6Q%<E9@0L(#"T(Y&8X"(H1!-<+R3;F03=NZ,3M*R:MP@*!+'1!
M<,-,8*^^G1D<!+K.O*>MNR$TBFE'$=F*Y"V%10@F7<*WR5`<^S#[=D5F=MR-
M473)YK8BZ2LN[!89;.;A9"BVR>[LN!NCZ)(M;$725]P@F[V'#,4V&7$WNI%$
M=1%,231U4V;>=]%O@$$U#4\9BATPI[XV1M(-3-Q2Z$MNL.$OY^##`<4.VZ7"
M3`T8B<7FE$G2E]Q@6[R'#<4.V\76L!F)Q>842M*77$RL,B!P7@Q/7*UVZ)SM
MM&DT%IY3+<D5S2T^/(0'+RPQ1W;W""%.'6X:39<O=$HFN:*YQ8>']7`^<[1W
M^4*W*HC16'QN65S1W.+#HWHXGSG8+3ZW,DC_\`_=TKBBN<4'\^SR#?L-@][-
MK9+P$L!42:/IYM&18`N(-K/Z:%Q,HAF9SRX:4R>F=3.-2,'DGB4LSY67BB.V
M8@2&MD_;WK)I^MH7T*55=,]^4+GGI?)RMH.AXQ$V5-+T>>9&BZIN<[9"0W]6
M7QZ@B6?0-HQ'(-X)H<\WV)2T?PO6?P$``/__`P!02P,$%``&``@````A`,"+
M>5"$!0``3AL``!D```!X;"]W;W)K<VAE971S+W-H965T,38N>&ULG)G9;JM(
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MYR\!38^G"NPVX8G8@UG[-X>6"6049":&R922_`P5@/]*EK*F`1F)7^OK2[JO
M3AMU.I^8"WU*`%<>:%EY*9-4E>2IK/+L?PZ11HJ+&(T(7!L18DYFAKE8?D5E
MVJC,;RK&Q%B:Q)Q_H2Z+1@6NWW\@Z!UU5N#:B!C+R8+HJ^GB\UE9-2)P;47(
MEU-+H$5P@UC3^+9#I/,9/K2U67[:(XVWFKH1.G$5WZ^+_$6!G@UJY35FXP2Q
MV&^TS8\WEJY!?M0>H2$RE9],IA:#IE9")WJ^-\ALK3U#PT\:QAYB3)'9<@:L
M[W3,N8@X+<*Z`OMMMPW<RA"QB-<2;1%?#@1R(.0!^-]5Q"!2379#C/1`T1"S
MZ*JG@0N=%=#Y>E9,H=$,CP1MYEDI,?.F5`>;(^^3:I!E5X<ZB=L!1B2</F'>
M'H0[T4<,4<3K$[*(SQ$A\Z)(@!+A`&%(C6(WP,A9B088X]:L!?=@\/N&>ZP4
M<Z]MF38/++K`5@XX<L"5`YX<\'E`2"E924D=8`Q=9,(A1G)X-\1,19UHB+DU
M6B&MLV^EE96"B?!][S6DWFMS!OYW/?Q6!=XG4,)!"1<E/)3P42)`B1`E=B@1
MC1&":3#%"GUA?`1C]$:%KM8981C2R&)S!BK0,;)9*.&@A-L2]?PEMEFOO?=A
M#7R4"%`B1(D=2D1CA&`3K-,$F]C<CT\XK)1LES2;V)Q9U@N!N0Y_8C*W_/Z(
MG0Y*N"CAH82/$@%*A"BQXP3/AME+1C0F(/@%,[C@UWBW8K3LDS3HVYP9\6&+
M$@Y*N"CAH82/$@%*A"BQ0XF($W.^Q!7,%*QBNW-Y68UW+59*LFPJ=1V;,V.6
MH82#$BY*>"CA<\(TZESID]NZJ9Y=`^FV-#V'J/X.):(Q0K`+=GC?L(N5DNV2
M5IDV9\;L0@D')5R4\%#"1XD`)4).-+UCV1_X=ZA$-$8(GK&-]3=,JXO)KDF+
M6+N!QFS#$0='7!SQ<,3'D0!'P@;A[L&YCSQK[W"-:!01[6,[X_=#Y/ALQLXF
M>IU-VE?8#31J&]<901Q<Q<41#T=\'`EP)&P0OKR8#?0Y7",:143;V);X"[;Q
M';2PN)]*,X%-.#3BR;9!5O5<0MP[R7D'N>\B]SWDOM_<'ZEB@",ACNQP)!I%
M1+/81ON]66R%/X/]`=+7^/Y<-$W:;]EP)LXZY$A&M@W"!Y3EDBSTE;2:<01D
M8>I+8R8AKH@L%ZNY+DVRGHB0^4J?2M7U&V2DN@&.A#BRPQ'V.N'CU'$#^>L"
M?E*;T>)(M_1\+I4D?V*O`EA?[Z+\-<666'`R"L=(4MPE%AQ_]N,^L>#0LQ^W
M#0O.H/KQK6'!450_[A@6G$CUXZYAP<%4/^X9%IQ/05SK*@IO,Z[QD?X9%\?T
M4BIG>H!'U"?LH+[@[T/XERJ_U@>=#WD%[S'JCR=X;T7A#%B?`'S(\ZK]PGZ@
M>Q-V_PL``/__`P!02P,$%``&``@````A`+^5S_3!!0``NQ4``!D```!X;"]W
M;W)K<VAE971S+W-H965T,30N>&ULK)A=CZ)(%(;O-]G_0+@?L4!%B3II1;ZR
MFVPVL[O7-**2%C%`?\R_GU-?0-5QG>Y,WS3MXZFW."^GJ&,MO[Z59^,EKYNB
MNJQ,,AJ;1G[)JGUQ.:[,?[X%7^:FT;3I99^>JTN^,K_GC?EU_?MOR]>J?FI.
M>=X:H'!I5N:I;:^>9379*2_39E1=\PM\<ZCJ,FWA8WVTFFN=IWLVJ#Q;]G@\
ML\JTN)A<P:O?HU$=#D66^U7V7.:7EHO4^3EMX?Z;4W%MI%J9O4>N3.NGY^N7
MK"JO(/%8G(OV.Q,UC3+SXN.EJM/',^3]1B9I)K79!R1?%EE=-=6A'8&<Q6\4
MY[RP%A8HK9?[`C*@MAMU?EB9#\1+R,2TUDMFT+]%_MH,_C>:4_4:UL7^C^*2
M@]OPG.@3>*RJ)QH:[RF"P18:';`G\%=M[/-#^GQN_ZY>H[PXGEIXW%/(B";F
M[;_[>9.!HR`SLJ=4*:O.<`/PUR@+6AK@2/K&KJ_%OCVM3-L>3>RI.R<0;SSF
M31L45-,TLN>FK<K_>!016ES%%BIP%2K$O3O`$0/@*@>,1RX9+QP79KTSTT0,
MA*L8Z(S(9#RC-WMG&'S+TH2K&#9_UW0S,0ZR^=A]POIB$\+U(_>Y$,/@VMVG
M/9^2Z<\2)%`Y_$'2$A+/Z*ZE%J\$5EA^VJ;K95V]&K!:X5$WUY2N?>)165E2
MW-ZNR/ZOQJ"XJ,H#E5F98!Q43P,+XV5MD_'2>H%BSD3,!L<0-6(K(VCE4EE?
M!SL=!#H(=1#I(-9!,@`6V-)Y`P7^&=Y0&>J-S&HCP<`LS0@9(8?X.MCI(-!!
MJ(-(![$.D@%0C("%^QE&4)F5"7^[(B&SN9KYAL?0%TH7-%5#MEU(YPXB.T0"
M1$)$(D1B1)(A44R"E]1GF$1E8#'"JZ0SP";:0MF(H'LN=2&=2XCL$`D0"1&)
M$(D1289$<0G>R8I+M[<N^5JAT<P,F<2&$QLJM;.'N-J;9ML%R6$^(CM$`D1"
M1")$8D22(5%RA_WE`[G3:#5W3B!WF=86$1^1'2(!(B$B$2(Q(LF0*(E"77X@
M41JM)LJ)S3HIMA%L!>%-#=L:.''@,B@$;9WLNB#I6("$0D2B;M10VE;?0G$7
M)*63H9!B!VV_\1X[HLU/>RJRITT%*<`F=&,M.+"7\AV6BJ@N<6+/^G(0,:R)
MY!LH)\Z<;\ECXJA9[+KO918!T@@1B;I1;*,?$]V;[GNIF@PU%&^@]_EU;ZB(
MZ@TGPPH2,;R5917$B0.7007I!G5!,I4`D1"1")$8D803PFY(L82V88HG-^H"
M.F!9&"Q<S5X@&RIRD-I$??9;&37O"LB72!VH;<`[&;7@535U->5`!O0]3RA1
M/UDDT=W)8ADE)B-$ZQ@2&<`F4XVDC=UPX?W$2-X'PM8KG_4&G@ZM+`>>R,#(
MF6ZDB!K45C]0:NTDLIEK\#-&50GD]_WJ#27JA2.)^JA8(B&\T%9C(K_GORV'
M#2ZA#=_0(-[]?_#-Q%2T`N2=I%:`KIKQ5@RT>\-]@1RG>P8[B2;,M\E\IBW1
M0,H,JTW,WRM'4J97CB7BRL2U%^H-)HJR6EJT#?QUYT0SV=_FAG"D59Q6\UL9
MU1>&+Q'=5.1O,.*BI2OD9\Q,=^IJSR20,GU]A1+UDT42W9TLEE%\LLG80?YV
MR<(J4?VE#>0]?[]55RBYFWOF\-TH^M"AP1S9?8);.+*AJWR`?(QV&`48A1A%
M&,48T7.C_B:X%_P<B/]<+_/ZF&_S\[DQLNJ9GO'`@/6RP_P`:C/QH/4&,W4^
M]:`MO<%G'G1Q-S@!(9@`?^.['G15F$>N!RT1YO[<@R8#\VCNQ;>XO_!@K\3Q
M<+3VP!I?/3-ZY'8C?F-[\',6ZVP<#W["8?XP\1YXPE8W`QR=7=-C_F=:'XM+
M8YSS`]@.QRQ0]34_?.,?6E&+CU4+9V:L+$]P2)K#"<9X!,&'JFKE!YC9ZHY=
MUS\```#__P,`4$L#!!0`!@`(````(0`ER3++]`4``)`9```8````>&PO=V]R
M:W-H965T<R]S:&5E=#4N>&ULG%G;CJ,X$'U?:?\!\=X!<R?J]&BXS.Y(N])J
MM9=GFC@)FA`BH*=G_G[+E$/L(@O)O#0)/G7PJ5,V%??SAV_UT?C*VZYJ3AN3
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M:1KE6]<W];\(8I(*21Q)`E=)$M\=Z\I8N,I8QULQSPX>>+XG.>!Z$0$?[YP\
MR!PR`-?+!!9G;V$6!U.RHB]>GMOFW8!*ASQUYT*L&[8&0N%&`)[>=@-L$#$?
M1=`0"N@.2NCK2Q@_6U_!]5)"$H2$IC%"(J9#TAL01X=D-R"N#LEO0+P18H'*
M42J8K4J=ERC`NL3('FF'+"0("8?"$FE)Z8V,WLB5&]K4H);NGYH`;TR@NJ;6
M)U-#2#18\^0$=ACJ@%0%1($^F*F#S/,C=DWHH#Q7`4\L9+'"K^F"HE9UB>IR
M%ZM+!!%]9(8)0N#OF`*2@101P9"!R`]<F_DD!]DB23Z'T'3"RGE<IP@B.LD4
M$X2@"L=WHTAW*L5Q;U!),I#16+IP+K'7'+I7>DU=\"/J1!!1=Z7'!820.1<1
M@?I]%OJV319AMLB1SR$TF;!9/6ZB""(RZ5:($!3A.8QXG.*PF@7%AR%1V3Q#
M/LN@211-%-GM/:B#^:U0!.D28^)"@A"4R"*/&)WB,)8I>0MD))1D)[^$+E<I
MO`,?UR:"B#8RP00AJC]DI:6(D.I%C4ZJ=)$CGT-H%C+8/ZG.Y3UUB")"R<LV
MD1BI@[G$BE2.W[:1!I,=.Q^#EXUDXI5.JO0.A=@(J*_%F&QYR<"\,>>\E)!+
M$OP`REG?=+-EEGP6HMLI6@)%[/Q29-A`:"+)]!*)007P=O9(0:<2H&9ALN/<
M@<EG'J1+%.W"_1*QN=`DD@67,,2@1"\,226G<APKE59!ID6S,')C4NFYAH`4
MNB&[;FFZ-LBBJNV^#H>)*+(:R8)))$9UB:0AE1!,0^QZ`7.IV=DR33X+T=6*
MGN%^)['#T)PDF4[$+S_(A"Q6UZ5-6BH!_V>E&LXB&[I5?;'F^@-8Y/KQ%:*+
M$XV"(NY.*[&]T$1>:P7['#;7@@R05$)&*Z,XLDD?D2W3Y+,07:UH&AY7BZV&
MJC8BTTS8I1T1OPLC)=M2Z67XYHL`^YUYBGP<ODFARQ3]`Y&YW/$P[#I4F9.6
M1V+0,<?WB>FI'%?7[W2759N?*4<^SZ$+%0W$XT*Q[="$DM=%PN9:$^DI0N0J
M9D%`EGFVS)'/0C2IS@]U0$,4V7/)>R.1&-GAV*1]2/5A?:/)]$&;4.?C\'+-
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MJ3..?`=3L%<A=$,MGJCCE[XY#V>8KTT/)^'#QP/\YX/#8:6]`O"N:?K+%_&`
M\7\I+_\!``#__P,`4$L#!!0`!@`(````(0"9GE9BHP(``"`'```8````>&PO
M=V]R:W-H965T<R]S:&5E=#8N>&ULE%7);MLP$+T7Z#\0O%N;+7F!Y2!VZC9`
M"Q1%ES--4181411(>OO[#D7;L>0D3G001?'-TYLW0VIZMQ<EVC*EN:Q2''H!
M1JRB,N/5.L5_?B][(XRT(55&2EFQ%!^8QG>SSY^F.ZF>=,&80<!0Z107QM03
MW]>T8()H3]:L@I5<*D$,3-7:U[5B)&N"1.E'09#X@O`*.X:)>@^'S'-.V8.D
M&\$JXT@4*XD!_;K@M3ZQ"?H>.D'4TZ;N42EJH%CQDIM#0XJ1H)/'=2456960
M]SX<$'KB;B97]()3);7,C0=TOA-ZG?/8'_O`-)MF'#*PMB/%\A3?AY-%@OW9
MM/'G+V<[??&,="%W7Q7/OO.*@=E0)EN`E91/%OJ8V5<0[%]%+YL"_%0H8SG9
ME.:7W'UC?%T8J'8,"=F\)MGA@6D*A@*-%\66B<H2!,`="6X[`PPA^V;<\<P4
M*>XG7CP,^B'`T8IIL^26$B.ZT4:*?PX4'JD<270D@?%($L;>((J'HX^P](\L
M,)Y8(B\:Q6&<W-;BN[P:FQZ((;.IDCL$K0?*=4UL(X<38+;^).#RR_Z`,3;F
MW@8UH8#64-/M+`S"J;^%0M`C9OX"IHU8G!"V?J#F+`ELZDKJWY1D@]J2XKC]
MO?D+D&$;LKB&1&=$2R-8U=4X>+6M3K;9(&@@C"YL>^9OK)T[S.`"TTEC\1:B
MI1%(NAIO^VB#4@P^7&CLGSUP&AUFY`H_'`7MY85;AON9XCF%ED`P[%+@VSUG
MP5UA@_:7YPXS=L*^]#JZ%Z\NMU0E'U%EP5U5S]DZNQPF<:KBP%UMY7`$6I[7
M,$Z?.^3<[JW)FOT@:LTKC4J6@].!-X3\E#OBW,3(NMD2*VG@:&H>"_@3,=C"
M@0?@7$ISFMA->/ZWS?X#``#__P,`4$L#!!0`!@`(````(0`W+$A^_@4``%X9
M```8````>&PO=V]R:W-H965T<R]S:&5E=#<N>&ULG%G;;J-($'U?:?\!\1Z;
M;BXV49S10#2[(^U(J]5>G@G&-HHQ%I#)S-]O-=6FNPI\25YFXO3IXM2IKCJX
M\_#I1[5WOA=-6]:'E2MFGNL4A[Q>EX?MROWG[R]W2]=IN^RPSO;UH5BY/XO6
M_?3XZR\/;W7STNZ*HG,@PJ%=N;NN.][/YVV^*ZJLG=7'X@`KF[JIL@X^-MMY
M>VR*;-UOJO9SZ7G1O,K*@XL1[IM;8M2;39D73W7^6A6'#H,TQ3[K@'^[*X_M
M*5J5WQ*NRIJ7U^-=7E='"/%<[LON9Q_4=:K\_NOV4#?9\Q[R_B&"+#_%[C^,
MPE=EWM1MO>EF$&Z.1,<YQ_-X#I$>']8E9*!D=YIBLW(_B_O4#]WYXT,OT+]E
M\=9:/SOMKG[[K2G7?Y2'`M2&.JD*/-?UBX)^7:M?P>;Y:/>7O@)_-LZZV&2O
M^^ZO^NWWHMSN.BAW"!FIQ.[7/Y^*-@=%(<Q,]C3R>@\$X%^G*M71`$6R'_W_
M;^6ZVZU</YJ%"\\7`'>>B[;[4JJ0KI._MEU=_8<@H4@-0:0.X@-[O2YG<AF*
M,+H>98Z,^@2?LBY[?&CJ-P=.#3RS/6;J#(I[B'S*#'D,N9Y+%>BI()]5E#X6
M9-%"?;X_"B]ZF'\'37.-21"S<!V#H8CTA%"E`'H#1\B<<_2AAM/JGRBI3922
M7-#G)1,0BDC'B-`$(1Q!N_=S5)O@+-B2>"9^+VV"F,#"A(SD)03A"$%LCI?U
M4^"5"P*8<GE+^N0$,<N^X'<BBCU.C0(6@1@"$&+0!#8Q=0B#L^UU*K#:Q,6+
MA_@H'F*`Q9`$9W@)03A&E.-E\128B2<\Q@TQ42^>'X0^74[MY<B+#&_""MJ)
M*W>]-=0FSLY4!I5##+*3T9()FY+EQ4(.Y`D[Y7]LN%QGIS9Q=B8^LD-,H`]>
MP*1-[6413'.+/\)-;>+<6.$2Q"`W$9BZ]<Q3>U4*TU!$-P'3[?W"];LX.Y,]
M*J=!6CK)AG3*ELUNRF_"-:X75N!\)R-%,'T2#=+RL=5T6#4-[9_34,WN=Q\^
M@1.?C&3!1$HTZ-)8N0BA6JKQ_7Z>./2IEMPZ!(*PB>]"/V9'-:6`(%Z:*4`Y
MJCG^?HXX_2E'4RU]'A&DS^,B9NNIP'6=@_1B,XDH137(+8J7Y[-Z>1LULHFL
MJ2%(/]H/K9.&O:RC:(!8+$P$RHUYQVW^)B9,1+))EVC0J<2!&)48HZ"^?G2.
M(?.1*^I-&(@T1T>K9UO$G0QCP1"I(`@AEJ;/J'P?LA&!)D`Z67(?T2`X8V=?
M$"Y"*$]F*5=$G/`2R:J7"`2=3E@4C=J#`I;"S`#"37[(4?I=S%&D\00LM`;I
M#A;\(*1TW9I!E""SE,OBR0DKD<PL$@W2Q`)6^W18-K6W.IR28UYRA1QZ")E[
MW&@3B:!399<^[PX&B*WW1\KM0_XAT1IH=YBSHRN+H$O=H>-,0RA/-<BM`:V&
MX/5W!JEV\1/(FB#1(-0RBF*?3<E4`VR69TO]+A]17[Q'],R,U3(BZ,S3>TRJ
M`V$*,O2ER9&JR*SDRDF<L!`N3B*)0XRDPU4D)KSXS(R6S$!NK.Z$D?!&2/K0
M*W>H;C2B:/N(C`)K0E'M/N0C$GV$=+//9DFB03AJ1,!&9$J6[X1ETI0@,Y`;
M19PP$I\;B;1]`EX$(Y9!2@#2E]:+.>&H6I:W\?7OZOTNUL8^4RG1("QT*#V?
M#?24`.3"\\S,I!R9E]RFHS_A*9Q"HD'(,19^S&9F2@"A)ZTO#Y2CFO]L'-Z@
M([H&&=N^:4F<-SZ"['DS4O(2A/)4'F#QO#QP?'0,B#Z\3XG12XT&Z699CA0\
MN8ZZ1EQ:KQ.4ES(&B]>--5:[^#ED!!(?09I?R,?-L&QR/&<F<"?]$9)C4XE9
MNR9]Y)6+5V\+UNWJ+EREJ5?-7E00K[GQ%K@JFFV1%OM]Z^3UJ[K"%G"I,OP6
MK]<3N%[O[Z+GPP+<;A^S;?$M:[;EH77VQ0:V>K,%/+C!^W'\T-7'_A+VN>[@
M7KO_<0=_QRC@TMB;`7A3U]WI@[KV'?XR\O@_````__\#`%!+`P04``8`"```
M`"$`;G<CZSP'``!P'@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RL
MF6USHD@0Q]]?U7T'R_>GXD-$*LE6?`!45*3V[EX3Q4A%Q0*RV?WVU\/0,\RT
MRR5W^R::G]U_IJ=[AAZX__+]?&I\B](L3BX/3:/5:3:BRR[9QY>7A^:?7^T_
MS&8CR\/+/CPEE^BA^2/*FE\>?__M_CU)7[-C%.4-4+AD#\UCGE^M=CO;':-S
MF+62:W2!7PY)>@YS^#=]:6?7-`KWA=/YU.YV.G?M<QA?FES!2C^BD1P.\2Z:
M)KNW<W3)N4@:G<(<QI\=XVN&:N?=1^3.8?KZ=OUCEYRO(/$<G^+\1R':;)QW
MUOSEDJ3A\PGB_F[TPQUJ%_\0^7.\2Y,L.>0MD&OS@=*81^U1&Y0>[_<Q1,"F
MO9%&AX?FDV$%1J_9?KPO)NBO.'K/*M\;V3%Y=])X[\67"&8;\L0R\)PDK\QT
MOF<(G-O$VRXRX*>-?70(WTYYD+R[4?QRS"'=`XB(!6;M?TRC;`<S"C*M[H`I
M[9(3#`#^-LXQ*PV8D?![\?D>[_/C0[-WUQH,.ST#S!O/49;;,9-L-G9O69Z<
M_^9&1BG%1;JE"'RB2*?5[PZ&YF=4^J4*?)8J\*WFJC"^8NCP6=H/6^9@T+\S
MAX!J'*'V"T?X+!V-3LOH=^Y8R#5^H](//M&O-30ZH]Z_7,_`^6%?/A0:5$R9
M%OCRN>",.W2%+SC,#X5G#-$3OJ!G78!M7DM%:4[#/'R\3Y/W!JQWJ);L&K+=
MP[`,F&4L2CZWHDQ_5J50GDSEB<D\-&$P4(`9+*UOCUVC>]_^!LMA5]J,J8VA
M6DS0@M4^DYWJ8*8#6P>.#EP=S'6PT,%2!YX.5CI8ZV"C`U\'6QT$%="&](@<
M02G^BAPQ&98CG-TQ@DK2M(2@!;I,=3#3@:T#1P>N#N8Z6.A@J0-/!RL=K'6P
MT8&O@ZT.@@I0$@(K_5<DA,G`)EY9-(:I+8DQMV'K7:RL@98D82*R1,B,$)L0
MAQ"7D#DA"T*6A'B$K`A9$[(AQ"=D2TA0)4K2X`[U*Y+&9&"SA*U2)*1K]-24
MC$NCNJP)$Y$U0F:$V(0XA+B$S`E9$+(DQ"-D1<B:D`TA/B%;0H(J4;(&MWDE
M:[>;);P-,>LB.3BI8TZZL))%N@QSJ*9K(HS0;4K(C!";$(<0EY`Y(0M"EH1X
MA*P(61.R(<0G9$M(4"5*+J!+^40NF+6:"TX@%SC-$T*FA,P(L0EQ"'$)F1.R
M(&1)B$?(BI`U(1M"?$*VA`15HDP\["/*Q/,FK<5ZV?P8[U['"10W=`\W%D</
MFC'>HC$1-1\EJ>2C),4YAG=@G/2JVYUAFNKZF0DC3*Q-B$.(2\B<D`4GAAS0
MDA!/>%67^$@=XDH8X1#7A&P(\0G9$A)PPH>H9`WF3,G:C>S`*0;3PZS5]'#2
MEPW;I"2F6$#3DL`Q1VYOHXX:^TP88>PV)P-^-&2=MD.(*[QJI.?""*47)9%C
M7!+B":\:Z94P0NDU)Y51;PCQA5>-]%88H710DF+42A)A9I4D_J>EQT34W')2
MS6U)Y+Q-.1ET^'&JHS<9,_$[1F$3#8<05W@5A[2.?DJ;B]]1=4$TEH1XPJM4
MU1JBE?@=5==$8T.(+[QNCW4K?D?5H*JAY!'6IYK(^M58F*LI*U$?A"IK3>O7
M)Z55MY)'1+!12,>AUL7/4-XHTFUT^NHBMJ4*!NL@DM=R$<E-8RZ%*Y<?:8?S
M!75<(I+R'J+:4%;RBBQO))2U5,%0-HCDM7Q$,I2M%*X))5`<U2)@)VSZM..3
M-U*#G]/A"(##'Y>HK[29(VT13$JKGMQVI^@(IY:ZVN!7[/=Y;6BE8Z.NO$LZ
MB.2E7'DI'/8<$73?\NJT-/C5>U)^2>4]U*J-9(56MR-9HZZ\U`:1C,1'D>)9
M;=&F;!'51A*@5B&O5@8[ZO__RN`/#)3*X$C9-?1#_H0];(0;A+)IE'ZLQ<-'
M:@;=-$JK.UX8AM;UV"@LUY"#2%:O6Z(^?^C,VH$Y(FA)Y>5I993CEO)+*N^A
M5FTH*[3Z22AK%);7VB"2H?BH(D/9(JH-)4"M0EXM#?9$H:XTOB97N%/<[+XK
M_1U[3JPU`8A&8B.94#2E:$:139%#D4O1G*(%14N*/(I6%*TIVE#D4[2EB+V<
M*::PF"^>(_ZRA3_1/D?I2S2)3J>LL4O>V(L46%"/]P+SMSSC.PL.6K`%ZMSH
MX>L?[1??M*!CI![^R((.A/+`M*`/H1S>+ST59RU-?\S>.]VP'W<M>`))=<8P
MT&+KTW2>^M833-$-A[X%#UAN\($%AWW*%Z8%31_E2]."UH]RS[2@6[_!1Q8T
M?I2O30O:/\HWI@5-(.73H05'0\J]H07G,<K'IC6^I3,QK<DM/C4M."-1G>G(
M@B:;<MNTH-6FW#$M:+@I=TT+#DHW^,B"=AMX6V02WO==PY=H%:8O\25KG*(#
ME'&G:%!2_L:0_Y.7>\YSDL.;OF+[.<*;W0CV[DX+-MI#DN3X#[N`>%?\^`\`
M``#__P,`4$L#!!0`!@`(````(0"=$VFR$P@``+$E```8````>&PO=V]R:W-H
M965T<R]S:&5E=#@N>&ULK%K;;MLX%'Q?8/_!\'MMZV+'"9(4L8CN+K`++!9[
M>59L.19J6X:D-.W?[_`B\1R2M2.C+W4S/.=P-"2'U.7^X]?#?O2EJ)NR.CZ,
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M>ONE+C>_E\<":F.<Y`@\5]5G&?K;1D)(GGK9G]0(_%F/-L4V?]VW?U5OOQ;E
MRZ[%<,]Q1?+"[C;?1-&LH2C*3.*YK+2N]B"`?T>'4DX-*))_5;]OY:;=/8R3
MQ61^,TLBA(^>BZ;]5,J2X]'ZM6FKPW\Z*#*E=)'8%,&O*1+/)LOY/%TL;U#E
M3&9B,O%K,L_'IR8>OP&Z?D=3?;E*/9&W^>-]7;V-,"5Q0<TIEQ,\ND.Q3C9=
MH1?R>SI"0%GD259Y&-^,1Y"HP>!_>8R2Y?WT"P9L;6)6@1@>D741<G1D64&`
M*?CVI*'O#R`MJTC277>K#K!7$3L,NX@N11"`,<0XN@P3S.GP;.Q4E$F8=TS%
M6\Y@I6,B*O6<AV1]2,^2(HPF1MRE*1?-P-&753!_8*5GAM\$G2/>A_3$*<*(
M@R0E?EY7&:SX=757!KFEC-.9HV,?U*4)BC`ZBR%T9#"GHY%8.9R:^9F'"(JP
MOJ'H^Z60P;QO@R3],L@,`NWM<*81%T<$@^QR80SE'DL\YOQ@R6#.4"-4'0\1
M%&%]8XAIW\K?HIN)M>-W>YRLQ(EI)(9+$:$2+E36!_6SB"*,:P2'H&3/"Z6B
M.2$#@5'76>9#@D&<@#1<,E)*K53MF$,](=+>#5/HJ*P,Y.B5.GK9J"Y1,(@3
MEOY+"%]03+LUXZ0AII@'B8A"G("T5D)`*K9(KIE>D3%I*IB&',%<NS>)Y!($
M@SA?Z:B$[P7!C/]23AHBO661!PD&<0+20PD!*5B\N&I!RIW*69$&<A1;N%-,
M)Y)K$#81LXX3EL9+"%]03-LTFV+&N;E-W+B<^B@[[2G$.4GW)9R4B$D\P74-
MW+KE0<+54$..ALYI+C.)3,,^T=-0VC/A>T%#;>9,0^/OU-@\2"!#7HSFQ`63
MGDL(*&.+TJO6J;9OQJYW=+H1.">W+.JC[`A3B!'&;L<(GU=,1?.MP$!D?#(?
M$@SB!`);P77&)B>2,\4,)'_LSCEWSU\VJA>,09ROM&@RPA<$TX9.!S&F'J\/
M83XD&,0)!':"&]Q"#EZ2L;\1&,C1RSF293;*ZM7O(.Z2C`=M!"K:F6">ZV<F
M"C0M`1K%]9(F3`9,+LGEK;PY'^IA,L6=8!IR!+/'4S.^?93E2R'.5[HQX7MA
M@FGO9A.,VKDAX$$BIA`G$##]:(99.]#R8]_R#>3(Y9YD;925Z[N6'TLO?K]<
MVKF97-3,C5P>)%0W0<N/I;<2`FJ/G%^S'K5),VZ];U/_<D^RBD''35V!8!`;
M7?ET@-(]/[U4-%^/!B*++_,AP2!.(&#XT75;9.([OH&<&>8>96U4/\,8Q`D/
M<OS$=WP#,<6\34"P*$X@X/AS7/K`]9CX?F\@1RWW&&NCK%K?]?MDD-^K:&=^
M42?7Z]%$$0$%@[A:TEG)>KPPP;4/TT67&(@\J>@@4"/G".=H+<)1]D#+:4K_
M?3]-[=:,IC%P\C`G\2#!($X@9/-7KD/?Z1-CV)CG1#'WJ&JC[,SJ$P%QPH.<
M/O&=WD`X6G6]93XD&,0)!)S^NJ-JXEN]@>2YSPJV<(^J-JJ[!,$@QC<=9/4J
MFB]%`U'!?$@PB!-PK/[\4DQ]-^\@LA0[B"W%A7-$%>$H>R[C-*49OWLIIMJZ
MZ5(T$&YRNE')?$@PB!,(&'RRO.:(FOH>;R!G8KEG+AO578)@$.<[R.-3;>A,
M,`VQB>5!PB3J*$[`\7AYYKKJ'BCU[=]`CE[NF<M&6;UTK1#=05Z?^EYO(*:7
M\7IK9H)%<;T<K[^P$'T[3PU$%Z*!,&[$L)R3EN@2:51J#QB<Y2"#3WV#-Q!;
MASJ*0()%<0(_S.#Q!MJ]5320O'DF>EDI]%''1MEYI6LA$9#FJ]].Z_>KAZ)^
M*;)BOV]&Z^I5OGF&YH_W/:Q?BZ_2V^Z]N-<2HT5-(Z\E08OJUFM)T9)*0E[+
M'"WJQ;?7LD#+(IBS1(MZ]NOF).@'1[U`/PFJX7`3:KE!BWK;ZE5#/]C>0SE0
M!QMIH"6=@9LR=K=:C&JX+0SDQ*B&.[!`2X)JN#4*M>"[!=R#A%HP/K@Y"+5@
M?'`X#[3$R-%NX;%&CIY*7@NTQI.54#6,*1Y^A%HP"GB2$&K!*.!&/M`2(2<*
MYD3(P?/>4`ZTUAN(RSJ"UGCB&<B)H;5>]VY.#*WUS83;$B$'KZT"U2+DX/U0
MJ`5:X\5-J`5:XQ5)J`5:X]U%J`5:XR6!WX(/6Y["O2`A$+^24R"$RTD3P)_2
MNR?]X8PKBESK@805F(:(KC"^P>'%&`:7"T90#>"T[Q@?S)SRE^*/O'XIC\UH
M7VQA:S/U%+W6G]SH/]KJA!,K/INI6GPJH_Z[PZ=1!;[IF,DG,-NJ:KL_H.BT
M_]CJ\7\```#__P,`4$L#!!0`!@`(````(0!;KI#WP0D``&DP```9````>&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;*R;6W/:NA;'W_?,_@X,[SM@(!<\2?84
M?+_;L\\YSY0X"5/`&:!-^^WWDBU9EOXNAW3ZTB0_K;5T^4NRENS>__U]MQU\
M*P_'3;5_&!I7X^&@W*^KI\W^Y6'XGW^<O^Z&@^-IM7]:;:M]^3#\41Z'?S_^
M^<?]>W7X<GPMR].`(NR/#\/7T^G-'(V.Z]=RMSI>56_EGDJ>J\-N=:(_#R^C
MX]NA7#W53KOM:#(>WXQVJ\U^V$0P#Y?$J)Z?-^O2JM9?=^7^U`0YE-O5B=I_
M?-V\'46TW?J2<+O5X<O7M[_6U>Z-0GS>;#>G'W70X6"W-OV7?758?=Y2O[\;
ML]5:Q*[_@/"[S?I0':OGTQ6%&S4-Q3[/1_,117J\?]I0#]BP#P[E\\/PDV$6
MD^EP]'A?#]!_-^7[L?/[X/A:O;N'S5.TV9<TVJ034^!S57UAIOX30^0\`F^G
M5B`[#)[*Y]77[:FHWKUR\_)Z(KFOJ4>L8^;3#ZL\KFE$*<S5Y)I%6E=;:@#]
M.]AMV-2@$5E]KW^^;YY.KP_#"4V-S^7QY&Q8J.%@_?5XJG;_:PH-'J)QGG!G
M^LF=IS=7U[?CJ4%UG7.<<D?Z*1PG%SG.N"/]Y(Z754C-J;M)/[F?,;FZ-<;S
MZ>WYEMYP1QJ4C[5TSAWI)W>\OJB'!DV!1A$:^X]5:0@]V"_<];+A,80@[!?N
M>>$`&4(2@X;J@^V]%5VE7[CKA8-$<C2#=*DNHV;>U\O(6IU6C_>'ZGU`>Q.-
M\O%MQ78ZPS0HFEA`S;1OE]3/5A0M)1;E$POS,*1^T*(YTC;P[=&X&]^/OM'2
M77.;18^-:K$4%FR=LK"6#FP=.#IP=>#IP-=!H(-0!Y$.8ATD.DAUD.D@UT'1
M`2.2I]6(IO/OT(B%81J)T5T(($6;:((("^%BZ<#6@:,#5P>>#GP=!#H(=1#I
M(-9!HH-4!YD.<AT4':`(0KO$[Q"$A7D8TK^=16.H"BP:&Z.[LJY5DV5KTJH$
MQ`;B`'&!>$!\(`&0$$@$)`:2`$F!9$!R($67**+11OT[1&-A:+.DK;*CFK[5
M<:-SJK4FK6I`;"`.$!>(!\0'$@`)@41`8B`)D!1(!B0'4G2)HAH=3Q35^@]V
MXC'$K&MQQ*`N.*%C2$<N?9MKC82;!<0&X@!Q@7A`?"`!D!!(!"0&D@!)@61`
M<B!%ERA:T`GG`UHP:U6+ADSJ$WW]?%\"L8#80!P@+A`/B`\D`!("B8#$0!(@
M*9`,2`ZDZ!)EX&D?40:>'=(F=%042<;%QS062-6D(92B==?'5'O"M$;M^@!B
M`W&`N$`\(#Z0`$@()`(2`TF`I$`R(#F0HDL4F>B9H,AT?J]BUJH6#9E,VA/:
M$H@%Q`;B`'&!>$!\(`&0$$@$)`:2`$F!9$!R($67*`-/N_L'!IY9JP/?$!KX
M[B*8:8N@-6H7`1`;B`/$!>(!\8$$0$(@$9`82`(D!9(!R8$47:)HP1+X#XA1
MFZMJ<-1=!X@L1#8B!Y&+R$/D(PH0A8@B1#&B!%&**$.4(RH4I&K!,DH]N_^E
M!X?1Y*9T[!6S?\&1MFKTY$1:"4<+D8W(0>0B\A#YB`)$(:((48PH090BRA#E
MB`H%J<JQU+.KW/EG";OQTO8TCI15U%AUD(56-B('D8O(0^0C"A"%B")$,:($
M48HH0Y0C*A2D:L%2RJX6[/@UO6,7ROR2]^+S%[M?U'5JD+:,;K2'#W=4I&L=
MQ<JRT<I!Y"+R$/F(`D0AH@A1C"A!E"+*$.6("@6ITK&\LBO=_UE&/`WM[G(<
MS=N-;\FN?)F($EF(;$0.(A>1A\A'%"`*$46(8D0)HA11ABA'5"A(U8+EE1_0
M@J>A72T:I"V56WVIM%9B75CLC1`IUED]-B('D8O(0^0C"A"%B")$,:($48HH
M0Y0C*A2DRL.RSP_(TR2KRH&`YZ^=_(6]%%$'WD)D(W(0N8@\1#ZB`%&(*$(4
M(TH0I8@R1#FB0D&J%BS%[&K1O)6Y8B_K3J^;]9=%18\@.I+U;&=3>OO"W\DT
MB:HB$4==B3B2MS(6NVTFU::4;W4NS>[4=69+*['.'$0N(@^1CRC@B`ZW(GR(
M*)*.W:;.U:;&TDK$2A"EB#)$.:*"HZ:IJI`L9>T*V2,8'2-:Q9H,5U&L03/Y
MVF9)Q4R>F=P9+8$H*Y.*S;5;:5M:B6%P.+IN7FRS=VXN(D\ZG@GO2RL1/A!(
M-C5$%`ETMO6QM!+A$XXZK4\19=+Q3.MS:27"%P+5K5=U9>EO5]=?6Z!-$DW5
MB"H7=*BHM>W*S9&TLKC5];A^TSH9&]J%G2T-1&1'1)9A7$2>=&3O<"FR=E7N
M2P,1.<`P(:)(.O+(6IMC:2`B)Q@F191)Q_XVY])`1"Z4,(JT=#VM2GM^R=;F
MZOT%1S,*U%F,VHN]);>BSTU$HRR!:/N5CK=:1FV+\$;SFGVLW5,Y,HH([`HD
MZ_($DA/-EX$[U<^U"1"@8RB0#!\)=+8KL:RQ_F)`[THBHXBNI`+)NC*!9%=R
M&?A,5PK%49T$?1<GQO4''\`3O#3A:*9<-<ZUI;#D5E.Y*UO"D9*^<W.CJ7$V
M:^:&-G4<$5<^4UV!9%6>K$J,NB\093ZR=IP:3>U3&3[$\)&(=;8GL;#J[TDB
MXLJJ4H%D3S(1I/X`K3X4Y0*=[4DA8M7AU9FA7\S\TL[/4AAZA'=W?HZ47>,.
M-@U^@R-GOR7\V-&P_?8&-XW&<7;33`Q#.R$Y/,I$KB%7(%F7)^N2,Z,-W*D>
M9P9OMPP?8OA(AN_$TKL2"ZN?="41@65=J4"R*YF(TGP4R`X^N4"4L\B1U+M2
MB%AU>'5JL`N9<X>"?ZJWGYW:.X=`]BY.GQL<R1N'I;"2R$)D(W(0N8@\1#ZB
M`%&(*$(4(TH0I8@R1#DB]L5I/83UX#0:-5^0-I^^[<K#2[DLM]OC8%U]95^'
M4JKS>-_BYM/5A3$QV:T@374HF5))O:E`R8Q*9KT^UU12SS;PN:&2FSZ?"=5#
M?>EI`;GT>MR:]'JRQ_[.I+=G/7QNTIN<'FZ,J4WU[@>MI2]ZZ=X:?>B<;;)3
M=%_)G$KZZJ$C-D7K*Z$/AS_UCSTY]-2Q(+%Z[6D(^T;PTXSB]Q4L2,%>`4F_
M/ODHQS'9$1B[3:F.R4["6$(9C\GRF;Z2.97T^5"R8[(#,?I0SF.R<S&64"9O
MLMP:2RAQ)DGZ2A84C:4AZ$.)I[GL+:'\TV39)?I0JD(E?=$H]3194H(^E(&:
M+#?!$DI$J3]]]5#B0B6USZB=L?2A]]OJI8Q7AY?-_CC8EL^TU,?U(>[0?"K>
M_''B^_+GZD2?>M=;]"M]TE_20V',/K)XKJJ3^(,:-6K_D\#COP```/__`P!0
M2P,$%``&``@````A`-LK1D9[!P``>R(``!D```!X;"]W;W)K<VAE971S+W-H
M965T,3,N>&ULK%K;;MLX$'U?8/]!T'MMDY)\0Y+"=M'=`KO`8K&79\668Z&V
M94A*T_[]'EXLD\.)$QG[TC0SP^'1F>$A)>;NX_?#/OI6U$U9'>]C,1C%47%<
M5YOR^'0?__W7YP_3.&K:_+C)]]6QN(]_%$W\\>'GG^Y>JOIKLRN*-D*&8W,?
M[]KV-!\.F_6N..3-H#H51WBV57W(6_Q:/PV;4UWD&SWHL!_*T6@\/.3E,389
MYO5[<E3;;;DN/E7KYT-Q;$V2NMCG+?`WN_+4G+,=UN])=\CKK\^G#^OJ<$**
MQW)?MC]TTC@ZK.=?GHY5G3_N\=S?19JOS[GU+T'Z0[FNJZ;:M@.D&QJ@X3//
MAK,A,CW<;4H\@:(]JHOM?;P0\U4ZBX</=YJ@?\KBI7'^'S6[ZN67NMS\5AX+
ML(TZJ0H\5M57%?IEHTP8/`Q&?]85^*..-L4V?]ZW?U8OOQ;ETZY%N3,\D7JP
M^>;'IZ)9@U&D&<A,95I7>P#`O]&A5*T!1O+O^N=+N6EW]W$R'F2342(0'CT6
M3?NY5"GC:/W<M-7A7Q,D;"J31-HD^&F3B.E`3C.1C566*R,3.Q(_[4@I!JG,
M)E,]?SAR:/!K.C[E;?YP5U<O$7H,")M3KCI6S)'MS(/)T#'S&C%@1"59J"SW
M\22.\,P-JOGM08YF=\-OJ,#:QBS#&.%'K,X1JG"`UV$$/_\#1I5%853%5*"7
M9X,#F@`Z1U!`((H"2M""?/.<.5*#T"8.1R*A')D8X1*9$4Q="`65AJ!41_>L
MI,J"7H#.=:44J?0Q+&W0-9A="(4)2"YWUSE3P1I-5S1K2;HRKJP%$[*(O4X:
M]YE<!?N3&XO4TJ)[:.5:O)G`C?N8>EU-Q0!@>Q9$)?)1&(O$:G$>./%+M.J"
M*/]J!W,6_'7^5;`_N;%@\G-%5J[%HV#FSZ0HD')V`P4JD8_"6`@%*:&@"Z(4
M"*S5]W.@H_WIK<EEP3-Y-`@E:P[CBH?I3&TK?5M!9R)(C&82)JAFV($&KP^.
M:.OU=A!&$*$.Y^HOK<FCPD1QLRGQ(E2DH]D`JZCGJA!6!ETDQD2H&).FL`,Y
M<$JR''!O4&$%S@5@3`3`A`+HHH*V5$KF`%"-DDSD8')#IZA4I%.,B:";4G1=
M5(!.29V#[@UZC#!ZG6*UTI$.X9K\ON3T<S*]03S49DJIZ,3155"R%Z_L0*Y3
M>FFHVDLI`%<SS49BH[C9&!T5(ZRQODLFE%'12:1#1#:B/=%%T9[`3MBC)W2T
MWY369)[:$.&9O)Y0K>MVH-Y317K+^M"I"!1.23-Z1+4##6`?72\EE:&26I-)
M;;EX54DEHZ0BU2\K??M"IR)<<%*:D5/@R@[DN.@EI3*44FORN'A5-]5.&O3%
M.+NI+T+=U-EQ<D%[7(Y;&3UN7:*"-=)+-V6HF];D<?&J;DI&-Q.\5.*Y>LJ%
MSD3:@M/-C!Z[[$"N+7KII@QUTYH\*EPI]1<DIYLW;2$R5$YK(EU!SUV7*-H5
MZG71[=GKNZF.]FMA32X5GLFC(F&4<X+O%;V;0B<B0%C=I,<N.Y!IBH3HIE;U
M&Y!U@NHN4W*\6>K)@!^-W"UF6K1+3%`T(KIO%,V(J'L$2JS)>7L]FZ!N'2*1
M77#[=>REJTFHJ]:$/1;/9O88S^3/IL30.?'IRMRT@!*5B;2-,:E-SWEN>@:S
M`Q$5U**7K":AK%J326VIL++*S,;(ZBUGL,0HJ-<35E0](L;T#&8'<D004;UU
M_71JZ]1C3+;\96*CKJZ?+B:H&5'D-]9/J+J)-7F+Q0'IM6_:2V)UM-^BUN0N
M%L_DS\9([#BYY0R2&D%U>\2:_,4RIF>02Q0E/B4:>YUX'4VH,.KJ+A8;Q71D
M2F12=Z2<W+#=Z$P$B9%00@4]@]B!'+A>$IJ&$FI-'A4FBIN-DU#8>I[%TDX_
M+XLS)5OL\AQT;6U>8H(6Z:6G::BG9Y.[-AV,_F)1FN?L+&_THU%(;T$8D[<T
M79,_&Z>0-[Q`IYU$@CR]8RRM2;T)77:Q,:G,ZA(5L-Y+$7$A1K=1:_*70TJ_
M.5VB.@#F9LQ<!1V*^JE8%?M]$ZVK9W7KE8UPB=.9[95<FLT7YDZ.>-!ZN*W3
MUV2!9P*/OG,)/%-X]->SP#,[W_T1SR*9`D&JS@+$@XUIOL+FQ'C2$;+I\PX=
MDZH[1OTU*O!(>/0I(/`D\.CC6^!)X6&Q26##FPN#3>))\8[`>!*@QGF>\P`U
M3M.A9Y'(^0+GA-"#8R_&L,^3`#5.@-P8U!3'+\XSAF?,>E!M'H$$`J./E#<)
M1K%^F'DDL.%#`.<!-KS2<AY@PPLSYP$VO)HR'H$Q^!+)>3`&[PJ<!S4U@D2?
M1Z"F^*[&C)&HJ5$L.D:BIN;5B'H$QN!J@<DF,`;?]3D/N,9G><X#KO$!G/.`
M:\%R+<`U[A'#,;BB7_"S8``3OU0MP-D!BL.T2-'.;"*UTKA$J"-;1E21+2)J
MR"Y+5%`7<-A5`U?_I_RI^#VOG\IC$^V++41RI$]WM?GC`?-+6YUP7,$?`%0M
M+OWU?W?X(X\"U\TC=?[95E5[_@6,#KL_&WGX#P``__\#`%!+`P04``8`"```
M`"$``YIN>F\#``!&#```&0```'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6R4
M5\MNVS`0O!?H/PBZ1S+E5VS8#IP&:0.T0%'T<:8ERB(BB0))Q\G?=Y>49;V<
MR!?+6B]G.+OD9+.Z>\U2YX5)Q46^=HDW<AV6AR+B^7[M_OG]>'/K.DK3/**I
MR-G:?6/*O=M\_K0Z"OFL$L:T`PBY6KN)UL72]U68L(PJ3Q0LAU]B(3.JX57N
M?55(1B.S*$O]8#2:^1GEN6L1EG((AHAC'K('$1XREFL+(EE*->Q?);Q0)[0L
M'`*74?E\*&Y"D14`L>,IUV\&U'6R</FTSX6DNQ1TOY()#4_8YJ4#G_%0"B5B
M[0&<;S?:U;SP%SX@;581!P58=D>R>.UNR?(^(*Z_69D"_>7LJ&K?'96(XU?)
MH^\\9U!MZ!-V8"?$,Z8^11B"Q7YG]:/IP$_I1"RFAU3_$L=OC.\3#>V>@B(4
MMHS>'I@*H:(`XP531`I%"AN`3R?C>#2@(O35/(\\TLG:'4^].1DMQG-`V3&E
M'SE"NDYX4%ID_VR2452!!"4(/$\@,V\Z'XT)<'X`XML-&7T/5-/-2HJC`X<&
M*%5!\0B2)0#W"P(EF+O%Y+4[=QW8JX(NO&S(XG;EOT#EPC+GWN;`YSFGRO"!
MM&(&MN',F(S,6%K<RKT-U&F"?IKQ-328#+VI;WZQJ'`ML\V9U'*F549#(*0,
M%XC)T`,PC'/=.K6U20.HX3P,I\9D0UT5MXS`-:DV`X;3KW)V#14F-ZG*2&"N
M7_UXP"FK2S`W;@+]?O^$XJHF01D!234MI%\+VO7@RX#)3:HR8@R@<1(635S4
MLH#BOB\%%S7QRTA3RH5C3P!_N!:3W20[A;IJ"%[Q6IF&R3&K6A0(!*&FH'%_
M;\A5?F&R6VRE9?0(:GD$"IH2#ZWY_181ZP5P:ZNK<PHU-4TN:+K*(DCE$6>V
M,M2C"3;0;M)LXGTL"=>U"E>&X%&[0A=,CUSE!R:[Q58Z0H^D/DL@TP&:NJY`
M>FUA=J%-5_D">GB[@A>=@?18PZ`V==W!0'5NT[Q?4G"5/9CL9IM.H6Z;@AY[
M&"+)K&N1]!K$>>*P)FNG-CO59$SNV1>6ILH)Q0$GL@#FE"I:38M;\P>G'9\L
MM[`+N%U^]0M,<07=LQ]4[GFNG)3%@#DRWB#M'&A?M"A@[S"&"0WSF_F:P+S.
M8%89X0F-A="G%R2H_@/8_`<``/__`P!02P,$%``&``@````A`'P"Y7Y,!@``
M,AD``!@```!X;"]W;W)K<VAE971S+W-H965T.2YX;6RLF5V/HS84AN\K]3\@
M[C<$2$*"DJPFX5NM5%7;]IHA)$$30@3,9/;?]QC;8/MDT\EV;I;-P_%K_/K8
M'#S+K^_E27O+ZZ:HSBO='(UU+3]GU:XX'U;Z7]^"+W-=:]KTO$M/U3E?Z=_S
M1O^Z_O67Y;6J7YICGK<:*)R;E7YLVXMK&$UVS,NT&567_`QW]E5=IBW\K`]&
M<ZGS=-<U*D^&-1[/C#(MSCI5<.N/:%3[?9'E7I6]EOFYI2)U?DI;>/[F6%P:
MKE9F'Y$KT_KE]?(EJ\H+2#P7IZ+]WHGJ6IFY\>%<U>GS"<;];D[2C&MW/Y!\
M661UU53[=@1R!GU0/.:%L3!`:;W<%3`"8KM6Y_N5_F2ZB>GHQGK9&?1WD5\;
MX?]:<ZRN85WL?BO..;@-\T1FX+FJ7DAHO",(&ANH==#-P!^UMLOWZ>NI_;.Z
M1GEQ.+8PW5,8$1F8N_ONY4T&CH+,R)H2I:PZP0/`OUI9D-0`1]+W[GHM=NUQ
MI5O6:&)-G;D)\=ISWK1!031U+7MMVJK\AT:93(NJ6$P%KDS%GHVFSMCN1.XT
MM%E#N/*&T]%\.IW,Y@YT?Z?EA+6$*VOIC,S)>$:>^DXSN-N-%ZZLF;GX2+L9
M:^?T[>P//BBLM*Y'N#[RH`O6#*X//:@)*41GE.02G:S_>%2#YD278E[:INME
M75TU6+<PZ<TE);N`Z1)=GES4WS[=?I1MD&9$Y8G(K'1P#O*H@27RMC9GSM)X
M@[3.6,SF1HP<L>41)(>)K*<"7P6!"D(51"J(59`(P`!;>F\@U3_#&R)#O.&C
MVG`PF&4I1O`(WL13@:^"0`6A"B(5Q"I(!"`9`4OW,XP@,BL=_A629"Z/?$-C
M8#L=@J9RR+8/Z=U!Q$<D0"1$)$(D1B01B602[%*?81*1@<4(6XG@DKJ46-`]
ME_J0WB5$?$0"1$)$(D1B1!*12"[!IBRY=/LEQK<5$MV9P0>Q802V3,&>A9(A
M?1!OYB'B(Q(@$B(2(1(CDHA$&CN\8!X8.XF6QTZ)U54+W?ZX1<1#Q$<D0"1$
M)$(D1B01B310R,L'!DJBY8%28L%V-$RR,U8FN0_J)QD1'Y$`D1"1")$8D40D
MTMA)U2V^4.\G.(F6QTX)C)T/:XN(AXB/2(!(B$B$2(Q((A)IH+`$'Q@HB98'
M2HDU&0;*"*UAN_<_)3:8+22"*2>"WP=QQP(D%"(2]:U$:>4]'/=!7#H1A20[
M2/$D^4$KJ1&I<=MCD;UL*A@#E!HW$L*&BHG5441%]JD3AII]-AC%$%SX<WD,
MV?.N^++&IJVX-`3P-@&6"3&*AH:DK`-EU:0A@"LGDHQL$RFVQ/7Q<S;1D@W>
MDKS+C4F1F$\,P85'>0S9,(U"1B&OJ!9$\8;!T)"C$*,(HQBCA"&X@);L#JG`
M1'=N)`M\_?390@LVR0:*+'G)3.1DV)HL:O#/XTANJ-1>/H]:T#2;.HIRP`.&
M<C?D:.@LXNAN9S&/8IV9IE(L)CR@ZTPVDI1I#QC)JKKA$3<F138L2"%39JJ1
M+$I,L;XASQ2?:UF=:_`)*ZL$_/ZPGD..!N&(HR$JYH@)+Y2EF?#[71/9(%*A
MB0;]W#ID=9[H&T5*`BH%[-9D44-#CR';[A>=S]&D\VTRGRD+->`R8K8AY8C+
M#,HQ1U39="REA$PD9=DY4M_]?^=8E3@8L"%G.K#W*QFGY/R61PV)X7%$WC3]
MY[>#EBZ3GW5F.E-'F9.`RPSY%7(T=!9Q=+>SF$?1SB9C&_G;#Q;M@:2LO.?O
MM^KRHQ>IN#?2ZE3:&\6"E1;0)D(>1CY&`48A1A%&,4:)A.1<@PT2>6%-1V#>
MHP<T1$DI+"BR8+\2TD:9J"WY%(>&$,6W,P\C'Z,`HQ"C"*,8(W*\.CP$=8@>
ME]*SK#*O#_DV/YT:+:M>R5$H-%@O>TS/:3>FPP]JU3L3%[Y887PJG[KP-7>#
MSUSX^+G!H8-N*U)UYB[4T3?B31""V<=WO(4+=2WFT<*%HA1SJ/]<'ZHN?`?J
M-S>^>0>*(;C3+6WE>>%$^ZG[`%'XAIQTW^AC8[EP=H3[WM@NG)=@_C1QGV"&
MX(;1]P`GUI?TD/^>UH?BW&BG?`_3..[*YYJ>>=,?+5O]SU4+1]7=1G"$OTWD
M<%PX)NMB7U4M_T$ZZ/_:L?X7``#__P,`4$L#!!0`!@`(````(0`/P-ZTCP(`
M`(H&```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;)15RV[;,!"\%^@_
M$+Q'E/RL!<N!TR!M@`8HBC[.-+62B(BB0-)Q\O==BK8LQT'K7"23&L[L+'?7
MR^MG59,G,%;J)J-)%%,"C="Y;,J,_OIY=_6)$NMXD_-:-Y#1%[#T>O7QPW*G
MS:.M`!Q!AL9FM'*N31FSH@+%;:1;:/!+H8WB#I>F9+8UP//ND*K9*(YG3''9
MT,"0FDLX=%%(`;=:;!4T+I`8J+G#^&TE6WM@4^(2.L7-X[:]$EJU2+&1M70O
M'2DE2J3W9:,-W]3H^SF9<''@[A9G]$H*HZTN7(1T+`1Z[GG!%@R95LM<H@.?
M=F*@R.@Z26_FE*V677Y^2]C9P6]B*[W[8F3^33:`R<9K\A>PT?K10^]SOX6'
MV=GIN^X"OAN20\&WM?NA=U]!EI7#VYZB(>\KS5]NP0I,*-)$HZEG$KK&`/!)
ME/25@0GAS]U[)W-7970<1_,D7HSGR+(!Z^ZDIZ1$;*W3ZD\`)7NJ0#+:D^#[
M0#*+IO-XG*#F?TA8"*CS=\L=7RV-WA&L&92T+?<5F*1(_+8A=.*Q:P_.Z)P2
MC-7B)3RMDL5DR9XP<V*/N0D8?!XQ/8*A:*^,:I<K>[!7]JGUH=R$C:',Z&V9
M\7MD/!CO9AC\8MKS!N6`F0PP1\2)081<;M"#\0YP7ASS=I;;`+I`&NOA<FD/
M[J3[Y.YWL$T&P<SZ/)RXG+U'RH-/I?8[HZ[]AN6!53:T$#IN'/E^^7>1^H.G
M&OL=E!K8F;^R$WH_](8"4\)GJ&M+A-[ZOAYAM?>[_<A9=V&_WI^DZZY06?\!
M1T'+2WC@II2-)3442(D#`+V8,$S"PND6(\=>U@Z'0/>SPID/6/!QA.!":W=8
M^''5_XNL_@(``/__`P!02P,$%``&``@````A`!TB9O0R`0``0`(``!$`"`%D
M;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````)R104_#(!B&[R;^AX9[2^FR:4C+$C4[N<3$&8TWA&\ML5`"
M:+=_+^NZ.J,GC^1]>7B^CW*YTVWR"<ZKSE2(9#E*P(A.*E-7Z&FS2J]1X@,W
MDK>=@0KMP:,EN[PHA:6B<_#@.@LN*/!))!E/A:U0$X*E&'O1@.8^BPT3PVWG
M-`_QZ&ILN7CG->`BSQ=80^"2!XX/P-1.1#0BI9B0]L.U`T`*#"UH,,%CDA'\
MW0W@M/_SPI"<-;4*>QMG&G7/V5(<PZF]\VHJ]GV?];-!(_H3_+*^?QQ&394Y
M[$H`8H?]M-R'=5SE5H&\V;/=FVL3[YL2_\Y**08[*ASP`#*)[]&CW2EYGMW>
M;5:(%3F9I82D^=6F('2^H//Y:XE/K?$^FX!Z%/@W\01@@_?//V=?````__\#
M`%!+`P04``8`"````"$`CD$=&64"``#.!@``$``(`61O8U!R;W!S+V%P<"YX
M;6P@H@0!**```0``````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````"<54U/
MXS`0O:^T_Z'*'=(6M%HA-RBD`:(M2=6XW6-DD@FU2.W(-A'LK]])0VD*%LOV
M-IZ/YS<SUC.Y?-Y4@P:4YE),G-'IT!F`R&7!Q</$6=+KDY_.0!LF"E9)`1/G
M!;1SZ7W_1N9*UJ`,!SU`"*$GSMJ8^L)U=;Z&#=.G&!88*:7:,(-']>#*LN0Y
M3&7^M`%AW/%P^,.%9P.B@.*D?@-T.L2+QAP+6LB\Y:=7]*5&PA[QZ[KB.3/8
MI7?'<R6U+,T@?,ZA(FX_2)!="OF3XN;%&Q*W?R1ISBH($-@K6:6!N'L'N076
M#FW.N-(>:<Q%`[F1:J#Y'QS;V!G<,PTMG8G3,,69,$BK3>L.6[NJM5'>;ZD>
M]1K`:.)B0N?<FOW<OLW/O?%HFX'686:+T#'!P"%'RDT%.BGG3!D;Y5&?\Y9%
MQ[@CM-MBAF\C"X7!>661Z+;-99_Y6P]!$D_#.`VG&5II,HNF/L7#E3_SXR#\
MGY*48N7=,27=F%YG^B]FK]>,CZ!V=D3-N;4FC6[BZ#H*_)AF?A`DRYA&\4TV
MQ_D%D7T$4;P*8YHLHC"U0N+X5^&"1E>S,(L3:@=):1+\RNC"CU,_H!%NS(IU
M[4>+;.7/EF%V%_KI<H%[B:DU]?-.[)OIM9)1=H\/U@K]OJ//<C^G85]VGT:*
M`E<\59#)$E]\@TKV-4HQ4PH5J(%L"E\L.;C*>LO'+;7HC%?V.=FW92LY$(YW
M4C'CXE$O:RJGS,!."P^=)%TS!06JQ"Z^=Y!;E$%5M2#!FHD'*'8Y'P.M<J^Z
M[\D;G9\.SX8HRCT?<?<?D?<7``#__P,`4$L!`BT`%``&``@````A`*>-UH:N
M`0``/`\``!,``````````````````````%M#;VYT96YT7U1Y<&5S72YX;6Q0
M2P$"+0`4``8`"````"$`M54P(_4```!,`@``"P````````````````#G`P``
M7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`.)-`988!``#9#0``&@``````
M```````````-!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4
M``8`"````"$`XK-5&:\"``!W!P``#P````````````````#3"0``>&PO=V]R
M:V)O;VLN>&UL4$L!`BT`%``&``@````A`)/J'QZ.`P``)@T``!@`````````
M````````KPP``'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+`0(M`!0`!@`(
M````(0"YAJB[^`(``.X(```9`````````````````',0``!X;"]W;W)K<VAE
M971S+W-H965T,C`N>&UL4$L!`BT`%``&``@````A`+XXR%'N`@``IP@``!D`
M````````````````HA,``'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M+0`4``8`"````"$`_U>?UHP#``#W"P``&0````````````````#'%@``>&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````(0#O6AX/U`(`
M`),'```9`````````````````(H:``!X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L!`BT`%``&``@````A`)%?6WM?`@``1P4``!D`````````````````
ME1T``'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4``8`"````"$`
M^V*E;90&``"G&P``$P`````````````````K(```>&PO=&AE;64O=&AE;64Q
M+GAM;%!+`0(M`!0`!@`(````(0#6<17H3PL``'IA```-````````````````
M`/`F``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`!`59HHC)@``_7(`
M`!0`````````````````:C(``'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`
M%``&``@````A`!E$1?`D!0``(!,``!@`````````````````OU@``'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````(0#E2*QZ"`4``-`3
M```8`````````````````!E>``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q0
M2P$"+0`4``8`"````"$`LDE-"9(#``!;#```&`````````````````!78P``
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!`BT`%``&``@````A`,"+>5"$
M!0``3AL``!D`````````````````'V<``'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"+0`4``8`"````"$`OY7/],$%``"[%0``&0``````````````
M``#:;```>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+`0(M`!0`!@`(````
M(0`ER3++]`4``)`9```8`````````````````-)R``!X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"+0`4``8`"````"$`F9Y68J,"```@!P``&```````
M``````````#\>```>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`BT`%``&
M``@````A`#<L2'[^!0``7AD``!@`````````````````U7L``'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0!N=R/K/`<``'`>```9
M``````````````````F"``!X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!
M`BT`%``&``@````A`)T3:;(3"```L24``!@`````````````````?(D``'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+`0(M`!0`!@`(````(0!;KI#WP0D`
M`&DP```9`````````````````,61``!X;"]W;W)K<VAE971S+W-H965T,3`N
M>&UL4$L!`BT`%``&``@````A`-LK1D9[!P``>R(``!D`````````````````
MO9L``'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"+0`4``8`"````"$`
M`YIN>F\#``!&#```&0````````````````!OHP``>&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0!\`N5^3`8``#(9```8````````
M`````````!6G``!X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"+0`4``8`
M"````"$`#\#>M(\"``"*!@``&0````````````````"7K0``>&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;%!+`0(M`!0`!@`(````(0`=(F;T,@$``$`"```1
M`````````````````%VP``!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`!@`(
M````(0".01T990(``,X&```0`````````````````,:R``!D;V-0<F]P<R]A
<<'`N>&UL4$L%!@`````>`!X`!`@``&&V````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="nump">$ 609<span></span></td>
        <td class="nump">$ 1,247<span></span></td>
        <td class="nump">$ 2,198<span></span></td>
        <td class="nump">$ 3,690<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and Administrative Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="nump">345<span></span></td>
        <td class="nump">840<span></span></td>
        <td class="nump">1,255<span></span></td>
        <td class="nump">2,155<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Cost of Revenue [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 220<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 220<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTE<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTE [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTE</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>NOTE 3 - CONVERTIBLE NOTE</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> <font style="COLOR: black">On September 18, 2013, the Company completed a private placement of $69.0 million in aggregate principal amount of 4.50% convertible notes due 2018</font> (the "Notes")<font style="COLOR: black">,</font> including $9.0 million aggregate principal amount of Notes related to the initial purchaser&#39;s over-allotment option, which was exercised in full<font style="COLOR: black">. In connection with the completion of the offering, the Company entered into an indenture (the "Indenture") with The Bank of New York Mellon Trust Company, N.A., as trustee, governing the Notes. The Notes accrue interest at a rate of 4.50% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2014. The Notes mature on September 15, 2018.</font></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> The net proceeds from the offering, including net proceeds from the exercise in full by the initial purchaser of its option to purchase an additional $9.0 million in aggregate principal amount of the Notes, were $66.8 million, after deducting the initial purchaser&#39;s discount and commission and the estimated offering expenses payable by the Company.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> Holders may convert their Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018. The initial conversion rate for the Notes is 173.6593 shares of the Common Stock for each $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.76 per share of the Common Stock. Upon conversion, the Company will deliver a number of shares of Common Stock, per $1,000 principal amount of Notes, equal to the conversion rate. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> Prior to September 19, 2016, the Company may not redeem the Notes, and no sinking fund is provided for the Notes. On or after September 19, 2016, the Company may redeem for cash all or part of the Notes (except for the notes that the Company is then required to repurchase in connection with a fundamental change, as defined below) if the last reported sale price of the Common Stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on the trading day immediately preceding the date on which the Company provides the notice of redemption. The redemption price will equal the sum of (i)&nbsp;100% of the principal amount of the Notes being redeemed, plus (ii)&nbsp;accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date, plus (iii) the sum of the present values of each of the remaining scheduled payments of interest that would have been made on the Notes being redeemed had such Notes remained outstanding from the redemption date to the maturity date.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> The following table sets forth total interest expense recognized related to the Notes (in thousands):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6">Nine Months Ended</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6">Three Months Ended</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September&nbsp;30,<br /> 2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"> September&nbsp;30,</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">2012</p> </td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September&nbsp;30,<br /> 2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September&nbsp;30,<br /> 2012</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 10pt; WIDTH: 56%; TEXT-INDENT: -10pt"> Contractual interest expense</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">104</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">104</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 10pt; TEXT-INDENT: -10pt"> Amortization of debt issuance costs</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 15</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 15</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 10pt; TEXT-INDENT: -10pt"> Total</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 119</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 119</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETEAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTE (Narrative) (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 18, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTE [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
        <td class="nump">$ 69,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Debt additional principal amount</a></td>
        <td class="nump">9,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="nump">4.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate', window );">Base value for conversion rate</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleConversionShareNumber', window );">Number of shares for basis conversion</a></td>
        <td class="nump">173.6593<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
        <td class="nump">$ 5.76<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
        <td class="nump">$ 66,800<span></span></td>
        <td class="nump">$ 66,930<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity</a></td>
        <td class="text">Sep. 15,
				 2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt Instrument Convertible Base Value For Conversion Rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DebtInstrumentConvertibleBaseValueForConversionRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleConversionShareNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt Instrument Convertible Conversion Share Number</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DebtInstrumentConvertibleConversionShareNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY)  (Parenthetical) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Common stock issued for cash, issuance costs</a></td>
        <td class="nump">$ 1,780<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Authorized</a></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.5in"><strong>a.</strong></td> <td><strong>General</strong></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#39;s proprietary ProCellEx<sup>&reg;</sup> protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health (the "Brazilian MOH") in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&trade; by Pfizer Inc. (<font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer<font style="TEXT-TRANSFORM: uppercase">"</font>), the Company&#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the <font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer Agreement<font style="TEXT-TRANSFORM: uppercase">"</font>). The Company, through Protalix Ltd., markets ELELYSO in Israel.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel, and, subject to the effectiveness of the Brazil Agreement (as defined below), in Brazil. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, and, subject to the effectiveness of the Brazil Agreement, in Brazil, where the Company retained or will retain exclusive marketing rights. <font style="COLOR: black">In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold</font>.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;&nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the "Brazil Agreement") with Funda&ccedil;&atilde;o Oswaldo Cruz ("Fiocruz"), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO<sup>TM</sup>. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement becomes effective upon its approval by the Brazilian National Institute of Industrial Property, which is expected to occur very shortly.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.&#39;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Mexico, Chile and Uruguay. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil and Israel. In addition, patients are being treated globally through the Company&#39;s clinical trials and related studies, compassionate use programs and other programs. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.<br style="PAGE-BREAK-BEFORE: always" clear="all" /> </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&#39;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>b.</strong></td> <td><strong>Basis of Presentation</strong></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2012, filed by the Company with the Commission. The comparative balance sheet at December 31, 2012 has been derived from the audited financial statements at that date.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 36pt">&nbsp;</td> <td style="WIDTH: 17.85pt"><strong>c.</strong></td> <td><strong>Net loss per share</strong></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> Basic and diluted loss per share are calculated by dividing the net loss by the weighted average number of shares of the Company&#39;s common stock, par value $0.001 (the "Common Stock"), outstanding for each period.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> Diluted loss per share does not include options, restricted shares and shares issuable upon conversion of the convertible notes issued in September 2013 (see Note 3) in the amount of <font style="COLOR: black">7,169,035</font> and 7,879,601 shares of Common Stock for the nine months ended September 30, 2012 and 2013, respectively, and <font style="COLOR: black">7,508,240</font> and 8,817,090 shares of Common Stock for the three months ended September 30, 2012 and 2013, respectively, because the effect would be anti-dilutive.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 36pt">&nbsp;</td> <td style="WIDTH: 17.85pt"><strong>d.</strong></td> <td><strong>Convertible notes</strong> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> <font style="COLOR: black">The convertible notes are accounted for using the guidance provided set forth in</font> FASB Accounting Standards Codification <font style="COLOR: black">(ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely.</font></p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>NOTE 4 - STOCK TRANSACTIONS</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> <font style="COLOR: black">During the nine months ended September 30, 2013, the Company issued a total of approximately</font> <font style="FONT-SIZE: 10pt">64,768</font> <font style="COLOR: black">shares of Common Stock in connection with the exercise of a total of approximately</font> <font style="FONT-SIZE: 10pt">64,768</font> <font style="COLOR: black">options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $103,000.</font></p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>NOTE 2 - INVENTORIES</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> Inventory at September 30, 2013 and December&nbsp;31, 2012 consisted of the following:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; WIDTH: 80%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September 30,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">December 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; WIDTH: 78%">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">2,574</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">2,118</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">140</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">192</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Finished goods</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,863</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,729</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7,577</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,039</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> <font style="COLOR: black">Prior to the FDA&#39;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses</font>. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes all manufacturing costs associated with taliglucerase alfa.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>22
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\S,3<X,#5E.%\T8S0R7S1E-C%?8C!C9E\V
M-#EB,#=B,#=A9CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S$W
M.#`U93A?-&,T,E\T938Q7V(P8V9?-C0Y8C`W8C`W868Y+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]35$%414U%/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$
M7T-/3E-/3$E$051%1%]35$%414U%,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-
M13(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TY$
M14Y3141?0T].4T],241!5$5$7U-4051%344S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]3
M5$%414U%-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?4$],24-)13PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5D5.5$]22453/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].5D525$E"3$5?3D]4
M13PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-43T-+
M7U1204Y304-424].4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D9!25)?5D%,545?345!4U5214U%3E0\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y324=.249)0T%.5%]!0T-/54Y424Y'
M7U!/3$E#244Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^24Y614Y43U))15-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$T+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^0T].5D525$E"3$5?3D]415]486)L97,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y324=.249)0T%.5%]!
M0T-/54Y424Y'7U!/3$E#244R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$V+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^24Y614Y43U))15-?4V-H961U;&5?;V9?26YV96YT/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].5D525$E"
M3$5?3D]415].87)R871I=F5?1&5T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$X+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^0T].5D525$E"3$5?3D]415]38VAE9'5L95]O9E])
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1/0TM?
M5%)!3E-!0U1)3TY37T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C`N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y&04E27U9!3%5%7TU%05-54D5-14Y47T1E=&%I;',\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2
M968],T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H
M965T/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^
M1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O
M=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O
M;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F
M="!%>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\S,3<X,#5E.%\T8S0R7S1E-C%?8C!C9E\V
M-#EB,#=B,#=A9CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S$W
M.#`U93A?-&,T,E\T938Q7V(P8V9?-C0Y8C`W8C`W868Y+U=O<FMS:&5E=',O
M4VAE970P,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15!#044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DYO=BX@,#$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE
M;G0@06YD($5N=&ET>2!);F9O<FUA=&EO;B!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P+5$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#Y397`@,S`L#0H)"3(P,3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N
M="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S(P,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@4&5R:6]D($9O8W5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG43,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D:6YG(%-Y
M;6)O;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U!,6#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B=04D]404Q)6"!"24]42$5205!%551)0U,L($E.0RX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<P,#`Q,#`V,C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@
M1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)RTM,3(M,S$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B=!8V-E;&5R871E9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@
M4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDS+#4V,2PW-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S,Q-S@P-64X7S1C-#)?-&4V,5]B,&-F7S8T
M.6(P-V(P-V%F.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,3<X
M,#5E.%\T8S0R7S1E-C%?8C!C9E\V-#EB,#=B,#=A9CDO5V]R:W-H965T<R]3
M:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%4#5!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T
M<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$($)!3$%.0T4@4TA%1513("A5
M4T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#55)214Y4($%34T544SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q
M=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DQ
M+#,Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-3(L,#,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE+2!4<F%D93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP-3,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0Q,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$W,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);G9E;G1O<FEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RPU-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#`S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#4L,C`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$L,3<P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&54Y$4R!)
M3B!215-014-4($]&($5-4$Q/645%(%))1TA44R!54$].(%)%5$E214U%3E0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#8W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!2
M3U!%4E19($%.1"!%455)4$U%3E0L($Y%5#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30L,S0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,38L,S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$149%4E)%1"!#2$%21T53/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,C$L,34V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S@L-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1S('!A>6%B;&4@86YD
M(&%C8W)U86QS.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1R861E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#,Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3(L-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$L,#4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PU,3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#0S-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U
M<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(U+#(R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(U+#<U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,3TY'(%1%4DT@3$E!0DE,251)
M15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5F97)R960@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0S+#0Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0X+#@X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@;F]T97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8V+#DT-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQI86)I;&ET>2!I;B!C;VYN96-T:6]N('=I=&@@8V]L;&%B;W)A=&EO;B!O
M<&5R871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#0R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&EA8FEL:71Y(&9O<B!E;7!L;WEE92!R:6=H=',@
M=7!O;B!R971I<F5M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#(W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L,#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@;&]N9R!T97)M(&QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3(L-C,V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38L,S(Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$S-RPX-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX,BPP.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0T%0251!3"!$149)0TE%3D-9/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-BPW,#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,RPS-3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,@;F5T(&]F
M(&-A<&ET86P@9&5F:6-I96YC>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,C$L,34V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`W."PW,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S,Q-S@P-64X7S1C-#)?-&4V,5]B,&-F7S8T
M.6(P-V(P-V%F.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,3<X
M,#5E.%\T8S0R7S1E-C%?8C!C9E\V-#EB,#=B,#=A9CDO5V]R:W-H965T<R]3
M:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%2D-!1SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$(%-4051%345.5%,@3T8@3U!%
M4D%424].4R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E
M(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!/4$52
M051)3TY3(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)%5D5.5453/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(L,C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#<R-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."PQ,38\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,S+#8Y.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0T]-4$%.62=3(%-(05)%($E.($-/3$Q!0D]2051)3TX@04=2145-14Y4/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`W-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C8V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR-S4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-/4U0@3T8@4D5614Y515,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L-3@W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(L,S8W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#,L.#<V*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L.38V*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=23U-3(%!23T9)
M5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW-S(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`R,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M-3$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C<L-#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y215-%05)#2"!!3D0@1$5614Q/4$U%3E0@15A014Y315,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<L-S(S*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L,S(V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(S
M+#0V-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R-RPW,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y,97-S("T@9W)A;G1S(&%N9"!R96EM8G5R<V5M96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP.#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DV,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M,#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PV-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y215-%05)#2"!!3D0@1$5614Q/4$U%3E0@15A014Y315,L
M($Y%5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PV,S<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPS
M-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3<L-#$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(R+#`V,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=%3D5204P@04Y$($%$34E.25-44D%4259%
M($584$5.4T53/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#<X
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R+#(R,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@V+#`V-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W+#,U,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/4$52051)3D<@3$]34SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PV-#4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PU-C`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38L.38X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L
M,#`U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1DE.04Y#24%,($E.0T]-12`H15A014Y315,I("T@3D54/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY%5"!,
M3U-3($9/4B!42$4@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#4L-S0W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H-2PT-SDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-BPY,#4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+#<T,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^3$]34R!015(@4TA!4D4@3T8@0T]-34].(%-43T-+.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0D%324,@04Y$
M($1)3%54140\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XQ.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XP,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY714E'2%1%1"!!5D5204=%
M($Y534)%4B!/1B!32$%215,@3T8@0T]-34].(%-43T-+(%53140@24X@0T]-
M4%5424Y'($Q/4U,@4$52(%-(05)%.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0D%324,@04Y$($1)3%54140\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDR+#0S,RPU,#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,2PY,CDL
M-#0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3(L,S`W+#$W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDP+#0Y,2PT,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S,Q-S@P-64X7S1C-#)?-&4V,5]B,&-F7S8T
M.6(P-V(P-V%F.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,3<X
M,#5E.%\T8S0R7S1E-C%?8C!C9E\V-#EB,#=B,#=A9CDO5V]R:W-H965T<R]3
M:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%2U5!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$(%-4051%345.5%,@3T8@3U!%
M4D%424].4R`H4&%R96YT:&5T:6-A;"D@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C
M:"!A;F0@1&5V96QO<&UE;G0@17AP96YS92!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE92!3
M97)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@06QL;V-A=&EO;B!O
M9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$L,C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R+#$Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPV.3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD
M($%D;6EN:7-T<F%T:79E($5X<&5N<V4@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16UP;&]Y964@4V5R
M=FEC92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL($%L;&]C871I;VX@;V8@
M4F5C;V=N:7IE9"!097)I;V0@0V]S=',@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB
M87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPQ-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<W0@;V8@4F5V96YU92!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@
M06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C(P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\S,3<X,#5E.%\T8S0R7S1E-C%?8C!C9E\V-#EB,#=B,#=A9CD-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S$W.#`U93A?-&,T,E\T938Q
M7V(P8V9?-C0Y8C`W8C`W868Y+U=O<FMS:&5E=',O4VAE970P-2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P131:0D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].1$5.4T5$
M($-/3E-/3$E$051%1"!35$%414U%3E0@3T8@0TA!3D=%4R!)3B!32$%214A/
M3$1%4B=3($5154E462`H0T%0251!3"!$149)0TE%3D-9*2`H55-$("0I/&)R
M/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y4;W1A;#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D:71I;VYA;"!P86ED
M+6EN($-A<&ET86P@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^06-C=6UU;&%T960@1&5F:6-I="!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N
M8V4@870@1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@R-BPP-S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,30U+#@Q-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3<Q+#DW-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN
M;FEN9R!"86QA;F-E("AI;B!S:&%R97,I(&%T($1E8RX@,S$L(#(P,3$\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-2PV,S`L,34W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:R!I<W-U960@9F]R(&-A<V@@*&YE="!O9B!I<W-U86YC92!C
M;W-T<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#,X.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-2PS.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D(&9O<B!C
M87-H("AN970@;V8@:7-S=6%N8V4@8V]S=',I("AI;B!S:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PQ-S4L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M+6)A<V5D(&-O;7!E;G-A=&EO;B!R96QA=&5D('1O('-T;V-K(&]P=&EO;G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,C$W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L,C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T
M:6]N(')E;&%T960@=&\@<F5S=')I8W1E9"!S=&]C:R!A=V%R9"P@;F5T(&]F
M(&9O<F9E:71U<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#@T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#@T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A
M=&EO;B!R96QA=&5D('1O(')E<W1R:6-T960@<W1O8VL@87=A<F0L(&YE="!O
M9B!F;W)F96ET=7)E<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!O<'1I;VYS
M(&=R86YT960@=&\@96UP;&]Y965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#$S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#$S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F
M(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE97,@*&EN('-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$U-BPQ.#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&QO<W,@9F]R('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L-S0Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PW-#$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;F1I;F<@0F%L86YC92!A="!397`N(#,P+"`R,#$R/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#<W,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<X+#,Y-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W,RPW,3@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;F1I;F<@0F%L86YC92`H:6X@<VAA<F5S*2!A="!397`N(#,P+"`R,#$R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,L-#8Q+#,T,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M96=I;FYI;F<@0F%L86YC92!A="!$96,N(#,Q+"`R,#$R/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S+#,U-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,"PQ-#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.#,L-3DU*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F5G:6YN:6YG($)A;&%N8V4@*&EN('-H87)E<RD@870@1&5C+B`S,2P@,C`Q
M,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS+#0X.2PX,#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(')E;&%T960@=&\@<W1O8VL@
M;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#DU/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C@Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E
M;G-A=&EO;B!R96QA=&5D('1O(')E<W1R:6-T960@<W1O8VL@87=A<F0L(&YE
M="!O9B!F;W)F96ET=7)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPU-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU-3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M92UB87-E9"!C;VUP96YS871I;VX@<F5L871E9"!T;R!R97-T<FEC=&5D('-T
M;V-K(&%W87)D+"!N970@;V8@9F]R9F5I='5R97,@*&EN('-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#8V-RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I
M<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE97,@*&EN('-H
M87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-"PW-C@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&QO<W,@9F]R('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$V+#DP-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$V+#DP-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E(&%T(%-E<"X@,S`L(#(P,3,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,38L-S`V*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$X
M,RPW,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#(P,"PU,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC92`H:6X@<VAA<F5S*2!A
M="!397`N(#,P+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3,L-34R+#DQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\S,3<X,#5E.%\T8S0R7S1E-C%?8C!C9E\V-#EB,#=B,#=A
M9CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S$W.#`U93A?-&,T
M,E\T938Q7V(P8V9?-C0Y8C`W8C`W868Y+U=O<FMS:&5E=',O4VAE970P-BYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14Y%04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].
M1$5.4T5$($-/3E-/3$E$051%1"!35$%414U%3E0@3T8@0TA!3D=%4R!)3B!3
M2$%214A/3$1%4B=3($5154E462`H0T%0251!3"!$149)0TE%3D-9*2`@*%!A
M<F5N=&AE=&EC86PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@
M4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T].1$5.4T5$
M($-/3E-/3$E$051%1"!35$%414U%3E0@3T8@0TA!3D=%4R!)3B!#05!)5$%,
M($1%1DE#245.0UD@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960@9F]R
M(&-A<V@L(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$L-S@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K+"!P87(@=F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@4W1O8VLL($%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$U,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Q-S@P-64X7S1C-#)?-&4V
M,5]B,&-F7S8T.6(P-V(P-V%F.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\S,3<X,#5E.%\T8S0R7S1E-C%?8C!C9E\V-#EB,#=B,#=A9CDO5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%04Y!1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$(%-4051%345.
M5%,@3T8@0T%32"!&3$]74R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL
M97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($]015)!
M5$E.1R!!0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#$V+#DP-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#$L-S0Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU<W1M
M96YT<R!R97%U:7)E9"!T;R!R96-O;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A
M<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!B87-E9"!C
M;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-#4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-BPP-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@=W)I=&4@9&]W;B!O9B!F:7AE
M9"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C@Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPW-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9I;F%N8VEA;"!E>'!E;G-E<R`H:6YC;VUE*2P@;F5T("AM86EN
M;'D@97AC:&%N9V4@9&EF9F5R96YC97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q-#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG97,@:6X@86-C<G5E9"!L:6%B:6QI
M='D@9F]R(&5M<&QO>65E(')I9VAT<R!U<&]N(')E=&ER96UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B!O;B!A;6]U
M;G1S(&9U;F1E9"!I;B!R97-P96-T(&]F(&5M<&QO>65E(')I9VAT<R!U<&]N
M(')E=&ER96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E8G0@:7-S=6%N8V4@8V]S=',@86YD
M(&1E8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A=&EN
M9R!A<W-E=',@86YD(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8W)E87-E(&EN(&1E9F5R<F5D
M(')E=F5N=65S("AI;F-L=61I;F<@;F]N+6-U<G)E;G0@<&]R=&EO;BD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L,SDS*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L.3@Q*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC
M<F5A<V4@:6X@86-C;W5N=',@<F5C96EV86)L92!A;F0@;W1H97(@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W.3@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPP.3DI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;F-R96%S92!I;B!I;G9E;G1O<FEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,RPU,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,2PW-SDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92`H9&5C<F5A<V4I(&EN
M(&%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U86QS("AI;F-L=61I;F<@;&]N
M9R!T97)M("D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L-#$S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(U+#DQ,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#$X-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($E.5D535$E.1R!!0U1)5DE42453
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!U<F-H87-E(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-C8X*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.#$W*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT<R!F
M=6YD960@:6X@<F5S<&5C="!O9B!E;7!L;WEE92!R:6=H=',@=7!O;B!R971I
M<F5M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Y,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=F5S=&UE;G0@:6X@<F5S=')I8W1E9"!D97!O<VET/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&-A<V@@=7-E9"!I;B!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PX,S$I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PY,3`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-!4T@@1DQ/5U,@1E)/32!&24Y!3D-)3D<@04-4259)5$E%4SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<')O
M8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VYV97)T:6)L92!N;W1E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8L.3,P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^27-S=6%N8V4@;V8@<VAA<F5S+"!N970@;V8@:7-S=6%N8V4@8V]S=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U
M+#,R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#`Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I
M;F%N8VEN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV-BPY-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-BPT,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5&1D5#5"!/1B!%6$-(04Y'12!2051%($-(
M04Y'15,@3TX@0T%32#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,30T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DY%5"!)3D-214%312!)3B!#05-(($%.1"!#05-(($5154E6
M04Q%3E13/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.2PS-C(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,RPR,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D)!3$%.0T4@3T8@0T%32"!!3D0@0T%32"!%455)5D%,14Y44R!!
M5"!"14=)3DY)3D<@3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,BPP,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-RPP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)!3$%.0T4@3T8@0T%32"!!3D0@0T%3
M2"!%455)5D%,14Y44R!!5"!%3D0@3T8@4$5224]$/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY,2PS.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PR,38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4U504$Q%
M345.5$%262!)3D9/4DU!5$E/3B!/3B!)3E9%4U1)3D<@04Y$($9)3D%.0TE.
M1R!!0U1)5DE42453($Y/5"!)3E9/3%9)3D<@0T%32"!&3$]74SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S
M92!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&-O<W0@<F5L871E9"!T
M;R!C;VYV97)T:6)L92!N;W1E(&]F9F5R:6YG(&YO="!Y970@<&%I9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AE<F-I<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Q-S@P-64X7S1C-#)?
M-&4V,5]B,&-F7S8T.6(P-V(P-V%F.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\S,3<X,#5E.%\T8S0R7S1E-C%?8C!C9E\V-#EB,#=B,#=A9CDO
M5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%
M4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M
M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z
M+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA
M;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@
M<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X)SX@/'-T<F]N9SY.3U1%(#$@+2!324=.
M249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453/"]S=')O;F<^/"]P/B`\<"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)
M1%1(.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`P
M+C5I;B<^/'-T<F]N9SYA+CPO<W1R;VYG/CPO=&0^(#QT9#X\<W1R;VYG/D=E
M;F5R86P\+W-T<F]N9SX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^("9N8G-P.SPO
M<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6XG/B!0<F]T86QI
M>"!":6]4:&5R87!E=71I8W,L($EN8RX@*&-O;&QE8W1I=F5L>2!W:71H(&ET
M<R!S=6)S:61I87)I97,L('1H92`B0V]M<&%N>2(I+"!A;F0@:71S('=H;VQL
M>2UO=VYE9"!S=6)S:61I87)Y+"!0<F]T86QI>"!,=&0N+"!A<F4@8FEO<&AA
M<FUA8V5U=&EC86P@8V]M<&%N:65S(&9O8W5S960@;VX@=&AE(&1E=F5L;W!M
M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!O9B!R96-O;6)I;F%N="!T:&5R
M87!E=71I8R!P<F]T96EN<R!B87-E9"!O;B!T:&4@0V]M<&%N>28C,SD[<R!P
M<F]P<FEE=&%R>2!0<F]#96QL17@\<W5P/B9R96<[/"]S=7`^('!R;W1E:6X@
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M96QY(&AE<F5I;B!A<R!T:&4@(E-U8G-I9&EA<FEE<RXB/"]P/B`\<"!S='EL
M93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;B<^("9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6XG/B!/;B!-87D@,2P@,C`Q,BP@
M=&AE(%4N4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H(D9$02(I
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M2&5A;'1H("AT:&4@(D)R87II;&EA;B!-3T@B*2!I;B!-87)C:"`R,#$S(&%N
M9"!B>2!T:&4@87!P;&EC86)L92!R96=U;&%T;W)Y(&%U=&AO<FET:65S(&]F
M(&-E<G1A:6X@;W1H97(@8V]U;G1R:65S+B!486QI9VQU8V5R87-E(&%L9F$@
M:7,@=&AE(&9I<G-T('!L86YT(&-E;&PM8F%S960@<F5C;VUB:6YA;G0@=&AE
M<F%P975T:6,@<')O=&5I;B!A<'!R;W9E9"!B>2!T:&4@1D1!(&]R(&%N>2!O
M=&AE<B!M86IO<B!R96=U;&%T;W)Y(&%U=&AO<FET>2X\+W`^(#QP('-T>6QE
M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;B<^(%1A;&EG;'5C97)A<V4@86QF
M82!I<R!B96EN9R!M87)K971E9"!I;B!T:&4@56YI=&5D(%-T871E<R!U;F1E
M<B!T:&4@8G)A;F0@;F%M92!%3$5,65-/)G1R861E.R!B>2!09FEZ97(@26YC
M+B`H/&9O;G0@<W1Y;&4],T0G5$585"U44D%.4T9/4DTZ('5P<&5R8V%S92<^
M(CPO9F]N=#Y09FEZ97(\9F]N="!S='EL93TS1"=415A4+51204Y31D]233H@
M=7!P97)C87-E)SXB/"]F;VYT/BDL('1H92!#;VUP86YY)B,S.3MS(&-O;6UE
M<F-I86QI>F%T:6]N('!A<G1N97(L(&%S('!R;W9I9&5D(&EN('1H92!E>&-L
M=7-I=F4@;&EC96YS92!A;F0@<W5P<&QY(&%G<F5E;65N="!B>2!A;F0@8F5T
M=V5E;B!0<F]T86QI>"!,=&0N(&%N9"!09FEZ97(@*'1H92`\9F]N="!S='EL
M93TS1"=415A4+51204Y31D]233H@=7!P97)C87-E)SXB/"]F;VYT/E!F:7IE
M<B!!9W)E96UE;G0\9F]N="!S='EL93TS1"=415A4+51204Y31D]233H@=7!P
M97)C87-E)SXB/"]F;VYT/BDN(%1H92!#;VUP86YY+"!T:')O=6=H(%!R;W1A
M;&EX($QT9"XL(&UA<FME=',@14Q%3%E33R!I;B!)<W)A96PN/"]P/B`\<"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;B<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6XG/B!0<F]T86QI>"!,=&0N
M(&=R86YT960@4&9I>F5R(&%N(&5X8VQU<VEV92P@=V]R;&1W:61E(&QI8V5N
M<V4@=&\@9&5V96QO<"!A;F0@8V]M;65R8VEA;&EZ92!T86QI9VQU8V5R87-E
M(&%L9F$@=6YD97(@=&AE(%!F:7IE<B!!9W)E96UE;G0L(&)U="!R971A:6YE
M9"!T:&]S92!R:6=H=',@:6X@27-R865L+"!A;F0L('-U8FIE8W0@=&\@=&AE
M(&5F9F5C=&EV96YE<W,@;V8@=&AE($)R87II;"!!9W)E96UE;G0@*&%S(&1E
M9FEN960@8F5L;W<I+"!I;B!"<F%Z:6PN(%1H92!#;VUP86YY(&AA<R!A9W)E
M960@=&\@82!S<&5C:69I8R!A;&QO8V%T:6]N(&)E='=E96X@4')O=&%L:7@@
M3'1D+B!A;F0@4&9I>F5R(')E9V%R9&EN9R!T:&4@<F5S<&]N<VEB:6QI=&EE
M<R!F;W(@=&AE(&-O;G1I;G5E9"!D979E;&]P;65N="!E9F9O<G1S(&9O<B!T
M86QI9VQU8V5R87-E(&%L9F$N(%1O(&1A=&4L('1H92!#;VUP86YY(&AA<R!R
M96-E:79E9"!A;B!U<&9R;VYT('!A>6UE;G0@;V8@)#8P+C`@;6EL;&EO;B!I
M;B!C;VYN96-T:6]N('=I=&@@=&AE(&5X96-U=&EO;B!O9B!T:&4@4&9I>F5R
M($%G<F5E;65N="!A;F0@<VAO<G1L>2!T:&5R96%F=&5R(&%N(&%D9&ET:6]N
M86P@)#4N,"!M:6QL:6]N(&-L:6YI8V%L(&1E=F5L;W!M96YT+7)E;&%T960@
M;6EL97-T;VYE('!A>6UE;G0N(%1H92!#;VUP86YY(')E8V5I=F5D(&%N(&%D
M9&ET:6]N86P@)#(U+C`@;6EL;&EO;B!M:6QE<W1O;F4@<&%Y;65N="!I;B!C
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M9VQU8V5R87-E(&%L9F$@;VX@82`T,"4@86YD(#8P)2!B87-I<RP@<F5S<&5C
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M=',@;V8@9V]O9',@<V]L9#PO9F]N=#XN/"]P/B`\<"!S='EL93TS1"=&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ
M(#!P="`P<'@@,'!T(#%I;B<^("9N8G-P.R9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE..B`P<'0@,'!X(#!P="`Q:6XG/B!/;B!*=6YE(#$X+"`R,#$S+"!0
M<F]T86QI>"!,=&0N(&5N=&5R960@:6YT;R!A(%-U<'!L>2!A;F0@5&5C:&YO
M;&]G>2!4<F%N<V9E<B!!9W)E96UE;G0@*'1H92`B0G)A>FEL($%G<F5E;65N
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M<G5Z('!U<F-H87-E<R!A="!L96%S="!A<'!R;WAI;6%T96QY("0R.#`@;6EL
M;&EO;B!W;W)T:"!O9B!T86QI9VQU8V5R87-E(&%L9F$N(%1H92!"<F%Z:6P@
M06=R965M96YT(&)E8V]M97,@969F96-T:79E('5P;VX@:71S(&%P<')O=F%L
M(&)Y('1H92!"<F%Z:6QI86X@3F%T:6]N86P@26YS=&ET=71E(&]F($EN9'5S
M=')I86P@4')O<&5R='DL('=H:6-H(&ES(&5X<&5C=&5D('1O(&]C8W5R('9E
M<GD@<VAO<G1L>2X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M,6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T
M(#%I;B<^(%1O(&9A8VEL:71A=&4@=&AE(&%R<F%N9V5M96YT('=I=&@@1FEO
M8W)U>BP@4&9I>F5R(&%M96YD960@:71S(&5X8VQU<VEV92!L:6-E;G-E(&%N
M9"!S=7!P;'D@86=R965M96YT('=I=&@@4')O=&%L:7@@3'1D+B!4:&4@86UE
M;F1M96YT('!R;W9I9&5S(&9O<B!T:&4@=')A;G-F97(@;V8@=&AE(&-O;6UE
M<F-I86QI>F%T:6]N(&%N9"!O=&AE<B!R:6=H=',@=&\@=&%L:6=L=6-E<F%S
M92!A;&9A(&EN($)R87II;"!B86-K('1O(%!R;W1A;&EX($QT9"X@07,@8V]N
M<VED97)A=&EO;B!F;W(@=&AE('1R86YS9F5R(&]F('1H92!C;VUM97)C:6%L
M:7IA=&EO;B!A;F0@<W5P<&QY(')I9VAT<RP@4')O=&%L:7@@3'1D+B!A9W)E
M960@=&\@<&%Y(%!F:7IE<B!A(&UA>&EM=6T@86UO=6YT(&]F(&%P<')O>&EM
M871E;'D@)#$R+C4@;6EL;&EO;B!F<F]M(&ET<R!N970@<')O9FET<R`H87,@
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M/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;B<^("9N8G-P.SPO
M<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6XG/B!0<F]T86QI
M>"!,=&0N(&ES(')E<75I<F5D('1O('!A>2!A(&9E92!E<75A;"!T;R`U)2!O
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M/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6XG/B`F;F)S<#L\+W`^
M(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN)SX@26X@861D:71I
M;VX@=&\@=&AE(&%P<')O=F%L<R!F<F]M('1H92!&1$$L('1H92!)<W)A96QI
M($U/2"!A;F0@=&AE($)R87II;&EA;B!-3T@L(&UA<FME=&EN9R!A<'!R;W9A
M;"!H87,@8F5E;B!G<F%N=&5D('1O(%503%E33R!I;B!-97AI8V\L($-H:6QE
M(&%N9"!5<G5G=6%Y+B!);B!A9&1I=&EO;BP@=&AE($-O;7!A;GD@:7,@8V]O
M<&5R871I;F<@=VET:"!09FEZ97(@:6X@:71S(&5F9F]R=',@=&\@;V)T86EN
M(&UA<FME=&EN9R!A<'!R;W9A;"!F;W(@=&%L:6=L=6-E<F%S92!A;&9A(&EN
M(&%D9&ET:6]N86P@8V]U;G1R:65S(&%N9"!J=7)I<V1I8W1I;VYS+B!#=7)R
M96YT;'DL(&UA<FME=&EN9R!A=71H;W)I>F%T:6]N(&%P<&QI8V%T:6]N<R!H
M879E(&)E96X@9FEL960@:6X@82!N=6UB97(@;V8@8V]U;G1R:65S+CPO<#X@
M/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6XG/B`F;F)S<#L\+W`^
M(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN)SX@0W5R<F5N=&QY
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M86US+B!/;B!*=6QY(#$S+"`R,#$P+"!T:&4@0V]M<&%N>2!A;FYO=6YC960@
M=&AA="!T:&4@1G)E;F-H(')E9W5L871O<GD@875T:&]R:71Y(&AA9"!G<F%N
M=&5D(&%N($%U=&]R:7-A=&EO;B!496UP;W)A:7)E(&0F(S,Y.U5T:6QI<V%T
M:6]N("A!5%4I+"!O<B!496UP;W)A<GD@075T:&]R:7IA=&EO;B!F;W(@57-E
M+"!F;W(@=&%L:6=L=6-E<F%S92!A;&9A(&9O<B!T:&4@=')E871M96YT(&]F
M($=A=6-H97(@9&ES96%S92X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P
M>"`P<'0@,6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P
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M<&%T:65N="!P<F]V:7-I;VYS(&EN(&]T:&5R(&-O=6YT<FEE<RX\+W`^(#QP
M('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;B<^($EN(&%D9&ET:6]N
M('1O('1A;&EG;'5C97)A<V4@86QF82P@=&AE($-O;7!A;GD@:7,@=V]R:VEN
M9R!O;B!T:&4@9&5V96QO<&UE;G0@;V8@8V5R=&%I;B!O=&AE<B!P<F]D=6-T
M<R!U<VEN9R!0<F]#96QL17@N/&)R('-T>6QE/3-$)U!!1T4M0E)%04LM0D5&
M3U)%.B!A;'=A>7,G(&-L96%R/3-$86QL("\^(#PO<#X@/'`@<W1Y;&4],T0G
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X(#!P="`Q:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$
M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>"`P<'0@,6EN)SX@26X@861D:71I;VX@=&\@=&AE(&%P
M<')O=F%L(&]F('1A;&EG;'5C97)A<V4@86QF82!F;W(@;6%R:V5T:6YG(&EN
M('1H92!5;FET960@4W1A=&5S+"!)<W)A96PL($)R87II;"P@365X:6-O(&%N
M9"!O=&AE<B!C;W5N=')I97,L('-U8V-E<W-F=6P@8V]M<&QE=&EO;B!O9B!T
M:&4@0V]M<&%N>28C,SD[<R!D979E;&]P;65N="!P<F]G<F%M<R!A;F0@:71S
M('1R86YS:71I;VX@=&\@;F]R;6%L(&]P97)A=&EO;G,@:7,@9&5P96YD96YT
M('5P;VX@;V)T86EN:6YG('1H92!F;W)E:6=N(')E9W5L871O<GD@87!P<F]V
M86QS(')E<75I<F5D('1O('-E;&P@:71S('!R;V1U8W1S(&EN=&5R;F%T:6]N
M86QL>2X@02!S=6)S=&%N=&EA;"!A;6]U;G0@;V8@=&EM92!M87D@<&%S<R!B
M969O<F4@=&AE($-O;7!A;GD@86-H:65V97,@82!L979E;"!O9B!R979E;G5E
M<R!A9&5Q=6%T92!T;R!S=7!P;W)T(&ET<R!O<&5R871I;VYS+"!I9B!A="!A
M;&PL(&%N9"!T:&4@0V]M<&%N>2!E>'!E8W1S('1O(&EN8W5R('-U8G-T86YT
M:6%L(&5X<&5N9&ET=7)E<R!I;B!C;VYN96-T:6]N('=I=&@@=&AE(')E9W5L
M871O<GD@87!P<F]V86P@<')O8V5S<R!F;W(@96%C:"!O9B!I=',@<')O9'5C
M="!C86YD:61A=&5S(&1U<FEN9R!T:&5I<B!R97-P96-T:79E(&1E=F5L;W!M
M96YT86P@<&5R:6]D<RX\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P
M<'0@,6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@
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M92!O9B!T:&5S92!A8W1I=FET:65S+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X(#!P="`Q:6XG/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P
M+C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG
M/CQS=')O;F<^8BX\+W-T<F]N9SX\+W1D/B`\=&0^/'-T<F]N9SY"87-I<R!O
M9B!0<F5S96YT871I;VX\+W-T<F]N9SX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^
M("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`U-BXW
M<'0G/B!4:&4@86-C;VUP86YY:6YG('5N875D:71E9"!C;VYD96YS960@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&]F('1H92!#;VUP86YY
M(&AA=F4@8F5E;B!P<F5P87)E9"!I;B!A8V-O<F1A;F-E('=I=&@@86-C;W5N
M=&EN9R!P<FEN8VEP;&5S(&=E;F5R86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI
M=&5D(%-T871E<R`H(D=!05`B*2!F;W(@:6YT97)I;2!F:6YA;F-I86P@:6YF
M;W)M871I;VXN($%C8V]R9&EN9VQY+"!T:&5Y(&1O(&YO="!I;F-L=61E(&%L
M;"!O9B!T:&4@:6YF;W)M871I;VX@86YD(&YO=&5S(')E<75I<F5D(&)Y($=!
M05`@9F]R(&%N;G5A;"!F:6YA;F-I86P@<W1A=&5M96YT<RX@26X@=&AE(&]P
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M(&UA>2!B92!E>'!E8W1E9"!F;W(@=&AE(&9U;&P@>65A<BX\+W`^(#QP('-T
M>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@-38N-W!T)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P="<^(%1H97-E('5N
M875D:71E9"!C;VYD96YS960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T
M96UE;G1S('-H;W5L9"!B92!R96%D(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE
M(&%U9&ET960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN
M('1H92!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE('EE87(@
M96YD960@1&5C96UB97(@,S$L(#(P,3(L(&9I;&5D(&)Y('1H92!#;VUP86YY
M('=I=&@@=&AE($-O;6UI<W-I;VXN(%1H92!C;VUP87)A=&EV92!B86QA;F-E
M('-H965T(&%T($1E8V5M8F5R(#,Q+"`R,#$R(&AA<R!B965N(&1E<FEV960@
M9G)O;2!T:&4@875D:71E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!A="!T:&%T
M(&1A=&4N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P
M="<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE.+51/4#H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#,V<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=724142#H@,3<N.#5P="<^/'-T<F]N9SYC+CPO
M<W1R;VYG/CPO=&0^(#QT9#X\<W1R;VYG/DYE="!L;W-S('!E<B!S:&%R93PO
M<W1R;VYG/CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+51/4#H@,'!T)SX@)FYB<W`[/"]P/B`\<"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;B<^($)A<VEC(&%N9"!D
M:6QU=&5D(&QO<W,@<&5R('-H87)E(&%R92!C86QC=6QA=&5D(&)Y(&1I=FED
M:6YG('1H92!N970@;&]S<R!B>2!T:&4@=V5I9VAT960@879E<F%G92!N=6UB
M97(@;V8@<VAA<F5S(&]F('1H92!#;VUP86YY)B,S.3MS(&-O;6UO;B!S=&]C
M:RP@<&%R('9A;'5E("0P+C`P,2`H=&AE(")#;VUM;VX@4W1O8VLB*2P@;W5T
M<W1A;F1I;F<@9F]R(&5A8V@@<&5R:6]D+CPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X(#!P="`P+C<U:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$
M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN)SX@1&EL=71E9"!L;W-S('!E<B!S
M:&%R92!D;V5S(&YO="!I;F-L=61E(&]P=&EO;G,L(')E<W1R:6-T960@<VAA
M<F5S(&%N9"!S:&%R97,@:7-S=6%B;&4@=7!O;B!C;VYV97)S:6]N(&]F('1H
M92!C;VYV97)T:6)L92!N;W1E<R!I<W-U960@:6X@4V5P=&5M8F5R(#(P,3,@
M*'-E92!.;W1E(#,I(&EN('1H92!A;6]U;G0@;V8@/&9O;G0@<W1Y;&4],T0G
M0T],3U(Z(&)L86-K)SXW+#$V.2PP,S4\+V9O;G0^(&%N9"`W+#@W.2PV,#$@
M<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N
M9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,B!A;F0@,C`Q,RP@<F5S<&5C=&EV96QY
M+"!A;F0@/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K)SXW+#4P."PR-#`\
M+V9O;G0^(&%N9"`X+#@Q-RPP.3`@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!F
M;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3(@
M86YD(#(P,3,L(')E<W!E8W1I=F5L>2P@8F5C875S92!T:&4@969F96-T('=O
M=6QD(&)E(&%N=&DM9&EL=71I=F4N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#`N-S5I;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE.+51/4#H@,'!T)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
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M)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I
M;B<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^5&AE(&-O;G9E<G1I
M8FQE(&YO=&5S(&%R92!A8V-O=6YT960@9F]R('5S:6YG('1H92!G=6ED86YC
M92!P<F]V:61E9"!S970@9F]R=&@@:6X\+V9O;G0^($9!4T(@06-C;W5N=&EN
M9R!3=&%N9&%R9',@0V]D:69I8V%T:6]N(#QF;VYT('-T>6QE/3-$)T-/3$]2
M.B!B;&%C:R<^*$%30RD@.#$U(')E<75I<FEN9R!T:&%T('1H92!#;VUP86YY
M(&1E=&5R;6EN92!W:&5T:&5R('1H92!E;6)E9&1E9"!C;VYV97)S:6]N(&]P
M=&EO;B!M=7-T(&)E('-E<&%R871E9"!A;F0@86-C;W5N=&5D(&9O<B!S97!A
M<F%T96QY+B!4:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@=&AE(&-O;G9E<G1I
M8FQE(&YO=&5S(&%S(&$@;&EA8FEL:71Y+"!O;B!A;B!A9V=R96=A=&5D(&)A
M<VES+"!I;B!T:&5I<B!E;G1I<F5L>2X\+V9O;G0^/"]P/B`\(2TM16YD1G)A
M9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\S,3<X,#5E.%\T8S0R7S1E-C%?8C!C9E\V-#EB
M,#=B,#=A9CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S$W.#`U
M93A?-&,T,E\T938Q7V(P8V9?-C0Y8C`W8C`W868Y+U=O<FMS:&5E=',O4VAE
M970P.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/DE.5D5.5$]22453/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^24Y614Y43U))15,@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^24Y614Y43U))
M15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\(2TM1$]#5%E0
M12!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I
M;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH
M=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R
M=$9R86=M96YT+2T^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^(#QS=')O
M;F<^3D]412`R("T@24Y614Y43U))15,\+W-T<F]N9SX\+W`^(#QP('-T>6QE
M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X(#!P="`P+C<U:6XG/B!);G9E;G1O<GD@870@4V5P=&5M8F5R
M(#,P+"`R,#$S(&%N9"!$96-E;6)E<B9N8G-P.S,Q+"`R,#$R(&-O;G-I<W1E
M9"!O9B!T:&4@9F]L;&]W:6YG.CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@
M,'!X(#!P="`P+C<U:6XG/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"="
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,"XW-6EN.R!7
M24142#H@.#`E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97(G(&YO=W)A<#TS1&YO=W)A<#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A
M<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/E-E<'1E;6)E<B`S,"P\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO
M=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O
M;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/D1E8V5M8F5R(#,Q+#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@
M8V5N=&5R)R!C;VQS<&%N/3-$,CXR,#$S/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!4
M15A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/C(P,3(\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<B<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$-B!N;W=R87`],T1N
M;W=R87`^*%4N4RX@9&]L;&%R<R!I;B!T:&]U<V%N9',I/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#XF
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@-S@E)SY2
M87<@;6%T97)I86QS/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(
M.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M5TE$5$@Z(#@E)SXR+#4W-#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=7
M24142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[(%=)1%1(.B`X)2<^,BPQ,3@\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\
M+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#
M2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^5V]R:R!I;B!P<F]G<F5S<SPO=&0^(#QT9#XF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ-#`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$Y,CPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T)SY&
M:6YI<VAE9"!G;V]D<SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`T+#@V,SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@,2PW,CD\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^5&]T86P@:6YV
M96YT;W)Y/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H="<^(#<L-3<W/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<^(#0L,#,Y/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V
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M=F%L(&]F('1A;&EG;'5C97)A<V4@86QF82!O;B!-87D@,2P@,C`Q,BP@=&AE
M($-O;7!A;GD@8V%P:71A;&EZ97,@86QL(&UA;G5F86-T=7)I;F<@8V]S=',@
M87-S;V-I871E9"!W:71H('1A;&EG;'5C97)A<V4@86QF82X\+W`^(#PA+2U%
M;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0T].5D525$E"3$4@3D]413QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-/3E9%4E1)0DQ%($Y/5$4@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0T].5D525$E"3$4@3D]413PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T14
M1"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM
M/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y;&4],T0G
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X)SX@/'-T<F]N9SY.3U1%(#,@+2!#3TY615)424),12!.
M3U1%/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@-38N-W!T
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M8VLG/BP\+V9O;G0^(&EN8VQU9&EN9R`D.2XP(&UI;&QI;VX@86=G<F5G871E
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M(&EN9&5N='5R92`H=&AE("));F1E;G1U<F4B*2!W:71H(%1H92!"86YK(&]F
M($YE=R!9;W)K($UE;&QO;B!4<G5S="!#;VUP86YY+"!.+D$N+"!A<R!T<G5S
M=&5E+"!G;W9E<FYI;F<@=&AE($YO=&5S+B!4:&4@3F]T97,@86-C<G5E(&EN
M=&5R97-T(&%T(&$@<F%T92!O9B`T+C4P)2!P97(@>65A<BP@<&%Y86)L92!S
M96UI86YN=6%L;'D@:6X@87)R96%R<R!O;B!-87)C:"`Q-2!A;F0@4V5P=&5M
M8F5R(#$U(&]F(&5A8V@@>65A<BP@8F5G:6YN:6YG(&]N($UA<F-H(#$U+"`R
M,#$T+B!4:&4@3F]T97,@;6%T=7)E(&]N(%-E<'1E;6)E<B`Q-2P@,C`Q."X\
M+V9O;G0^/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P
M="<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`U
M-BXW<'0G/B!4:&4@;F5T('!R;V-E961S(&9R;VT@=&AE(&]F9F5R:6YG+"!I
M;F-L=61I;F<@;F5T('!R;V-E961S(&9R;VT@=&AE(&5X97)C:7-E(&EN(&9U
M;&P@8GD@=&AE(&EN:71I86P@<'5R8VAA<V5R(&]F(&ET<R!O<'1I;VX@=&\@
M<'5R8VAA<V4@86X@861D:71I;VYA;"`D.2XP(&UI;&QI;VX@:6X@86=G<F5G
M871E('!R:6YC:7!A;"!A;6]U;G0@;V8@=&AE($YO=&5S+"!W97)E("0V-BXX
M(&UI;&QI;VXL(&%F=&5R(&1E9'5C=&EN9R!T:&4@:6YI=&EA;"!P=7)C:&%S
M97(F(S,Y.W,@9&ES8V]U;G0@86YD(&-O;6UI<W-I;VX@86YD('1H92!E<W1I
M;6%T960@;V9F97)I;F<@97AP96YS97,@<&%Y86)L92!B>2!T:&4@0V]M<&%N
M>2X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@-38N-W!T)SX@
M)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P
M="<^($AO;&1E<G,@;6%Y(&-O;G9E<G0@=&AE:7(@3F]T97,@870@86YY('1I
M;64@<')I;W(@=&\@=&AE(&-L;W-E(&]F(&)U<VEN97-S(&]N('1H92!B=7-I
M;F5S<R!D87D@:6UM961I871E;'D@<')E8V5D:6YG(%-E<'1E;6)E<B`Q-2P@
M,C`Q."X@5&AE(&EN:71I86P@8V]N=F5R<VEO;B!R871E(&9O<B!T:&4@3F]T
M97,@:7,@,3<S+C8U.3,@<VAA<F5S(&]F('1H92!#;VUM;VX@4W1O8VL@9F]R
M(&5A8V@@)#$L,#`P('!R:6YC:7!A;"!A;6]U;G0@;V8@3F]T97,@*&5Q=6EV
M86QE;G0@=&\@86X@:6YI=&EA;"!C;VYV97)S:6]N('!R:6-E(&]F(&%P<')O
M>&EM871E;'D@)#4N-S8@<&5R('-H87)E(&]F('1H92!#;VUM;VX@4W1O8VLN
M(%5P;VX@8V]N=F5R<VEO;BP@=&AE($-O;7!A;GD@=VEL;"!D96QI=F5R(&$@
M;G5M8F5R(&]F('-H87)E<R!O9B!#;VUM;VX@4W1O8VLL('!E<B`D,2PP,#`@
M<')I;F-I<&%L(&%M;W5N="!O9B!.;W1E<RP@97%U86P@=&\@=&AE(&-O;G9E
M<G-I;VX@<F%T92X@5&AE(&-O;G9E<G-I;VX@<F%T92!I<R!S=6)J96-T('1O
M(&%D:G5S=&UE;G0@:6X@<V]M92!E=F5N=',@8G5T('=I;&P@;F]T(&)E(&%D
M:G5S=&5D(&9O<B!A;GD@86-C<G5E9"!A;F0@=6YP86ED(&EN=&5R97-T+CPO
M<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`U-BXW<'0G/B`F;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@-38N-W!T)SX@
M4')I;W(@=&\@4V5P=&5M8F5R(#$Y+"`R,#$V+"!T:&4@0V]M<&%N>2!M87D@
M;F]T(')E9&5E;2!T:&4@3F]T97,L(&%N9"!N;R!S:6YK:6YG(&9U;F0@:7,@
M<')O=FED960@9F]R('1H92!.;W1E<RX@3VX@;W(@869T97(@4V5P=&5M8F5R
M(#$Y+"`R,#$V+"!T:&4@0V]M<&%N>2!M87D@<F5D965M(&9O<B!C87-H(&%L
M;"!O<B!P87)T(&]F('1H92!.;W1E<R`H97AC97!T(&9O<B!T:&4@;F]T97,@
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M870@;&5A<W0@,C`@=')A9&EN9R!D87ES("AW:&5T:&5R(&]R(&YO="!C;VYS
M96-U=&EV92D@9'5R:6YG(&%N>2`S,"!C;VYS96-U=&EV92!T<F%D:6YG+61A
M>2!P97)I;V0@96YD:6YG(&]N('1H92!T<F%D:6YG(&1A>2!I;6UE9&EA=&5L
M>2!P<F5C961I;F<@=&AE(&1A=&4@;VX@=VAI8V@@=&AE($-O;7!A;GD@<')O
M=FED97,@=&AE(&YO=&EC92!O9B!R961E;7!T:6]N+B!4:&4@<F5D96UP=&EO
M;B!P<FEC92!W:6QL(&5Q=6%L('1H92!S=6T@;V8@*&DI)FYB<W`[,3`P)2!O
M9B!T:&4@<')I;F-I<&%L(&%M;W5N="!O9B!T:&4@3F]T97,@8F5I;F<@<F5D
M965M960L('!L=7,@*&EI*29N8G-P.V%C8W)U960@86YD('5N<&%I9"!I;G1E
M<F5S="P@:6YC;'5D:6YG(&%D9&ET:6]N86P@:6YT97)E<W0L(&EF(&%N>2P@
M=&\L(&)U="!E>&-L=61I;F<L('1H92!R961E;7!T:6]N(&1A=&4L('!L=7,@
M*&EI:2D@=&AE('-U;2!O9B!T:&4@<')E<V5N="!V86QU97,@;V8@96%C:"!O
M9B!T:&4@<F5M86EN:6YG('-C:&5D=6QE9"!P87EM96YT<R!O9B!I;G1E<F5S
M="!T:&%T('=O=6QD(&AA=F4@8F5E;B!M861E(&]N('1H92!.;W1E<R!B96EN
M9R!R961E96UE9"!H860@<W5C:"!.;W1E<R!R96UA:6YE9"!O=71S=&%N9&EN
M9R!F<F]M('1H92!R961E;7!T:6]N(&1A=&4@=&\@=&AE(&UA='5R:71Y(&1A
M=&4N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`\<W1R;VYG/B9N
M8G-P.SPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P
M="`U-BXW<'0G/B!4:&4@9F]L;&]W:6YG('1A8FQE('-E=',@9F]R=&@@=&]T
M86P@:6YT97)E<W0@97AP96YS92!R96-O9VYI>F5D(')E;&%T960@=&\@=&AE
M($YO=&5S("AI;B!T:&]U<V%N9',I.CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X(#!P="`U-BXW<'0G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS
M1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,"XW-6EN
M.R!724142#H@.3`E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9#XF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B
M;VQD.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0V/DYI;F4@36]N
M=&AS($5N9&5D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT
M97(G(&-O;'-P86X],T0V/E1H<F5E($UO;G1H<R!%;F1E9#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P
M="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U14
M3TTZ(#%P="<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%
M24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^4V5P=&5M8F5R)FYB<W`[,S`L/&)R("\^(#(P,3,\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@
M,7!T)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4
M.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R(&YO=W)A
M<#TS1&YO=W)A<#X@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-
M05)'24XM5$]0.B`P<'@G/B!397!T96UB97(F;F)S<#LS,"P\+W`^(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X)SXR
M,#$R/"]P/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'
M+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/
M3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#Y397!T96UB97(F;F)S<#LS,"P\8G(@+SX@
M,C`Q,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U7
M14E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P/E-E<'1E;6)E<B9N8G-P.S,P+#QB<B`O/B`R,#$R
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'
M+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,3!P=#L@5TE$5$@Z
M(#4V)3L@5$585"U)3D1%3E0Z("TQ,'!T)SX@0V]N=')A8W1U86P@:6YT97)E
M<W0@97AP96YS93PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@
M,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)
M1%1(.B`X)2<^,3`T/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(
M.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!724142#H@."4G/BT\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
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M1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M3$5&5#H@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T
M)SX@06UO<G1I>F%T:6]N(&]F(&1E8G0@:7-S=6%N8V4@8V]S=',\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M,34\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^("T\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4
M+4%,24=..B!R:6=H="<^(#$U/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!4
M15A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0G/B`M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2
M.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R+C5P=#L@4$%$1$E.1RU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@
M+3$P<'0G/B!4;W1A;#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q,3D\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`M/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H="<^(#$Q.3PO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H="<^("T\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G
M/B`\<W1R;VYG/B9N8G-P.SPO<W1R;VYG/CPO<#X@/"$M+45N9$9R86=M96YT
M+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,S$W.#`U93A?-&,T,E\T938Q7V(P8V9?-C0Y8C`W8C`W
M868Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q-S@P-64X7S1C
M-#)?-&4V,5]B,&-F7S8T.6(P-V(P-V%F.2]7;W)K<VAE971S+U-H965T,3$N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY35$]#
M2R!44D%.4T%#5$E/3E,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY35$]#2R!44D%.4T%#5$E/3E,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4U1/0TL@5%)!3E-!0U1)3TY3/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(
M5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O
M5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I
M=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\<"!S='EL93TS1"=&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ
M(#!P="`P<'@G/B`\<W1R;VYG/DY/5$4@-"`M(%-43T-+(%1204Y304-424].
M4SPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P="<^
M(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^1'5R:6YG('1H92!N:6YE
M(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,L('1H92!#;VUP86YY
M(&ES<W5E9"!A('1O=&%L(&]F(&%P<')O>&EM871E;'D\+V9O;G0^(#QF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^-C0L-S8X/"]F;VYT/B`\9F]N
M="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/G-H87)E<R!O9B!#;VUM;VX@4W1O
M8VL@:6X@8V]N;F5C=&EO;B!W:71H('1H92!E>&5R8VES92!O9B!A('1O=&%L
M(&]F(&%P<')O>&EM871E;'D\+V9O;G0^(#QF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P="<^-C0L-S8X/"]F;VYT/B`\9F]N="!S='EL93TS1"=#3TQ/
M4CH@8FQA8VLG/F]P=&EO;G,@8GD@8V5R=&%I;B!E;7!L;WEE97,@;V8@=&AE
M($-O;7!A;GDN(%1H92!A9V=R96=A=&4@<')O8V5E9',@:6X@8V]N;F5C=&EO
M;B!W:71H('-U8V@@97AE<F-I<V5S('1O=&%L960@87!P<F]X:6UA=&5L>2`D
M,3`S+#`P,"X\+V9O;G0^/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\S,3<X,#5E.%\T8S0R7S1E-C%?8C!C9E\V-#EB,#=B,#=A9CD-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S$W.#`U93A?-&,T,E\T938Q7V(P
M8V9?-C0Y8C`W8C`W868Y+U=O<FMS:&5E=',O4VAE970Q,BYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9!25(@5D%,544@345!
M4U5214U%3E0\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY&04E2(%9!3%5%($U%05-54D5-14Y4(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9!
M25(@5D%,544@345!4U5214U%3E0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@
M6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R
M9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\
M9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QP('-T>6QE/3-$)T9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>"<^(#QS=')O;F<^3D]412`U("T@1D%)4B!604Q512!-14%3
M55)%345.5#PO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V
M+C=P="<^(%1H92!#;VUP86YY(&UE87-U<F5S(&9A:7(@=F%L=64@86YD(&1I
M<V-L;W-E<R!F86ER('9A;'5E(&UE87-U<F5M96YT<R!F;W(@9FEN86YC:6%L
M(&%S<V5T<R!A;F0@;&EA8FEL:71I97,N($9A:7(@=F%L=64@:7,@8F%S960@
M;VX@=&AE('!R:6-E('1H870@=V]U;&0@8F4@<F5C96EV960@9G)O;2!T:&4@
M<V%L92!O9B!A;B!A<W-E="P@;W(@<&%I9"!T;R!T<F%N<V9E<B!A(&QI86)I
M;&ET>2P@:6X@86X@;W)D97)L>2!T<F%N<V%C=&EO;B!B971W965N(&UA<FME
M="!P87)T:6-I<&%N=',@870@=&AE(&UE87-U<F5M96YT(&1A=&4N/"]P/B`\
M<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P="<^("9N8G-P.SPO
M<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`U-BXW<'0G/B!4:&4@
M86-C;W5N=&EN9R!S=&%N9&%R9"!E<W1A8FQI<VAE<R!A(&9A:7(@=F%L=64@
M:&EE<F%R8VAY('1H870@<')I;W)I=&EZ97,@;V)S97)V86)L92!A;F0@=6YO
M8G-E<G9A8FQE(&EN<'5T<R!U<V5D('1O(&UE87-U<F4@9F%I<B!V86QU92!I
M;G1O('1H<F5E(&)R;V%D(&QE=F5L<RP@=VAI8V@@87)E(&1E<V-R:6)E9"!B
M96QO=SH\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@-38N-W!T
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V
M+C=P="<^($QE=F5L(#$Z(%%U;W1E9"!P<FEC97,@*'5N861J=7-T960I(&EN
M(&%C=&EV92!M87)K971S('1H870@87)E(&%C8V5S<VEB;&4@870@=&AE(&UE
M87-U<F5M96YT(&1A=&4@9F]R(&%S<V5T<R!O<B!L:6%B:6QI=&EE<RX@5&AE
M(&9A:7(@=F%L=64@:&EE<F%R8VAY(&=I=F5S('1H92!H:6=H97-T('!R:6]R
M:71Y('1O($QE=F5L(#$@:6YP=71S+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X(#!P="`U-BXW<'0G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>"`P<'0@-38N-W!T)SX@3&5V96P@,CH@3V)S97)V86)L92!P
M<FEC97,@=&AA="!A<F4@8F%S960@;VX@:6YP=71S(&YO="!Q=6]T960@;VX@
M86-T:79E(&UA<FME=',L(&)U="!C;W)R;V)O<F%T960@8GD@;6%R:V5T(&1A
M=&$N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P="<^
M("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`U-BXW
M<'0G/B!,979E;"`S.B!5;F]B<V5R=F%B;&4@:6YP=71S(&%R92!U<V5D('=H
M96X@;&ET=&QE(&]R(&YO(&UA<FME="!D871A(&ES(&%V86EL86)L92X@5&AE
M(&9A:7(@=F%L=64@:&EE<F%R8VAY(&=I=F5S('1H92!L;W=E<W0@<')I;W)I
M='D@=&\@3&5V96P@,R!I;G!U=',N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#4V+C=P="<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X(#!P="`U-BXW<'0G/B!);B!D971E<FUI;FEN9R!F86ER('9A
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M=64N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P="<^
M("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`U-BXW
M<'0G/B!4:&4@9F%I<B!V86QU92!O9B!T:&4@9FEN86YC:6%L(&EN<W1R=6UE
M;G1S(&EN8VQU9&5D(&EN('1H92!W;W)K:6YG(&-A<&ET86P@;V8@=&AE($-O
M;7!A;GD@:7,@=7-U86QL>2!I9&5N=&EC86P@;W(@8VQO<V4@=&\@=&AE:7(@
M8V%R<GEI;F<@=F%L=64N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@
M,'!T(#4V+C=P="<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@
M,'!X(#!P="`U-BXW<'0G/B!4:&4@9F%I<B!V86QU92!O9B!T:&4@8V]N=F5R
M=&EB;&4@;F]T97,@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$S(&ES("0W,2PW
M-C`L,#`P+B!4:&4@9F%I<B!V86QU92!W87,@97-T:6UA=&5D(&)A<V5D(&]N
M('%U;W1E9"!M87)K970@<')I8V5S+CPO<#X@/"$M+45N9$9R86=M96YT+2T^
M/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,S$W.#`U93A?-&,T,E\T938Q7V(P8V9?-C0Y8C`W8C`W868Y
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q-S@P-64X7S1C-#)?
M-&4V,5]B,&-F7S8T.6(P-V(P-V%F.2]7;W)K<VAE971S+U-H965T,3,N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4Q04%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-)1TY)
M1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,@*%!O;&EC>2D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY324=.249)
M0T%.5"!!0T-/54Y424Y'(%!/3$E#2453(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\(2TM1$]#5%E012!H=&UL
M(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O
M14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT
M<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M
M96YT+2T^(#QT86)L92!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3BU43U`Z(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P
M)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D
M/CQS=')O;F<^1V5N97)A;#PO<W1R;VYG/CPO=&0^(#PO='(^(#PO=&%B;&4^
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+51/4#H@,'!T
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I
M;B<^(%!R;W1A;&EX($)I;U1H97)A<&5U=&EC<RP@26YC+B`H8V]L;&5C=&EV
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M86YY)B,S.3MS('!R;W!R:65T87)Y(%!R;T-E;&Q%>#QS=7`^)G)E9SL\+W-U
M<#X@<')O=&5I;B!E>'!R97-S:6]N('-Y<W1E;2`H(E!R;T-E;&Q%>"(I+B!)
M;B!397!T96UB97(@,C`P.2P@4')O=&%L:7@@3'1D+B!F;W)M960@86YO=&AE
M<B!W:&]L;'DM;W=N960@<W5B<VED:6%R>2!U;F1E<B!T:&4@;&%W<R!O9B!T
M:&4@3F5T:&5R;&%N9',L(%!R;W1A;&EX($(N5BXL(&EN(&-O;FYE8W1I;VX@
M=VET:"!T:&4@175R;W!E86X@365D:6-I;F5S($%G96YC>2`H(D5-02(I(&%P
M<&QI8V%T:6]N('!R;V-E<W,@:6X@=&AE($5U<F]P96%N(%5N:6]N+B!4:&4@
M0V]M<&%N>28C,SD[<R!T=V\@<W5B<VED:6%R:65S(&%R92!R969E<G)E9"!T
M;R!C;VQL96-T:79E;'D@:&5R96EN(&%S('1H92`B4W5B<VED:6%R:65S+B(\
M+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;B<^($]N($UA
M>2`Q+"`R,#$R+"!T:&4@52Y3+B!&;V]D(&%N9"!$<G5G($%D;6EN:7-T<F%T
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M92`H1T-$*2!T:&%T('1H92!#;VUP86YY(&1E=F5L;W!E9"!U<VEN9R!0<F]#
M96QL17@N(%1A;&EG;'5C97)A<V4@86QF82!W87,@86QS;R!A<'!R;W9E9"!B
M>2!T:&4@27-R865L:2!-:6YI<W1R>2!O9B!(96%L=&@@*'1H92`B27-R865L
M:2!-3T@B*2!I;B!397!T96UB97(@,C`Q,BP@8GD@=&AE($)R87II;&EA;B!-
M:6YI<W1R>2!O9B!(96%L=&@@*'1H92`B0G)A>FEL:6%N($U/2"(I(&EN($UA
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M<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6XG/B`F;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN)SX@5&%L:6=L
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M(&)Y(&%N9"!B971W965N(%!R;W1A;&EX($QT9"X@86YD(%!F:7IE<B`H=&AE
M(#QF;VYT('-T>6QE/3-$)U1%6%0M5%)!3E-&3U)-.B!U<'!E<F-A<V4G/B(\
M+V9O;G0^4&9I>F5R($%G<F5E;65N=#QF;VYT('-T>6QE/3-$)U1%6%0M5%)!
M3E-&3U)-.B!U<'!E<F-A<V4G/B(\+V9O;G0^*2X@5&AE($-O;7!A;GDL('1H
M<F]U9V@@4')O=&%L:7@@3'1D+BP@;6%R:V5T<R!%3$5,65-/(&EN($ES<F%E
M;"X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN)SX@)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;B<^(%!R
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M;65N="`H87,@9&5F:6YE9"!B96QO=RDL(&EN($)R87II;"X@5&AE($-O;7!A
M;GD@:&%S(&%G<F5E9"!T;R!A('-P96-I9FEC(&%L;&]C871I;VX@8F5T=V5E
M;B!0<F]T86QI>"!,=&0N(&%N9"!09FEZ97(@<F5G87)D:6YG('1H92!R97-P
M;VYS:6)I;&ET:65S(&9O<B!T:&4@8V]N=&EN=65D(&1E=F5L;W!M96YT(&5F
M9F]R=',@9F]R('1A;&EG;'5C97)A<V4@86QF82X@5&\@9&%T92P@=&AE($-O
M;7!A;GD@:&%S(')E8V5I=F5D(&%N('5P9G)O;G0@<&%Y;65N="!O9B`D-C`N
M,"!M:6QL:6]N(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@97AE8W5T:6]N(&]F
M('1H92!09FEZ97(@06=R965M96YT(&%N9"!S:&]R=&QY('1H97)E869T97(@
M86X@861D:71I;VYA;"`D-2XP(&UI;&QI;VX@8VQI;FEC86P@9&5V96QO<&UE
M;G0M<F5L871E9"!M:6QE<W1O;F4@<&%Y;65N="X@5&AE($-O;7!A;GD@<F5C
M96EV960@86X@861D:71I;VYA;"`D,C4N,"!M:6QL:6]N(&UI;&5S=&]N92!P
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M:6]N(&]F('1A;&EG;'5C97)A<V4@86QF82!O;B!A(#0P)2!A;F0@-C`E(&)A
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M<V5S(&%N9"!C;W-T<R!O9B!G;V]D<R!S;VQD/"]F;VYT/BX\+W`^(#QP('-T
M>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN)SX@)FYB<W`[)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;B<^($]N($IU;F4@
M,3@L(#(P,3,L(%!R;W1A;&EX($QT9"X@96YT97)E9"!I;G1O(&$@4W5P<&QY
M(&%N9"!496-H;F]L;V=Y(%1R86YS9F5R($%G<F5E;65N="`H=&AE(")"<F%Z
M:6P@06=R965M96YT(BD@=VET:"!&=6YD829C8V5D:6P[)F%T:6QD93MO($]S
M=V%L9&\@0W)U>B`H(D9I;V-R=7HB*2P@86X@87)M(&]F('1H92!"<F%Z:6QI
M86X@34](+"!F;W(@=&%L:6=L=6-E<F%S92!A;&9A+B!4:&4@8G)A;F0@;F%M
M92!F;W(@=&%L:6=L=6-E<F%S92!A;&9A(&EN($)R87II;"!I<R!54$Q94T\\
M<W5P/E1-/"]S=7`^+B!4:&4@9FER<W0@=&5R;2!O9B!T:&4@=&5C:&YO;&]G
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M<'5R8VAA<V4@870@;&5A<W0@87!P<F]X:6UA=&5L>2`D-#`@;6EL;&EO;B!W
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M=&\@;V-C=7(@=F5R>2!S:&]R=&QY+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X(#!P="`Q:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@
M,'!T(#!P>"`P<'0@,6EN)SX@5&\@9F%C:6QI=&%T92!T:&4@87)R86YG96UE
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M;V8@87!P<F]X:6UA=&5L>2`D,3(N-2!M:6QL:6]N(&9R;VT@:71S(&YE="!P
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M1FEO8W)U>BX\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I
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M97)E;V8N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;B<^
M("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6XG
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M=')I97,N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;B<^
M("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6XG
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M;W1H97(@<')O9W)A;7,N($]N($IU;'D@,3,L(#(P,3`L('1H92!#;VUP86YY
M(&%N;F]U;F-E9"!T:&%T('1H92!&<F5N8V@@<F5G=6QA=&]R>2!A=71H;W)I
M='D@:&%D(&=R86YT960@86X@075T;W)I<V%T:6]N(%1E;7!O<F%I<F4@9"8C
M,SD[571I;&ES871I;VX@*$%452DL(&]R(%1E;7!O<F%R>2!!=71H;W)I>F%T
M:6]N(&9O<B!5<V4L(&9O<B!T86QI9VQU8V5R87-E(&%L9F$@9F]R('1H92!T
M<F5A=&UE;G0@;V8@1V%U8VAE<B!D:7-E87-E+CPO<#X@/'`@<W1Y;&4],T0G
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X(#!P="`Q:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$
M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>"`P<'0@,6EN)SX@06X@0515(&ES('1H92!R96=U;&%T
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M:65S+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6XG/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN)SX@
M26X@861D:71I;VX@=&\@=&%L:6=L=6-E<F%S92!A;&9A+"!T:&4@0V]M<&%N
M>2!I<R!W;W)K:6YG(&]N('1H92!D979E;&]P;65N="!O9B!C97)T86EN(&]T
M:&5R('!R;V1U8W1S('5S:6YG(%!R;T-E;&Q%>"X\8G(@<W1Y;&4],T0G4$%'
M12U"4D5!2RU"149/4D4Z(&%L=V%Y<R<@8VQE87(],T1A;&P@+SX@/"]P/B`\
M<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;B<^("9N8G-P.SPO<#X@
M/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6XG/B!);B!A9&1I=&EO
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M=F4@9&5V96QO<&UE;G1A;"!P97)I;V1S+CPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X(#!P="`Q:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>"`P<'0@,6EN)SX@3V)T86EN:6YG(&UA<FME=&EN9R!A<'!R
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M('1H92!O=71C;VUE(&]F('1H97-E(&%C=&EV:71I97,N/"]P/B`\(2TM16YD
M1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\(2TM1$]#5%E0
M12!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I
M;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH
M=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R
M=$9R86=M96YT+2T^(#QT86)L92!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU43U`Z(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/B9N8G-P.SPO
M=&0^(#QT9#X\<W1R;VYG/D)A<VES(&]F(%!R97-E;G1A=&EO;CPO<W1R;VYG
M/CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+51/4#H@,'!T)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS
M1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P="<^(%1H92!A8V-O;7!A;GEI;F<@
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M:&4@9G5L;"!Y96%R+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P
M="`U-BXW<'0G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P
M>"`P<'0@-38N-W!T)SX@5&AE<V4@=6YA=61I=&5D(&-O;F1E;G-E9"!C;VYS
M;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@<VAO=6QD(&)E(')E860@
M:6X@8V]N:G5N8W1I;VX@=VET:"!T:&4@875D:71E9"!C;VYS;VQI9&%T960@
M9FEN86YC:6%L('-T871E;65N=',@:6X@=&AE($%N;G5A;"!297!O<G0@;VX@
M1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q
M,BP@9FEL960@8GD@=&AE($-O;7!A;GD@=VET:"!T:&4@0V]M;6ES<VEO;BX@
M5&AE(&-O;7!A<F%T:79E(&)A;&%N8V4@<VAE970@870@1&5C96UB97(@,S$L
M(#(P,3(@:&%S(&)E96X@9&5R:79E9"!F<F]M('1H92!A=61I=&5D(&9I;F%N
M8VEA;"!S=&%T96UE;G1S(&%T('1H870@9&%T92X\+W`^(#PA+2U%;F1&<F%G
M;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S('!E<B!S:&%R93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@
M4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%
M3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R
M86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE
M;G0M+3X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M+51/4#H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G
M/B`\=&0^/'-T<F]N9SY.970@;&]S<R!P97(@<VAA<F4\+W-T<F]N9SX\+W1D
M/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU43U`Z(#!P="<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X(#!P="`P+C<U:6XG/B!"87-I8R!A;F0@9&EL=71E9"!L;W-S
M('!E<B!S:&%R92!A<F4@8V%L8W5L871E9"!B>2!D:79I9&EN9R!T:&4@;F5T
M(&QO<W,@8GD@=&AE('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F('-H87)E
M<R!O9B!T:&4@0V]M<&%N>28C,SD[<R!C;VUM;VX@<W1O8VLL('!A<B!V86QU
M92`D,"XP,#$@*'1H92`B0V]M;6]N(%-T;V-K(BDL(&]U='-T86YD:6YG(&9O
M<B!E86-H('!E<FEO9"X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P
M<'0@,"XW-6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P
M<'@@,'!T(#`N-S5I;B<^($1I;'5T960@;&]S<R!P97(@<VAA<F4@9&]E<R!N
M;W0@:6YC;'5D92!O<'1I;VYS+"!R97-T<FEC=&5D('-H87)E<R!A;F0@<VAA
M<F5S(&ES<W5A8FQE('5P;VX@8V]N=F5R<VEO;B!O9B!T:&4@8V]N=F5R=&EB
M;&4@;F]T97,@:7-S=65D(&EN(%-E<'1E;6)E<B`R,#$S("AS964@3F]T92`S
M*2!I;B!T:&4@86UO=6YT(&]F(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C
M:R<^-RPQ-CDL,#,U/"]F;VYT/B!A;F0@-RPX-SDL-C`Q('-H87)E<R!O9B!#
M;VUM;VX@4W1O8VL@9F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB
M97(@,S`L(#(P,3(@86YD(#(P,3,L(')E<W!E8W1I=F5L>2P@86YD(#QF;VYT
M('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^-RPU,#@L,C0P/"]F;VYT/B!A;F0@
M."PX,3<L,#DP('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@9F]R('1H92!T:')E
M92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$R(&%N9"`R,#$S+"!R
M97-P96-T:79E;'DL(&)E8V%U<V4@=&AE(&5F9F5C="!W;W5L9"!B92!A;G1I
M+61I;'5T:79E+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P
M+C<U:6XG/B`F;F)S<#L\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O
M1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW
M,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@
M+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\=&%B;&4@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM5$]0.B`P<'0G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9#X\<W1R;VYG/D-O
M;G9E<G1I8FQE(&YO=&5S/"]S=')O;F<^(#PO=&0^(#PO='(^(#PO=&%B;&4^
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+51/4#H@,'!T
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N
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M(&)A<VES+"!I;B!T:&5I<B!E;G1I<F5L>2X\+V9O;G0^/"]P/B`\<"!S='EL
M93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;B<^("9N8G-P.R9N8G-P.SPO
M<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S$W.#`U93A?-&,T,E\T
M938Q7V(P8V9?-C0Y8C`W8C`W868Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S,Q-S@P-64X7S1C-#)?-&4V,5]B,&-F7S8T.6(P-V(P-V%F.2]7
M;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY)3E9%3E1/4DE%4R`H5&%B;&5S*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DE.5D5.5$]2
M2453(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN=F5N=&]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T14
M1"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM
M/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y;&4],T0G
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X(#!P="`P+C<U:6XG/B!);G9E;G1O<GD@870@4V5P=&5M
M8F5R(#,P+"`R,#$S(&%N9"!$96-E;6)E<B9N8G-P.S,Q+"`R,#$R(&-O;G-I
M<W1E9"!O9B!T:&4@9F]L;&]W:6YG.CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X(#!P="`P+C<U:6XG/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS
M1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,"XW-6EN
M.R!724142#H@.#`E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97(G(&YO=W)A<#TS1&YO=W)A<#XF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO
M=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P/E-E<'1E;6)E<B`S,"P\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS
M1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P/D1E8V5M8F5R(#,Q+#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@
M,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'
M3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CXR,#$S/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD
M.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/C(P,3(\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<B<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$-B!N;W=R87`]
M,T1N;W=R87`^*%4N4RX@9&]L;&%R<R!I;B!T:&]U<V%N9',I/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A
M<#XF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T
M*2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@-S@E
M)SY287<@;6%T97)I86QS/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@5TE$5$@Z(#@E)SXR+#4W-#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`X)2<^,BPQ,3@\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D
M/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^5V]R:R!I;B!P<F]G<F5S<SPO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ-#`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$Y
M,CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T
M)SY&:6YI<VAE9"!G;V]D<SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`T+#@V,SPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT)SX@,2PW,CD\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^5&]T86P@
M:6YV96YT;W)Y/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H="<^(#<L-3<W/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H="<^(#0L,#,Y/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@
M,'!X)SX@)FYB<W`[/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S
M,3<X,#5E.%\T8S0R7S1E-C%?8C!C9E\V-#EB,#=B,#=A9CD-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S$W.#`U93A?-&,T,E\T938Q7V(P8V9?
M-C0Y8C`W8C`W868Y+U=O<FMS:&5E=',O4VAE970Q-2YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3E9%4E1)0DQ%($Y/5$4@
M*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#3TY615)424),12!.3U1%(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE
M(&]F($EN=&5R97-T($5X<&5N<V4@4F5C;V=N:7IE9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M
M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z
M+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA
M;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@
M<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X(#!P="`U-BXW<'0G/B!4:&4@9F]L;&]W
M:6YG('1A8FQE('-E=',@9F]R=&@@=&]T86P@:6YT97)E<W0@97AP96YS92!R
M96-O9VYI>F5D(')E;&%T960@=&\@=&AE($YO=&5S("AI;B!T:&]U<V%N9',I
M.CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`U-BXW<'0G/B`F
M;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O
M;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XM3$5&5#H@,"XW-6EN.R!724142#H@.3`E)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT
M97(G(&-O;'-P86X],T0V/DYI;F4@36]N=&AS($5N9&5D/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4
M.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0V/E1H<F5E
M($UO;G1H<R!%;F1E9#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/"]T<CX@
M/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@;F]W
M<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P/3-$;F]W
M<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'
M3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^4V5P=&5M
M8F5R)FYB<W`[,S`L/&)R("\^(#(P,3,\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS
M1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^
M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C
M96YT97(G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`P<'@G/B!397!T
M96UB97(F;F)S<#LS,"P\+W`^(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P>#L@34%21TE.+51/4#H@,'!X)SXR,#$R/"]P/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G
M(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`]
M,T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4
M+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y3
M97!T96UB97(F;F)S<#LS,"P\8G(@+SX@,C`Q,SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W
M<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO
M=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/E-E<'1E
M;6)E<B9N8G-P.S,P+#QB<B`O/B`R,#$R/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`]
M,T1N;W=R87`^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T
M+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M3$5&5#H@,3!P=#L@5TE$5$@Z(#4V)3L@5$585"U)3D1%3E0Z("TQ
M,'!T)SX@0V]N=')A8W1U86P@:6YT97)E<W0@97AP96YS93PO=&0^(#QT9"!S
M='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`X)2<^,3`T/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@
M."4G/BT\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$
M5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$
M5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!724142#H@."4G/C$P-#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=7
M24142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#@E)SXM/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@
M/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@
M,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX@06UO<G1I>F%T:6]N(&]F(&1E
M8G0@:7-S=6%N8V4@8V]S=',\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^)#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,34\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!R:6=H="<^("T\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#$U/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`M/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@4$%$1$E.1RU,
M1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/B!4;W1A;#PO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G/B`Q,3D\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#(N-7!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G/B`M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^
M(#$Q.3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^
M("T\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`\<W1R;VYG/B9N8G-P.SPO<W1R
M;VYG/CPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S$W.#`U93A?
M-&,T,E\T938Q7V(P8V9?-C0Y8C`W8C`W868Y#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S,Q-S@P-64X7S1C-#)?-&4V,5]B,&-F7S8T.6(P-V(P
M-V%F.2]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!,4%'/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@
M4$],24-)15,@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E
M>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`P.3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^4')O=&%L:7@@0FEO(%1H97)A<&5U=&EC<R!)
M;F-O<G!O<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^4&9I>F5R($EN8V]R<&]R871I
M;VX@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`Q."P@,C`Q,SQB<CY0<F]T86QI>"!,=&0N(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,#D\8G(^
M57!O;B!&:6QI;F<@;V8@4&5D:6%T<FEC($EN=F5S=&EG871I;VX@4&QA;B!T
M;R!%34$@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q,CQB<CY5<&]N($9$02!!<'!R;W9A;"!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F(%-U8G-I9&EA<FEE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&9I>F5R($%G<F5E;65N
M="P@=7!F<F]N="!P87EM96YT(')E8V5I=F5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#8P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T
M;VYE('!A>6UE;G0@=')I9V=E<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!F:7IE<B!!9W)E96UE;G0L(&9U
M='5R92!R979E;G5E<R!A;F0@97AP96YS92!S:&%R:6YG('!E<F-E;G1A9V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=7!P;'D@8V]M;6ET;65N="!F;W(@96YT:71L960@<FEG:'1S
M('1O(&)E(')E8V5I=F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C@P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E(&%N9"!S=7!P;'D@86=R965M
M96YT('!O=&5N=&EA;"!F=71U<F4@<&%Y;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#4P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=7!P;'D@8V]M;6ET
M;65N="!P97(@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E('!E
M<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP
M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!T;R!P=7)C
M:&%S92!C;VUM;VX@<W1O8VL@;F]T(&EN8VQU9&5D(&EN(&1I;'5T960@3%!3
M(&)E8V%U<V4@=&AE(&5F9F5C="!W;W5L9"!B92!A;G1I+61I;'5T:79E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PX,3<L,#DP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPU,#@L
M,C0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RPX-SDL-C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-RPQ-CDL,#,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%-D5!0SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY)3E9%3E1/4DE%4R`H4V-H961U;&4@;V8@26YV96YT;W)Y($-O
M;7!O;F5N=',I("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@
M=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^24Y614Y43U))
M15,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)A=R!M871E<FEA;',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BPU-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,3$X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7;W)K(&EN('!R;V-E<W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1FEN:7-H
M960@9V]O9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#8S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PW,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!I;G9E;G1O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-RPU-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#0L,#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\S,3<X,#5E.%\T8S0R7S1E-C%?8C!C9E\V
M-#EB,#=B,#=A9CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S$W
M.#`U93A?-&,T,E\T938Q7V(P8V9?-C0Y8C`W8C`W868Y+U=O<FMS:&5E=',O
M4VAE970Q."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P151%044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0T].5D525$E"3$4@3D]412`H3F%R<F%T:79E*2`H1&5T86EL<RD@
M*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A+"!U
M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`Q."P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T].5D52
M5$E"3$4@3D]412!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-CDL,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@861D
M:71I;VYA;"!P<FEN8VEP86P@86UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!R871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+C4P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-E('9A;'5E(&9O<B!C
M;VYV97)S:6]N(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R(&]F('-H87)E<R!F;W(@8F%S:7,@8V]N=F5R<VEO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<S+C8U.3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N
M=F5R<VEO;B!P<FEC92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-2XW-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<')O8V5E9',@9G)O;2!I<W-U86YC
M92!O9B!C;VYV97)T:6)L92!N;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`V-BPX,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#8V+#DS,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA='5R
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y397`@,34L#0H)
M"3(P,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,S$W.#`U93A?-&,T,E\T938Q7V(P8V9?-C0Y8C`W8C`W868Y#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q-S@P-64X7S1C-#)?-&4V,5]B
M,&-F7S8T.6(P-V(P-V%F.2]7;W)K<VAE971S+U-H965T,3DN:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5,2T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3E9%4E1)0DQ%
M($Y/5$4@*%-C:&5D=6QE(&]F($EN=&5R97-T($5X<&5N<V4@4F5C;V=N:7IE
M9"D@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@
M;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#3TY615)424),
M12!.3U1%(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G1R86-T=6%L(&EN=&5R97-T(&5X<&5N
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E
M8G0@:7-S=6%N8V4@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3$]!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY35$]#2R!44D%.4T%#5$E/3E,@*$1E=&%I;',I("A54T0@)"D\8G(^26X@
M5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P
M<F]C965D<R!F<F]M(&5X97)C:7-E(&]F(&]P=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,#DV/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#97)T86EN($5M<&QO
M>65E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES
M92!O9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-"PW-C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M('!R;V-E961S(&9R;VT@97AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S
M=65D(&EN(&-O;FYE8W1I;VX@=VET:"!E>&5R8VES92!O9B!O<'1I;VYS/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-"PW-C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,3<X,#5E.%\T8S0R
M7S1E-C%?8C!C9E\V-#EB,#=B,#=A9CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO,S$W.#`U93A?-&,T,E\T938Q7V(P8V9?-C0Y8C`W8C`W868Y
M+U=O<FMS:&5E=',O4VAE970R,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,3X\<W1R;VYG/D9!25(@5D%,544@345!4U5214U%3E0@*$1E=&%I
M;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1D%)4B!604Q512!-14%355)%345.5"!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&86ER('9A;'5E(&-O;G9E<G1I8FQE(&YO=&5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#<Q+#<V,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S$W.#`U93A?-&,T,E\T938Q7V(P
M8V9?-C0Y8C`W8C`W868Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S,Q-S@P-64X7S1C-#)?-&4V,5]B,&-F7S8T.6(P-V(P-V%F.2]7;W)K<VAE
M971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M
M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL
M92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q.2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT
M4&%R=%\S,3<X,#5E.%\T8S0R7S1E-C%?8C!C9E\V-#EB,#=B,#=A9CDM+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>49</ContextCount>
  <ElementCount>116</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>12</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY)  (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY)  (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>102 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>103 - Disclosure - CONVERTIBLE NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNote</Role>
      <ShortName>CONVERTIBLE NOTE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>104 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>105 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesPolicy</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>302 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>303 - Disclosure - CONVERTIBLE NOTE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNoteTables</Role>
      <ShortName>CONVERTIBLE NOTE (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory Components) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40301 - Disclosure - CONVERTIBLE NOTE (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNoteNarrativeDetails</Role>
      <ShortName>CONVERTIBLE NOTE (Narrative) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40302 - Disclosure - CONVERTIBLE NOTE (Schedule of Interest Expense Recognized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNoteScheduleOfInterestExpenseRecognizedDetails</Role>
      <ShortName>CONVERTIBLE NOTE (Schedule of Interest Expense Recognized) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40401 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40501 - Disclosure - FAIR VALUE MEASUREMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurementDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY)  (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>plx-20130930.xml</File>
    <File>plx-20130930.xsd</File>
    <File>plx-20130930_cal.xml</File>
    <File>plx-20130930_def.xml</File>
    <File>plx-20130930_lab.xml</File>
    <File>plx-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
        <td class="nump">$ 2,284<span></span></td>
        <td class="nump">$ 3,724<span></span></td>
        <td class="nump">$ 8,116<span></span></td>
        <td class="nump">$ 33,698<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherGainsLosses', window );">COMPANY'S SHARE IN COLLABORATION AGREEMENT</a></td>
        <td class="nump">1,075<span></span></td>
        <td class="nump">1,666<span></span></td>
        <td class="nump">2,275<span></span></td>
        <td class="nump">678<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
        <td class="num">(1,587)<span></span></td>
        <td class="num">(2,367)<span></span></td>
        <td class="num">(3,876)<span></span></td>
        <td class="num">(6,966)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
        <td class="nump">1,772<span></span></td>
        <td class="nump">3,023<span></span></td>
        <td class="nump">6,515<span></span></td>
        <td class="nump">27,410<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
        <td class="num">(7,723)<span></span></td>
        <td class="num">(8,326)<span></span></td>
        <td class="num">(23,467)<span></span></td>
        <td class="num">(27,717)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">Less - grants and reimbursements</a></td>
        <td class="nump">2,086<span></span></td>
        <td class="nump">1,963<span></span></td>
        <td class="nump">6,049<span></span></td>
        <td class="nump">5,655<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
        <td class="num">(5,637)<span></span></td>
        <td class="num">(6,363)<span></span></td>
        <td class="num">(17,418)<span></span></td>
        <td class="num">(22,062)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
        <td class="num">(1,780)<span></span></td>
        <td class="num">(2,220)<span></span></td>
        <td class="num">(6,065)<span></span></td>
        <td class="num">(7,353)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
        <td class="num">(5,645)<span></span></td>
        <td class="num">(5,560)<span></span></td>
        <td class="num">(16,968)<span></span></td>
        <td class="num">(2,005)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES) - NET</a></td>
        <td class="num">(102)<span></span></td>
        <td class="nump">81<span></span></td>
        <td class="nump">63<span></span></td>
        <td class="nump">264<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
        <td class="num">$ (5,747)<span></span></td>
        <td class="num">$ (5,479)<span></span></td>
        <td class="num">$ (16,905)<span></span></td>
        <td class="num">$ (1,741)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER SHARE OF COMMON STOCK:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED</a></td>
        <td class="nump">$ 0.06<span></span></td>
        <td class="nump">$ 0.06<span></span></td>
        <td class="nump">$ 0.18<span></span></td>
        <td class="nump">$ 0.02<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">BASIC AND DILUTED</a></td>
        <td class="nump">92,433,502<span></span></td>
        <td class="nump">91,929,445<span></span></td>
        <td class="nump">92,307,170<span></span></td>
        <td class="nump">90,491,421<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_GrantsAndReimbursementsReceivedOrReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The Company's share in collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_OtherGainsLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development expenses, net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ResearchDevelopmentAndEngineeringExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> Inventory at September 30, 2013 and December&nbsp;31, 2012 consisted of the following:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; WIDTH: 80%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September 30,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">December 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; WIDTH: 78%">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">2,574</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">2,118</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">140</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">192</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Finished goods</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,863</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,729</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7,577</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,039</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4ZBG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY) (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional paid-in Capital [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit [Member]</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2011</a></td>
        <td class="num">$ (26,077)<span></span></td>
        <td class="nump">$ 86<span></span></td>
        <td class="nump">$ 145,814<span></span></td>
        <td class="num">$ (171,977)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">85,630,157<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="nump">25,388<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="nump">25,383<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (net of issuance costs) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,175,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Share-based compensation related to stock options</a></td>
        <td class="nump">4,217<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,217<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
        <td class="nump">1,848<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1,847<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-based compensation related to restricted stock award, net of forfeitures (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees</a></td>
        <td class="nump">1,137<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1,136<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,156,184<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="num">(1,741)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(1,741)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2012</a></td>
        <td class="nump">4,772<span></span></td>
        <td class="nump">93<span></span></td>
        <td class="nump">178,397<span></span></td>
        <td class="num">(173,718)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,461,341<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2012</a></td>
        <td class="num">(3,357)<span></span></td>
        <td class="nump">93<span></span></td>
        <td class="nump">180,145<span></span></td>
        <td class="num">(183,595)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,489,809<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Share-based compensation related to stock options</a></td>
        <td class="nump">895<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">895<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
        <td class="nump">2,558<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,558<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-based compensation related to restricted stock award, net of forfeitures (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,667)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees</a></td>
        <td class="nump">103<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">102<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">64,768<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="num">(16,905)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(16,905)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2013</a></td>
        <td class="num">$ (16,706)<span></span></td>
        <td class="nump">$ 94<span></span></td>
        <td class="nump">$ 183,700<span></span></td>
        <td class="num">$ (200,500)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,552,910<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to employee stock purchase programs during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EP5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 91,397<span></span></td>
        <td class="nump">$ 52,035<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable- Trade</a></td>
        <td class="nump">2,053<span></span></td>
        <td class="nump">1,410<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other assets</a></td>
        <td class="nump">4,173<span></span></td>
        <td class="nump">3,686<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">7,577<span></span></td>
        <td class="nump">4,039<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">105,200<span></span></td>
        <td class="nump">61,170<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="nump">1,467<span></span></td>
        <td class="nump">1,247<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
        <td class="nump">14,340<span></span></td>
        <td class="nump">16,310<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">DEFERRED CHARGES</a></td>
        <td class="nump">149<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">121,156<span></span></td>
        <td class="nump">78,727<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
        <td class="nump">3,313<span></span></td>
        <td class="nump">5,267<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
        <td class="nump">12,400<span></span></td>
        <td class="nump">11,051<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
        <td class="nump">9,513<span></span></td>
        <td class="nump">9,437<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">25,226<span></span></td>
        <td class="nump">25,755<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
        <td class="nump">43,419<span></span></td>
        <td class="nump">48,888<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
        <td class="nump">66,944<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Liability in connection with collaboration operation</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">5,425<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
        <td class="nump">2,273<span></span></td>
        <td class="nump">2,016<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
        <td class="nump">112,636<span></span></td>
        <td class="nump">56,329<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">137,862<span></span></td>
        <td class="nump">82,084<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
        <td class="num">(16,706)<span></span></td>
        <td class="num">(3,357)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
        <td class="nump">$ 121,156<span></span></td>
        <td class="nump">$ 78,727<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableOtherCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableTradeCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.10)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount for overfunded plans recognized in the balance sheet as a noncurrent asset associated with a defined benefit pension plan or other postretirement defined benefit plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361610&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement and postemployment benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361610&amp;loc=d3e2417-114920<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361610&amp;loc=d3e2410-114920<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361610&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td><strong>General</strong></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#39;s proprietary ProCellEx<sup>&reg;</sup> protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health (the "Brazilian MOH") in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&trade; by Pfizer Inc. (<font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer<font style="TEXT-TRANSFORM: uppercase">"</font>), the Company&#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the <font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer Agreement<font style="TEXT-TRANSFORM: uppercase">"</font>). The Company, through Protalix Ltd., markets ELELYSO in Israel.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel, and, subject to the effectiveness of the Brazil Agreement (as defined below), in Brazil. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, and, subject to the effectiveness of the Brazil Agreement, in Brazil, where the Company retained or will retain exclusive marketing rights. <font style="COLOR: black">In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold</font>.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;&nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the "Brazil Agreement") with Funda&ccedil;&atilde;o Oswaldo Cruz ("Fiocruz"), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO<sup>TM</sup>. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement becomes effective upon its approval by the Brazilian National Institute of Industrial Property, which is expected to occur very shortly.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.&#39;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Mexico, Chile and Uruguay. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil and Israel. In addition, patients are being treated globally through the Company&#39;s clinical trials and related studies, compassionate use programs and other programs. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.<br style="PAGE-BREAK-BEFORE: always" clear="all" /> </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in"> Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&#39;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td><strong>Basis of Presentation</strong></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2012, filed by the Company with the Commission. The comparative balance sheet at December 31, 2012 has been derived from the audited financial statements at that date.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td><strong>Net loss per share</strong></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> Basic and diluted loss per share are calculated by dividing the net loss by the weighted average number of shares of the Company&#39;s common stock, par value $0.001 (the "Common Stock"), outstanding for each period.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> Diluted loss per share does not include options, restricted shares and shares issuable upon conversion of the convertible notes issued in September 2013 (see Note 3) in the amount of <font style="COLOR: black">7,169,035</font> and 7,879,601 shares of Common Stock for the nine months ended September 30, 2012 and 2013, respectively, and <font style="COLOR: black">7,508,240</font> and 8,817,090 shares of Common Stock for the three months ended September 30, 2012 and 2013, respectively, because the effect would be anti-dilutive.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td><strong>Convertible notes</strong> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> <font style="COLOR: black">The convertible notes are accounted for using the guidance provided set forth in</font> FASB Accounting Standards Codification <font style="COLOR: black">(ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely.</font></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in"> &nbsp;&nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The accounting policy related to the nature of operations of the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_NatureOfOperationsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2208565<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>29
<FILENAME>0001144204-13-059668-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-13-059668-xbrl.zip
M4$L#!!0````(`(&%9T/L6"$>USD``*V"`@`0`!P`<&QX+3(P,3,P.3,P+GAM
M;%54"0`#H@E\4J()?%)U>`L``00E#@``!#D!``#L/6MWVL:VW^]:]S],N6U7
MLI;!",S#3G/.Q1@GOL<Q/C;N:3\.T@#3Z%6-%)O\^KOWS.@%$@8;B.MFM4E`
MFMFSWZ\9B5_^^>#8Y`L+!/?<]Q6C5J\0YIJ>Q=WI^\K=;;5WV[^XJ!`14M>B
MMN>R]Q77J_SS'__]7[_\4*WV`T9#9I'QG/S*W9!.&3GG-LP5Y$WEU_/*VVI5
MC_0#SXI,&.JYI%$WFE7#J-8[Y'^)<7+4(=>?U,"'<6`3P,@5)P#E\_O*+`S]
MD\/#^_O[&MZK><'TL%&O-P_Q]I@*5M'#??LA-QK6"ZG-'VJFYQSB@O7C9CT>
MC*#X"N#<17K-!/C#+'3LW/C[IAQM'!\?'\J[R=`EO'-#\6X\U&(I#G)]P<S:
MU/MR"#<DRM6Z46T:\?!(5*>4^LF4"15C"5G?*)C"A7?4,#JK*%4C](1U6`)B
M(N07I.-$F#/FT!LV(9*NDW#N@WH([O@VLDY>FP5L\KX"TJG&0J@]"*M"#A4<
M(/6DYS#7@C_AN4VGA%OO*[DKM4;KJ%NKI_]5B.FY(7L(;Q#T)/"<:DPZ_!]Z
M^MMQ%=9:G`NS_S&AMF"_'"XMG6+4CX(`+W)A4OMW1H.!:YV!HDODRFYN'<]J
MU6B`,!6F9:NF2)]Y9N0D0ZY9P#WK'*X)B77IW:VC_>^FPKATQ3*4D:HRA)-[
M6T<7;Q<AG*RXC*ZB):L3A7=V@JJZG4<XM^HRNB,PRQR6>&'KR!GUZK_S:.$R
M*38#-^3AO`_7`VI?N!9[^!>;2[0*[VP=OWJ];M3K[497&U3AJDOH>H[CN;>A
M9WZ^G=&`B6$4RE`((2Z+^XIAM6;W^*B<$"JJWJ2:1$1C:3A.B%RN1@L)O4(L
M9G('W-C["E!VW&RUC4Z[E:-K!4:+1$+$9D$?5&?J!5F)Y*YO71X]TV0`7Z8/
M<J4L^KFE%_&]85,N0&IN>$4=ED$X?V/K&%_?#$>]RXO?R.G%</1Q<-.['MR-
M+OJW!^3BJE_+HI]'),5_%%`4P.W<&7NV1#QW9?L87_ZFT,HMH_"!D`SASPM"
M_I6&D/P-)V=L'%X($6&8[WLB%#H6KQRS;9Q37;^[/<LJ>K4)/J8%5OS+X1JH
M;YO&EI''\D'P$Y=#3A@&$2LFN9$CN9&0G`>U3++.(P4ORB(A%S,.?_MT>2M3
MKVJ:J!YNG>+&6E+M%$DU/_<%2[7Y%*EV"J7:W+%4^U3,;";$X($%)A=L.)'>
M?>@C>8K@U4/V:JF=9B+3U5AME\!%,]VF72X0V-B<0,^VZ=B#D,>_L%X`X6'*
M9/H6>!,>RC`-F9S)5!TMZ=UD!LKHN-9HMHZ[M5:SVWXTWT@D>PS#BN8E]/M1
MP+(,,""=JAUIZC?!\1LPH_U$9BS.6\V,]K.8(7T3&'T@\^:^YWYAX+G&-CNE
M@OU*[8B=>X&ZC'V:FZ3LV'P>Y)?-YN-&(AF2]P)&=VGNHYX]L9$G8+H&>]()
MDK57D3-FP6K.%$Y!PM;+T1,^;)*C'P$G.LU:NW7<?(0;A=AE&>$'`%5&M&QT
MZ[E63P@67C@^Y0'"U$Q8=_A>8T.CW3W.*,:Z..Z'#?N+((U.)H8\A0T?L,`0
M,.*&<6<<!4*Z&G'#3`;>QQH&ZA,%O9)\V&#\7O6A73]*]6$#)/?%B?VI1*O=
M:KUH3NRM)FC4N^T7S8DU8NA32X6%&'K<;CZ/$Q>N&3`(LQ?N):=C;O.0,P'A
M%I(2'^+._-H&H`!S\&?$_<1K;CQKOYV`;B=ARL:8?@O6[,^)=!O&-EASR2%-
M%0QNWD:^;\][TX"I7-8+X6].[?,HA%3XFL[Q*N9QUM"]8CK7507;<X'4&FU(
MMQH=H[LJC<^H5KMJM%/5:F.R)D'4"X&LU+`&NN*8D<\E).7K)PZU8NBY\5#)
MI\6+V`5N0QG2KC=J+:/=V%!OVJ@W$D2]$,A*SZO(UG0O(I;2<461WN%DZ&,3
M%RO=:\_FYGP$V)W:4/]*PAX=M?6>Y\]V^.Z':O5LV!_]?CT@N#=+KN].+R_Z
MI%(]//Q/LW]X>#8Z([]]''VZ)&!99`1.57!$CMJ'AX.K"BEHT8QNU#ZO@9/U
MQVJ8F5FS0JM"JM6?I^$[Q,'B7_`CR7S6J-V&-`C/`SI%AJH)<E0H8Y$(YS8#
MC>C=?+BXJIX.1Z/AIQ-2]V'0^?!J=$(,^$Q&W&&"7+%[<N,YU#U0%P[(+0OX
MY!W1LT?#:SD5>,IL6_C4E-OZ=?7=IY85?[_G5CB#6K9>_ZF2(A3$V/PZN!E=
M]'N7U=[EQ8>K$Q)Z?F:8%0_[S\79Z".L6&MQ5][_F3K^.W<L?$G[86AE)L4<
M@3+(<Z?X[0-S04ML.32]NCCS,`PRGY%GR5=_-]Q3\/.D^,N+;KJ`!`Y_'N2_
MAF89N=8G%\@I]T8S8(C/HI";,!N\>8V\,3W;9B8V&.PYR"V<$?2V(AH+;G$:
M<%PGG#%2Z7M0-+CSRML#0EU+CKJ?P>1YU;MWF95.F1^DBUZ&5@W&!XR,N>=#
M$>I04ZY/;3!,!`@+D`ENC*K#'+B4Q0`93P5(7`H&.M@+`XBJC"'>A$!]XSEC
M[D+$P4DQ701/:C#N"H+'.1*0&GG)]?]I'K\3.,X'ZL!XYHAN'S1X\"`5*/(3
M70O85,E'7XRA$_8`!9;`RIJ(N0B90]Y4$BB5MS5@+DC'AQO80H#"['B!*4`S
MU%\6T.<A]F6L!-]JP5TDP:;W`@G'SQ`)8!)$6TMDX)[6?@5F`W;@\ER4*6`G
M)8I3!A$&:>J23\SB8+C`]MZ4N>8<,!]\ZE7>$@J1"`0CIP&=)M"'P'*3[URX
M6R.C0I:&]UY.<:3<`S9A00!$A1[)Z1H0@)RD0JG7;69BK;)CH]B;]0V!WW1.
MC`,\I=10EG17NZV1<\^SI'*?!=&4]"R'NW*/3W+_3>7\3$LD\+X@[T"^4SLR
M0<T%(]2>4-0?D,X?2LP')4H^X8$(4S`6KJ6.3H4'R'F0*'._0B@&,?DVF*:T
M.65.H!C@IM_*A:3^@0.MABQP2(C'M.1(4$=J179(?$`<2P>E;Q0U<,*E@H-(
MIZXGN-)=/#M@D`\T,E'I+2XPG01]6J8/)M"LD1[D+!ZM!P'B)-#4@(T#6,/"
MV6\^],_>`L8TS#(E=BJ`421PNSVQUL+5[Y$YMO!2WHWG$MR%""BS.?FDY#5'
M)#XR:@/5;Z0>)P.&'T&"/.\&4`4TH-.`?H4,&@VR#%1F2`SL$PW,F3SQ)I5'
MP]*6B_$>/%9DTQ"WWFD4SKQ`YN@(&L@+*8!0_L;T(C>4ME;"?(2KU,?'K%Z&
M^*KRJ8^XWB6>@3(34"*4@EK<H7_`]P)4Y[778OC%3!TS5#V'!I\9'E30WA6<
M*GZ#1"Z$]5*//PY0QBZ>2AA<#BY_OQU*],%+6.P=,O=ZPK_"6!7(D8H)Y+HQ
M(:/!;Z/JZ*9W=7L^O(&L!0H-"*)XQA$15!X6Q^,W!>@Y$-Z6N:#EX.U#O@J9
MF71`J"C<2EG!'DP;[/,+N!M5(DDU%[)((C2NDI!VJ?XLO&?,78BL>$=S1MK1
M\QE#DOKL62S*Q4WD5^!%T]EBLJ2T0\0B1\XHG_)J;",OKBDVH5@B,@Q)L1(<
MD'LOL"VH)E)]@#1"N_*EW)`5Q<G4G!9E":XX"L$+H5?$&#OS8$[`I[-0I$R7
MR>X!IC48:G%UJ::3B<IC7$R2=%*FW'4*G[P!!;?81$(?`\;W;V5VIL;EE(',
M,-[@1)DG42)\J*(GX%.I#66MLIM'M1T<*@WD63)$!_)3'PID'O=IDD".!3%W
M(XS-F40;2/*"4(]:8B-@"WP'_Y0S<XEVH+N%*+G(APK;Q71@'N<'/[:ACB8.
MMVVDH20Y90_,C.+,ODA6R@U`C`AM&5,@`YF$2ENP[%0U,_FQE5G*M"&N8IV1
MH;(:,%L>$7/B1D2,:EX<69JR\!O9!99@E%$'\2_C$%5T!&A(:D&4*(@)8`<S
M#G$?LQ(390HJK31ES%!9('4.P8C0;:9(H2#]*/!!JX4JF$!=(R:C]]3E*FV4
MRDU-TY-Z8X-7NE<BA0M(ODBF65$0:Y8O#X@BI@HMO):N*U,G<\9AGJ6XFOIM
M[>[%<GHFMSD5R[3L\:[+Y!S9``1R;$\@0DJ$VA37*A8+^`PW*#FJ_R0GM>%?
MR&VX.)!F$]<H!^B*('U3>.D[\<(+>+$<9LM8Q/:U#<^2<2.H&J`,.5XF+@U0
MNP=EU1<RP57%&)2G\G>UI2#9'UX.;T[(&(J"S])K0T$+QF1BQA;K08%T<OD+
M3?&5)BOKP3@-U=XN`A\%OMV1,)3J4P=S4ZTC#E1/8Y0RUBPP'CMX$#)0$02U
MM5>+84)5CC%":$7`DUM8(T"I!:,]V\J%XSV&TSU6F_\7@0D:75EO-A=[#B`*
MZ3BX*X/,K4ZK@%DC9LY<S_:F<]6_G.2<;[8<22]#12+MXAPD3B6-ILDL;BMZ
M04UL2%,],A3WU+8\T@^BKUC9<L^$3ZJ-!!KAY)5<5SL'Y7$HGQ@7#TOM`[/N
MNVN9.Z>]G=&G;%-'P52UCJQO-4)ARI,PY@E`$^@0R9S10.E93M-C?64/(7/1
M@TZ\Q2`U`0.LXG2YF,R"7;`$!KY`.0[?AN*@#`.%;`EJX%GYU$TB@_(E*KF>
M>!&V7^E46P='3Z1Q1-<30X'/6D(J5Z#8Y0V5DHC/X$S0S?T9\4#3EI?<%,J^
MP%5-!$^&JC``NY7-0N\>0B9UHPDU0Q5+X!/F)N!FJ1H"-LIB(U9=1H"B'_62
M<4Z@F6.=>T!FX+C(GQ'5`+3!I_XS+AH*O7\-XFN!EXHIGU%5M_!0NW.(H^9,
M3@Z)S6C<4WG@#CA\6.3'HS0M@)05C*(XZ&2"J-:W>T^KDE:Z!!O90L3(#MQ&
M?LI1*8H\(X<M(@BA7:Y4([U$8^W%ABXN[GIA#H&<WD+*"XHNM6V5,8&7!P.-
M*8I)$*4T-+IK$:%,9"D;'V/7`J"G&B)C#^I=DI(M]6:NJ+9:/%_%PRB4!%VX
M%JAB`-&=Q%N?<8H&K$$%-K7B>*8)=@=&,8^SUU=3Q4%!H`V8:K'3](2BC@Q*
MM`=);><HAX,\7[/25QEA3OMD2AD_:9>FE+$W2M1+:]YR*H8+J4:4KO;0`:Z*
M(6-(@G!0'H]>FHPKN)MAH$E5*"Q:6%H+0FV1L`_\)UA#Y.@42;9?\R9B-&JM
MQ$9DKH2\SB9JV:)4UQJK!/`VXQ(T&K.D-YHBR0+9D8T3L>Q.)@3,X`NL(#(,
M]1:JV$QY-&8SX'Y9*;7*J6=BUZLQLB6_FW/ZH!J43!C$3`R$>*GU4ZQT6N8F
M2$B0J=P*U:F`E@&,EKYORE0_/953MBE'!51%H6Z89U#)^?LE7PN^'!^-D%D`
M9C]JHRG3ORMM9:@8F!3D2S-U/>.@EG%7._/"^FP)*15N5#`*'`A14K5D9>)-
M7HW&7*3)9LR).+P)Y1%T2^(@OY\Q_)CP?R$33XO%)$ZB"QBC`./F':RDLFRY
M2<$>N.D=D/Z,V\JKW`71-*+S6A:[?">)HS/UU+$.6"G;".`J2,<%-$;5L?0R
M!8B5EP.9##S9^Y"X_0$YF;"XJ1[Z(/K):$QZ,O#5_D3LO=.-4@&L@!`F>3$!
M:I7-$%<='<==EV2?Y;4H6(9!R:Z?W."7>QNA?H6#\M@E;9<T(*JN2TG32ULP
M"DEWP//ZLV+YJ>V-,7--FNPEFQ-QCU`F<TH?XBZ.""-+GGZ0YQ3D7C\F.I&0
MK1]0?$=D,HGX4DT5X;`REM]0A-?S>DY=%S3"E/UFW0([!W::L\+M,-`N*[$Q
ML,=>!/>Y4&HX8H[O!12B`;$2FN[`Q\4#WO1&=U!F@TGHH0"ZE]-D-)<[K+5*
M[";-:#([OHN[MZ]%L7O`W]%=O/>9$8<#M0MUN7"(/*42[VHJL>D=VVNUJZY4
MXI9.&`A/GZ\`A^70SQ"1/;>:VXJ'P5\HM^6^K0SG6IW!&LX#?&(/>WMH+P`G
MXMAGCL;@>,A,+8E=`TBC.3Y\",$2\$;T<</@7B1"*@`*2^G^=D:N9?8Z9J`#
MK-05Q@JB#Q4@\V)U+3DZ$I]3+-&X)+((!I63-!-EP)G60KHG(J/!S!,^%"&V
M6`POA5NP9NR^M,=(DAV`M,0TU<N4FS'@)*@IS\0DR8CL>F(7RHIG*&A"/6&X
MO-7^6BQE,<=88O12;(=R_3-RN^"$U]+1!#\VI<6#&DC*.#E$>-W[,*B>W@QZ
M_ZJ>#LZ'-X,36/J>SD4%W#K4*^\KH"<5<IB>[GN%G,]D=R5%$=I9:KW%@3;>
MD(BW%%0"EXENB0KC?H6T@DEDQS5`9MMN.<)F)9T+FYC2I64B$N-"!8ED)&=[
M54O3QYX!IN_8K5&97])#`]?$IVXN=":Y;K92$J!`<L5$M[#Y&;@T[G!!-9]N
MHZ&I)P5V",*175W,`6)WF(OH:J\+CRO92&QFKPVN65B:A=+I8NT*&:QJAB9$
M'A`^P8X78'&09.`Q;-5*DEZ.N]A)RN(H&Z6@"^`F15F]7,"9Y&P?:@8#[!'A
M#&^(B>_UL.19E+1?R8/,SEA6J@A0[@>^'O<V3)2LH,)8+#513$N<DU4`W%!V
M(SV@!;IH8MA)-;KT;*IZMD)F#O+M5_&I/`CY*#G,XS*"%2'S\^JNZR,PU5EJ
M$/D=;A,346SA4N%A1QV)P(.A:ATO"K%9JLT:70G*71XC6)3R#]7JP+7RY\_E
MD.R)]?B+>@K@T5/\F<<"9"$UG&1/AZHG`0IN[.Z1H<6'M/'M29J6`CQ2](?H
M/3^`+,2EVAQ%U!<O[O=IV48G?29P$9/-$=_?<TCM3G>;>._O=23U[3)\?T\*
MMMOM-1"_UCW&<U@\?B'*<))Y8=05"X>30;PSCV1M-J7`/-9XL<I3K>79+U;9
M!S_V^%1YJ]E([6XS1#,\T5M[/9E5C;Q3=@M^7TPXLT:>?MI4ONK*9M:-/H"'
M?-EX&CZ=UWGT`;_L"QCB9_HZ3WBF3W(F?;AM<W13#MU`D,6CW6=I8H7/4;I3
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MV-&#+$$VT@:.;WMSQF1PB^N1:]5VO\$&H>`ANU7G?-1KOF_2IT$4R[[-VBJ%
M,.K=#KY;Y#AE\7-+_0*06XS#?V^)08KS-(FMS)F^2VRG-G;4;2UP=V.;6@:Q
M\@52QZV\'_PVU'\7O[2O]<2_TD`W$S_^'LQW^;\,^:/YMUN-+8?8`I#?'?86
M+?9)$EMMP=\EMDL;*RTJMMM%^QY87XS0][>K\!<.IW'#E5D%/Z[Q#`![Y;\A
MCR%LRO\2S!>8J(ZU,JM$7&HS0+%KK:$ZXK<ZS5JCW7KDK9^K0_PRC)4]'>.X
MFV?26OCNGAT83M=CQ^KXN1D[FNWC^LMD1V,#[2C?!]R0'>WZ\<OD1G,#Y2C?
M"]R0&T;CJ/,BV0&&#ZBUG^LZ"F`\\I[DUHMD!QC^FNQ8Z3HV9$?#>*GL:&R@
M'>6N8T-V-(]>*#>:&RA'N>O8D!O=HY<95K"3#W\O4/+L3OXRR%T4K;MQ'07(
M;]X8?XP!2^>/7J1V`/Y/UHYR1_(7UH[F!MI1[CN^A7;D?A'Q'%\(BV^$+_O)
MQ/R`;_%+G^L@OET2_RH'BA)ZW9!;W([P*9];?`)3/O,QP'>U6,S"<[^H%5&H
MZ1W0`)^3$=<LD'JCCKXJQFP#TNZ4I/"GCSO=SG&[;F0491M$O'0.[ZAY4LQA
M`VKA9NOOQN'=G+0MY'"W:W2@P/Z[<7@W)WB+=;A5[S:.=LQA_)4^'6'DQ]T?
M;S2,5CL?)>7"C^.UTV-4X)(;G371RAW]RE[9.?/JK<;BX=#L^ILBNU..M@VY
M@[`>KJ?X>I;A1)]=`ZU53VH6_3;3>D.__T#3:_R!IL;_MW?UO6WC2/^K",4N
MT`*)UY(LR>[=%7#ST@NV3?(DZ1Z>YY^%8C&)GG4DGV2WS7WZXPSU;DJ6;(FV
M4BX6;:T7:F8X)(?#F=]L5Z$)50:2C*_I+`L!^B#:G[->DV$.K/A;"'PV8^61
M7B#Y?.79*P<1&^A8<6`CAO\*Z=!R$*OH@>T[&.CF,@8GR6$R9("J%@%9V$&$
M5878WPQL!DNW),.7/N;2-A<`LLSPXP!/"3!0%J6U*]Z^^32=7K]Y%U6G65)^
MGS/$N1Z@!&(O#Y1I%G6<-O6B.#["BM*OPL()B`@Q#YD7$2.!/D8R*>_W+PI\
M-P+;]5:(LKLN$<2'P?3VA>M%J!6T>^S'"/X5/FBGQWG*6\!7C&$I`EC8$0W!
MP_3U=UDD]C0O'TE0'FPW2#\<<T&5?#5?IDB5L8`B_`3H%Q@%M+VTKR)A.`/E
M*@%'JVX'T;!`CC%1+NTVUW,0L>P;*1*31=E.D$OCEA]65"0(_MB]U@L>82'9
M<EB%3_YJ#@4=`#S!B8`W_G_E%9`W,DUO:#`:25.FN#<$04)H4^>`J*D.CW]/
MN@-1HQF$ZBGM7,28TY/:4@Q_+D*GBD=]0@]FWB"*&0."P.F%5997[NTYS@#A
M$R%+`"-9:SW%9:(*CY41$BC!F%$N;PAQ1O\`]G=$CFAFDG#-F.PR`RE@[J,'
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MQM]O$QHO<RIE3J7,J90YE3*G\F?,J12I0Z]FU=;-B-<&B[9J#<9&_%IN`9YM
MLVI#W4H,@8,C.0R8^SF7[.'`BFTA!2R9&2Y-"*Y#AT->0BSF+`I<8Z/4H9:L
MDXUAPS>BX?N=P'DL>%N_T5G_D61<^0SGIWRK.\,2QY1%?_87.*<#A9K=*Z+\
M,AP,AVH41,7J("L(]@TQ4-32A@T=TI-LR-AZTM&PS4I/9$^=\OO'\4F8LS[\
M1;0OIL)>!BXNBY'H61`P_M,%B'286M`M0.=ZVEUAQA/!KBQ=>(09+2Y"JZ]E
MY.C*VY`0Y9(^H^COXC4AW?]O#(RTCE1S<C34C5QT(=)J'8VMR9%).S_5G:P"
M).N+!]Y=>GGY%$;+3$JC/HQ6`FB11?7E8U3A>@TJC>'X2!L-UZD<'XU5ZV@X
M&6ZB<OD4D.W)O"<S&PY/TBA7Y7N\H(-'XSA&Q]JGWLOEBKM<.=LL5R?%(5AH
M0_D)EZN-X_2..W?A0L8VB-$F@?G&82P]KERVC4Q.,D*"QRN0RNWEA_OY]/:C
MDJ)0P.[1<^R`;H%.?`=!*M"6WDCEV^GMR3MEK!K15I#1LI9QR>(L\!@+W<@X
M].ELX3C,/D_F;)SRE6>Z`839("1H(!.6()OG.[X'+MNL/RMZ*I?E4A0BNFC=
MR+EVA$?1$)OR"'DS:!NP#`"V!+A@\"_I+C<.V8N%6%"2W0!*ML(*R<.6G-CA
M$WT5_CJC?4%M#M@`3)<G=A"`$^,/-$(`GZ36DUW#X$U4?9+'ZJM%5M<\=UR5
MEYH'!\CSJ`;/:LKSJ`G/`,BH'B#/1JU^3F`_C4;]/-14LQN>66VE"V\&'GMR
M2MC?%:SS7Q`*J*U/=%.K(0X^J6*E(JXXE*9K:IW)H)94,$D!/3[0`"9V0M`)
MQ+:A$,KO<^;Y"MSQ+:;]5J#&=V.P.*G78;#^'-\:@[['JJO9P56`_GP'IX48
M^C=A=,-S;:_<?])-^I^X)<RJ,-5@]&=DU'<S:5WRW.J,+H)GO!O&@7C@DLCS
M6KS?:K]RP:IQ/LK#_5;0TR9C[75>!XPE&XA3<K\\M]T`^_?4#6=S/V11%\C@
MQN>ZMJDMU3*+7&XDJI+;2]^;9;"G2^]VS9EI3D:C*LY24MKBIQ>+1KB\>KB)
M,O,90YDK8HV\L54P>;.D-*5;G!EF3LPVZ>ZF>`.W2LW8:I'N;DHB<,U>LS;=
M,";3F2H/LEIR3^*GMNBV+,5/U95CY>3J$EW1'S^?*7"1YQD6")C:Q6'V)O?G
M5?8,*05;R#H_X_PX!U'LZ)YN290480]Q<29Y7)S$$1G'_^3"4$<#8_@KQZGI
MT(%-OS[.^WG962.<:85OWFUDYRC_,CN(`Y?N+UD2J^F[C`*#<M@L+L#,0(!H
ME-H=9$Y+(9S_&"+YH[R2!0O:3X%NR`]($0HC^(+5?+Z1#PPSXD7!K@<J^P\/
M!+S6^4[+XV-`KT"<)IUF8FR_^'<,?8&)YK;W%TJ`JMO_^L%?RA="N?+H=`#N
M[`3MZW(P'2#8PQ*N$W(4933$;GP4(/-I,UG:LUFPBF*,2(C1(;8"KN]4'>+4
M7#AM?F$G5^3998%8&'L$*=D,72"&#E0-EJ&2JJ\![>&Q,VOJGCRZGA<%Z\<O
MH8J/LN0]8S`6/)-M"Y\;5SK,^Q_!E,^M3>)Q4IU*1Q#_R5BU8\V.@P_6QDL<
MFAT=D.2`'O+(5(TFDT3?Z'@#7)Y?3',PCE^G2HK06@QR)U;/JJ'LT.48FX[Q
MEUBX4Q+-3K47$]2=1$0I4D^LN/GHJ5<6]?9/?^Z0(,1HOV@*CXZ8HJ&^Q&AQ
M3#6@_>4'\00*5@Z.]WLX[T-$*!:?D/QV:)/N\S-Q7(8`L(#4+E0]SK!$Y8U[
M,G/^AK-*?'!V&45+**JE#TQCHJ\'ON1#`W#N^$4]HM9=Q=+PEB2N326>7=<(
MH:_/"`?6P!A89B9FA$/)0/F:#P3)S^R8-NZ0N?L-<11X03W9UH[P8YMX.DKS
M[M,3QT2@<;1?7LINF$7\2H->8="&$'(/]C`=\0!-B$1#:`Q$2."3":#02[0\
ML"/2E;>P72=9*E[9Z+F.1T1&HR>HT6:^DV%XL:0&AY#G["S'0I<5.F8P"^UA
MQ1"0DA/SG.YC"B](&:?!.A^-/HA09';XQ`*H`P0ZS4VW=!`P/+DD[@>OKIV<
MLQ14+Y?3$9!DZN?D^MC(DQTEY$"ZZB-!:R.//PFY1HCX`>@Z`0:\0KP`'97I
MT%L;XTD$:H++H^K#7_.!5IG1BY2GT`RHK_&+VA!ROG!ZHA,7E4<<&0")E+3G
M(&87D2"_D7=Q\A$(1!]F;\5M',/D%\5>$Q9"%TV/F8^4S(Z8A8C&5!;%,.Z`
M#$XA=E(D&NCGY\4R">5-?T>\XXB-)@5$*T$PL;?NNW2\0'A/++O*M3G*3V6Z
M!>A@B_F*2LS--E8Q"62MD(RAD+G]H#`86I\!H2(@CY/8Q!G>&.YG_'GW798W
MQ@8&,;!PQS`Q)Y-X]^<HFRJ</5&;8H[ILB])JD1BX.(P8"%A:1C^L^V0N%=Y
M8L$,>4QTBG<@SQ'V83:P,C:\"DS%,S?:LI!PU4VT-&\[79A`.]P_<RW8!Q_2
MQ'$@1/L&%CH#&R:`9$E[);+48MC0_Q"GN,N+IC8,F_%7(10E>/?^4$+./U[=
MG)[='-.]XN?I]>W9>ZQ!8"]"LD78V.>S\[OW43C7WY0H:&XR_'5C:%^-:+Y[
M?[GTG[,!?76#]X"-XW^=77SZYQTT,W?HBCD]/;VX_)1$R:D-8@$C@<6OXNX:
M&E`PF8))K?`Y!,&.^)CA'AJ<;R`0[Q]O3/SR)82!?6&1HV<0.2J,GUZ(YPXC
M:P7*)QMJV40IZ6+X/;`7_WC#_FZ[%WC-%P>ZD&[1N*0DMF!*DCY$[]E]$`$-
M@"=P?V)X'6+>$/'[HQC'&RVPY;W#6XCJ-@M''H4V9-_*(?0JQ*R)%D.39>=O
MRL?IR>^?;JZ^7IX>1[[^X/'^K38<'6F&<43_?L=+@,A*:TX>EBGAS'Y3,6<@
MLMX,\]=(OA>7IV=@#QZK26(`A),%@%;,L8<W)U/\6GMQ7*<XW\8O]5Y%)-'D
MW3%[5QV.MO]PD]R1]MAMV@:7[^.^<2T[^4`Z>=<YZON3NR2\B8DS?^;G]O+9
MJFR&FC[3+7NFSH5#[I<L-1(2@K`"0KF(NMP&%=G:I.)-VD-58/RK1B/V2NBJ
MP[!P8;5B3)2(K6+<]%QJ4L5^#A4384@6Z=0&QJ+A_'P'OM3ZDL`O[-;GV(3B
M^*O[.2GK]J:#I+S-[#A1)PT9;7&H"!)<!XUO-V1Z*C^I>#^GXM5)[-_+Z=J6
MR=LE,<CK0<P76``)VLYD')PD)^;7<&BL)F'-M9X>Z&.]3MXNQC:KX[7'ZV4\
M:6\^0,Q-GN5:]%4)X=R>D2D[Z5[G.;W9-HOKH?_%I*`R2JJ8N8@\0C?VDK#T
MKVL2@'L.4(/6V:MZO%6&%RM>\MK(*..VBK`J_K]$A^:G&-:TQF_V-A!<(]$`
MV<L'YS-FBXD&'R":#6^7<I7]_#H7"*GPLIY84+@NDPK2):&WP#@Q<Q*81@+3
M_$S`--W"9I6IY@X656'R+<[:#R0(B'."55W9?)VYTG4>JCJ:%`R&S,>;4MJ#
M#-.8Y"@][R23.\N_U3ELD*'JW![(D[$[%YT"`4U&NK4K%X54YM*[7??(2!^I
M_$&Q1DI;_'3:-Z,Q_6]+?B#B]"/QZ#^6UW/;FX803WGN!_`CNAZN\]GLK>ZG
M.'---YM1N"^Q=*H6JC9J52QG-N;\A3%,"`+83CTGAD<%(6QXIM/\_E)_P'"@
MCE,I;""Q"YZ[PP:HX'FH[9?GSG`%JG@V]\MS9Y@$(GCFN18V/"/=#*_2S2#A
MVB5<NX1KEW#M$JZ],[W?TMNT83TN+/#(_-7#V0^65@OG)%<>'[.3K?8-7A`*
MU:46H-2:$"I6)N)@P([5@E]I>Z'P0/;R=F#E$](*[#@H`!&L#.58.9]>W"A_
M3#]_/5.^G$UOO]Z<?3F[O*N.%.@CCE7V&.*9V`RR$BND,4N'F6&HB?D;T<,L
M11N6D[3$E(V^#GPU/K$`K%WE/'W;#>'``E*PO3C+'6$![,P*$A6@SE2S0A`"
M0/[PV#>.&(*"R]*,0;T>$+HC<TZ"13;I8PX)H-([/&,S3(1[LOS.LL>A?B<"
M,;B0:)]4QLKQN/<B61V6,HS.T\+H/`VP>*@=YH9/6+`VT^=/+C6@@]G3"^LI
MA*&A??L?,##N0Q)\0_.-`0UD+KC>8H6EFED^>"35;,,(IL5LD?O`MQU6)3>,
MH;[0J"3A+'#O8YB*?2:/=_"MSU@56'VO_,_*!^L8QT.HO%UY,:C+.U80$K$M
MF,I&H"#1\2H)0[2,2U2786RP@4G_E1N7F.S/Z^5']UN$;_%$MU"0V11U.9:=
MC6B.NO>5C0W&G/9>N4KU..J41.K)#!8I.&QY_LWZSR_V%<//F/E!X-_[0;QO
MC>8>VD'VJY2?_E[YRID)0'@X&WP''!BJADN8UP'>)2L16"3L;[8[AU=K:2F=
M%_A*JK].);WPDC@%=#8DTLG##]$MV!PG:;C'@B269/;DN?]>D:3&Z`_WF3Z#
M[ZT8GABGW^C,#M\J/LF;[2/@#VJ:8EEW/YZ>/">IS1JRVM<D@+7W19E!<>FE
M$KCA7S#7`:8=3%AA&,-AIOR]LGXLJ';D[\B6YHU#UL*DYFSLUOCN!XA7-;,7
M+H"R%`H+N[#N1E"/`$SISFS$G6*H<:R37("D8K5&?B+Q<F-LZ+TU_X<.0OS%
M4H\L<PA@;VM3$2*1)OB%R:H0+06Q?8F+1U&R6SHG*C>)A1VG'Q#WT6-1`[.7
MN]0"_F2[WF<Z+K]Z`;'G"1A_DQ<$NR;R`;E-"!4K$Y&NB5%+,OG$JHA//6?J
MP!Q/9QRL/WP683N!&#8\(U0;S*&9KY"S@;@NN!77SY9NZ'OG5AQ^O34>[IU;
M<:CWFK8+MP$=U->!_^"RX)C,;['CT2A4K,H0TH1B@46VK)$Z;(5D@0/#TEJA
M6)ARZT--KT=QL8K9A1?%>H?7#/\9Q@/#LOR<>B^0N>U>%3H\CHU1X1!A.Z+W
M+S-Q`U0W)P(E=H/N9K:%K91/^J!0#;(FXYK22`GLEG>!4_5P4E<5ZC-?"-TM
MX;SPE.!)0Y]LFC0*]'7%M,`MS6@R5MME^L(#P'0_*)_[,D^(K8QEZ)M&=8:T
MMOD4UZG4<-DT@"OX9,FG6?N]<$VL'T(MLI*C91OBBQU1D>VS:[^TDOI3DRMQ
M=G$'7:)OTR5;6<Q==`DDRYW%:.TY"#`.NZ4/BQU7PU%5)Y82*48./1^B[<E!
MW*`^;'WHZ?Q`%U[_&79*15Y3K!(PGO-!:=N^+./5.C_7DD4:9)$&6:3A4,0C
MBS2\(NASB3`OBS3(OI5#Z/#%+(LTR"(-$K__,+B6G7P@G2R+-$@$_0,05H\1
M]*6*]4-8/58Q6:1!8N5+K/R^R4\JWL^I>*^M2,.VYYK%HU46N?3"J?<0'9^6
M/R"/2#M6(83TT)1CY>+R#[JL7]U<G-U6*U-?<#RR\$>)B@$``">%$?)N3\FL
MZ$I4(X0G3,D-,7,]2CZ-SY4[.@"N!=TD]@!XW-4!,,^5$;M_VSJ&:Z^EW=S4
M2GQ2(YKL/0L@'EL*'5+=4;WU:6^Y!NX@ID,Z?M?B,[[=3YQ>FT1V/QP2KI3;
MCN6Z)UMM^TLXT2"\S[[].K@=4".>KEM!J.3BK+KD:3^'==&J:D4N_AO[NP(`
M"8%KSRM\V8=U'J,=&5;O3F1V8UA5QUTPW-EA#'<'^R\_0`R91>`_TNT<1]^V
M%?;V9U[L@"]":VWG6_MB8E*QI/3`_UONISZ';/LGN@MZ]'WGD$[<NO3PCX[&
M9H75),]&RCV61Y;6P&>YC_.1VH?850[!NRB2/'(QU.>XS^YHBZ[]5D-6^^>0
M[D1THZ.AWKDO7X0O6B!(&31;"?=^#:B&<:K&^>DT4Z;`7D#YQ`C\S9Z[C_/5
MC`1V2!1[_F`?4;O;6SU`_!O6.L1HDESNQ]HKRG<2("I:#"L'Z2)_4P(;*B$>
M*>%J]A0U@P]&H70.(*A1<XL`+B-##@;T17^!`'[10VQ5C='J!PK#T@:D3#LI
MQ$"YV\`3X*M]L5^4R'^9QSM,:::BF<^Y[-MAZ,]<E,!W%Y)EUC[1$E1;E>^_
MY!@AMD(^@1&2/T#(W>J\>ANU"PH9>#PR=N>BV^)<=(W>G@LHT)*CG5[H6NX6
M77CX%-./-Z.SVVIX=)9O2N>-_?U+[`7($YR]T[6$-;JMYU.>I6)7%CH5OD8W
MZENS`/OC"^\Z\`$V.L]#[E;W]02'?!YR5.S.1+<3S$1KS$01C:D`2]6IS'5K
M;.8I+D5+JB:S4ZF.M>%XU)C*J>=@@9LG?PX`PU"'8_E2))W[4.=BIP/6,,L8
MXI+4#9>=]IHUMC2K'2:SE7C7+W>_0FA::6]Q2_`V(;W;E<&P#&-;T@NE5KEW
M.A\JJF;JI<(O*YK:G(E.>\$P]8+=68<'WWN\(\$S`$\4F>#>XG1%G4KA]7NF
M%>R);=CJMG-&6F&$<,G(<T&-6JCM1-?S;ZY#G(\O7^F6]\([9S#MWN,4MK'I
M6EG_<;$XK>;$S!M=]0D5)P^!T(+F2!MU*0\P!\-E;7EP'A>+.:B.=;6./#B$
MBI.'2(3UB5IKO&PKCZL%`7CGNO+@/"Y6/S1CHM92$`ZEX@0BM#K@V&Q+'BP0
M&7#Z8Y;3*X*G`7,R-(ILI<0TI5QD?S!<[[8(%X9W=FQ8(ZM%PH5A?!\;HP*Z
MYTZ$4T55AV-K8%`53`FH@:]6J?F<)CNP=&L-A.VXJQP=A\(=%?5H;+3<=>LM
M[JOGMN*MLN,.A#?H-Y-.5WE2FO?4>AN"%YF:7%3W25,NFBPXON?'=@![)@M#
M6WI7[!8Q?^I72E1;G`G=[`EF39SUH`XUP;P),S`*>/`U.;O*/Y/,&ISKPDUK
M,W]VQR%I%UX$&MM4YXQ.61%H?INC;ED1:)`;!1_?9E8@LB>MG1'"'C;CIBV_
MW7D0BFKEEZ-R4MKCJ%/GLVX6_`5U.;JV7[`&Z+D?X*$R<<)SJC?X>IE7K>$[
M8@'?M?R\WI#6?0A'W,Q:*/S2BFSN_.GLWRLW(+0).B$L7Z[GMK><>@X<Q;(H
MO:Q8-C\N5EW,PJI9GTYQXA!84F6L6MV(XX9J4^#.EL0Y@0*Y#^[,7I+PZN&4
M+/S0+1'*AI>$:LI(JQ;,!EKW(YZ^%9BXIA:WZWM4KW`2NO8I@V1)607&Z56X
M0)X7<Q\E\9%XY,%=@BJ&Y2?U+;?9>9"(5K!-6J:_CP+O-K1EJ)H'(O"H+826
M=>]7@($2;A8I[RVA4Z/60'X\8O<E(8$^HI%H"64=+@V>%VM\%?;&#>@4*1"!
M:E((O]Y>(!ES_@2@`>Y]NE7W@VBLE-T=Z..)L9%9RAO\'S'+?E%FB^]N]`@/
MV7\9=LOH:HTY:Z#IYE`'1[RV)8\6?8?72&5H6"N<TAT9M?+H9OX4@7S7>,W=
M%QW_I5<QF*.L319[9]_NP*T^UFLX^_2LWK)?ZGCMW<T=.J[4V)H=>A&!3<.6
MA,-A_K90!B=5(S)/5SE[&'A^M<`5^NP'"68NY"L6N>0^)71X5HQ-+G%=<2S0
MCS&<F(?!,^TI33?&DX%N#7<Y!><U4BT!?4<!\-T\<4Y@U0/=9WCIHS65+J6F
M7<:ZS?HR=75;QFZB'&GZT&F:(9VU>BN?$+MAU$=FWL]825O;C`HTZ"U+W2>C
MP@XZ+4O3]\BGN*@!O>#L:,0G%I8/(Y;8#Z'C;JRJ1>H9%?4(%3=N=-V<C'>A
M5)CB:UHAH[0AH<(T5[>T.H3"#L99S:GMFZ0<1^?&G!*^=1]N6\E_:CQJ"=,L
M89H/":58PC1+F.;#`"66,,T2IEG"-$N89@G3O!W#$J9Y<_,2IKFU;TF8YKV#
M#4N89@G3+&&:)4RSA&FN#=.\)61O75=IP1O[9`?DHQT2!W"(B1>R8M[H>^7>
M$AM7,#+RASY\FG9G2=S!@SDTC>U8"J]62XCZ`7=ARDWV*COGYJ`JU#D<KP)C
M"/%+65:&D.MC&-I$+;*2)6A;+@PN.75.PK?@8C2>C(>3+K@8U>9"3;D8;</%
MV##UH6I877!A-.B+9$P86_:%J>HCM3X7?#Q1\3BIQZII#?,GGYM`0YO0WFE,
MR+&N&U9WI(]JD%Y0__JD:^;0ZI#VBE#E,J6O3?O(LK3.*.]F&>"%.8ZZ5/H.
M%H'-2:LM:W\'2P`O\*+#R:>3!4!L/U#57L<LJC,<-B$=%;-;=:L0]MORB*C)
M16%`-.5B6$R<:7E,U.2B,"0:<C$RQFJ'LY-1OR]R@Z(A%]98GW2WPL&XJ,:>
M*AT8#>&F(LB5+H=&34:*8Z,I;M98-R;=CHZ:C!2'1V,`,'72K?%4OT?R(Z0Q
M([I5R&MKSLBEOR2<8D<E_)4\+</0VG>3T;;"9>![C_#S\NKN3!DIQ\KMW=7)
M[\K=S?3R=GIR=W%U>8M>L?3)@E/M5197.V6UP2"DSG,]HCS3AY]"A7@.<3AQ
M>OEZ8VX8KJ#XF;)$![S_P(J7_7#A('W._/!QP;,U4C"VX_;B_\X8ITB-.3JR
MS''U>VLL,#\`?)W21>E7<*S!\2H=.![46*/76*VS)RC9QG))D-K]$NZS[!;E
M_D69D6!I4XI9RCXA246X2-0#Y8[^L!\?`_)(282#8\R4X7&)1>IB-D/&(O12
MED/E%W6H']'Y;I"CN24W<MVYCC.A7J!*,:V\ICKN.\Q_PZZ?^P%5_&_N+`I2
M;O;*H`QBMU5,7:Y;ZE@U3:L@H=ITBQ<3'ZNW57!>KIA4KGW7A:#HC(JW:@@H
M>72/@C%4BV,O;J2X@4"JCCR:OR<JJ9`K+'-$Y^*:HJIU=%+90&GF9?/7^B.U
MS<F9@H6VEUF]QR+;VPRO&J8Z'G4NM#_L^8HT6@WY;Y1J5S]@^;N7C@!%XF:.
MUU@,^33O07VJO7RME`(H5L(S.,Z,0Y40M[Y`ZP4%B@[J$<=O=:@2XE<IV+F\
MQ"8G67^FH.VDLULQA)Y(1R!B0M]FG8UR:0NP=B1$+K7VM/DG][:`U]K-YFD5
M(`CARY!FZ&/.D?4AB.(USJA;2T/03`'J4'^JV$(=&N\BR]\2L^_>R?;?<?O8
MKK`.?:-T4,+:QZ:I6$>H-\+:R_Y)U3GA8GV0UFO=2[6O4Z_1`FA=EP3MK8I0
MB;T9;@*W6:I>WZ530T;_(I`Q1ISI-Q+8C^1R!9$05P_HF<ZD$WRT0W<&R&KN
M?+6,!+7=J]TI%#]50M.'@/R7"FP[LO<OM8YTC"^UX6BBCC3U%4BM&_RY$ET;
MZ;HQU%Z!U+H!P^-+39UHD]'(:$=J/^Z#N?L>OH@2B+Z(]Y*[S\2&")T/[!=[
MY.^_Y>]A8[^EK7%;A_F9W[0;^G3X6._I$UNUO*!/5E(-#VQ+\Y\+$OR);!<^
MX;A0TCZZEGN5]@%!7/SD9E.6\8W?JEK,?.Z4>/ZSZU5_<%/W%;^XWFA\-\-W
MF?RB$8`B;`R`GI<R\99QG&WF*B7`@\I1)%!",/U(SC@,R6SPZ'_[[>3B]S<?
MZ/I/=[RF-E9C:M.7"YSEOA5]:8$&0O'[(<2GGMI+\B'E+&XEO5=XB=#1EWU%
M':<?=C(OQ%<SGXXO18*M(>OR.7ID6/I`,]/Y>@\23P5)'I,J;)D;#B7CQV+N
MSMSE%Q9NZKC/K*K(/][$,Q^KWWF[I)*#-C[[,XS4F?YPPV3;@&TEI,+/>-]@
M_L9NOOE0"Q.7D?'WW[C4K8V@/%N[ZY>UC7[IP[WHES:R3*E?'/WZ1#PZB<^I
M>DV=9X#M64(=VF]$:EA##5/ISD9J&$?#3OQP24T_>TY"J4UUM:GOML?AR=H\
M5LU4UB;8>9JI8@RJI8[-@:'3/WH^=.]>%N3J81H$MO?(*BPV';2+^0^HD[&T
MY^Z/STMGOP,6NJRA$IG=&K`-SG!ZJD+)O,\R8B#:W/>@4N[6\__4<:)4NVO;
M=2Z\$WOA4OW:KVJI!S<_-3FSD;J5[(X@'8TX9W;@N=[CG@V,7BF5W'#W;L/=
M)_V2&^X^;KA[I6'KJ6,]53%VOGOA.>0'<>Y\/`J.4Y+9GUO9\6=1DK94J;HJ
M)7TXA^[#Z94VK85`]E2;VK?;&0(&!K=(?:JK3WWW"1Z8K"NC'^3VJ&?;(ZVY
MSUG;HW[)[5'OMD<]TS!IRQZT+=LS;>JU[7&0LFZ0X=+3@?LS'"5IS<W:O:J6
M/$KJP5%2WY1*[I5ZMU?JDW[)O5(?]TI]TC"Y5SKTO5*OM$GZ_0_;[]\S?>K[
MWOO096V"K/7QQ,2@`G.(.Z3>+P7)X+V=$<^FPMHJAB!^^>XIV&L@P79J9':G
M1I!=EZ8.LE],C:Q(C72I1NMJ]-W?GQ+%7=9`B>)^%:Y$Q?IZ?9OW#TC6F;).
M*LPA(-YBZ<4^B)?AR"P_I)PDC4=W6I14=66XOL]EK\LAG5.,W!#J7#&D._DP
MW<G[4PE--R9CF4RWEDSW$6QH$M@+LEJZLQ`<-<'"#]`]\S/IADRTS.C&@_L?
M$OR4JB!]9(?G(]N?-O3:%!<@*89)U/M-2PY>J`M)Q5G]Z(*16?U<0T1X5G]>
M!<PN56!3+?">*L#KW[=&'2=,,>2^]>#WK8)50AJD!VV0"M:&'IM9W4LJ7\%>
MKK&]66.[W:D4%4.NL3U88X6JA%QC#WR-%:H-O5YCNY64FEHC([G&]FB-53LV
MOHJ*(=?8@U]C!:N$7&,/>HT5K`T]7F-WEQ2[0O_Q7U!+`P04````"`"!A6=#
M7TI>>Y,+```S@P``%``<`'!L>"TR,#$S,#DS,%]C86PN>&UL550)``.B"7Q2
MH@E\4G5X"P`!!"4.```$.0$``-5=6W/B.A)^WZK]#U[.R\P#%V.N4Y,]RQ"2
M0U4&*&#F[-N6L450C9$XEDC"^?7;,C8QQ`;9L8@]#P$\LKO[ZU9?=//7WU_6
MCO:$7(8IN2GIE5I)0\2B-B:/-Z4?LW)OUA\.2QKC)K%-AQ)T4R*T]/N___F/
MK_\JE_LN,CFRM<5.^XD)-Q^1=H<=N)=IGTH_[TJ?RV6_Y<:E]M:"II1H]9IN
ME'6]7&MK_]'T+XVV-OF^;PBW_OHB_BQ,AC1@C;`O&^?EIK3B?/.E6GU^?J[`
MD[CIX)>*1==5\:A:UP"N]XU?%JYC\T-[\;-"W4=H5VM6]_]Y:"KH'#WYV?#:
MZMUNM^K][Z$IPU$-X:%Z];_?'V;6"JW-,B8")0O!70Q_8=[%!VJ9W(,V='N8
M*Z-Z$#>VA?A5#IJ5Q:6R7B\;>N6%V0&+;X2))E("E#5MC[-+'31%2TU\_I@.
MXT$6#:I]2FQ$&++A"Z,.MH7BOYF.D'BV0H@S8,5[[LI%RYL2J*T<:$<P^INX
M8%F+0S.^VX`Q,;S>.`!9-5O&9AS^KA'A;+SLFVQUY]!G.089M9;791$X7)GD
M$;$AF:U,%ZVH8T.''/RUQ7S7-S<8GG:+EMC"T#-WLD)@ABP[SX),H`7A*\2Q
M93J)I-I<W83&&^1Z_5C6AN@'LI@&6)HYIK?4V@K6>L0>$`X&,"1+ZJX]%B68
MLDV$LV9I2)Z`(>IB)*-&E>1%Q+"W#AHO@XN[/EUO(+R"+F\1-[$CQ2*C./M.
M'N)S;BX<.;!XUES,\"/!X"M,,"'+HENP(?(X`<NWY-3'S,Q-^BQ+\EH#SC+7
MV5G6O$^9P`&<90\:I]:ON6L29EJR'I1E;TVG7"10%U<11B'EYA@ZUXAR)..C
M2=8\W)G8_6DZ6_0=F6SK>F%$@I'ET_H:G,BK!QA2K1]I+VB1S`WWA)61Z8HH
M_X3D`;((40U0.)QQY"+&!R\;D:U,D47!,?V-["3\0E1#K@3/D-Y86\?+*![@
M=]`><P=NJ-7J6ED[9$CPO3\>W0Y&L\&M^#8;/PQO>W/X\:WWT!OU!]KLC\%@
M/@NH"C$SJXCV(J`7CN`.>U^#!4(XU/);.>8".3<EN/"_'F-P>Z55:[8K>J/2
M.H8M7-PN3;;PRKPM*S^:YL:KB*O(X2RXXB%<KNE^P?B;?]FG<<RB(\I5Z@8P
M2_#8W[HBVP16.PW%K/JDI#@.F4;/#9A?NG1]'E].+\A&7:AHO'$2\:^D/2/\
MN.+["R5MXV)(F_@.K*^D;1FP1S>"A=<TW'2M-Y9U7*G[+:ILN]XGRY!;H1.?
M"VVD5"2*+0(VB0A\X1.PS+U@=]05/_SK;$2)Y8O:J;?5J3$Q.]=0];LP\LW!
M*(8Y3%P*12+?";F\N@P*\XUPCB/$*WJSKNO*5'^.]#6T+"VZK]%&,30*QHO`
M*"$",9"^W>[657;>5U)7ZIC1LODJJA=#16+T$0Q.?`BC>S(=4>/W>!\RN1T4
M:5[F6VEU&H8RU4FQD)U*8U."0+.)(2E6U/4+<`;)+P+A1(Z,>`!*L]5JJLN3
MSE"^HGYE`2A61Q[S%7)?16(AF72CTU*7J,<3OJ).):4O5D)T&'SUL@"]H[>4
M*3%,ZHIJBY6P6'G.`S87V,$<HX/(>EVOJU/76X+O*)1]=S@Q=Z+KS%W31B%O
M6%,>#B((9V&"4DHYC0D70"AFI/>%\GSDJU#=JVDV3/BC-1L'0K&"?5!\3!'X
MS^W!4MM=0UV<CZ9Y=7U>%KU803XD/!0=WD30T<($`86A+B>_1#Y]7(D2I6W4
MU`T!I&1>WCAE]1.8Z@4$"FNG0N3659*;#U9@G,S%"A9]NEYC[JW#$<,:U)M\
M1T1,O5?:():Z@9UXPA^L6$E(BI7NA?`(30<(N[U*^$@X+R*3UX3$:'>;ZO+5
M6+(9F^E9M<0D.-$8%,PR*7F<(W=]BQ;\"(.VP@GD:*(?H5$)\8N5"TP0$0OR
MP75ZY=2$,NXBCO=K8^"JN(#6&X?NQ(70W"6+@:[1J*N;U\V8VX^P()6`%VNH
M+;2TYZ0[M8UF1V$J$T/V(ZQ!"H/<YJCR8$34&1&9>0QDN8V06<L?-622.^5_
MK9[*_@"_Y1?+M>46R\WF\/%],)K/M/&=UN_-_M#N'L9_OGO9W-G].HF7ST5/
M,$\0J,4>$LM%)H..O?^LM#J&NM"8A)/T6?U@N406'R\'+Y:W`6<*8(Y)-.U*
M5]?5+35(PDD6GOU]F@XZ>UK\<NL"(ZU$3-F"+!.7/F'H1]]V/Z`3#HF8(F2B
M/.]9'#_Y?M&H-]2-/\DSDA\320E>[N)$&@OQMY:="ME2-](LSTCN+>02>,4J
M3&.$O,/$)-8;(9OJ`HT\([FWD$O@%:M^G)A>B<SFM&<!5"Z*77H+XAD-=<-3
M\HQD82'O"JZ'48ATV,6E(>5\6XA88>]2"R&;W0&.WL!+)%X-HZ9P97HR;G)G
M*VE0C(LY.3>80[>8@G0NMJ!N[(MA&K'OE2.H'&_1AC+L=8ZNPN'.A.SDSF12
MX1B7R>;59D)]8LC85FS*&R_%M"0EWDPF("H*/F^;(JO4C68W*A1%[5!,^&R%
MZI=+NT)[8-)"4JQ"-RRH)]C88X<-7I`K3A"Q*WJSIG"V\R+]7)K$9:2*5:J$
M93L9T`=YNBKGP^(IYU+SY]`IU@"&=^S0-],;7%X+/^8]L**WNC5UW3V:J$)-
MRXW''!;)7<;$5W*K&$J&[,1%%MZCMJ9@N'_OOQ/;VQ4Q7&],['I5$L2P3M0X
M9F18EW]N;G2;$@I?W^UBZ/OLW+P_%>]G+=Z\N[J!ZP2<Y,9$TJ+GVTBG&#9R
M.@@W)&\W(59TO:YP^;X,"[FQBL1X^>;0+4CY]U:^T*EF()BA<+_F6=HYMH`X
MA(+BKU98W9]L41+1T;+<+;*/UH)`.J!R_V<:IG)L+8DQ#<RH((,(=]0%_LA^
M\8^U"YT==V]B\D`9^T$`"D<<;E71:PV]J\QVDK"2&XM)C5_1!J<E\BNQ_\'%
MBZTWMN)E60KG,Y+RDQN+>1^2<;.D.36;MP[U9%N"\)T-=69RD7YNS"(94KX9
M-(L19``@$(^ND?"''@;J=A(=T<J-=N,1*-:<0WCT9;P\C,7N#Z]J=A6>JG>.
M<F[4+`M/[H:;W[NNVDBSKGH\&4Q[\R$TR')=]=M#[!,OK+YWH9>")2S%Y'"M
MW597+X4HI5\7[0<(,,R6KO"<E8!,%KWM/,)!=XH4K%@.T\OQ1"G`A.?WYYNC
MHE_D6/WIW=>#_BS?N7-?%[9Z,3Y>!EE4NV&HW*D>(G4]9<5*6+`B,]]Y8G3_
M#O*#(\:;"D\HC:"84?YS%ON#8[@@<+'<\X@2>BS089+(,"+]=$;6%T?WFJJ4
M$SZWSOX""G(],\`BSM$6RYRGB"%HN[J%4.#0S>'%1(^8(.0"%KZ"Q3&)(J!'
M#>9&)B()'IR%!2?375JI"[;6\QX10,414Q#V&A/,^/X=&8=.6VM%*C2C2N4\
M]>MK/0D<!<N#`H,&V4(V?1"LV>FHK/+.T,Y"R^_S4:=]_C)$Q?+@]ZZY/TQJ
MBO!ZL779?EACOUP!V>/0X<0>.E&&$.G!$SPX/UI.BT;^//O[!M@:-="G5M9N
M,;,<*MX>!3^&HY^#T7P\'0YFVJ?@W40:76J'TY"UU[?M?=8^^>\F^IQ@L"WE
MN_P2#[CE^83J\PQ/S>?O)@>+-AVQ#J`3N0XS8\[#-+/HJQ?0?W/(=JS,Q7*U
M!WG^I.ZO(?&6BC-/H+:Z`X"BB7Z$%N.ESFW%=UZ-=R()!"=U3ZGM":2K7/P6
M1?0CU!@O=>[VL;PW!AK>N^Z.8F!_#$%P.A]^>QAHH_%\<!H(]Z_IT_QD0WM]
M45^Z>/CN%P*FB(Q'#P8%MYKJ)EE/J*6/C\<3H6*[3;`5;S\7:M3UIO3@PX6'
M9=/K+L$</<5[7K*B.=(C#(1H@Q?+V=IB]CLDM0"GH3)"RK%Q7;6G`B=W^5"L
M!_;_0_Q9F`S!E?\#4$L#!!0````(`(&%9T/C<K5#Y`T``$BJ```4`!P`<&QX
M+3(P,3,P.3,P7V1E9BYX;6Q55`D``Z()?%*B"7Q2=7@+``$$)0X```0Y`0``
M[5U;D^*X%7Y/5?Z#PSYD]H&+FVM/;6?CH>E9*MU`@-G*/J7<MFB4-19KR7W)
MK\^1;`,-QLA@@7HJ\\#01I;.Y9//14?R3S^_+CSC&044$_^F9%9J)0/Y#G&Q
M_W13^C8I6Y-NOU\R*+-]U_:(CVY*/BG]_+<__^FGOY3+W0#9#+G&XYOQ*_:9
M_82,.^S!O=3X5/KUKO1CN1RW7`;$#1UH2GSCJF;6RZ99KK6-OQOFYT;;&#U$
M#>'6WS_SCT>;(@-(\^GGI?=Z4YHSMOQ<K;Z\O%2@)V9[^+7BD$65=U6[K@/5
M4>/7Q\!SV:H]_[-"@B=H5VM6HQ]73?DX[WI^J8NVYO7U=57\NFI*<5I#Z-2L
M_NOA?N+,T<(N8Y]+R4%P%\6?J;AX3QR;"=%NW+Y)5;VZ8G=O"_Y7.6E6YI?*
MYE6Y;E9>J9N0N,-,^B`ED+)A1'(.B(?&:&;P_[^-^_N%S!M4N\1WD4^1"U\H
M\;#+%?_%]CC'DSE"C`(IHM]Y@&8W)5!;.=$.)_0'?L%Q'E?-V-L2P$3Q8NF!
MR*K%$C9A\+E`/J/#6=>F\SN/O,@12(DS.R^)0.'<]I\0[?N3N1V@.?%<F)"]
M/T+,WKKV$D-OMVB&'0PS\TV6"4R1X^K,R`A:^&R.&'9L+Q=7R[-#:+A$@9C'
MLA@B%R3Q&,&2PF5Z2YR0DV;Y;L]G`("^/R/!0I`H091K(UPT27W_&0@B`48R
M:E0Y/+<8;NBAX2RY^-8EBR685]#E+6(V]J1(I`07/\DWZ)S:CYZ<L%C15$SP
MDX_A66$#A!R'A(`A_VD$R'?DU$?MPB&=29*\UH"RPG6629KX7\9P`&7%"XT1
MY_=I8/O4=F2?H+1X-&U3D4-=3(49!9>;89A<`\*0S#/:+YJ&.QL'O]I>B!Z0
M3<-`F!$)0F;/BW-0(J\>($BU?J2?@HY?.'"W2!G8`;?RSTA>0([OJQ;0ICEC
M*$"4]5Z7W%L9(X?`@^F_R,U#+U@U%$C0;`=.0G;\=9/R50`$@6G5Q8MJW*9J
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M7TX?\3W]'L^-D2#1;R8#T-&"^,*+>Q#8KIBU3EL5\3NC21&^AJ85)"S,`K+(
MHP)&#O-+`H"(R-7R?R5C&6`(UM@;3("2$5(@D"PY%>O@/YZW1SZ"(J:AB92F
M+-?%T>@C&[M]/P9QS$6CTU2EM,R!SZY`23'$NKS24Y=C[K3YR.W9@<^3^@GU
MK>:5*BVF#WEV]1WD/%9<74_%K>R+"%TJ3;-5KS35*.S]4,<_X5?];"F*6J^8
M<@ZNE7.0-G(!R#N@C`1RL@)0^/@_Z)WGQA\X::@/7P4#C<JU8@VNABL`AQO:
M4DVV_-211-I^L>^@;9O-;7A%/OMGQR/@P]Z46!"B]44"X?XKZWFB)W#8T5.4
M1BH0DSLQ]ZD85&2XBL4@^'WO0H&*V:[7E!G=W?$4@C'%VF;SJ[>/),(V.@R9
M*)$`7P%(KS5;RE2U/=R9-97%K>X^$8"L3VF(W-LPX,LC".AS1>9Y@%[$+Q38
MN5(7HDB1<(&IET<JL9(;'TK)$6S?\=,VSZSE+1JT4'.&7&(]-_74L^7^)Z1,
ME#Y,R9Y86S#WQ1:IMP5?CA"U![W%TB-O"`F)C,+`F4.+44">`GLQ1F!\*&9H
M@H)G[*!(2/$B!K^YTNPTE7D0%^+IO$"\O.)B8+?U!';6\UC\-A3$T=XK1&H8
M1,3G;%VA5YN3'"T>:W+2BH'0^5!`B)[8>WE3&=_DI4<+*$C**\;"M9Y8&"#6
M]QVR0/>$@I&N7[64N:COACJO!O=RF:0D/F!@$5V^(T%LF(2+U5"VZI:+%"WF
MYV$I)=K7=+TK\[F3RMA5[2+/:#WU+R&G!`":)H"D/=K';8_VH-<J)@>XKHW+
MQQQ'$J]I<'&Z*F)0MO3$I,1:4DO7Q;2\!2R*&#F^@$42SE*J29!]B'^5-2&9
M]6\%(K+SO2!2$2,71&0G%R([JE=MLLL&-R#Y4W6+?[`AOTM7$S9R5A-.>#GA
M<-0;6],^-#`^O=N)55S1X.'=7OD+!)/D6F3^TC-PEN?%VUF'LW5E=V0JNX0R
MNK;09J?65+5L7C"M)RS3KLK>BR$I6HIO=$QEHE-"<1'%68KAMPI"%&OLNRF>
M4*(05:7&NCP/XC&0NV<!(]H34VE>F]?*XCDI$G2=L6DA75Z9ZETM$B4XUR%M
M+![A:5WQXE)%OF/&N,?C?4^GL2MXU6J;9V:G,)<XCYH2I,I*XSRAV@''^#20
M*@JY+P72\[)S/I"FY!%DI7&>Z.V$?(($(XI,[.EJ365HC"@"YN>6[]ZB9^21
MI0C)(_N6;#]HJMNP)3&^.LSN4=MZ-T8>V>B]/^HK\B%T]X`5RUV`I"B+-G2_
MY^:JT5960BI%P<5TG5<^>OM[W,L=SB:VAY(M1.:5N@JRG=$NIL4LOC4O$U:7
M(E"U?^EB29WCO$=%8CC5>SR0)#\++`ZX:5LR7!FZYD5W@IV29&_4S)IIE(U;
M3'F2+`P0S[GWOP[Z=_VN-9@:5K<[_#:8]@=?C='PGN^_GQB?XL-$\F34\YS=
ME#M[;@4!W\0O<O-@N`8@\O65S5.'XF=A79T;EY.4XZ?Y*!;Q%TRF<[#82Q0R
M[%".W&!)HL6)Q%C7F]>=78;33G_)T6T!D_I$O26S]3A1Z.VFCF;PP`KVL9#B
MFZ9K<U\O&BE/AE&]G<P$?_?,34AOFQUI'6W?K9%NLAC3VXVTP,"XV`MYZ#)!
M3@B4@:'IO3I>"#;E#B3%W860Q3Y"<LX`>`B10_&6WD&T)-]65KZCD.P3UE52
M^QS8"Q1'(<V.LISDH;&+F"SG@\IJ545:HMH7%JF6GJ(5C(\[T<XJD`\UT5(6
MA>0EJD6]U.GH4!76%(&.]'S/QM8@<%7&B+(`.\F",UWY@JV:K$,EU:,R.._7
MQ[M*_#P<ZQVI3!P$WB4FWWRZ1`[$^,B-^6^T6^JV6NP;]91RLJC+Z0O9T$%*
MIB`===MW%Y+TDA7MNL`J@P>]HZB$]*&/-DA/64;,%/_J[HN*/Y6'CS&-IR#D
M3>)33$HV_M?W7W8&I/.A=]2:$']'PF"#]I2G:*8.UK=?5`7I7.A^@$F<\T^8
M2(KPE46XJ2.>;L7VJ$L5$R>98\G]$9DJV09?%O_:!]49+*O>I7,6%*IBXC(H
M3(D[9?C7/^*<0NOA;".9'/%<[[14:3!UQ!,2*D?DP57E5Q0L#&8C5DY[JTS)
ML:+2OYXV0Q"*S*$&,%:5C]<)QFF9]6-%I7W%;68%Q?UJ(P?WM%,.^DV/%Z2Z
M/,$+R.H_JL#AY*9LM\M/;F%G^!XIYI7ES\7S=[-A+9?8)*-9Q>@<A/P),)Q-
MPD>*76SS%^Z)H@-9`M,Z.#<"T\YQ.L"7WBF044`<A%P:+0=Y\`NO"B$!K9B-
M3DO9*T?V#JN!0J5$HG=:Y0%[B#+BHY']QA]:`H^RJ<7MFS50218_>I_<N@80
M?D8;WA*`;(:96((:H0#"5_XV<<Y6VG',J6K*U;,&.CQ:$HG1KNFJX=6[BT9V
M,`Q$YB(ZZ"U92J^TS;JR#5H2XVNA_3Q2TOP0O!,K*ZP%EU^E53.5;7HJA$(-
M8%.TI#4_7&]#7)-PN?3X@4,++(YX&R/>.S#W`)^+<!&Q%OW.Q.FNIJGNC1E'
MTZ4!AHH1JN8GX&TQ!A/@-V1'!<2R#L6>/G30X&'N]#[1>(P\;N[`\K&WC:Q8
M!#<ZG&U<JYC-=EM9'4\.0C30^Y%BT_ND\WOL\)V]EN]&L+:>`A0YPH3!)[:]
MNY"%01+JB+UV0W^`8D<9Q-6NUV7+I$X=3`,0%"DOO5^&D+SE(<+WE'Q!$_!K
M*%_-G)(Q<A#?%^Z+K83N&#_-!6_MZY33E=)WON3N7@/MGR83S4OP9'/7.UN(
M5>;K\U9(J'Y-9>X*B1,`N4?H.V\1W".%C_"N2M6[`A3!X=(;2-2!ZBP*4?@@
M+`R9&2O/BD!U?-V`.C@<DL)J.>DCGX+02#D%83KL_L.8CJW!Q.K&!PH?<_`!
MSS!N%AZ<>MA!U[,IA!JBW[6_8M;,CJI3:U-'/*4V,#G*0_3XY4WTGQS(<7V&
MPW=WQBU@BLFI9?<@W"P9?#?5`1G"4;4(43!F__\V,%DM%OI",%T#XXT5^3VL
M-&M-94FS@\.?7=FY!*)W.BP;MZFG30G@7N:M4ND$:3;9#PIM-=N+]R$+0$2$
MY3[X9Z\\R2/83%Z4'GT*E[C>KBD[%T2.A./M6U;_/`"(-R_4VZ:R?5!R)!2`
M["/5F4`]MZBTWVV41R"*=D?HA.\+L'@Q?*=L!,DM*OWW,>5A29$1+U#[J2PF
MIV)&>QY0_-?Z)+6.[`&`61TI!F>&*E9OO9)D4^^]]KU=NF77S'J:*F27%<V7
MN@XE8)0?%GQ<$NID`ZZ(KP(-N.Q!P(<5)V/24N6CR;K9OIQV?)U_\#>IPI7_
M`5!+`P04````"`"!A6=#>"0D\?A,``!C'P0`%``<`'!L>"TR,#$S,#DS,%]L
M86(N>&UL550)``.B"7Q2H@E\4G5X"P`!!"4.```$.0$``.U]:W/C.);E]XW8
M_X"M_=!5$4Z7*$JD5#'-6:4M9RG&*7DM9?945&Q,T!)L<UHF/225E>Y?OWCP
M)?$%@`0$5T]$1[53Q.-<\MP'@`O@7_[U^\L>?(-AY`7^7W\P+@<_`.AO@YWG
M/_WUAR_K#[/UU6+Q`XABU]^Y^\"'?_W!#W[X5^=__H]_^5\?/ER%T(WA#CR\
M@:^>'[M/$-QX>U0W`C_^\/7FAY\^?$A*OH;![K!%10,?#`>&^<$P/@QL\'^`
M\<O(!G>?:4%4]>^_X/\\N!$$")H?_?+](=SOXK_^\!S'K[_\_#/^YV40/OT\
M'`S&/].'/Z1%<=6LY!]__''YATG*&M/I]&?R-"L:>54%4:/&S__^^7:]?88O
M[@?/QX)O(:H5>;]$Y,?;8.O&Y&T5JA=1F3]G$M26P/_ZD!;[@'_Z8`P_F,;E
M]VB70BP)4]W)#^C%`4!?71CLX3U\!/C_O]POLMJ/;O1`:AZB#T^N^_HS+O#S
MWGV`^Y_=[UYT#1_=PQZ_1]+,<P@?CU]XJ0'\#7^&^SC"O^#6H@_DLPZ,1(K_
M7=%N_/:*^!-Y+Z][]$I_[@A\^^SZ3_`6_XVZ'O8*OJ;M?@5X#-VG%^C'U\'V
M@/^?T*I7,1I[D",,>6=2A#AJ62:53(E4,L4%.#4!4RK!#KZ&<(O-</VK/ZJZ
M#\/3FM@"3;$%,BR"N:9-"9BOT7]DX"ZUVQMV'SZ)O.RDVBGBJM;ZAGH'0R_8
MS?V>,5<W*P?\.G;#!M,B#K_<<-\";(+8W?<+O=QDWZ"7L.>W?=I@[V\9A;#<
MAJ3E+9>:[!&TP.N-RSA9WRGQ<K?HKZ0D;K$AM*2>D4;+A9;A]QCZ.[BC$6?6
M=K!-2I%>_OH#^N$_9MMM</#CZ,Y]<Q_V<.;OT"_A`1DZSWU`(X38@]'5(0R1
M6Y\]1''H;N/+T7!X:1B7MJCWQ;^<.M_D9Q$\Q[+O<=0?A.EK/7JQLS!]`X]A
M\-+?"X@#U);[(-2684Z,T?AR.!B/;11S!.$.AFA\]P-X158O].*WO_Z`AGJ'
M"(D6O.*HT,UHY(;;%GXD)7[>!FAL]!I_V)=9B(I4OJL3JO0C'3NIXQJ=#F$4
M'$(RT'O9(W1X]`O]#U_6/P!OUQ=.)VT"O-(V`!I4`Q>WXNZC7_[EY_S52-4P
MZY]=PZP^-,RT1O3##O]TZE44C<-A*%.K`KY<I^X*.I4T`0IM7("D%?![VL[_
MZZ1QJ_@9ADF;EV-K.E#EO(H=]ZI"S1+5Z,I1)6+O)O3;C-^36C1)<0[OTH#'
M(<_ZIZX*KZ"6NFUF_JB2:5OT#8_>+6^+(B@VVW4X2N;Y`I"BF37NQ.--Z.Y@
M_M4M92:XV'&O/&Z6J(;'1Y6(L;#I^[??$Y6;I#B'"6[`XY!G_5-7A0E62]TV
M$WQ4:308TC=LO5O>%D50;(+K<%288%*THPF^AUOH?</M+6%<^.QCZ3:XJN=^
MF,PFTRF5*VMA@V$F!F/Z+NC,(H92.\P`*.=VF!7^`#I8YT8&2#7/9V)UK8&N
MK&6BP)J\^LG[I711!E4FN@U(SN.\Y`5`946-=!3!.+JT!F-;'G%)'QTI6H,S
M(R-];A@FG?"9#/3F705<Z10K]^G0WSI19OI.*#.MHPP.V`WZ1HQW09ICP!R>
MMF8QF(,[1UT[9'49N,(<RJ9IK:'$4<U15WU0JA;V,;/RM1UC0%=V)IHO`#3`
M5F.<*OM.C)3X;'SE1Y,S\)#.M?+8XN3%X:C7I*].\]7<1N!JQ@]-$)S9>CW?
MK$6XEL9MUF`RDFS7^HG_FU$?4RT;7QG#Y%UI/@]>CUJ-4:OJ.K%IG8+VT^\E
M,1"3R+*:L.QH.I7.4$TT7R=LPJTP2*M&D,1JVV1E6SQF.UUAMPQ+C8GKTZNV
M"5')Q=Q/#*93^EXUGWYN1Z_4`E9".+6$'<.\FB\K,=I31\^:V*\JE<Q,%%_S
M=3T6_`HCP68DSM67^_OY<@-H8,B9A7?E1L\S?X?_;_Y?!^^;NT<]1;/XR@W#
M-\]_^NKN#_#2FHQ,:7QE@M"-OX)2IH1FJTX^2S(\U'O%1$@>)8070>;@TB1K
M;HO_@'D]F:H@);+03A5*H0=;]:$QH4M<$[W7602DD1V:\$/*^4_^*-2Z`&X,
MTHJ`U.14B>#EQ8M?"`*$*?!CU!#TMQZ,+FUC:,CS"?4==Z0_CT09Z1LJ85MD
M46<\U7N>GD,*-;:>&8]SM?K\>;'YC*(<SHDOEL\MQY*?D\!EJ]U0:6C9U)1,
M]5Z;9)9!NH5F!.(4"E+S7"S*RV/_&PQC[V$/K^%#O$0O-)E/L<WQ1"*+:[KM
MRF%F:7(&UU4QAT/=[6XS=/E\;>S?*3P'N,`%R(OTS5))P<*96%H1*-15,<8#
M:X!,@SV>&)H/#EEE4!0DL*$Y8K$?Q+P&]AH^0M0N,N=1C!RI/96WT?"HJVX4
M;4&=TO*XF#FQ]#:857!E&\F*/IWT-T!^%#>+U5])BBF4SJV2R3LN9HP,:S*F
M2JGWT+\1MQ+3UH3`N9[?S._OY]?@ZM?9_:<YY[`G;?H>?H/^(4NJMZ>F+9UZ
MQWWVP\$V.4[)>%*>K#G2I9VIWMDG;`(HI6<CE-Q&AK28H-NM^<!2_:]"HM9Z
MY)/RYG1"4ZJG>J?DL<!7Y;$;,.3L3`H))K:<=%4<"4S'\M+V:KOME:M-TM30
MM1B%(W,PIOE#4[T389AE.(=UK473LX&M^-@J;*PZZK99VN+LQ]1*7K/>F8*,
M$BBVMS4P*DQNAV&3Y\/=1^BC/^([!(JF0]P$(?Y'\GM4`#(9VB.9UI@/3F>J
M=Y6^H`*<39$@+W&C>N?J=)9-E;7OA-*Y^;*\7H/%$MS/UW?SJPU8W8#YY[O;
MU6_S.;A??/IULP9?[E;X^69Q/\<K9:J439;_>!_*5N5O.)L:F>E*I]YYFQTE
M4^"?.L!SDNH@*0=PG0N0[/%Y#$+R0_JTPV3@PD=N$7'S;0EQ[OU$8B)HL:MN
M^M$".N7^<3&<I)5,%.B]XM$$6XE[:`#@I,^XEXRKOYD4:RV;:"4C>U1L:HUI
M+N!4[QGG>M"R36-MSQF[WLAF?3Z"%<XFO#2&AB6/7X6>NM&K&7+*KJ-2@^3D
M.FN@=WI,/6C9[*KMV2D\Z8%:4C:2R:56:1?942D\T3.E+TOO!=D&U!S^47P'
M67W_R?ZQ?0]$F_F[=1QL__X<[-&'B'`:;?R&/Z4I[^R<MNY[HR2K<!4\K:DZ
M,*86_0IZ+U5P2J+06#+`*5I0DD)("\GBN&P+>U:.-]GBFJHX"3GY%GHO&_.*
MHMIJLX`JFW+@PQ@$CV#KOGKXT0X-O;<>]+<]*T!^+/=`31#;B$*N/M3+RJH6
MA>VRAFW2KZ?W`HJ@1.=V!=6P:ER"\/YD;L)(F:K25#E*,USLWPS/WR<?3>]U
M<5&1E,R,"8)S;A>SCXO;Q68Q7X/EG"R77,WN%IO9+;B>WRRN%O/EU6_"BI+E
M0@V-H1*'T4N.$I,`%43/"@\&TQ%]PWHO5+1B5VC9*P$4;;A@2E+3QY0=QDMG
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M-K!`=M!['FXWA;Y5'P*;ER']$N]F:;!=#M4!<"LBYW:U_`0V\_O/7:)@9/8W
MR.J?'B`QM"7>+E/=:4<JLPJ2D;BF@C$8CNDKUGSEC@6_=)/,`,+!A3Z0T((>
MH3/_OMT?=OC8O70>XK,;'T*1B*/EH\NQQV=@;]D$UU3`%B)Y\YHOK3$)H,;H
MLD#)(HHWX/D`O0(?;O$+!']X\3/Z]QZU%(0N^2EXA?0O/C:3RW/S.\*BXYOQ
M+'GVN+[C;JSF$BAE=E.EX=A(/HC>JVS,,LBVSZQ`Z+WCA0OJHBXWU+%\=RFF
M^9Q$+IGHYDKH?_3EZ[U`QRZ$$E/-#"<AM,BE&7?0C]`KG_D[TL9=@*)O&'LA
MQ*=5HE_Q#_#E=1^\X1\*>^JBFNF6T6@H;S=HSVB[Z8G\5Y<J5^\]F=:$KBYH
M?C:77,%E^R.IZ)VD=9+Z1_7_N`/RX+@+4-S3BIQ>+_/VTM1`BM/\Y[`@)??<
M/Q71<(&NMVM^BJEDR94$`G)E*`SV\/9VVA"$(/2>GN,('%Z1D<F[XS0.(1X>
MQF\8#$:*DS5?<3-D6^]X:,B[.:"IZXYJRR=4IH.-U<R18=`M$)J?8LTCAAKM
M8`?DW-VO[N;WF]_`;'D-YO_WR^(.GY!R@5.#91!;3A!\9F*7P]/&:J.I03,%
MAGHG6W!((3UP9(;BI$4O2$P79QM!2'&!O?SKV(V)G5\]WGB^ZV\]=X_<BX<_
M3;8T,S9L>?1F0="-YF(RIFQGJHT][)!N3A[JO>8M(HYL_@M@<JY6R^OY<HT/
M2EXMUZO;Q?5L@_[Q<78[6U[-P?K7^7RS%EX1K]JT:)L#>>O@?6^/91(@IWCU
M%DTZ^!SJO538#EY)5-(*P^FZ#ZGIDTJRS.HX66%VRX4G@]0`Z)UZT8I=OD%M
M!N`4"_PEW4DZB^/0>SC$>/(9Q`&X<_EGAV:[_SQ$].JC37`/\>OT]A"%)0M_
M&[S`VR!"O^/KZE`@\\W;P=W'MR\1W"W\%5U6])]FV]C[1C?^9;Y9HN&5`;B;
MFBAYA=F5O3(Z,\SI8$C.L+0TOUM,A?A*W(\"09Q"'R#$MZWBTWZ1G0C3[LBY
M#7O4%?X5_TWN947?>8?3"H*T)^!F77$F=,E4#3DWQO]369?R??4R.K.'='Y'
M\[N6I<LN.XB0+<"1/4$&(^L"SV(`V@GX$7?S$WY,[KA-NP(/;^#'+]2P_`2R
M#D'>H_#0;_82A+'W#Y+BE(U'_2=Z6<]X*O'LXZ:>.RH]ETR9]C;5FH[TCL';
MP4O7GS8$3K$$/N\H*T,O'I-YBWF^E>Q/?8UY+B;?/>8X\DEV$>E^N;.(/.S4
M1Y;5"W;KV`UCL<!4!)^3SN*1TUO6OY+5&_('7L+Y.KO%]T&#V09\G']:+)>+
MY2=<\FY^OUA=2U4:XY]#:8P.2D/G&#2_QDI('EZEF?L[Z2J3H6-6F3GZO5=E
MN2/"HG`MA&X$KR']?T0F<R1M'R\/$AF:PRISL_[4M$(^+(V2-;^@J(M8'+,B
MXEN$.P!T\.EAB^75_7RVGN,+6&JU2H$2R;GC76\E*M\$S]/*<#BB^?^:W_LI
M+I3LX8LP,H>,U'%B`OFC4/D"T.H@K0]^3%OXB5^+]C"*YM]AN/4BN'HD*QHK
M\C&CRZ$YGE0ISNO^.]&&P=0<$%U`/[2TU9WY7#B+9&^H:(SPP4?TC>N]%8Y/
M$!6D9D;CI*5!6ARL'@&I`)(:<EB;GS>@.6USH!R\-9(5!;WW!O$)PL[;7;`]
MX"E/,NDC@[\Y*FJ(=P<(\)<%#V'P=[IKR(MBN`,P:2/"4T]9%G!$Z!TD#<KA
MM_U.Z%U:+65Y_?28#LVO=.,31,D*)A<D)[/(B+L)6<%3Z/HQ79),Z<Q]:>YK
M"+<>T<WBY"R*@\B%<(N75]<+L?H2DE0=`5Q)9O9VNQ&[$_[\(D/F1L@",4U.
MU?P.+G&A9(<DPLB<8DUPM):`ZM(;#$%>6[XF,(4M.JM".9SA_3AD^L#6_,8P
M<:%4A3G"")W-,P3NTU,(G]P8HA#G%?K(2>`,E2??^P=-1(E1F?3(+#I5BWYR
M8^#N"<E00$1*!!&YA"1&`#V<$4>W6Y.!K>>?_HI\#FTJHFT])#LO2>1UH'X*
MMTJ+7X+9/@I0,_BLF+2_9S=\PN!=ST<]0S?T/?\)9]I$ASU9W"9MX:)_(#I!
ML`O^(*N&"8+TJ1>";3)1#+[AF6*,C?[^B%X:_8TSL!-1)I8@3V=C4'&;-A\I
MZ88[S:]`%1=*25`H#._8.6*=/5::1^\[,@8B)RC,'Q_A-EX]SK\CC?6?X#VR
M&"N_>K;L<FH8IK3451XDW?2GF\RI`G&U0F;CQ]2NZ[V8V$4L)4K4`:`SO[E)
M;YW_]ZM?9\M/<W`_V\P!_7L-5G1A1($*25D#T5R%2F,SKE;&HU'R(?5.81$7
M2O;83!B90VMB3Y/6!;@R0,ZH=GF$3XEN@A!Z3SX](6C[M@E=/W+)J6V?4`2)
MTR:_^"%T]SCJO30&(V.*&34>RE`C'BS=U*BKU*DB\;6#0XL)_;9ZK\AW$8M!
MF:94F7PRNA+,;ND`T<EVAZ8CNPC\Z)%$X9\NR(:#'U]0&_LW]#A1NIV'%!%W
M!"/.)48QIDGQ4KJK5\E-<35CF_:`?F&]E^K%A9+MIH21.4E-D%8%A;H`5TX2
M\"]`W@*?&IVF"BS\V78;''`J@?N&=QKBH=QV&QZ0/2G>]FV8`WFW3HJ!ZJ9:
MO;V(5,E$&T0FU4Q,JMYS]OT(J&2(U0M4)T^+V:5I,7B^TDV:`J^T+1(\NK@U
M=T\=8'+B='[-!:>OZ\I-*5[O/2IIR1,*-CB9&(F1UCM+H@_Q9'O''C`Z%0EK
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MOLG/+F^]'M2V03Y98J+TWJLC+M298G]&>,X56:*/3LX&S+.L"W=U<YX3*,`E
M17&0-KK#$"#5MC&9C.G4N.;7<(J*I#YT8L)5%T?EQ]\EM87/ODL[6/B%Q8N;
M(*R]H`"GRT^KQLZ5Z?[<S?>C%5VD.=4.]K:PL;.2V;_WL8@G+)LJ?1$%F"O.
MPB\NRP'4!D@;22[4F!4OU%"F/4Q;Y]Z/^I0WT@E^0IM^PO>Q?"<L&[O^=-M6
MUQ7HT<"F$)V1>\1>LYMI7K.;:6#6D#)-8MEV]GX4J7:$P_<)DXP_S6__["R;
MTO&.*$KG#G7P[-(MH:G2'&L+G[+@:X(K3F'.#I/-ST1&2(9C>9MIV(%TTZ=.
M`J>*Q-.(84_IY([F5YH)RR0[@!,%YN"3P!L._LX/3,Y;D*\\4HZTU%EY2N=9
M<C4R'8SIPJ_F%UV*"\7A=\3/LA2&1Y2(W,3Q6E"BQTQU7.FJD\UFF*.IO%TR
M_'A4:5*]_/P*E4^F&K9%YU(UOW&PLVSZ>*=J@")>2GB*K@/KI"P/O2.M*PVF
M1#X\,JVC)#[1.U6@NW!*AE.=83KD/.:;V]7?UN#F?O49W"R6L^45OA1@=K59
M?%UL%O,UY_I1#2B\Z!O%I2!I)&\!B1V(%*UB$[A%G2H;,6P[^8)ZYR,(RW0F
MI]4*K,U990WT/:1JY)+*(946RL,ZI*IN!-F_)+S7>P%67*AS#JG:X>5#JO1R
M0R]3FYZ'4Q5@\L!F/!QHX'JD!G9<\O,K4R&BGXSH'.U0[W2@SK+IXYFJ`8IX
MJ+Z'4RRL4SF<TE'K6(=3C1\>F]7DR^N=)-%=N',.I]AAEH93B^77^7HC8SA5
M<4\H#I`L>=?QL@.1HE5L`K>H4V4CQL0VZ!?4>XE76*8S.:U68&W.JNIJ6OG*
MHW(XI87RL`ZGJAN9#LPI_:!Z)QJ)"W7.X50[O/)PJNJN>%EJ4PQLY&T#Y<>C
M2HOJY>=7IJ.(GFYP--]ES@2[;/IXIFJ`(AZJ[^$4"^M4#J=TU#K6X51#6S:R
MJY-IDCYCOLML"Q[ISCF@XL!9&E&M[N;WL\XCJ@4Y]Q2?SDC"H+%,SY7WU5D]
M&F$7J%\L9TPL.CXUM<]TJ(6MP$W4]4T\`'V8'.<)9G$<>@^'F!P\$P?@S@U%
M\DZK/F:>3_B^2)CCKF;AV+0M`X6LICT::3],J,?-SL/7($)V[9NXW:P%00BY
M1[_S$>[.?</9T4FR]1;"772#ONH*GYE4N68S,@?R`GI.--TXVUWTE-3<+9GF
M.'%E>J_4=Q-,MGGNA,Y):Y.--C^F#9`KGU``3\X,Z[YN+\PQ.>=LO`_]*I_%
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M)Y%U%4VZF^J&STGJD^".3NX=-P&2-L!1(\HT39*_>C>J5N&Q!#[X=&`FDTYZ
M+R9UEDV5!^N(TR&W'6*MZS`!V+\.SND]IX1]\K:9<B"1KW;U(O/H6]:*:26;
M'T=Z)Z*)"Z6#/ZM$QN[)DNH*]$=*FIG>^E/*+./[H,A*TE22D=X991VD4I))
M)HZO>%*VF]PNF!Z_^$;6A/OU2X5E,^0RO^$!X,,>7L,'/&Z?#B5.`M;WW%%O
MN$3*]*2YUE3S.8=V]-(]1RL$YRB9`10*`5Q*`G'E.("S$K=LX)MJC0=CO-W/
MGDQMS<?Y[%*H,>#,>$B"V^L1L[TH.KCHI>!1Q+;`<C^(N1-U"C@62;.KQZO@
MY27PUW&P_3OJ??68N)*('"9;E3=0>30N7]O]<5M(CBJZ,S1$%M;HH<:C]V/"
M^053:=VYT>6&'U<':7VP>@2T!4":`%B3T&]I*VHTA>DX]O>@*N6#V$4^&KVA
M?J1Y_F<GP=AUI=L1[)U0G@1+QRZ%Z$Q$=,:'=+(J;46-TK"<O/X>=*8QFF+\
M9LFE+2.]CPCL)ICRF(L;HK,H:$CT[*+^+E+ER)1GB\;AX@I",*S(9XSFWV&X
M]2*X(]$@.2-E(GNP4=E_?WK#*EZ5JM34Q5^(SKJ/WL_P@TD6=H5`T?]#T(=*
ML.!RT@>8]O2==@BC6A@A?5KHO(1O''K4U!U94YK%-](\?Y)3%)7#"P8\)\$1
M'3TD54!6AX_X:^PS/KJH'O(XV,60H._2L*8#>6RO[K0;Q9D%27E=5\$>#1+#
MHO>R-1-^V0QF`>&00A\><"E0+-8O4Z7,>IZ#J:7HO+H"V81O&#04'.N]\LLH
M@9)XFPT+)2V@I-V*DQ8-HLGZ%(KHW>CY9A_\D9^+,3:LB3P;V]!S1_YRR921
MN*D6.4Z"7F8XUGL)ED<,Z<:7'8MSM5I>SY?K^35`?ZU7MXOKV0;]8[U!__=Y
MOMRLP>H&%([Q$#T>9WUX?=T34.X^!;7P'X/PA6A/SI/A6-YY'HP@.JJ!J*29
M1K`V8$Q'`QH$CO6>S!>42+J>",%RUE_N[FZ)<LSN?P.+Y<WJ_O-LLU@M`?I?
MX<S0Y77EA0Q@N=K@8JO;K_A!KEN_*%,N.2&1CLI5CIF8&QBF6]#&>D]E"DJD
M)J82PB9/P\35:O7X"$.\?=[?D?%U.K]Z%40QGD&W!LP+S<S-]J<JO.BKM*6Y
M#7+39_(%]5XM$Y9)I3OB`>84*X*T)KG.FTX%96L!I+9T'6!:0M97"<H+QYP?
MAFYG&>M]YH*P3*J6BT4!'FM#D&H#SL.F2\1'RU^\*\0"?&)9'-97&QH#*(;O
M0B^.&>N]ZUM8)N5!%`^Z?`T8,QV$<(_W&.&=X*=9>+F:H'^!-YS!YWJ<"P:S
MEP"U^`^B[*O'[!(["FP\M>5EH#;UW$U?^&3"&L*"Z3_V#_O+H8V7Z[75"FXY
MI&L"+R*G6!"O_^[@0WQB_(E7(+_OO&B+-[]Q<GZW\^@GND/ZLO"OW%</*>EG
M^/(`P\O11-Y@N['GCJ3G$BIU"\VU#-.<HHIDZ[S>\[A<<B@Q_SR(G+PP,>$?
M/!\DY<'OM`;GU!(3&Z1,UIZ;XJ7!<',M:T(&9);FHU]V(60/=YF1%$E]UQ.I
M__-`C^[`QWY4XZA>#IPGN\U(\)6>2W47!D^A^W*/CZ.*O!BN8?C-V\([%%(%
MNWNX#9Y\TL/E>#*6&`:=1ZBNFJC)E\B5_#R`#'-BT64Y2_.9`TW>D"+?JX.L
M1XDRQ9R#XIB.3FX()3F>6PDEA0__;0[%O\2YS:%-MTM9FD\<Z?!ZY,=I9Y?1
M*6`@)QD>!X0@#P@O0%U2X05(X22K(MFIH@FB"Y!A`@DH0%&!`BQ)EO7A]-VU
MOI^O[OX`D>*.-#"A@N@5V<K>WBVW413MV3;T3C%6\P*T,6Q=I.C'=+UCRR1E
M']A_6Z91Y28TV3WC_;BV8?U)@K+.+X'=0G7:]J9,H-J!)I]M*>Q136>I!Q-Y
M]W>4NNNFO0SH4W4K%QU:TQ&-6O7>\=:"7+;K;>[>.3H&0VR*%U\G$+]A70A\
MI#C7P8OK^9?&Q#:E\;"RRVY<9)0BY6-U\?%DF+Q:O7<=,Z"7S<MV"`XM`K(R
MX'=:BO^ZX*JK&*5$2_)OD"P%(J?E)M8T&<WK/;)IQ*W(W3=AR.Z/)&<?QL\0
MO!*7SD>^>Q@CQL+=W`U]SW^*TH5/:SR4MCQ5W6<W-K+*D;*RICQ^Q1,ZVV[I
MG9W`)H"2I1$F*,YLNSV\'.@BQ35\]+9>+.C06[ZU%(]^!LZ6?'K=>[:,,75*
MEKY99,SX9?MU%A!.6@BDI0292@91T>H01['K[U!#EX:-NB"YY5)NB"YUV#%+
MF`7_T1[TX\+880WH6]5\YU0;=G9:4B^\CMTP%DSR;<'B?(1/GH]I"3ZZ>Y+"
M^*/G)T<[_=0?08UW3E"#B:`V/87"LO1.UFK%SDO0N2]XQT0;$F=.?I7*37E'
MSBBA9O5!,R=EK;%)7ZGF&[I;H,OVYRW]TWG,Z`(42@B>SW$R(Q#-OGL1/LQB
M*O^`CJJN.[*33ZK2$1V5U0Q[8B<!O][K`CQB2"<P.Y;2C!.*2W$IWJ@T[?$6
MQ;@+]"?YX/*2!\K]]<3=!OPEPN9ET2NUIO25ZIU>V8I=&35K`#A9`?`[+@)(
M&5$VKA[)+/]SL$=?)*)4+QX:)-'SLT#HB;-\4E8<C=10'8\3[&04J_>BDY`\
MRNC.`:KUU"1R:-*OL^6G^1HLEN!J=K?8S&[!]?QF<;68+Z]^$S_J)86[<1_V
M$'-'WH+6<5\]J4(-[A+G:3EL>>CDMZ7WXE4C;F4<KNB\:*[)8V["G2H%:M\<
M#"5.9Y5Z[$H]%@ER`I9+XSGM"7VA>B]?M8-7.:75!J8\I]4C->5,9*FD9GDJ
MJ_*%V@,Z26CKO0[0#E[=9%8;E)/9+`%6XJ,7X.[Z@`]5H$E7=$J"_GX3A$E"
M%HZMAT.)Y]1R@>F!S%T$/^(Y1T.C\7A*AR>VYM-FG013LJS;"2+31C743AQZ
M6_PONF?-_<,-=]GM%(]!^`B]^("*=9A%%J2BI#!:?QVLB,,Y&YH.$_.I=P9%
M)[GDQ_'BX)S\K#><:T&J)[L$DIT%T47Z%.<.I:WTJ%A+^`=Y1'AE&^=Q:AD(
MB8K4)"B3`A4:P*N\=!G-UGPQ4DB@\SNM.FAIEG%^*ERB&5LW>@8_5EV6%/TD
MR255$$J]*SJ3YO"YGF(#4YO.<MB:IYF(R'-65U,#BLG%H+JT1)^>I>82''MH
MR3M/A1^01+UA?0%,.E1W==;$&%CT6^N^1-95N/-[)1:85=>7@:?0]9.1%$PV
MM,L:*+603KV'TDSK^#Q776/3"5U7LG7/GN@HVUD]&@/`VNNHP"Q$.O=$UU`>
MWHZV:=^Y;^3G&9W#2'JXR&Y=B_`&[SN!+1HUTI#]FI7C^)&IVA-68Y&BCLQB
MMVAB73MX%BL9&.B^S-A!KG-Z/2:$/<\?*M$XE5Y0(XUC]7VU[4SIY=Z6K7O.
MBKA89_)X+-@:AW*D`7F3A:3YHXD`B0<E,V&0IT%-8K)HSLGD%0U6)N]@I9=7
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M9/,3#0.0.R?+"Y>V81K2SMIC`-!-\80DK#BPM+8R^5;)])?>>2`"TK#K2J<C
M_/B1'9UY>@%>W1!\P\7ET5_V6;SGIW_3>;VUE8<VO8C>FNB=C\$MB^P8CQ?0
M">-1'8!7FD@M.N;"(S":;2&L!33[8W:(G]'7^P<:]MF&Q&/I&SKNC?7M$E6P
MO52)&!^:V#G1.^.!0PKUQKT%T0G%\W+]\UFV-5?/YR;K7:J$#`O-(IGHG4[`
M+(-":]T(Y(3"M&P')D?QZO$>?H,^OA]E1/WT>"B'O(6^NM*U&7;.T&(Y9`M&
M26[34/=`N@$W`Q.GE(D^?,+.6]2JUF-PKE9K<J;*_?SK?/EEONZ#=9(LIF32
M55C%8C%SF!Q5/]0]>JU%+=_RU77MX$=X=2UYR'GC1')J<!KLYF<'V98\PM7U
MVHU[[+)D5T_4U1C;AMZKQRW(9=.QN7LG.XLZ&PL)'QUUVM-'-_*V,W]W[>T/
MR&Q?3@?V1!E/3SKOEZZMDM6Q]K3B>&30M8>AWF$EEQRJ&=T$IH+?%X!4`*Z_
M`TF57GF^BI]A>.U%VWT0X2SQ@FV3>!VQ("BI>L'^)ACUI;;!L35]7TZ`3[`S
M:U0S.C85NP"D%5!H1I:C::6=E*72=ZF`I052T09->V"B%S*:3`9X;&_:HY'>
M`X1^!56R1-HK9.=O\\6G7_&AHK.O\_O9ISE8?OG\<7Z/1\'K7V?W\S4Y8W3U
M^?-J"=:;U=6_@2_X/%)\VNCJ\]V7S6+Y"=RNUFMPARJ1&K_P:?$GZ,/0W2,!
M9KL7S_<PVMC[!N??\;8L-$0?6%-YIZ"W]-Y-+?E%2_6OK:8]29:Y3;WW:'#)
M(=N]\8!QDL+$=QT7!TEY2327,TNI!\_+4YDM59&A,LS)>$"W`9AZ)Z]RRZ)H
MRI,7E_-IOD2^X!;,EL@M7']>+!?KS?ULL_@Z!_-_O\,'4G/.C'["Z>,1`G`/
MO9>'`W)]),/G'FXAPK%;A?0O<JKPT!Q/J])/7_??";D'4W-`J(U^X&FX(\4[
M29"QG:,5,C5-L_)-O0<U':22;O*%H3FT*D!UP7%ED-8&JQ#D]15HA#%\]RIA
ME#T`[R>BFXM-O3,O.TC%KA.[8'O`S9*S"^3K1@8QU0T<&X7'NA&FNA&$R=^X
M/L"L`4_!-QCZ!/`>>'X4>_&![G+`#6V#/4(5A/0@AE<WC)'7HO?/(F$@>O7/
MI-P.?H/[X)4<AP*I!\.GGVP/80AWEPJTT'[W2E@:[G-289P<86WJO6VA@U1*
M!O+B^)Q;&$7@`]V65Z6'O&H01-%=&#QZ,8K5;9M<$S.5,@S)>^K*^R;(.:\+
MI9`)F]"4*5/O-(D&U!R\#)"5%>5E7?_.IWLRU7._NEEL>N"8G"D=J1RKB.GS
M4O9T0O-.3;UG/6LQRX_'JSMVR`-`G_`1B]YAG]T^DTUW#JV1O&G#FDZ[\8U9
MDI1Z=16PTJ9367HO*#-*()N6;#!:K^,B<^6KNSF>*T$%A!>VEC"FB&Z14B`0
M0VLLS2,?]=6-OVVP4]J>EIN,AXDAT#M%O!&W$L_<A,!9SC=T)>9F=0\VO\[Q
MBLQB=2TG>><<:Z=JDG=*@R/TTO?H=;^B0!_7"QZW)%69["K$9PAZ6Q1_[Y)6
M#,NVDCM53;W/!>HBEI+A40>`SL?9>G%%YJ^O%[=?D)'F-,"!'Z!^W1@1ABI<
MMI1AFE-YIV/5]MO1,'.(D[&^OLYP/-)[U;$5N^QXH@V`4RP`:`GP8U*&\U0W
MAH\KQ5B?CZME"UU;9SRR;'QOE#F9:'Y,&[,,:FPO(QKG9K&<+:\6LUNP6%ZM
M/L\1BY,5PI_`!X!"$CXRKXX[3<(<?'2O+)-;T6,W`K.)D%*WLO30M.AF`<WM
M;#MXV8:V%8&S*IE97(C3QC9^4RG#,K6T+`W1JDM/Q@8=;HST3L1@0*]DN-:.
MPTEF"Y(D.DY6XDR_3Z[G1[AE&)$%GJK@M'*)ZK1V1WJU8\FX=5J4S++0V'VD
M=Z9#&W3IYJZY?X?F5I,"@);HBU%,J0>J*%5.(JA\,1.ZL7.D=Z9`&W15Z0`M
M.)S-,R37E;C^VU\B>@L0/@?M>-G>?0HAF4+E7(BO_]8LJ^VJ>%<:>%2_LR3X
MT'MQO`VZDF%&"P@'IYC/EK_]94TSRVG6^>WM[..*3K&#V:?[.9EZYZ/;?9)0
M@J?_\G22;*`YGDSD'8#9V'<WYO**E=*XM9YMTD^B]ZHFCQBR/34'%N>^F-Y4
M*"V6:,Y(`CEIYN<G=SG%O+$B3GX>#<PTAM([,813$@:.]Y%>SH?*N9^OY[/[
MJU_I[/S\Z_QV=8<MN&!J>=I[H6L$9.X_>3Z$^'SE!,@2QL215^4$5`85'`WW
M0VPQ"4Y9SM(*229+O*S>^0$=I%)EX?FAY0:_:.QQHGFA=FK\`:JO0".8QG=Z
MJT1Y5,C]B1(KI?=*00>I5(TEQ2$>!T-5N=[D!C[.X:40G\;C=Z\2N0A"*H$=
M-\U^&NF=F=-!*NX@:2,^'RP.LSUJNN!?;$N.GT*C;LN0>'A\VDU7_M>"S;F=
M%C%'QHCNY!KKO5)1!UG)[$M-YX[8Z7?E#R1I^D0.FRH"ZJR(.:`9\&.]EV-K
M$,L/A*NZ==*?^5CT-^@]/2,K._L&0_<)+@\O#S!</9*,O=4ACF(4%B!#>9J\
M9TP&YE2:!1,#U8VAO;V(E,^B#5JVE>3IC_6>T>Y'0"66MQ>H79,<NS),BGE_
MCZI6<AVB#4[QI=?DZ^J]#-Z+?++=4A\@G;01D+0":#/X\-;DB.I"4[V?*%@Z
M#E5)UKVBHUV/'%0;EO_8/^SID57Z:@:7#-+=#`\:Y_@`K],3OS@/])KM"5?@
M+MUF`7<X;P`-;,ED4I9(.C7DN1$V#-T8+BIG=@D96_W)F.1@V);>LY("TLCV
M`/R0G*P*->]XFPGZNUA+;%&6DRMR+O'33R?*%_,QU2<7O5D6.8_$MO4>E`M*
MI&08(H;-*:K&ME!>Y+:$M;N'T6>(@RJR-T;RC0F%[KH1G0']\<T)Q:*F:>L;
MQC1!EFVQ:_K-+DP@3\#O]!GGINKZ+R;%VBKC6\F&EHHB!1Z/;<.^'-KCR5!O
M<]D.7HEE;(5Q>H>'("GG+Z_[X`W"-0R_>5M8;8<3,XW^PO>);(,G']^(1*\-
M)Q>?WGH^7,3P)<)S$O)VI_8,MN/X4O:;RX["[KFC,4XF)JY4[Z4IJ7++=B0R
MP3MIXR!IO7:L<`'R+JBM2#L!M!=Z2SCX'7<$2$^<]J/E:-?$50Q',H];8H'0
M3=<%I60\8SBI;D]LBWYBO9<Y!*21K6W\D!B.UQ;TJ"='^=PFZC?[[D670VLL
M;R-Q0\?=V,\E4<W14$>5)A/-CR9I!R^;T:T(G&0W<58$I&7`[[A4/ZR]#EY<
MST=?V99WLUMCUU*86R=5"W>3:I/I0.\L?1;X9^)O$4,3@VDY3@XW[@-(?,!H
M;)OGV5G51QPB)"'3-I1T3#^>3)(X4^]-J_S"R,]"XD34NNU*,`!9;Y_A[K"'
MJ\=^!B$;<O[O:&+(&]A+@=Q-U12]Q50YY71G6+:93)OK[;)4B"_;`"B0P4G[
MP(/Y_F<!2(^<UF:&+-8.6ZV;O?MT>7JE?=E(1'![^11\^WD'/6H?T!^G9@']
M=-QNQS7!1HC9RM]1*?K*QWIO3JN#+'U=N[I?)_L=X`><JR/X^@34HA=MW?UO
MR"_.D1]%@2&>]NZ)4G5==%P8806>+8_451@.Z)O4>ZL+"WSIRW3M&)RD#*"%
M`"X%YCC00N7XJ'F=;$4C6V5B]"T6_F,0OE`KGIV1;8XG-NO67I86N[%2$'/*
M4:;JACDQ##JC-M9[/D=$'-D<%L#DI'62O;JX%BA4$S[O.VV7Z@H-"F[0;Q'J
MN6WBGM7ZUO;1#]';H9]RNUS#&)HT$4OO)6HV`53QMQ%%SMC$#"<!)RG8A:/8
MG*>?N:_XH*:'/OE9#[N:G7EY8Y@D">J]:,L"7RTS*S&4>$G"@PZLI+S.0C^K
M;;J<EY-'[??#R&;(IWP\+FW2.,O2.XNL%;LJ)M8!R&F8V,5N`>H&X;H<&FU[
M7WFYAYOMAW*5`$^91@J9B:KJO11>!UD5KT[ZS>F$'W`F@I%H\@I5#MW]PM_!
M[_\&WRZ-25_A7V7['3.PF"!G:535I0<&?7MZ+W>T@Y=-N58$3C(>28H`4@:@
M0D(\)#=MK/%-&W2;6V&7VZ51>3US!U(V=-8+0WF$.:%K8U5Z:HUMZ7TJ(J<D
MBHC,""=C-2D/2(6+BJV7(B2_\?8PO$+>_BD(L=UJ6YCF8_51ZWW0N!GN,6^/
MR]*+>VU+[S6H%N1J>%G7?<I#\ARD!418=P^?2*J;'R_=%Q3W3_H:/E<UWP?O
M6@`?$^^T\"")M?5>R&G%KH9\]0!2^N4E`"["Q[]-Z&)3N7Y[>0CV>!MV3\0[
M:K<;XYHAIE0[+F4E;TGO99M:S+*I5=>QDSP`]`EONN(W%&8B"WCM1=M]$!T*
M^_N'4T->BE=#QUU3%3DDRA,5ZRL9YF0PGN*W/=9\&9M#"MED98?B+)9?Y\O-
MZGXQ%[]GM:*[#?P>?T3/_HX^^&0D+^6JJ>O>F=PD5`.7\VI3:VC1-Z^WE647
MX@Q,KD;B9"5!7A3\C@L#4EH*IZ5L>3TWITL[89NJD5WM$WHH\UCS]7,N.=B9
MW6%_+`^BHJD6Y/(-WA_T#'>?@F`7X0]NV/)9?-1I3_QM$Z3$W),*YMB>TOEF
M^YU8XD8!U'*U"8J3/@1/^&F_/)4;02CD:7W4<%QA:IDC^F;?2>C;`%]9I%"/
M(8\1+D#&4U+L`GP*@TB4KN2<:?1M+6G76!:[ZHF:U:!+A$R.EA]8B8J_$P]?
M`9O#2(H?3=X`P"$GG@,O+2%(MGOWC\\N,N.>NR<6A:X3RG7AQ3Y[HE^+&"4>
M'I?'/H=.P4ST3B1BPJ_6?3<@<=`S\)(^[)6@<GVW,H+6>^ZC\E/+FM*7JG<.
M)@-Z97Z[%D+1;6."9J6Z>>V_!>'?%_Y=&&QA1+ZP/9%O28\Z[8FI;8*4J'I2
M`9L`FO\PT3M/B4T`M=:T"8J#'^++75_IXWZ)*M>B*B1JO4T]KC#%!QV05ZMW
MOB8+?&56M1Y#T:RF1$W*"1G6?.-HUG"R>8ELR"Q,-%JF+6\\SPJC&Z<["%O>
M*]W:A&60$&VL^1FM@A+)U@4Q6$>;E`NJDF[(H]N,@?`"`S^#I$0FNJI+*7IA
M;8).FQLV_8YZCPZ%95(2XXBBRQT+YQ[\[38X^+'G/]T%>V_KP2A;M!X9\DXT
MKN^V&^<YQ,DV[]=7,4P;.6^Z%J1WDC>[$+(-/S,29[WXM%S<+*YFRPV875VM
MOBPWB^4G<+>Z75QUR8S`%YE$J\<[!!8FEX#._-W:>_*]1V_K^G$98FX++7,X
ME&;WNR#KIA?]OI-4=3JU2A9:3<H&O;-[^Q13B1/I$7";EIY!-:4XI'>NFB6O
MUHT"HW%BIO7>'M*?D+*]8F]('=(2'AX5VR+'P!5:`WES(&VO0U[6#+6TPY>"
M>=_@&FX/B`2HP?GW[?ZP@[L;1&5\9M0A3HZD*EW;](*Q7%H#0]ZJ1"\0.\:>
M<MY2%J?VTKPQH!N41E.]LQLD2"L]\NT=LE-L$N1M@K11@-D'"LV2P]V2AO'&
M<+K=[`+0QL^I]7*NA?JS:7WY4JE^2&5.!L,II97>N7=2Y%42=,M`[JS(UXA`
M'(!7U/^S&T%\;17>3QKA_:3`#V+@^8DU\'RPHW=W@MN[-7B`6Q=]4Q`_0P`?
M'^$V!G\$A_T./4`!0^Q]2.$JM0L?WZH;(.>3CVV)]RK*PWU6$\+U0GNR*XU]
M&@,ZHS^:ZIVXINP=:!YY,`M2&X^(7!M0W2?>&IJ<]#Z>R!ONMW4N0Z$;1&O6
MRD)%%!W2H>!`[U5)/D'.HQ\U:.I(?D&V+0O>+S`+0P2,7%40H8'_$GV:_)<-
M^BMRM\33IU<'2KQJ@!-+1U7H*'BF&9SM#">:Q[DB\DC7$P%03K$2F8="U3X4
MZH%B14'UN0KVZ%\!O62IT.%=&#QZ,7%BR)EM\738$R1GTU;M?JT\3Y>KZ6ZZ
MT%6*_)),GG;PB().*8P'>J_,=Y)+MFYT`><<50:%VH!6I],T(&]`B7H8PS^%
M?N1B=%"0Q/WKG8O;22YV!=DE1P&2X8(*1<E`GBA*T8N\4D6)4'V\JO&:-Z%$
M5^P_A:I4W+?,^[&29+V!WNG`G>12,EW8!:%S]^C]`X9@]A1"4ND"/!YB?/9"
M2&]TIH$83.Z"*NL,K\ID!][=N>$J)+>N[;ZZ^P-,IQ`N;<,T)-Y'W@J@JSH)
M2)CK4&MEG*TW,JTD(-`[VT5$'$4:PPW,N2K,E5^`5S<$WW!YK`I$+3@UX=;;
M8HW"2_>'U]?]6Z:`=T&,_NNY^QNBAW?N&_Z57-RT\I<PT>KH<FB;9M7(OM*?
M=.VMFTY(D#75F.Y-F].!J;<'ZDU&V0.;OH`Z24/D@A':5.Z@0-88H*V!I#E`
MV@,K'Z`6D]$0YQZ8_HC*-"#ZLVAE>=C4M6UC2+F@]R"J1RE5#:GZ@_PG4%*6
MD=B?14=+L6;7IFU*!+TW,_0GI)*XM#>XF7+BP5M$E=/-E/,U4\YDK/=*V^/3
MP\_>'J)HV$_1X+F!:=4Z:Z5>G=;NIB<,6%+>EXJ2>:-D0*QW)F,;=-GQ74O_
M3O8\M?9]$8HIFE+%J'*T4_U>#/I>]$Y<:8.N*BYIP5&@5F*K..=JZS\G2Q"@
MBEHE)UW]6H;TM>B]+-T&78E#;0%1IA6(0^_I"89PQ\>OY0$O8Z\>UX>'R-MY
M;NC!B'S7JHVOE1RK:J$;SQ@QI5RK+(XW6D[I*;V&WGE"+/!E.T@&#`XM`U:/
MH%BJ3[8Q>4O5="M[S?J711?Q#+UGY5C@J_*>#%A2W@6/:#Q0*-4G\5A<J6K>
ME5QJ_;N:T'>E=V8+"WPEKI4!2(%SXK:.+E`N_&T0OI(USL!/<\;0-Z[:!EC)
MN]IFNI&/!UW*P/HZY/71Z,30>^J360;9+I<52+K0?502_$[+<N80,GQT)A]\
M/DZ6O7'+>Z2[^`V]-W$SRZ#*+[,":B8GIX]F^/PLCOI\Y"RY[);72*]8,/2>
MB6:608GS9D73J]7$AQ/"740W$:4I2T&(HH;1Q))W1%IMOQV)S"%.1N3Z.OBU
MTVN=#+TGH9EE4$-D1C05>6Z'5_0Q\6I(,O,3PBWTOO%._##00,K6F_.QNAS/
M-M09#9,(3.],-581I$>S;#B<M%QZ:D.A)#=]8W?O??_H!9MG&+JO\!![VZC.
M/U>=7%P=/3"WVYFOXO@+!&9M!%N526)5])Y_%Q=*`<G%D#EI38"J@F+=O@(4
M;BZQC?,T5H:*D2#?YZ'73XR'>J\.B`NE;*PHBI!;*WC'DP*L8AI@:JP559$[
MU]>A*]>&WHO_XD*IBNW%X"GR$[?Q+N6-;51>D]/(^ZQZ/_1N0G/*XD)9TQYI
M?NUG/6A5@4JIYYQ@Z%'_+.(**N33J#Y$R`J3M&![9+V/(*`*MFHW7X%!,JLF
M6I%JTLJI"7TO>F<!-*!F9]0W&#X$7;UD&<$1GRY%"96<%4</E=L$'^$:$3]Z
M].!N$]S3*;.Y'WOQ'N[NO:=GDG..G#&S-^1NOR,E^Y`GXZQ`8Z/A5/.S`3I(
M)=TC"T-STJK)`:9@$X"/$&35\;^3!D#:`J!-J%,8-L?_CC2F(G3@;@T[2/P-
M-5_?ZR*7LN"C`T@'C:/`XSX(POS\4)>J4OSLQ@`GT:)G+T$(P?80Q<$+&OGA
MU!]R9BAN]`V\H-]!1+I\PT>,DN^)3R1]2(I@I4/_W,(P=M'SD&``!Y\40^V@
MT>0+:73G1=M]@+>2%4[VX,UFZ\)LIAF.=Z2IY1D/[L9L2A7-<T0ZB*5FUD,<
MH)-LP\3'^GHQ6=1\1"J9:5:B3E3?Q)8[[^$>'Y5PYX;Q6^$T-@HV6CT6?KLT
MQK8]D+8`RH&DFU9U$SE5)ZY6+'.L=Q:J@#2R0T-^2$Y2!9`ZQ<,%TU/NB:LI
M_*Y`5Z2DP.BM*R77P]&*?3D>61/;HF->O<=57<12XGHZ`$Q=3[[)^,7][KT<
M7I`S\B,/?1,ZXRZTTWB]A;Z+ON8-$B";B+4&5;ZE,@XKU^_&<B8\^<67I<+C
M@6%,Z&K%4&\[WPY>MEEO1>"D)0`N(CC+U?1%F0;E*BE6'E37O22:,#34VRRV
M@U<U/&Y%(IUK+*-*E52KN,:W^A715/:AWI/U[>"5N-E6&,Z7UP`?D..&8`/#
M%W"%VO>V[AY<PV]P'[P2_YIM78XZ\G#EP\)G-WB=:E:]'Q8VH3DE85X6K__;
MB9KJ/4_8BEV50ZT#D-LX5*)_:G%Y4_G<JO>E)^\G44Z]TYA;L:OVI'5`JDG&
M.7W;\%EY_*A\DM5ZT9/70[?=#/6>0&W%KM2'UJ&@+A2ZVV=P<STCQV#-#V'P
M"ET??(8[;^LAWLV>H+]%8];7US#XAMQK-V.W05PK?GKFH[`J&NB'BLV(3LE8
M+(WC$9ONXQ[JO1V)`;TJCUH/(3=WI(P,HG'Y535,J_>MI3=%4_R'>N^H8$"O
MVK_60U%`.1XGJX9QM8ZV4+KI]4V2I'J]$V+%A5+JFKGA49^-W?6L)X_\1U!@
M"/-AZ:7J/3&V`4V)KUE9'-985*M-O;-K6[$K\\,U``HF\8^@?VKQ>6#IW&KP
MOD?OQZ;ZI_D9^*W8E7O>&B#5)!,<V59\5BZG*YUD]0[W^/70U1KS?2QVU6)7
MZSYK4"1>TMOC>WB"1W"'1K-N''I;L/"_P2CVGNA*ZQUJ':?ZS#_/.MJZ+W[T
M"K<>SD!*+CD=V9:\Q)[:;OMA,8,TIV0N5S&L\8#.-6A^10&K"*I\<PN.S'I>
M@$))P:L^U]Z3C^IO73^>;;<XAP&IS%VP][8>C&X]'RYB^!(18\9\2BM;FQV9
M*HH[XRU;`V33)+W@2/-C_,4$DLYI$51.H1;(JX&T'O@=UP2D:I]\W[@/>T@X
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M`WSI/J4=0SX/_SM^R#ONP+<\K\B+CF;^[AY&>(85*0"Y&SHJ3(,S'_O$U&17
M(HJASIG)4M^P)D9RL*ZIN4$6D4<^=_E!.:022&J1&U?S>H!6%)WDY^,,VR!;
M.ZI7#+59/\,PN>!PI/E`0$0>90-N`7!<G.<=>/.QAVG-53O.E\-O]J^0K#9J
MG@<E(H^:`%L`F9,RW>W3NI^$]W<P_`VZ]!@V]G6`ZD8ZDID964;?NAIX1*+Y
M_'X+=.DQ1W/_Y1D6@$H`7*1GNK&%#V?A6T6(4%TE.;!QK/GL>RMX9<Z_#4GO
M)TN](O)NW3WT=VX(WO`V2GRF5/"".?Z'%S]+.$JJE5Y,,<19B%^.$ZIK)',_
MFL].M&%7X_];4%0<U(0Y^\9M<#<(T>IQEO.63CV9E:=1]S.!5MEE-XHR2I'R
ML[JX,1T-].9F(V[9(4!3YPY^B$UAX3$)0Y>!_Z%@%(M'(45"\VH?W<B+$(SC
M5=<W^M\-_!Y_1*7^?FF9PZIL_7X(S(:A&Z-%Y4PISEC?&(WIA*?F)Q^)B"-;
M(00P.:0.492LU@5-`G@#OR?_CZL"4E>N;DA9;M10-TKA"5M]^](P1Z,1'5Y;
M>J<W"DJD))01PY9KRAWJ(QTZ\.G#-7R(3TEAVT;5R>+]D+^BPVY,9Y(@I755
M8=.V]%YAJ0<MVWS7]NS@)_U9Y;D;XN7P"(7P9";NM,_I8"+OW,:6SKNQDUNR
ME*EM%0US,C$24Z#W)`FG)$H,+A\F9PECL`^BB`P@(UQ!#K^E6%PM^%VRQ&T5
MQZ,AS0RU])YUYI)#MKWF`>.DA<DT-"G>GT%?NO$A1$/AU6MR)FET"@7?`L>\
M6;RUN6XD%D&;\KB]+K8E@V1XH_?<";<LLOG,"\BA%<#J$>15E+*9:>U%'SJ7
MUV,87SG-FK'T7KOFED75:@TO,+)XX^9;(EXIH</D:/4X((LM/B4_&@\&.?F/
M5G`XUULXB,2R\J(/[4O1-ML',6C>C.;#16Y9E$3<O*B<3]!')??]36=(&3PJ
MG<XXHFT#@O_8/^POAY9MX6C/'D\T/FJ)4PKI5.7#XUP%_C<8QM[#'IG?((:<
MUYB1%*;G8(\^333_KP/Z*$O4R.PABD-W&U^.AY7'[_>5H]_4=P])=!QR'27/
MU==#%F*0[!?4_!)4/D%DA]%<:)SU9G7U;V!S/UNN9U>;Q6JY!K^G947RGDL=
M7]-<$.0."L;?-@UY4WS,.&30GDW<9A6H;`.'B/3(`\WO;Q6624T>B2"Z"D61
MKAT*/8$.VL'H("K;F`S,9/RD^8%8@B*=QVFTXG**]?X":$V`JX*\+OA=>"[F
M:N]&T>J1]'*;'_\R,";2]*.RRVZZP"A%2OOJXL/QD)X,,M*;X0SH99.Y'8)#
MBN#I$KHE1OR$H/G+ZSYX@W#F[Y:!#Y-_91M'QI,JIE9.F#2UU''9A@]CMFC3
M5`UY1R-9,QOI'8_PB"%]R88=BY.6)?NT"J4%]ZVPD8!I1OO<3"W/8[>_5WH9
MRTCOK"4>,53-7G-@:J<LYY0T&QU89J//3=ERQD?K:Z4WNXST3D/E$4--K@<[
M(.<JN1,]K1-E&=HP^Z6;L2W0H"K)KI&J?9*S%L<I'=,7-1H,IDFTI'E&1B-P
M5?Z\LO?<'/9+(BX?+9-%]7ZX^#[H7.-([V2(9N"J?6TEBC*=!+WIZ6?D\9\R
MZ53K(_/7828932/-DR`;@2OU@Y402IY/T$+1_?4+?P>_P]TF6$31(9L_HO\E
M6Z),>R`OQ9P-0S?&BLJ9$IFQOC$<&32[::1WTH&0/+)]L0BHY(0(D-3"N36T
MWE^B=#)39$]>$Q2\,3`YI]VT)1XXRH9!GEXTR<FB%X7ZZ),-DWD1?7,;A.4Y
MIU[4@6K7BPM`=KB*72-P%P9;"'?1#6)2\6"7^7<8;KT(GW@Y'HSEK1"W]M]-
M+43$2U6"H2X:Q`ZH*Q_KG1?!+8N2R(@7E7/E1L_HY=):`']F`).R-/V25.>]
M".89[@Y[F*Q2?'PC"Q+TH.S19%IUD%!?5\'4=MQQP9='HOPZF/I*AC4=TZG%
ML=XK7NQ"2%_%947BI"7S);"'-T`7Q<1N%<!M$!>QNSZ$>$\K1)\I.9R+_/>C
MBU3K*GAYA7Y$1L>7ACVT)&<!\2'J(>.A\RLXRGW@;<T:CI,%I+'>T\8]2*?$
M5W3'Z>`C:U`D%1$E\TA3`(V\T6OT(3GV@YZ?U-VC=*&?O$RC=Z.!U=E'W*U-
MQTG@H/>B>'?AI/NRK@B3TTYI$X"V`6@C%\D1D,G_?WC`+8%B4Q<`[P)&NG@3
MA(_0P[L9./41YY3G.5"%]-NQO."NNL]N2L4J1_'0A8KR)(=>[]7W%N2R"=_<
MO7.U6GZ=WV\6'V_G8+G:S(73M(_[*>P[L2;R9J-J.NV3F@V25'.S>,K%4.]5
MSF;@:IEYTCLY'*2?;,^V[REM3Y=R9I;"_9H*]!`@G+>(K<"[Y&A)!"6!.R.8
MDE7E(^R-ZX5?W?VAD"@=Y89[,)9WXEY3S]VHRR=3RM_F6OAEZ[UBRX1?MIUE
M`>'<S!;WX.OL]LL<?)[/UE_NYY_GRXUP-%#59^%`%WLD;WS8V'7_)&Z0JHG%
MA>/S;,T/J&:!?PX.GV!P<!E`"A7BAJA#X,#VN:6$#V<G<2F4:*Q&':"9[&G6
M.R>+3Q`E8047I!I3S;D#*M]SCF.:*@"7MCF2N!^J'4`WF@M)F.V58JAL#@=Z
M3SRP"R';>C,C.3H+@1X/66W5Y;%=BCG7BNTET\Y2V9A,IA-SB(R0;1IZIY&)
MB*/$S`L`HT'--T+_;;=S0A8^@@ZC>.%O@Q>\D2']8?X=ST\7=^7BE=K"UES#
M&LH+UT5A==.7'E]&JD7"34XMS:_+[2B9;._2#9Z3E@:T/MFLD_V6-'$\$8E;
M$3\(L#OUI+BH]ZJ')6\FVB0-L#6_1;Z[<$H\76>81YE$)6V\A]O@R??^P7MY
M//:Z"S^*0[*9IN".\9HO<<4W04A_CM!7OG=CB.+2H<V\R4Z@@^XK`MTE*BX7
M\+:&`A5;\]-1NHBE8A%,$!M=(LLK@^+@"5=/ADVH`9"W`'`3"M6&:5OA^]*;
M\@9%@>:,(?V.>B?T=!.,77FZ;7#LA/)]J!'+;LKWI465B]6<K=GT(^J=E=I)
M+F7+VJ((':(B=(;B$:G(-E>1L#\5R3N_"[TM1.RQ)1YKR@Q#DOJT2]NJ,Z4F
M3%OSW<V\HIPM,JO&<^I&+HI^Y*+H.4@MV7HA+:E)2[U@]R6E)HS)T!I99+Y5
M\T-QA&4ZKP]I0><4-.,5%Q"]'XD!`$G+7A[(T04X#F$^1(^O;>GL;Y:#0P>*
M#6%_KOE$M*!$&GB*"EB-XXZ"4I"J@-95HQ'=ANP:J03'0+VRI620.-;[>`!A
MF<X^/&\!J*^&=!J-:Z0@(G%3H:%D$*CWDHFH2+I$357@'/IOO#A"(J6(#+T?
MR%6^^0"\BR[<N%LX>\%W15W:UDCN#IZJ7OO4AR99JHE?J&%:FE]0UH)<;?!S
MVGUY5(Q+`%JD9WXJ&/(JXV>+82[4,.SA9&R2T92I=^(MJPAG,+RU8!PT9O6W
MWJN[!VYGSJ;KV'C^=!WC6_?N($*)PJHG>&G;0TN1E6W"T2>O^>2M9GIC&R;R
MAN^(\@RRJ+76[8#*]CM+QL"5+@"M!O)ZTA5$@9G72D%:7$%C&\9X.#7-2V,Z
MM,9_&DTY$>H,[H(#7IY>V'4U[#.^_!)]LFN\BHIGD!1YBV*_?9*_69YJLA_5
M,2?&>UK1JL"NUMJ7`92M>UH&7,M@JP+3K92M+:;YJ(YA#<;3T:4Q&8V,]S2@
M;!+B#*:W`8Z3/A,_-12?ZN.B5[AZQ+U>&J.)Q(.LZCON1EPN@:H.""U7FNJ=
MX-D.7K:E;47@W!V=])F6P3-XN%3_E)5^PJUJRC:>:7M::3+$M[2C0;RE^9&%
M[$(H,;;,<&CHX.YV'GU]^,UVF"B9O01A[/V#K"_1_M+>KX(HQKM#C3%S%GY+
M8]VHRH\TY6M;33SEI/G>>5819)M;1AQ.L1Q845.;VUY25A)/F=;0]2!J>96\
MI2I=H36'>B>+L`NA:AV<&9%#YZ)Q<."C5X$/"H?)UB=D9/>''3WLU4NG%M*'
M<4"/@@4[8IS]'0@>R(4LCYZ/NL$G5;I1%&P],F='#HB-GR$(X9[\0&IY6:@=
M78+9'O7@HX=@Z]+38U,`&;!3$)RW!S&SE&7)70]]*@4J+35M^MGU'A0RRZ`D
M3&%%<^P`D#I1BJ<.8,OO`$XV,N)]J..1],WQ26_="-P._70+;5IR:AMZ#P"K
M`<N.0BI[=4YWJ_;$K^G[Y=>TC5]$6_4>I]5!YC!W0>SNQ<Q=3>?.!C?9B5_8
M=,Z_8X^.@H.BL<1?3^+Q3ZPP>F4DC[`U5*UO8FH/],Z#XY1$L?%L@5.RJA?)
M\5!9'5"L)%LGI)[`H9M.U)ZPT=K$<#">#";(7$VF$[W/2A,524FT*P@.[ZPA
M9[<>W'UIF%;2D.(/M^@O]&/Z$_H/OLH`_?+_`5!+`P04````"`"!A6=#+\J?
MI$,?``"OQ`$`%``<`'!L>"TR,#$S,#DS,%]P<F4N>&UL550)``.B"7Q2H@E\
M4G5X"P`!!"4.```$.0$``.Q=W9?BMI)_WW/V?^#V?=C)0],8,(:<S-YE@)YP
M;@]P&R;9/.UQVX+VQMC$-CW-_/57DC\PX`_)MFS921XR/0PM5?VJ5"J5JDH_
M_>-]K[?>@&5KIO'Q3FAW[EK`4$Q5,W8?[[ZN[\?KR7Q^U[(=V5!EW33`QSO#
MO/O'?__G?_STM_O[B05D!ZBMEU/K%\UPY!UH/6HZ_%V[]>'NE\>['^[OO6\>
M+%,]*O"KIM'J=H3>O2#<=Z36_[2$'_M2:_7%_2+\U=]_1/][D6W0@J09]H\'
M_?WCW:OC''Y\>/CV[5L;CN3(NO;>5LS]`QJJ,^I!JMTOO[]8NNH$WT=_;9O6
M#GZO(SZX_QA\%<US,?*W'OZN,!J-'O"_!E^UM:@OPD&%A__]\K167L%>OM<,
MA)("X&_9VH\V_O#)5&0'0QOZ]3!5O8>`W=AOH+_=^U^[1Q_="]W[GM!^MU6?
MQ!MFHB>Y@RBW6B[.EJF#9[!MH3^_/L_C049?>)B8A@H,&ZCP!]O4-14)_I.L
M(X[7KP`X-B0%C_MJ@>W'.RBV>U\ZB-"_HP\4Y27XFG,Z0&6RM?U!AY`]%$O8
MVH'_WP/#L9?;B6R_/NKF-S(";5/9EDLBI/!5-G;`GAOK5]D"KZ:NP@4Y^^.H
M.:>)?-#@:%.PU10-KLP3*1.:#1259T96\!N&\PH<39%U*JX.I:O0\@`LO(Y)
M=<BLD,0LP)J%8SHUE2,B;6RH,\.!"C`WMJ:UQR02$*7*0"N:I+GQ!@DR+0V0
MB)'E]&C'4(\Z6&[]#T\3<W^`VRN4Y10XLJ83D6B;6O&+/$3G1G[1R<!RBJ9B
MK>T,#=H*&:J0HIA'J$/&;@4U7R$3GRT7KM*)))%+#5)6N,P22<-_DFP<D++B
M07-,Y?>-)1NVK)!:4+MX;;JF@D)<#HMM%+K<C@87U\)T`(F--HJFX5'6K%]D
M_0B^`-D^6G@;(2!D^[8O@Q)R\4""6,N'V`HJ1N&*>T7*0K;0+O\&R`%2#(,U
M0.'MS`$6L)W9^P%Y*\]`,:%A^@Y4&GKAK@8L`IH/<":H*]BE>((?^+^@.3K\
MC4ZGV[IO!2X2_'FR7$QGB_5LBGY:+Y_FT_$&_N73^&F\F,Q:ZY]GL\W:GQ;Q
M6=B1R.4!O#L`_H;J'L)\+G13\;ZERR]`_W@'/_@_SXA#7^Z$E`\Z4?`3ZPC4
M)TU^@2=L!YKUR=%"CM[XQ78L:-7:_6ZW+73;TB7&X9/P5K9?\)GP:-_O9/F`
MC\\/0'=L_Q,LCON.X)TN_^Y]G(6>2]YU=!`V+5^`-,Q#LZT";_"V.!ATRN(R
M/#$1-V&%'%L^9UO+W!<G5<>D`LFTX!$,!W;0?W>M@Z5!S\XYP?5QUSK:D!?S
M@,@]GQ1D2[G1_<M@@O>-AP,^:-PKKYI^M5KA-]!48`L@0>J3*]K8\?!@T&[8
M`'\SBXXLX7G'.K,_*DU'PA/SKB-Q('DZTFV<CM@VM,'78`V$`3OEB)HQNR%$
MD2NH`.@/%$1YDW5T/AP[$^@%G*"#C[VF]F#8[S'CB(B$8A2?2%J^:E-#TW1#
M"%TM`&%`'AEP0AN!R-P21LU<@4:0`M%4:X>M^YEY.\2]T!L.)&9Z$#]Q!5I`
MB(*G!+VF*4$03H1\MP5AR'"O"T]5@:!C.?5$VV^::%UXSKAT&?JX%U,5*-Q8
MZ@,CGJ(#3=W%T;68`=1/P(`_."M=-EPD'DT+_<7[W%Z8AN)9LV%7ZC-3`&IR
MRM217%@%N[_8+`5:6>8!6,X)(8#OW*!3?$!Q+VP>Q:X@,%.6I*G+U`MB")JZ
M^4?C-.)DAT@@N3WHB!)C6AEJXBAZ%PMS51^G!`6Y,X98(,/#/F,Q%G^R()1F
M!(_U.4G2"77JC3TQ;:C%DC1B=Z]P,57)3D0TC\'FT#`'(2%\W.LPO%/)>4&4
M)FX:MF+"XI0A]@8?0?#8SP`>K(_!79(TZK$+'47/69EBI$-0'Y-?N'5@LJFS
MN#Z^'1.2+W0')3)1E@;?^"HIO-?GY$/GL838/A_[PVBQ\V`2I\ZNQ%>F*!3,
MD$8BN]TZ=MJB-9I$3#%F.1J+IF[+3Z:QVP!K/P4O3HASH2N)[/;EZ$FKU`$"
M&)JZ-Z^`@:JSH)N*+[=6\,1B`4=S$R7AI^@#L#_HY@E]$`J+VI%8MX5^O\LN
M=%PPM57J'$O@Z[,3TREK*#/T:JE*/7'(+DTE;MHJ]8<(BV#?:FZ\`2X5G']_
M40\6AH_=)34I%46K"27+\>Y[U*&U`:Y.J5`FK]FF6F)J"%F?C?,O0/*S'SKU
MNAE?K+EBM]502BU1\2_P:.IE5(ASS&\I6LV?U"]X]V0M-DW6$W._UQQ<^XS2
M@$U<\`@,5.[8EB``##W-V(DY<2((H?$T8\"_9M#M>[>0M06IUV$7`;R=D!-%
M2$'"4P"I:0J0!ARRC[U2?(/(Z?G;,-)1\E1ER+^JT.TBH=8ECYHA0QLIZRO3
MUC#L/H2B(+';3D@H*$1CLK%ZF0,3D57Q)SB+YD,NBQFO<23[IX<;3)_@!Q15
MVQ)9U?9Z`__X,EMLUJWE8VLR7O_<>GQ:_IJ[?CNQ<Q1]';?Z_T?;]<4V)JJ&
MA]J#"Y/F!B0#/)DV_!Q-L[+,-PV.^>GT%1(T-[QV/L9NK#C:FZL^@:XQ=&98
M$)S];(_;2'V2L8CVJ*,`UIJV,!AUV-V!1D]:3'):&>H0N'_IX#7`>L?<GL/A
MH9W&<MB;EJ-]=W\V5+R3S?<'6;.0'-K=GCB,BC]']::@&+=^ZI(1LQKO5959
M;K';?-/]:%I`VQGN-89R"O5>^BQK!B+FJV$!N"%_!VI;Z/2%$3MD:&CA?N&>
M(?)7;G:H^;_[&+F+UP`[Y)P5E#3A7=5[38KPO3R[*T@*2KC7/;H4B028ZW,%
M46"NCH<'BLA:VLL1]Z'#J`CL3!\U0=SKX*W]RPDZ_U<D68U@V(T+@A?&SJUY
M$4<,"XB39N9>PVZC7X0X-C6B#C&%_H,-IL#],X2BU]8Y@+`K]5BVG""E([O?
M>CO'5?IQ6Q!Z?78!X=3Y"UD^>21Z[L!!@U130PT9D&2STU>S.&Z[+D&I=]UZ
MJ;+XO*6AJC5RZYO0(\9_0"6K.W*+1:C5.#(6@U+5)J(=/(_Z$HM1<P_O\8LF
MJ607H=,IT_D@(8KCW9H:TZ8>VE&/N(B30N#G1YP4>OW1B)FFT=.3?4>'DR@`
MJ/8C5+:Y;1]1[^KE%J60F0:^K(;$++=>",=&D?]15-E9Y&T)W=B%K)0B1!GJ
M)Y05FL#9E<2_5HH+[[!)*P6+?XE%:,_>@87>)5+;@MAQRU&9\)HZ?]4+:)BT
M@-(1X]_O]=;,&[!>3,K>;`$.5S5A;:$_8EF,&3]SU=J2:&Z34`ILZZ`K<JTG
MQ=A6Y/[;,?'*GNCFX;$Y,=$3E,.XRB<OECM6_CAJ%HAMY@=UH==G>$XDIX3E
M"J*3>K"$,J+(?VPN\S6PAPCJ#1JR+_B>*`)C!$N'Y6T<'3G\:E@F/`,UZ_+J
M%>=5LV#A/4,D+$V!@TS0/H9>9G.`O=Q.P0%E#B-<1OT2C5@*/?PJ6C9$`TWK
M29SZ"%DU+0;DI%M-"#)>@MU.B5X"DYRRB^O=MM#KNB6MS!@[3\9R@=#)SE\@
M"5CPOYU['C)>N=H;57'?^:UA/SD_5(,Q8-=A)&GF7!J=527*##WF7<T4)38$
M8@TM@1S@U6:5%%*Y1`$KX]2:VL1YRL8]VRT/_[>`6<NX"3!D4L!;M:7'FWF7
M&7ODA)1GVF^JDS.B59\;2KHZY1Q'JS+=A+RAP5+=!$+P^,\.9AUN1BNLSZZ7
M#CDA_-FC-+3JTV,EUAZ5NB8)+XZ:FF=-C@K2,K%7]IJ,((2_-9F&5E-[F<RV
M6Z#@A!3E539VX!EBNC2BW\EMCP2!W9O!-)14Z!=D!<Q3H!'_"D39NC>2\Q6`
M[*G79]/V8-AC]]03#245&J"L@/F1IP[_&I2YG5(\C`*3:#V;0SO=*^-L."OO
M!79*\65[BET(75#P'WL]X,4,@;&<HI>!T-AEP(0SWI:!D',9".=EP'\HW%T&
M,X/BHGI]/!QT#*.L^S#.C:UI[>7+QFE=461W:4=&1(5.:`:8?+5I7,C?]YGF
M1J@"Q<TTBLEB0SGW49>AD>4(U,,7HQ99U\'UM5`V5!IPRYEJ7I;P(&>A`[_7
M7]$OUG#K\[N]08>X9(5X6#YT(QL*#;B!C753=&`']07+;;CJ`'<MBTJUCU2$
MY+'XD#X%OS6^)<[?452D["B*&XK^/%Y\GJU;\T5K_?/X>?;S\FDZ>_ZO=6OV
MKZ_SS6^M#Y/Q:KX9/[6FL\?Y9#Y;3'[[P6<^=^M1Z$'@B)0]-W`3QXN&L5XN
MP!1L-45#_;XN,:=H3NJ-9^X/I@%GG9I[63/:PE#"'NJ`26@P:LH<!Y-S,=X7
ML'\!%CQ>#B5FU-],5X@=(!1#N+U_+,\5;O<D(>I$3MG$HHM5N+&J:BY^*UE3
MYX:W&#U!](?LCC*),Y>@AQ%I8F10--7;>`8.Q`>H,]DRH-ME^XP/1';=F:/G
MK$+ZZ=S7V.4@B^YM<.\6>+)GMUU>SI7=;`7C7$G9'K]K-F)AQ)Z%J*F+#;S$
M".3\'`HA"'QOH@$;T-4%<_@CIKW/7H#!?-5(+9+="C>7?*)B?`M&)ZL8XN-?
M#V)%/9.W<HBD0/)F4OCJBOM=+=O-%3IMVLNC8SNRH<)]'3+?$0<,17X]8042
M3^:Y-NYKOJO*6Z385E$59:!0E!.HTR.*?+J9%ZX\%^`;_B<;2K/+]/TF$B)8
M:W7TTV]TV-0G=S[#>X"W4.#KV`LD&![>B6C@14D2D&GJF>ZBY"TFL!']G,YL
M?]#-$P`8R]714E[A-U:6N;/D_3.`#H2M.6`-K#=-`2Z\J*)N9^`9VN)09-B#
MNQJF2E=C#H37U"*1Q&TDIJ67U&7J/]`2Q(M5)<6LJ=G%29M-+"J]TC4IGAY>
M%(D0L?J4.60,O]XBR*3M8I$GEIB>':Q:8Q;<OH0$^93N),,Z);]3]WE,"CNP
MS?9E'>YC1'WIX;Z;I-TTKNN6J4Z7HIL0^6(C\=*C?;<"3^:YV2G9"0Z%^_&C
M:7G''7SN[[/+RZ"BA2O7*QFI^E1\%W@2C(2$8?L).F)XT1X2K)I:V4X<HWFY
MCM&DQF'<NAIQV&=W!F!-?>GN>9GB".X51,Y5.KN_[R5>7_B1X=*?`?ODC"02
MBBYOHF'V)HWC)MV#FQ0.8@3(DJB"-@-IZ;V5IQOES[`?E)1AWVI]6&&.7H&C
M*;)>5<K]!1&9\^_IEA3KKJ8Y[4?V;?_L+5V6+(G#`3L7,@]E%=C3;)=>!,C6
M)I\I>_M(`GC91H[9K*U0'0@T1TL+3^<>4:%3AHU86Q)Z`C/^"`BH8*7<^+J4
M.-4FWXO:70T!X1Y%QT?G%?+V':@0`(;'IX2).5.0)%QJD_L2I1CY7;P>I8NW
M1C[><C5['F_F\`N%.6KV<NMU@;VIPZ4I??3*5GP+\$FV-65LJ%--/\+9\'LF
M4\U6=-,^6J$FA(+$,&$G(U'9MY!?@;9[A2./H<K(.[`XHAH>N(C0Y*$0^14=
M\.S2Z;%[_3(;4<740!6E%;YI*0#@VI@=2@?M&NL0F`-VZ;IQLV9?0RDZTQYU
M)':/4J1,SF11Q`LJB'B00Q(</W@/#M*WLC'W(-BTSHW[!WUVEC-FTNRZ_0S>
M@(%S@`<"P[.X/TTAZDJ,_+F2-8+)IAZ+\1;V6=8,&R7F>*\61^6]1S9%N?[M
M:@26R$-MCF\%&Q0V[\@5;E%0_&FY]99<6^KW&#ZV>#%7*:IZ^XQ=/+_\^W59
MGZA+0XE)R^#"-?6S!8W+RC*WZ&W!CB2Q>P`A-%,I6GK3QSB.U?I4A-&U*7Z&
M^,%94+?.*5R9NHG;YLW>T24W:`OB<,CP5>7$R2NR4A2`\%_IDM5L?;9D=)=K
MJ,]`V[\<X>Z,PTW/0`':&SS\6^Y/^/H:>1Q1_G"DUT0Q<#4.55;.FYKKEKJ`
MQ%KL8/ZJ#BUIU";4V&D&P)TBO06^`&[+T$C>(C6:8N1R+)H89]&H>><_`>_2
MOFWHMK[/P`"6K$,LQNI>,S0$)'J!-;#UG<&(X7DB9?J*MC\J4/BOJ\JZ`0:/
MZUU4[H@C=D\11LQ8C0><QGI]BC*IWQ6,*M-B]:94U6*.9[<^=3[97VJC]@M)
M(O\^<#4X)&9^SC<W<!GN$7U<.3YH97SCSC3,2VL;;+.]7F0HNB#S$S=O-6<N
M,AC.Q;+UNQ_+GW+2SY=RPBQ7^"(%I9A4X*`3B5M5$=VN9*QC[80_H9`RKKCX
M#E2W`@,G=CX%E1_"L,-N*15,;([T8G<.H,:T=_%6E#@2V%VZDM%0S$T\:R4)
MDHNI<6WJ?6F:76=2U%-X)&BMO`+UJ(/EMA@5<FMX^D-!9%?8Q(+D4K;ZV](G
MUNA77D!$LX2>/.9PT537:Q=>QC(*3YQ]*<4,ZE5U=0=N.\4R^:%XTH!2M9-%
M%7J?B@P1OM4T\0[,[VXO,GP:A8``ED*.TV"B.\);?/@6=DK$UV.GVY?85>X2
MD5"EP*DQXJ:0-X?A+B,O,X/A3LBE6LLZ\%_?$+H,JQ-NIBM1.6^?/DOBG?_4
MJHPI\XS.?VQ>^JH@2)!:*%;..2@(`[.3%S>VEC/("3W8"LL.B@J."JW[UM14
MCEYL-/A1-M36S(!?.[5"CTE2Q#[]D7"^!!HG8ACJ^&;2H.<3=$^,?+PO,@>%
M9,3L>ZL_^@;^9KLK=%+,I`V4]LY\>U"!YEI(^,.U880?70Q;B$7+B*N_7&+8
MY-MY'T.*543UHR[OVEZ!;@'"N1B7!^G$,<J-\4]<.BN_0>$4&F-47%/P&KH8
MGP=QI3%>H5M*(;9'S59D_3=XUG^$G\!=,]5'I!7<U0P\B2Z>^0ISX:F%YRJ@
MST%:"".;^$)S\"?`:``J3%TG$.'&DE$I^/JT?S%UE&%3D-@NQN5!5'&,5IA-
M3G+VQIP^@QV.@QG.0MY#VSXLRC9&#<^#L%+8KC!;FEAF$SB*)>MS>%)Y_R<X
M0>J+6EJ1X_,CM7C&*\QA)HEK'BWK8B\.7"FQJ.46-P4/PB-@O\)T9.)E]ZCI
MP)I`NG>FA70O[>*,;M%=C,Z#U)*9KO+1"W)#>=T'ZZ)+_JBH&$CZ9/S(DQ"2
M*K/'BXDG"ITN"B(&.<GP+_/%+[/%9OD\G]$T[YH;;W`6R/QU=PB*8*$_QNE,
MSUEB(X'=HP0)$^?)&+D9=`/!^`3_[?>V(`S[[!(UDZ8NZ/:.0E+G&#TA(#5.
M*LR['ON=KAOACUF1K0_^Q4K+W+8"1%OGIM0_M#Y,@2-KNDV3^!Q:ON>;FV#X
M\^C>T'\M\4MNGN5O7^#N;VFR;B-5'K+KW!PY)P>+.A:"&J]F,N'_:EJ_SXV5
M92K`QJPS;/P6/2D'XH\'H;F=F3S6'U&2%+29GTU3Q:P+$GOY7TS*@?SC06AJ
M5@X)7HQ:'K'<RE!G!"0^=GV/PE.5IKDW-<&Q#//?Z2:V(CBO]]E+/`VV/N`D
MG*Q^I?O+?WF.5^E19R?;C?]AF$+GHD%/8K>=D))1W0:3":@:NYSY`SHWQ\?U
M_/-B_CB?C!>;UG@R67Y=;.:+SZW5\@D]KT,3Y%EK.T/;:HIL.&-%,8\&JF)>
MF3IZ'2?[RKX=*E"+OL`NKSE^VNS+&A7\V\OM*KP2##41MK,&#WK=+C-N\U!6
MR.JGD+*_]HM"\T]L#OH=>H.0*8"4*)6\4:.Q9:$WNG`-/M2`!135^9,-_,F&
M:H2*\KV:@)[$SAV@I"6[+5EY&'_2S,TKL.0#.#J:8J-,9^M@NET(_&*<GCB*
MBCE$)M"2CUO,NL\I.]\89(2CQFL_63NVVG=@Q7$?%7Z,5H:X8?B2/1&S30TT
M9421S8NX95N_)T?U12UYB2Q#"B,7_'J5^GSS\E0R<[4)F%&_1);N`S(I26/A
MZ2=[H5[+W$%D#G6DPJ:/5Y(7?MO&@HY3SFM((/4JZL:FO8$U4(Z0,LC%[%W1
MC]`5?80XH;O.H^.5HMTT=#M%#^"^!"RQ:PW#D.[L:R!Z3)0JZI7QBD-V73[2
M)B]FN92H+D'U#SFJ=5QKMXRP.:85H1[1EA]EA2TQKF[O=&@_-<5OFF4'CNF@
M0^R%$PW)4*$39')^QYV6ZZ:>O-8*@&Z?9GXU[`-0X,X(5`^[OL3PL:S8:?-<
M0KA#;KZ9(?E%A4ZBM?;ZUPO14`IXSW<$27PT]5CH<[TT0(CKJ&XFB=(+?KUJ
MZ47ST70KLH$B"O,=M2,FK[[S`%5+,(Z7VAQH,\KPT3Q:(;:)'XBY_?VJ)1C#
M27T>A*(4H-\OQ.??=<R%`;MC2^24^;?P>%DSZM*9QQDA?M<]62S7RIN(`=]'
M)=2'8[D-A1==CGNI)8O911@Y98Y80+;0*)O0`(,@=9K.$DHP..1GAHMO14X,
M%CX%':W0YA*5V4$?&GW*WTT\>)W]^&+#P[&,DM7PQ1(QA5$C%&,)L\(9/#>0
MQEM3_6N<B0Y4VXW1Z?!?T,6A:=EMH3\<L,NHBYV7#WT@@Z6I1^8OF@YLQS3`
M2CXA0XM7`O&)Z_JW^9!H(D]-/7F=55=[`Z&]U'W,%H<D5\!2$/`[_';ED/BM
M<ZJA^5"![&@T]6`7JM]>R=;2PB<*]1=9/P+_;J8M"3UVK7\)".!%=ZB0JD]Q
M!&6.3;Z+OO$>0=\>=`1VA9^%D,B'TA6.=E-?)%X?#P<==Z/0'*_%(.H,@].%
MB'>TF$'X4`42#H-=2A*;)=TS>-<P/`,4P()8?H'_WQ_WKLJ[_P[M<UN0!('=
MY7EVPCA1JF*`#?2N?H_PI3QYHJ--'N[WSBD4:W*AL)?;T&=M090D=I?:%)3P
MH5E9H0M4:=`5FZ1*3YJ"'@5!93EXH8UW%G#/'J8#_Z_)^N/1.5K^X13W?5\:
M"^"=32#44J]'G'&0=S8^=*A0S,XV"FE6<Q1K=;245\BYN[(VYB>PAA*QT>7.
MQGP&"D`OTABXRDE]UG:O&!9I%/7>8W2"./7X?"A/3ES.ZM(3NF(MU247Q'&9
MV><TMY2K1VZN7YC"4$[>*]_][&F7:NXL?[JK++;+@)YW;AJE,P4F]9HWB+C7
M]869B/YSJ?7"&+U38>7"[G"7'/XY^PDL9.0(7CP[CK$YE[FCVQYB_SEUN&)R
MS.DK_>GX;.J=M=?OX`J_TS44@UZ777D[&0U5Z0D]0DV]RKYVN:XA&'6&[,(V
M*9-7I1T4F#3U8GP*7IQKMB5)B#H6%Z,*$1-6)?X4WFM\UYV_*53_QJ?;+"?_
M;&V>QXOU>+*9+Q=4?:#0=7$X2S&SKX9'>C5U*!I[]L<1BF-A.N>V8&(W,IN^
MJ%3LI+ESY&1'CAO9]%KJ"67SQZHE.*TD+PH+J=&JL0N8OZ53/^*(=K.<LW5Q
MNE[8>3LW3739A@X;'O<<-Q`Z`KL6R9%3YES-<]L^`G5ZM-!^A!\9<\M>PU6Q
MLW=@*9J-[Q#_7=ZU]*@-`^&_DFLO"/(@RY&E04):H*+LWBG-KI!*4@&MNOOK
MZ\G[X22VX]DDYH)V0?+8,_[L\3?CL3[%.V?R=T@*OADMF8.UN-I43>C(YM]6
M:,$:6WA[0J/\+N8*GU(Z?'L,^3):'6*HKV8'D$%V(/AZU+^EIEEQR812+,TC
M1%'P#!P$!P,-Q3Y6^!F0UX8]QJM;P]8'\=VYKGW@ZJ.+@(8]P;O2R=8'*<@0
M-6D,%7YU]2;>*</\**ND1//3F;[S[U_^N^N&UP3=Z+^T_N$#<^7/NI;0IV>=
M.1("CW6H`S[^,=DZ,V3FC!:GO_:D#$=57CZM5Q^X)8_O@3,3AI7-AUG30Z8R
M2OF7!,OA=W@&QK+?T/>K?N\W]9XIBEW%Z0P4BS9JH,/(BC`W6V(ID4I_M.:;
M)9&PE!(:3%.A<W"V#X081>9TL=V\.+O]ZO')T3;;O</!EBY\[Z][N9V(ED#-
MPB0I!*XH;Z),#`OOB5"Z3'$O-=]>)@`W12SR6"%4"I18C9*-/C8H8,!>:WO@
M647@+>>KG?8R?WIVM+4S__Z\<];.9L\!O^7A=`DNJJ[=`[19OI//@<&DL;2/
M:<19'UMX&3=UDL7Q2&LUDPEAFWBT8:UH*=CD,U:,4&:5W#%.S;%5#B[2D2H4
M8*1AMFV,437H9MP*V%1H0D:V82)&4)L[T"&,.=5SQV`VFKU=D3<="VYORW<=
M57!^5QXQGGN]P0LU9V`OXR^<?Q!RRF:S%!XMG$QUO(U8M%N=^,]2='C'8#?'
M1GGG+L-]`W4&X5;6%Z']NX#]I+6V>[@*JP"TM_)(*W_`JUD>CG&A$GMJXIZ!
M:5([.P0WJ6#`&.4P?P8HX9]7,J1OE]/1G8QL&S&KE;D;/9@@C$I2-5D_F_<$
MH9&#=W2WKZ"BH!KCYV2!Y05W,BD8]9`L'(KEZ>0QL8:K<&147P\WEX#`PCOF
M5<OMP=)0I095"]`Q+(Q!*EM8T'=DZ+K-G/?!UW8/C,\U_"230+'J8)4J@6S&
M@/%8^I=4/3L`"NB%.6%$0$"_Y@:C(I()HO2^$1^78?AA$<],S5?;UO$*4[+W
MHP?3AU5-R:31U5I5\@7`<TPJ<;9F.MZ]E1K)G7N==9H8<!5`&9R2WLPIQ=DC
MFO^JQ?C2(MI.V[E'_\T[?;@_I3!.::9*@1],Y2!S4;,A<%$%Y0!):IEHO2](
M^PPXSXIPKAOQ<))-8?;S>0!#9TWG9Y^@^R.J)!9LUA$%L/"OMROQY"86LTO;
MT%@G^PS/`%6E.(JQ'**$L)C<R7O+Z@=0BQC89NU&IP$P+ATE$V9X;FJU<Q+]
M`A\_R!&/?/,?4$L#!!0````(`(&%9T,A`)`]H`D``-)7```0`!P`<&QX+3(P
M,3,P.3,P+GAS9%54"0`#H@E\4J()?%)U>`L``00E#@``!#D!``#M7-USXC@2
M?[^J^Q]TO%SF@0#)S$XE-9D]!TS&=01SX,S=/*6$+4"U1O)(<A+FK[^6;,!\
MQA#OC6^7E\26NJ7NUL_]84M\^O5E&J(G(B3E[*;2.*]7$&$^#R@;WU0>!E5K
MT'2<"I(*LP"'G)&;"N.57S__]2^?_E:M-@7!B@1H.$-?*5-X3%";AL`KT5GE
M:[ORKEI-*2/!@]@'4L[01;UQ66TTJO6/Z!^H<?W^(^K=)X0O,KB6_H1,,5)8
MC(GJXBF1$?9AVHE2T76M]OS\?`Z#*1S2EW.?3VMZM/K5I18\)%/"5)N+:8N,
M<!RJF\KW&`A'E`05!)HR>1V%+WG&2HA?AB*D*^2ZY9R+,9#6+VN4:</X9$[/
MXNEVZD")FII%I`841%!_P<!9#A[.JFM\FBA0"[ZL5!]J2>>"5`8KXS]?SBD;
MM?_<=P;&W!6P/D+&_I@QL(@"/)BV>6L443;B:1,TPBK_=JW_#+$D?3)"+Z9%
M\)#L,9CNKODX]./03-%9#E!)1Y@(,KJIP#)5YZOQ"`SGH,R<0AOEIB+I-`K)
MO`T+?V/J5-/&U=55S5#58+$C(A0ELC87?6$FW;"??4ZZ0;FJXW+D6B'F"LB(
M,IK?6D#_)[96B(<DS&<H(/T3&RH21(*W/.`Q!(X_A+VTA!X(C_3%0]_9'0^,
MH9J<!81)$L"%Y"$-=,B[Q:%V_(,)(4I6$`T26_G^4!XJWT*ZN7S+!_YSO7Z!
MJF@`JV1"&UPWW6[+[@[LEKX:N!VG97EP<VMUK&[31H,OMNT-/M76!UJ?(P9]
M7/;97*_YXY0YI=C'N.J9\O.M0R\_Y^+ISL\"."8"<AJRFRUMG>/B=X#+8@6E
M.VIB.6F'_'D%-I+[HV*!\S$?<`8>_+NWN]X`N6W4M`9?4+OC_OL$H=)""!`T
MP6Q,I,,&$RS(A(<!)/#V]YBJ61-'%$:#_)?Z%$2>K8&,2N('Q0+MPX%`,SC[
M8G7O[`%RNN"QK+[]Q>VT[/[?!\C^UX/C?4-G3:OG>%8'M>RVTW3L;O/;NQ,B
M_QB([`$%4Q.B**S1-GA&Q>+SE_\1/A$Z6U'M!-C2`A:BL`L9J%%]+0SS8L%W
M>4P4=GMVW_(<(#A!Z/\"0GM<&B_8F[U_&Z!./JI4`'O29?`P)%VN2`8WK$C,
M-(P3:E'IAUS&@B2@^6KW/>>V8Z.NZ]DG%)0&!5TLM%-Y(BVB,`VST8FQ0C/W
M]_7+>N,U9*"SA4#OT%DJT\EKE`<O^OU]$(?$'3E,@2!2V2^1#EM]XO,QHS](
ML`5)DE,B"D?3Q>MHFHN+^`C-!4:IQ&@I\@EK9<2:A^%B!4>J2`A=OAZHT%DB
MPPD5/Q$5+>['.ONT6&`S!26^PT9<3(VR2W`$F-!B4U\3K-*YLY>8!2@1!&4D
M.2'DYR&DC:GXBL.8W!.LGV2]3$MDC)ZFQ>:W'];=1MMR^NBKU7FPT;UM#1[Z
MIA0Z(:)<B-C(2P`8!><D'S8SW.W8..4;94")`^D&4US0;)91:!1I;":I#J08
M7<_M._;I=5LYUCY;TR2-LR:?1ISI]VX;7H-",5/L-ZWW]8M-OY&!R7H9D\J(
MED*>ZI>R86J]=J$%ER[[W,JI:BD!%@9TS.B(^A@*%]_G,10,;-SCH?XJF<&%
MQ(6^L&]L.I*!<]=UVD[3@JS#:C;=AZ[G=.]0S^WH+XFG&%16C&P$'H!*P6'G
M<+2<XDSI<6/^SU9@4ZB+V9*KO`J:1*839GXF9A3W?_,$9A+[:_L09*&Y2<-\
M,U[%A^<V_XF\OM4=6,W31H.R(6$STJB"`\W[+3YC`Q.GV%(H.C[5U@_2I"VK
M!V[,<1L*A:10B&T]_K3K#%)R<JK#?3/8'A9]5YWS5753M7%1O6R<P]3S[?*'
MBK$`WH%BS/F.$L.,)XE_/N9/M8!0<X"K6F_`(#OEV,JC+ZI+Y@,EV#AYE=,$
M<P:M^X<CC;_]E%@>`;*<W811"W*E%Z'QRYO%.4Z4-\BQLK`4*G^I#L9#ABV]
M/@H5(RR'1K%85L<81[GEV,I8(Z&2\Y8WRZ/M+`L2R(QU_',SM[H?"^U19WKP
MBT.6:X5Q<5==#G.L0#J%%[.#X9/EF]^\W3Q214(/V3A$E`63N:HNV8]W\E=)
MNL+(6.^$S/=DAT*L<.U[LM/SNT:2FXHU!:GH#S.V.VJ1H7*DC'7$:G*9.7/U
M^"HAHV&HW[_=5)2(]4DS?:KW>IB<X+JI!&1H7@::U@C<#P\\<[0MB$7Z35O&
M0ZFHBO7=G>!Q=%-)R*DBTPI*3L(E+5/.(&D2,P=Z]#![--0'@4(BI?U"A-[Y
M[HY,)NA&J^7`XVMTI=6/:[EXLGO,$D(?$=#=/<%'5)F3`CW0B)B#XQEU#V/;
MKGU6SR3343G5A!"DN?7X.70T<(/QA=F*D-DO<PLYC?G@V>8B:=9'[/LXL\_S
M\2CF5U;;%R3X.<N]4YNE!F;Q(-<8$I'#"COXBE[PI$7J*60N-:'<\*DQ9=;U
M6"RPI"3*F4:8BI4=#X^'\)3U:=ZWZ\>""044KQF-<U&OZXK3GMU+>Y26,"AE
MXQPZVM,HY#-"0.HN6":]NR>K@-U/];OKE/QFQ'7`IYBR`Y3:I49I!;\#UZ\D
M6+E/Z'08"YD<O.@3GT!D"%R17&F9EUH=Q%1:7^HPF!N"@,,Z%`]I2/5A>0@&
MO>3D_*P7XN39^A[3:-77',%:6C-TJ*\W!H.T@SB*PIDU%B3)!;B"OQ2'[5C%
MD`_@F6[583-P69>DN4(FAWK[2&7UR_<4<D,%]*GH2YTW>\JJ0Q=KVZ^<J#(?
M*#SRHFY#R'672N4@?3U!.,YQJ?D4>30RR0IDZC`^#2A>V=+TN+VW<+G3%J;(
MF(@<0KMJ0L0=.&?9X9"69`3>["FMS^B-Z`_0EOE<1#R9:CWR[2$I71`$_^,3
M$LBVX--Y7>N.FGP*)C%E(/@H=Y2>H,BLV*%\974-O?1SR2WE'F`01P0F\.7^
M]3V`IXP+;H3OJ&"77IFN\HD?"W\"T1/*G)@IC]^2`4PG]4^P>3S-PDQ%$)*@
M3\>3;)`^AO=H/W1,D7@`;OM$$@SJM,@3"7FTJ(7&E!&BRY'TT8/'<&F`@YC*
M^L0.(-."B,;;/!;K"-[65SH(SX5TV4;-M*6KM.)[$[%9]&WM+*\*SWRG`LNN
M\HF_;SM0!YYE/4;&[^6E+]OKDKUR>ZMU>1[:WT&_0%U/9OIU;CPT5CQ6T\P+
M=_-N07/Z^O<@S&O##9#F(R\?<'5M;!IPZ(Y&)N3HDEFKL^/KRP$LI2T9DE<"
M.C>FRKP3(.(;Q.$U);<1E"#[2#:1)-_BX/:_4$L!`AX#%`````@`@85G0^Q8
M(1[7.0``K8("`!``&````````0```*2!`````'!L>"TR,#$S,#DS,"YX;6Q5
M5`4``Z()?%)U>`L``00E#@``!#D!``!02P$"'@,4````"`"!A6=#7TI>>Y,+
M```S@P``%``8```````!````I($A.@``<&QX+3(P,3,P.3,P7V-A;"YX;6Q5
M5`4``Z()?%)U>`L``00E#@``!#D!``!02P$"'@,4````"`"!A6=#XW*U0^0-
M``!(J@``%``8```````!````I($"1@``<&QX+3(P,3,P.3,P7V1E9BYX;6Q5
M5`4``Z()?%)U>`L``00E#@``!#D!``!02P$"'@,4````"`"!A6=#>"0D\?A,
M``!C'P0`%``8```````!````I($T5```<&QX+3(P,3,P.3,P7VQA8BYX;6Q5
M5`4``Z()?%)U>`L``00E#@``!#D!``!02P$"'@,4````"`"!A6=#+\J?I$,?
M``"OQ`$`%``8```````!````I(%ZH0``<&QX+3(P,3,P.3,P7W!R92YX;6Q5
M5`4``Z()?%)U>`L``00E#@``!#D!``!02P$"'@,4````"`"!A6=#(0"0/:`)
M``#25P``$``8```````!````I($+P0``<&QX+3(P,3,P.3,P+GAS9%54!0`#
IH@E\4G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!0"``#UR@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EA1AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2009</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Protalix Bio Therapeutics Incorporation [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Pfizer Incorporation [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 18, 2013

</div>
          <div>Protalix Ltd. [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2009

</div>
          <div>Upon Filing of Pediatric Investigation Plan to EMA [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Upon FDA Approval [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NumberOfSubsidiaries', window );">Number of Subsidiaries</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="nump">$ 60,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment triggered</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40.00%<span></span></td>
        <td class="nump">60.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights', window );">Supply commitment for entitled rights to be received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">280,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits', window );">License and supply agreement potential future payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplyCommitmentPerYear', window );">Supply commitment per year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 40,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,817,090<span></span></td>
        <td class="nump">7,508,240<span></span></td>
        <td class="nump">7,879,601<span></span></td>
        <td class="nump">7,169,035<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementProfitSharePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative arrangement profit sharing percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CollaborativeArrangementProfitSharePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License And Supply Agreement Potential Future Payment Based On Net Profits</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_MilestonePayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfSubsidiaries">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of subsidiaries.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_NumberOfSubsidiaries</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SignificantAccountingPoliciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplyCommitmentPerYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor purchase amount that one or more customers of the entity must satisfy per calendar year to comply with the terms of disclosed arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplyCommitmentPerYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromCollaborators</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>NOTE 5 - FAIR VALUE MEASUREMENT</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> The fair value of the convertible notes as of September 30, 2013 is $71,760,000. The fair value was estimated based on quoted market prices.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EANAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (16,905)<span></span></td>
        <td class="num">$ (1,741)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="nump">3,453<span></span></td>
        <td class="nump">6,065<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DepreciationAmortizationAndAssetImpairment', window );">Depreciation and write down of fixed assets</a></td>
        <td class="nump">2,689<span></span></td>
        <td class="nump">2,772<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income), net (mainly exchange differences)</a></td>
        <td class="num">(140)<span></span></td>
        <td class="nump">14<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
        <td class="nump">145<span></span></td>
        <td class="nump">218<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributions', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
        <td class="num">(26)<span></span></td>
        <td class="num">(24)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
        <td class="nump">15<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenues (including non-current portion)</a></td>
        <td class="num">(5,393)<span></span></td>
        <td class="num">(4,981)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
        <td class="num">(798)<span></span></td>
        <td class="num">(2,099)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
        <td class="num">(3,538)<span></span></td>
        <td class="num">(1,779)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals (including long term )</a></td>
        <td class="num">(5,413)<span></span></td>
        <td class="nump">369<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(25,911)<span></span></td>
        <td class="num">(1,186)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(1,668)<span></span></td>
        <td class="num">(1,817)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
        <td class="num">(121)<span></span></td>
        <td class="num">(93)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit', window );">Investment in restricted deposit</a></td>
        <td class="num">(42)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(1,831)<span></span></td>
        <td class="num">(1,910)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
        <td class="nump">66,930<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses', window );">Issuance of shares, net of issuance cost</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">25,328<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
        <td class="nump">30<span></span></td>
        <td class="nump">1,096<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">66,960<span></span></td>
        <td class="nump">26,424<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH</a></td>
        <td class="nump">144<span></span></td>
        <td class="num">(113)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="nump">39,362<span></span></td>
        <td class="nump">23,215<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
        <td class="nump">52,035<span></span></td>
        <td class="nump">27,001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
        <td class="nump">91,397<span></span></td>
        <td class="nump">50,216<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="nump">187<span></span></td>
        <td class="nump">821<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalOfferingAndStockIssuanceCosts', window );">Issuance cost related to convertible note offering not yet paid</a></td>
        <td class="nump">150<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CashlessExerciseOfStockOptions', window );">Exercise of options granted to employees</a></td>
        <td class="nump">$ 73<span></span></td>
        <td class="nump">$ 72<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CashlessExerciseOfStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash due from broker assisted exercises of employee stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CashlessExerciseOfStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DepreciationAmortizationAndAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DepreciationAmortizationAndAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in liabilities for property, plant and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of common stock net of expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalOfferingAndStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplemental offering and stock issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplementalOfferingAndStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossUnrealized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3095-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForProceedsFromOtherInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitContributions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTE (Schedule of Interest Expense Recognized) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTE [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
        <td class="nump">$ 104<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 104<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AmortizationOfDebtIssuanceCosts', window );">Amortization of debt issuance costs</a></td>
        <td class="nump">15<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">15<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total</a></td>
        <td class="nump">$ 119<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 119<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AmortizationOfDebtIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_AmortizationOfDebtIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpenseDebtExcludingAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTE (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTE [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense Recognized</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> The following table sets forth total interest expense recognized related to the Notes (in thousands):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6">Nine Months Ended</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6">Three Months Ended</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September&nbsp;30,<br /> 2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"> September&nbsp;30,</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">2012</p> </td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September&nbsp;30,<br /> 2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September&nbsp;30,<br /> 2012</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 10pt; WIDTH: 56%; TEXT-INDENT: -10pt"> Contractual interest expense</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">104</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">104</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 8%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 10pt; TEXT-INDENT: -10pt"> Amortization of debt issuance costs</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 15</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 15</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 10pt; TEXT-INDENT: -10pt"> Total</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 119</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 119</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 30<span></span></td>
        <td class="nump">$ 1,096<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Certain Employee [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees (in shares)</a></td>
        <td class="nump">64,768<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 103<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued in connection with exercise of options</a></td>
        <td class="nump">64,768<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Nov. 01, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">PLX<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">PROTALIX BIOTHERAPEUTICS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001006281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,561,765<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value convertible notes</a></td>
        <td class="nump">$ 71,760<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Convertible Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509036<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleDebtFairValueDisclosures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
